var title_f40_22_41312="Air bronchogram CT II";
var content_f40_22_41312=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pneumonia with air bronchogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 211px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymphocytic interstitial pneumonia in a patient with HIV infection. The main changes are ground glass opacification in the right middle lobe and consolidation suggestive of air space disease in the right lower lobe with a clearly visible air bronchogram.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_22_41312=[""].join("\n");
var outline_f40_22_41312=null;
var title_f40_22_41313="Erythema nodosum leprosum";
var content_f40_22_41313=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema nodosum leprosum (type 2 reaction)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical inflammatory ENL lesions, some of which are undergoing pustulation and ulceration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James L Krahenbuhl, PhD and Robert R Jacobson, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_22_41313=[""].join("\n");
var outline_f40_22_41313=null;
var title_f40_22_41314="Non-small cell lung cancer treatment; stage I to III cancer";
var content_f40_22_41314=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/22/41314/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/22/41314/contributors\" id=\"au1952\">",
"       Howard J West, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/22/41314/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/22/41314/contributors\" id=\"se4114\">",
"       James R Jett, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/22/41314/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/22/41314/contributors\" id=\"de7369\">",
"       Michael E Ross, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/22/41314?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      NON-SMALL CELL LUNG CANCER OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Non-small cell lung cancer (NSCLC) accounts for between 85 and 90 percent of all lung cancers; the remaining 10 to 15 percent are small cell lung cancers. This distinction is important when considering treatment.",
"    </p>",
"    <p>",
"     This article will discuss the treatment of non-small cell lung cancer confined to the chest (stage I, stage II, and stage III disease). The treatment of stage IV non-small cell lung cancer is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/63/17396?source=see_link\">",
"      \"Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)\"",
"     </a>",
"     .) The risks, symptoms, and diagnosis of non-small cell lung cancer are also discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/3/1076?source=see_link\">",
"      \"Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      STAGING NON-SMALL CELL LUNG CANCER",
"     </span>",
"    </p>",
"    <p>",
"     Once lung cancer is diagnosed, the next step is to review its size, to determine its exact location and to find out if it has spread. This process is called staging. Determining the stage of a lung cancer can be complicated because many features of the tumor are used at the same time. The stage of non-small cell cancer is based on:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       The size and location of the tumor",
"      </li>",
"      <li>",
"       Whether the tumor has invaded lymph nodes and tissues inside the chest",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Whether the tumor has spread to places outside the chest (for example lung cancer can spread (metastasize) to places like the lymph nodes or adrenal glands or elsewhere)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Non-small cell lung cancer stages range from I to IV. In general, the lower number (stages I and II) suggest that the tumor is smaller and has not spread far. In comparison, the higher numbers (stage III and IV) suggest that the tumor is larger or has metastasized. &nbsp;",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Stage I &mdash; The tumor is smaller than or equal to 5 cm in maximum diameter and has not spread to any other tissues or lymph nodes (",
"       <a class=\"graphic graphic_figure graphicRef53379 \" href=\"mobipreview.htm?26/31/27120\">",
"        figure 1",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Stage II &mdash;Stage II means that the tumor is either between 3 and 7 cm in size, or it has spread to the lymph nodes, or it has invaded the tissues surrounding the lung, or it has started to invade the large bronchial tubes (",
"       <a class=\"graphic graphic_figure graphicRef60551 \" href=\"mobipreview.htm?22/59/23473\">",
"        figure 2",
"       </a>",
"       ). &nbsp;",
"      </li>",
"      <li>",
"       Stage IIIA &mdash; Stage IIIA disease means that the tumor can be bigger than 7 cm, or has spread to the lymph nodes in the center of the chest (called the mediastinum) or has spread to the rib cage, heart, swallowing tube (called the esophagus) or to the trachea (",
"       <a class=\"graphic graphic_figure graphicRef86985 \" href=\"mobipreview.htm?7/16/7426\">",
"        figure 3",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Stage IIIB &ndash; Stage IIIB disease means that the tumor has spread to lymph nodes on the other side of the mediastinum or to the lymph nodes above or behind the clavicle (collar bone). Stage IIIB also includes large tumors that have spread to the rib cage, heart, swallowing tube (called the esophagus) or to the trachea when there is involvement of the mediastinal lymph nodes (",
"       <a class=\"graphic graphic_figure graphicRef86986 \" href=\"mobipreview.htm?10/24/10627\">",
"        figure 4",
"       </a>",
"       ). &nbsp;",
"      </li>",
"      <li>",
"       Stage IV &mdash; Stage IV means that the cancer has spread outside of the chest or has spread to a critical location or has caused some complication. Possible complications are that the cancer has caused fluid to collect around the lung or heart (called a malignant effusion), or it has spread to the opposite side of the chest, has spread to outside the chest (",
"       <a class=\"graphic graphic_figure graphicRef74377 \" href=\"mobipreview.htm?6/8/6278\">",
"        figure 5",
"       </a>",
"       ). (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/63/17396?source=see_link\">",
"        \"Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In general, lower-stage cancers require less treatment than higher-stage cancers. Stage I to III non-small cell lung cancers are referred to as localized cancers, while stage IV is called advanced cancer.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      STAGE I AND II TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Whenever possible, surgery is recommended as the first treatment in people with stage I or II non-small cell lung cancer. Radiation therapy may be recommended for people who are not good candidates for surgery due to severe lung disease or other underlying medical problems. In some cases, the initial surgery or radiation therapy may be followed by adjuvant (postoperative) chemotherapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgery to remove the cancer is the preferred treatment for stage I and stage II NSCLC. Options for surgery include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Lobectomy, which involves removal of one lobe of the lung.",
"      </li>",
"      <li>",
"       Segmentectomy (the removal of a part of one lobe) may be considered in some patients with a small tumor of 2 cm or smaller.",
"      </li>",
"      <li>",
"       In some people, it is necessary to remove the entire affected lung (called pneumonectomy) because lobectomy cannot completely remove the tumor. Pneumonectomy requires that the remaining lung be relatively healthy.",
"      </li>",
"      <li>",
"       A surgery that removes less than a lobe of the lung is possible for some people who could not tolerate conventional lobectomy. This might happen in a person whose lungs do not work well.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Radiation therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radiation therapy involves the use of X-rays to destroy cancer cells. Radiation therapy may be recommended for people with stage I or II NSCLC in the following situations:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       After surgery, radiation therapy may be recommended for patients with tumor left behind at the margins of the surgical resection or for patients felt to have a high risk for locoregional (nearby) recurrence. It is not a clear standard therapy, and it is relatively contraindicated in patients with lung cancer and no lymph node involvement, with some evidence suggesting that it can have a net harmful effect in such patients.",
"      </li>",
"      <li>",
"       Radiation therapy may be used alone or with chemotherapy, without surgery, in people who are unable to tolerate or who do not want surgery.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Radiation treatments are brief and not painful, similar to having an X-ray. Treatments are usually done five days per week for several weeks.",
"    </p>",
"    <p>",
"     A different technique to give radiation, called stereotactic body radiation therapy (SBRT), involves giving more radiation to a small area over a few daily treatments (five or fewer). Studies of SBRT demonstrate very promising outcomes.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Radiation side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radiation therapy can cause side effects during treatment. Side effects usually resolve after treatment ends. The most common side effects of radiation therapy for lung cancer are:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Difficulty swallowing due to swelling and irritation of the esophagus (the tube between the mouth and stomach); this is called esophagitis.",
"      </li>",
"      <li>",
"       Swelling and irritation of the normal lung surrounding the tumor (called pneumonitis).",
"      </li>",
"      <li>",
"       Fatigue.",
"      </li>",
"      <li>",
"       Skin irritation in the area being treated; this can look like a sunburn on the chest.",
"      </li>",
"      <li>",
"       Hair loss just in the area being treated.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Adjuvant chemotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Postoperative chemotherapy is a treatment given to slow or stop the growth of cancer cells. Even after a cancer has been removed with surgery, cancer cells can remain in the body, increasing the risk of a relapse.",
"    </p>",
"    <p>",
"     Chemotherapy can get rid of these cancer cells and increase the chance of cure, but it is indicated only in patients with a high enough risk of recurrence to justify the side effects of chemotherapy. Chemotherapy in the postoperative setting is called adjuvant therapy, meaning &ldquo;helper&rdquo;.",
"    </p>",
"    <p>",
"     Chemotherapy is not given every day but instead is given in cycles. A cycle of chemotherapy, which is typically 21 or 28 days, refers to the time it takes to give the treatment and then allow the body to recover from the side effects of the medicines. Most treatments involve a combination of two chemotherapy drugs (called regimens). Most of the drugs are given into a vein (intravenous, IV). Most adjuvant treatment regimens for non-small cell lung cancer last about three months. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/63/17396?source=see_link&amp;anchor=H761923659#H761923659\">",
"      \"Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)\", section on 'Chemotherapy'",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Your healthcare provider can describe which chemotherapy drugs will be needed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common side effects of chemotherapy used for NSCLC include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A lowered white blood cell count (which can increase the risk of infection). Chemotherapy is associated with a 1 to 2 percent risk of fatal infections.",
"      </li>",
"      <li>",
"       Fever related to a low white blood cell count",
"      </li>",
"      <li>",
"       Nausea and vomiting",
"      </li>",
"      <li>",
"       Bowel changes, which may include constipation or diarrhea",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Other side effects may occur, and these vary with the exact regimen of therapy being administered. Fortunately, the common side effects of chemotherapy are, with rare exception, only temporary.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      STAGE III TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     There is no one \"best\" treatment for people with stage III NSCLC. Treatment depends upon the size and location of your tumor, lymph node involvement, and whether surgery has been done. The options generally include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Radiation therapy (see",
"       <a class=\"local\" href=\"#H5\">",
"        'Radiation therapy'",
"       </a>",
"       above)",
"      </li>",
"      <li>",
"       Chemotherapy (see",
"       <a class=\"local\" href=\"#H7\">",
"        'Adjuvant chemotherapy'",
"       </a>",
"       above)",
"      </li>",
"      <li>",
"       Surgery (see",
"       <a class=\"local\" href=\"#H4\">",
"        'Surgery'",
"       </a>",
"       above)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In many people with stage III NSCLC, a combination of chemotherapy and radiation therapy are recommended as the cornerstone of treatment, and in some cases, surgery may be pursued after initial chemotherapy or chemotherapy with radiation (this is called chemoradiotherapy). Chemotherapy and radiation therapy may be given together (called concurrent chemoradiotherapy) or one treatment after the other (called sequential chemoradiotherapy). It is appropriate for recommendations for stage III disease to be individualized by a multi-speciality team to a particular patient&rsquo;s needs, based on the extent of the tumor, the pattern of spread, and the patient&rsquo;s underlying health.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      PANCOAST TUMORS",
"     </span>",
"    </p>",
"    <p>",
"     The term Pancoast tumor (also called superior sulcus tumor) refers to a non-small cell lung cancer that is located in the top part of one of the lungs, in a region called the superior sulcus. Pancoast tumors can involve nerves, causing a unique set of symptoms referred to as Pancoast's syndrome.",
"    </p>",
"    <p>",
"     Initially, symptoms may include shoulder or arm pain, weakness of the muscles of the hand, and flushing or excessive sweating on one side of the face. As the tumor progresses, the flushing can disappear, the eyelid may droop, and the involved side may not sweat.",
"    </p>",
"    <p>",
"     Treatment of Pancoast tumors usually consists of a combination of chemotherapy and radiation followed by surgery, as long as there is no evidence of distant spread.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Progress in treating lung cancer requires that better treatments be identified through clinical trials, which are conducted all over the world. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Whenever possible, patients with lung cancer are encouraged to enroll in a clinical trial. Ask for more information about clinical trials, or read about clinical trials at:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"        file://clinicaltrials.gov/",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804446475\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5517849\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/44/3779?source=see_link\">",
"      Patient information: Non-small cell lung cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/34/35363?source=see_link\">",
"      Patient information: Lung cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/13/11475?source=see_link\">",
"      Patient information: Lung cancer screening (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5517857\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/63/17396?source=see_link\">",
"      Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/3/1076?source=see_link\">",
"      Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/8/22659?source=see_link\">",
"      Patient information: Small cell lung cancer treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/61/13273?source=see_link\">",
"      Overview of the initial evaluation, treatment and prognosis of lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/31/14841?source=see_link\">",
"      Diagnosis and staging of non-small cell lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/43/22201?source=see_link\">",
"      Pathology of lung malignancies",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/5/1114?source=see_link\">",
"      Management of stage I and stage II non-small cell lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/36/39498?source=see_link\">",
"      Management of stage III non-small cell lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17833?source=see_link\">",
"      Adjuvant systemic therapy in resectable non-small cell lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/58/14250?source=see_link\">",
"      Pancoast's syndrome and superior (pulmonary) sulcus tumors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/45/9946?source=see_link\">",
"      Bronchioloalveolar carcinoma, including adenocarcinoma in situ",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/lungcancer.html\">",
"      www.nlm.nih.gov/medlineplus/lungcancer.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancernet.nci.nih.gov/\">",
"      www.cancernet.nci.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Global Resource for Advancing Cancer Education (GRACE)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancergrace.org/lung\">",
"      www.cancerGRACE.org/lung",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Lung Cancer Alliance",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.lungcanceralliance.org/\">",
"      www.lungcanceralliance.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/22/41314/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 15, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/22/41314?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41314/abstract/1\">",
"      Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41314/abstract/2\">",
"      Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable). Cochrane Database Syst Rev 2001; :CD002935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41314/abstract/3\">",
"      Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998; 352:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41314/abstract/4\">",
"      Pisters KM, Evans WK, Azzoli CG, et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 2007; 25:5506.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f40_22_41314=[""].join("\n");
var outline_f40_22_41314=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           NON-SMALL CELL LUNG CANCER OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           STAGING NON-SMALL CELL LUNG CANCER",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           STAGE I AND II TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           STAGE III TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           PANCOAST TUMORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/31/27120\" title=\"figure 1\">",
"           Lung ca I PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/59/23473\" title=\"figure 2\">",
"           Lung ca II PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/16/7426\" title=\"figure 3\">",
"           Stage IIIA NSCLC",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/24/10627\" title=\"figure 4\">",
"           Stage IIIB NSCLC",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/8/6278\" title=\"figure 5\">",
"           Lung ca IV PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f40_22_41315="Deep brain stimulation";
var content_f40_22_41315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F83124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F83124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Deep brain stimulation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 560px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_22_41315=[""].join("\n");
var outline_f40_22_41315=null;
var title_f40_22_41316="Zafirlukast: Pediatric drug information";
var content_f40_22_41316=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Zafirlukast: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=see_link\">",
"    see \"Zafirlukast: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/57/37780?source=see_link\">",
"    see \"Zafirlukast: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Accolate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F235422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Accolate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Leukotriene Receptor Antagonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=see_link\">",
"      see \"Zafirlukast: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 5-11 years: 10 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years and Adults: 20 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F235399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 10 mg, 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Accolate&reg;: 10 mg, 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F235384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer at least 1 hour before or 2 hours after a meal",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1062967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store tablets at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light and moisture; dispense in original airtight container",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis and chronic treatment of asthma (FDA approved in children &ge;5 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F235459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Accolate&reg; may be confused with Accupril&reg;, Accutane&reg;, Aclovate&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F235457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, dyspepsia,  nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, myalgia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, angioedema, arthralgia, bleeding, bruising, depression, edema, eosinophilia (systemic), eosinophilic pneumonia, hepatic failure, hepatitis, hyperbilirubinemia, hypersensitivity reactions, insomnia, malaise, pruritus, rash, urticaria, vasculitis with clinical features of Churg-Strauss syndrome (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to zafirlukast or any component; hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1062963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients receiving warfarin and patients with liver disease; dosage reduction in patients with hepatic impairment may be needed; discontinue therapy if liver dysfunction occurs; where no other attributable cause of liver dysfunction is identified, do not resume zafirlukast therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1062962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zafirlukast is not indicated for use in the reversal of bronchospasm in acute asthma attacks, including status asthmaticus. Therapy with zafirlukast can be continued during acute exacerbations of asthma. An increased proportion of zafirlukast patients (&gt;55 years of age) reported infections as compared to placebo-treated patients; these infections were mostly mild or moderate in intensity, predominantly affected the respiratory tract, were dose-proportional to the total milligrams of zafirlukast exposure, and associated with coadministration of inhaled corticosteroids. Rare cases of eosinophilic vasculitis (Churg-Strauss) have been reported in patients receiving zafirlukast (usually, but not always, associated with reduction in concurrent steroid dosage). No causal relationship established.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Hepatic adverse events (including hepatitis, hyperbilirubinemia, and hepatic failure) have been reported. Female patients may be at greater risk. Discontinue",
"     <b>",
"      immediately",
"     </b>",
"     if liver dysfunction is suspected. Periodic testing of liver function may be considered (early detection is generally believed to improve the likelihood of recovery). If hepatic dysfunction is suspected (due to clinical signs/symptoms) liver function tests should be measured immediately. Do not resume or restart if hepatic function tests are consistent with dysfunction.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Postmarketing reports of neuropsychiatric events including agitation, aggression, anxiousness, dream abnormalities, hallucinations, depression, insomnia, irritability, restlessness, suicidal thinking and behavior (including suicide) and tremor have been observed.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F235446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C19 (weak), CYP2C8 (weak), CYP2C9 (moderate), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F235393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erythromycin (Systemic): May decrease the serum concentration of Zafirlukast.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May decrease the serum concentration of Zafirlukast. Zafirlukast may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Zafirlukast may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1062982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food decreases zafirlukast absorption by 40%",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F235395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F235408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have not been observed in animal reproduction studies. Based on available information, zafirlukast may be considered for use in women who had a favorable response prior to becoming pregnant; however, it is not a preferred option in new patients (NAEPP, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1062970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pulmonary function tests (FEV-1, PEF), improvement in asthma symptoms, periodic liver function tests",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1062974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Obtaining plasma concentrations not clinically indicated; plasma zafirlukast serum concentrations exceeding 5 ng/mL at 12-14 hours following oral doses have correlated with activity; mean trough serum levels at doses of 20 mg twice daily were 20 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zafirlukast is a selective and competitive leukotriene-receptor antagonist (LTRA) of cysteinyl leukotrienes C",
"     <sub>",
"      4",
"     </sub>",
"     (LTC",
"     <sub>",
"      4",
"     </sub>",
"     ), D",
"     <sub>",
"      4",
"     </sub>",
"     (LTD",
"     <sub>",
"      4",
"     </sub>",
"     ), and E",
"     <sub>",
"      4",
"     </sub>",
"     (LTE",
"     <sub>",
"      4",
"     </sub>",
"     ). This activity produces inhibition of the effects of these leukotrienes on bronchial smooth muscle resulting in the attenuation of bronchoconstriction and decreased vascular permeability, mucosal edema, and mucus production.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1062978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Asthma symptom improvement:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 2-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1062979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Food decreases bioavailability by ~40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Extensively excreted into breast milk; breast milk to plasma ratio: 0.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      dss",
"     </sub>",
"     : 70 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%, predominantly albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively metabolized by liver via cytochrome P450 isoenzyme CYP2C9 pathway",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination: 10 hours (range: 8-16 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 2-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Fecal (90%) and urine (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 5-6 years: 9.2 L/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 7-11 years: 11.4 L/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 20 L/hour",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1062969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/57/37780?source=see_link\">",
"      see \"Zafirlukast: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take regularly as prescribed, even during symptom-free periods. Do not use to treat acute episodes of asthma. Do not decrease the dose or stop taking any other asthma medications unless instructed by a physician. May cause dry mouth. Nursing women should not take zafirlukast. Notify healthcare provider if experiencing symptoms of abdominal pain, nausea, fatigue, lethargy, itching, jaundice, flu-like symptoms, or anorexia.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Guidelines for the Diagnosis and Management of Asthma. NAEPP Expert Panel Report 3,&rdquo; August 2007, www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics--2002,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2002, 110(5 Suppl):S141-219.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/22/41316/abstract-text/ 12542074 /pubmed\" id=\" 12542074 \" target=\"_blank\">",
"        12542074",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12887 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-641A5F4110-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_22_41316=[""].join("\n");
var outline_f40_22_41316=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235421\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235422\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062971\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062964\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235399\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235384\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062976\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062967\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062975\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235459\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235457\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062980\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062963\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062962\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235446\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235393\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062982\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235395\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235408\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062970\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062974\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062961\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062978\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062979\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062969\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12887\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12887|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=related_link\">",
"      Zafirlukast: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/57/37780?source=related_link\">",
"      Zafirlukast: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_22_41317="Posterior approach to open repair of popliteal aneurysm";
var content_f40_22_41317=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F55149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F55149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Posterior approach to open repair of popliteal aneurysm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 720px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right lower extremity popliteal artery aneursym repair: With the posterior approach, a vein or prosthetic graft is used to reconstruct the popliteal artery. A &lsquo;lazy&rsquo; S-shaped incision is started superior and medial to the popliteal fossa&nbsp;and carried&nbsp;inferiorly and laterally to minimize problems with scar contracture (A). After gaining vascular control, the popliteal artery is&nbsp;opened and the graft sutured to normal artery proximally and distally (B). Upon completion of the repair, the aneurysm sac is closed over the repair, provided enough arterial wall remains (similar to other aneurysm repairs) (C).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_22_41317=[""].join("\n");
var outline_f40_22_41317=null;
var title_f40_22_41318="Acetaminophen hepatotoxicity - medium power";
var content_f40_22_41318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acetaminophen hepatotoxicity (medium power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is a dropout of many hepatocytes in the pericentral area and replacement by red blood cells. There is no inflammation or scarring.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_22_41318=[""].join("\n");
var outline_f40_22_41318=null;
var title_f40_22_41319="Measurement of urinary excretion of endogenous and exogenous glucocorticoids";
var content_f40_22_41319=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Measurement of urinary excretion of endogenous and exogenous glucocorticoids",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/22/41319/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/22/41319/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/22/41319/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/22/41319/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/22/41319/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/22/41319/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/22/41319/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H518434\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of urinary excretion of corticosteroid (any steroid hormone produced by the adrenal cortex) metabolites has been used to evaluate adrenal function for many years. However, measurement of urinary cortisol excretion is more sensitive for the diagnosis of hypercortisolism and has largely supplanted the older assays. Evaluating daily urinary cortisol (and corticosteroid) excretion has the advantage of providing an integrated index of steroid production over a period of 24 hours, whereas measurements of serum cortisol only provide information about an instant in time. This is important because corticotropin (ACTH) and cortisol are secreted in discrete pulses, resulting in plasma concentrations that rise and fall episodically. This is true not only for normal subjects but also for some patients with Cushing's disease and a few patients with Cushing's syndrome caused by adrenal tumors or ectopic ACTH secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The measurement of urinary excretion of endogenous and exogenous glucocorticoids will be reviewed here. Other methods of cortisol measurement are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/132?source=see_link\">",
"     \"Measurement of cortisol in serum and saliva\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16435?source=see_link\">",
"     \"Basic principles in the laboratory evaluation of adrenocortical function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1622638\">",
"    <span class=\"h1\">",
"     URINE COLLECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The validity of the results is critically dependent upon normal renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/5\">",
"     5",
"    </a>",
"    ]. Individuals with moderate (creatinine clearance less than 60",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    and severe renal impairment (creatinine clearance less than 20",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    have progressively less cortisol excretion.",
"   </p>",
"   <p>",
"    Additionally, over- or under-collection of the 24-hour specimen can bias the results. Because of this, measurement of cortisol excretion must include concurrent measurement of creatinine excretion. The completeness of the collection (and the reproducibility of a series of collections) can be estimated from knowledge of the normal rate of creatinine excretion (which is equal to creatinine production in the steady state). In adults under the age of 50, daily creatinine excretion should be 20 to 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (177 to 221",
"    <span class=\"nowrap\">",
"     mmol/kg)",
"    </span>",
"    lean body weight in men and 15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (133 to 177",
"    <span class=\"nowrap\">",
"     mmol/kg)",
"    </span>",
"    lean body weight in women.",
"   </p>",
"   <p>",
"    From the ages of 50 to 90, there is a progressive 50 percent decline in creatinine excretion (to about 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in men), due primarily to a fall in muscle mass. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35190?source=see_link\">",
"     \"Calculation of the creatinine clearance\"",
"    </a>",
"    .) However, the excretion of cortisol and its metabolites varies diurnally whereas creatinine excretion does not. Thus, inadequate urine collections",
"    <strong>",
"     cannot",
"    </strong>",
"    be corrected on the basis of the creatinine value. Furthermore, creatinine excretion is not affected by fluid intake, while cortisol excretion increases with increased fluid intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/6\">",
"     6",
"    </a>",
"    ]. The importance of adequate collection should be stressed to the patient. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/41/21151?source=see_link\">",
"     \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     URINARY CORTISOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 24-hour urine free cortisol (UFC) is one of the first-line diagnostic tests for Cushing&rsquo;s syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The development of UFC assays in the 1970s represented a major advance over measuring urinary 17-hydroxycorticosteroids (17-OHCS), which measures both cortisol and its urinary metabolites. Serum cortisol measures both cortisol bound to CBG (cortisol binding globulin) and free hormone, while urinary free cortisol measures only non-CBG bound cortisol (which is filtered by the kidney unchanged).",
"    <em>",
"    </em>",
"    Therefore, UFC is unaffected by medications and medical conditions that affect CBG, such as oral estrogen use, which increases CBG and serum cortisol concentrations, while UFC is unchanged.",
"   </p>",
"   <p>",
"    The use of the 24&ndash;hour urinary free cortisol test in the diagnostic evaluation of Cushing&rsquo;s syndrome is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21913?source=see_link&amp;anchor=H7#H7\">",
"     \"Establishing the diagnosis of Cushing's syndrome\", section on 'Daily urinary cortisol excretion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177133547\">",
"    <span class=\"h2\">",
"     Types of assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest high performance liquid chromatography (HPLC) or gas",
"    <span class=\"nowrap\">",
"     chromatography/mass",
"    </span>",
"    spectrometry, when available, to measure 24-hour urinary cortisol excretion. Normal ranges vary substantially, depending on the method used, so it is essential to interpret test results in the context of the appropriate normal range. On-line catalogs and laboratory result forms provide the reference range and (sometimes) the test methodology. For immunoassays, it may be necessary to contact the laboratory or review the assay kit information to determine whether there is cross-reactivity with non-cortisol substances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192363607\">",
"    <span class=\"h3\">",
"     Antibody-based",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some immunoassays are relatively nonspecific because of cross-reaction with other steroids and steroid metabolites (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    , the biologically active metabolite of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , 6-beta-hydroxycortisol, an inactive metabolite of cortisol and A-ring dihydro- and tetrahydro metabolites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    Urinary cortisol nonspecific immunoassays have normal ranges of 20 to 90 to 100",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    (55 to 250 to 285",
"    <span class=\"nowrap\">",
"     nmol/day),",
"    </span>",
"    considerably higher than the normal ranges for specific immunoassays and HPLC (10 to 55",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    [27 to 150",
"    <span class=\"nowrap\">",
"     nmol/day]).",
"    </span>",
"    Results obtained with nonspecific immunoassays should be interpreted with caution, recognizing the possibility that non-cortisol substances are being measured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/11-15\">",
"     11-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An example of the variability in immunoassay results comes from a study of 13 normal subjects given a single inhaled dose of one of three glucocorticoids (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    propionate,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    ) or placebo. Twenty-four hour urinary cortisol excretion, as measured by four widely used immunoassays (Abbott TDX, Bayer ACS 180, DPC Immulite, ICN Corti-Cote), ranged from a 100 percent increase to 62 percent suppression of basal urinary cortisol excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7114?source=see_link&amp;anchor=H13#H13\">",
"     \"Major side effects of inhaled glucocorticoids\", section on 'Adrenal suppression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Structurally-based",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary cortisol can also be assayed by structurally-based assays that do not use antibodies, such as high performance liquid chromatography (HPLC) or gas",
"    <span class=\"nowrap\">",
"     chromatography/mass",
"    </span>",
"    spectrometry. These methods are more specific than immunoassays, have a lower normal range (10 to 55",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    [27 to 150",
"    <span class=\"nowrap\">",
"     nmol/day]),",
"    </span>",
"    and correlate well with each other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, immunoassay values were 1.5 to 2 times higher than HPLC values; the effect became more marked at higher concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A limitation of HPLC is that it can give falsely high values if the patient is taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , either by interference from an unknown metabolite of the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/18\">",
"     18",
"    </a>",
"    ] or by coelution of carbamazepine and cortisol from the HPLC column [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/17\">",
"     17",
"    </a>",
"    ]. The same interference phenomenon has been described in two patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition to HPLC, urinary cortisol can be assayed by combined gas",
"    <span class=\"nowrap\">",
"     chromatography/mass",
"    </span>",
"    spectrometry, in which cortisol metabolites or other interfering substances are also measured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/20\">",
"     20",
"    </a>",
"    ]. This method eliminates drug interference and has the advantage of high throughput and short run time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/21\">",
"     21",
"    </a>",
"    ]. Measurement of exogenous glucocorticoids is a useful diagnostic test when factitious use of glucocorticoids is suspected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177133736\">",
"    <span class=\"h2\">",
"     Normal values",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, urinary cortisol excretion in normal subjects ranges from about 10 to 55",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    (27 to 150",
"    <span class=\"nowrap\">",
"     nmol/day),",
"    </span>",
"    measured either by specific immunoassays or HPLC. Normal subjects who have very high fluid intake (eg, 5 L per day) may have an increase in urinary cortisol excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary cortisol excretion results from glomerular filtration of serum free cortisol (unbound minus some that is reabsorbed) and is therefore an index of the integrated 24-hour serum free cortisol concentration. Although urinary cortisol represents less than 1 percent of the cortisol secreted each day, it provides a valid index of cortisol secretion. Because it reflects 24-hour serum cortisol concentrations, one should be suspicious of a high urinary cortisol value in a patient with a normal evening serum cortisol concentration and of a low urinary cortisol value in a patient with a normal morning serum cortisol concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177133931\">",
"    <span class=\"h3\">",
"     Hypercortisolism/adrenal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The binding capacity of corticosteroid-binding globulin (CBG) is nearly saturated at normal rates of cortisol secretion. Serum total cortisol concentrations exceed the binding capacity of CBG at about 25",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (690",
"    <span class=\"nowrap\">",
"     nmol/L);",
"    </span>",
"    above this concentration serum free cortisol concentrations increase rapidly, leading to a rapid increase in urinary cortisol excretion. Urinary 17-hydroxycorticosteroid (17-OHCS) excretion, on the other hand, continues to rise at a nearly constant rate. Thus, increased urinary cortisol excretion is a more sensitive indicator of endogenous hypercortisolism.",
"   </p>",
"   <p>",
"    Patients with subclinical Cushing&rsquo;s syndrome may have normal 24-hour urine free cortisol (UFC). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21913?source=see_link&amp;anchor=H4#H4\">",
"     \"Establishing the diagnosis of Cushing's syndrome\", section on 'Adrenal incidentalomas and subclinical cushing's'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urinary cortisol excretion is low in patients with primary and secondary adrenal insufficiency and in those with congenital adrenal hyperplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177133945\">",
"    <span class=\"h3\">",
"     Adequacy of glucocorticoid replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary cortisol assays are not a good indicator of the adequacy of cortisol or cortisone replacement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/24\">",
"     24",
"    </a>",
"    ]. The same daily replacement dose of cortisol (eg, 30 mg) results in a greater increase in 24-hour urinary cortisol excretion when given as a single dose than when given in multiple divided doses.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      is absorbed within 20 to 30 minutes. As a result, serum cortisol concentrations temporarily exceed the binding capacity of CBG and serum free cortisol concentrations are temporarily high. This free cortisol is excreted in the urine until the serum total cortisol concentration, falling rapidly, reaches the binding capacity of CBG.",
"     </li>",
"     <li>",
"      When multiple doses are used to give the same total amount of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      , serum cortisol concentrations may never exceed the binding capacity of CBG. As a result, the 24-hour urinary cortisol excretion is lower and more representative of the integrated serum free cortisol concentrations to which the patient's cells have been exposed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177133960\">",
"    <span class=\"h3\">",
"     ACTH/CRH stimulation tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary cortisol excretion is also disproportionately high after major episodes of endogenous cortisol secretion, as may occur during ACTH and corticotropin-releasing hormone (CRH) stimulation tests. Because of this, measurement of urinary cortisol excretion for the diagnosis of Cushing&rsquo;s syndrome should be avoided on days when these compounds are administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H522961\">",
"    <span class=\"h1\">",
"     OTHER CORTISOL PRECURSORS AND METABOLITES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other cortisol precursors and metabolites can be measured by HPLC",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mass spectrometry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      THS, the tetrahydro metabolite of 11-deoxycortisol, can be measured by gas",
"      <span class=\"nowrap\">",
"       chromatography/mass",
"      </span>",
"      spectrometry. Its excretion is increased in patients with P450c11 deficiency, some patients with adrenal carcinomas, and after",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/12/15556?source=see_link\">",
"       metyrapone",
"      </a>",
"      administration. It may be useful to confirm the diagnosis of congenital adrenal hyperplasia in a newborn [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pregnanetriol can be measured by gas chromatography with or without mass spectrometry [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/27\">",
"       27",
"      </a>",
"      ]. Its excretion is normally less than 2",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (6.3",
"      <span class=\"nowrap\">",
"       mmol/day)",
"      </span>",
"      in adults and less than 0.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (1.6",
"      <span class=\"nowrap\">",
"       mmol/day)",
"      </span>",
"      in children. Its excretion is elevated in the P450c11 and P450c21 deficiency forms of congenital adrenal hyperplasia, and may be used to confirm those diagnoses in a newborn. While this provides an integrated measurement of steroid production, its use in monitoring treatment of CAH is not established [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/28\">",
"       28",
"      </a>",
"      ]. Although urine measurement of metabolites is not the first-line approach recommended in a clinical practice guideline, its potential utility is acknowledged [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adrenal carcinomas are relatively inefficient producers of steroids and can secrete excessive amounts of several adrenal steroid precursors if the expression of some steroidogenic enzymes is decreased. Urinary metabolites of several steroids and precursors of androgens (pregnenediol, pregnenetriol, androsterone, etiocholanolone) or glucocorticoids (17-hydroxyproesterone, tetrahydro-11-deoxycortisol, 6-hydroxy-cortisol, tetrahydrocortisol, and &alpha;-cortol) are increased in patients with adrenal cancer. This pattern distinguishes them from cortisol secreting adenomas, which produce cortisol, but little androgens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cortisone can be measured in urine by HPLC and tandem mass spectrometry [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/25,31,32\">",
"       25,31,32",
"      </a>",
"      ]. Its daily excretion is increased in patients with Cushing's syndrome; results of this test may be combined with urinary cortisol to aid in the diagnosis of factitious Cushing's syndrome produced by ingestion of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      . In such patients, urinary cortisol excretion is high, but urinary cortisone excretion is low. It is decreased in patients with the syndrome of apparent mineralocorticoid excess in whom the ratio of urinary cortisol:cortisone may aid in the diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1622789\">",
"    <span class=\"h1\">",
"     EXOGENOUS STEROIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urinary excretion of",
"    <strong>",
"     exogenous",
"    </strong>",
"    synthetic steroids can be measured using liquid",
"    <span class=\"nowrap\">",
"     chromatography/tandem",
"    </span>",
"    mass spectrometry or gas",
"    <span class=\"nowrap\">",
"     chromatography/mass",
"    </span>",
"    spectrometry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. This approach can be very helpful in patients suspected of having adrenal suppression or glucocorticoid excess on the basis of iatrogenic or factitious steroid use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177133119\">",
"    <span class=\"h1\">",
"     OUT-MODED ASSAYS FOR MEASUREMENT OF URINARY STEROIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the development of immunoassays and structural assays, biochemical assays were used to measure urinary steroids. Because of the availability of more specific assays, these biochemical assays are rarely used today. Information is presented about them to assist in understanding earlier literature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     17-hydroxycorticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steroids with the 17,21-dihydroxy-20-ketosteroid configuration can be measured colorimetrically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/36\">",
"     36",
"    </a>",
"    ]. In normal urine, most 17-hydroxycorticosteroids (17-OHCS) are tetrahydro metabolites of cortisol and cortisone (THF and THE), but THS, the tetrahydro metabolite of 11-deoxycortisol, also is present. As a result, 17-OHCS excretion roughly parallels cortisol excretion. However, drugs that induce CYP3A4 enhance metabolism of cortisol to derivatives that are not measured as 17-OHCS.",
"   </p>",
"   <p>",
"    Urinary excretion of 17-OHCS in normal adults ranges from 2 to 6.5 mg (5.5 to 18",
"    <span class=\"nowrap\">",
"     mmol)/gram",
"    </span>",
"    of creatinine, independent of body weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/37\">",
"     37",
"    </a>",
"    ]. Urinary 17-OHCS excretion is increased in patients with all forms of Cushing's syndrome and decreased in patients with primary and secondary adrenal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33800?source=see_link\">",
"     \"Clinical manifestations of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In conditions where steroidogenic enzyme deficiencies are present, steroid precursors can be measured as 17-OHCS; an example is ACTH-independent macronodular adrenal hyperplasia in which steroid hormone synthesis is relatively inefficient, as a consequence of several decreased steroidogenic enzymatic activity. In this setting, urinary 17-OHCS (which measure precursor steroids) are more often elevated than urinary free cortisol levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/45/730?source=see_link&amp;anchor=H15#H15\">",
"     \"Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177134061\">",
"    <span class=\"h3\">",
"     17- ketogenic steroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 17-ketogenic steroid (17-KGS) assay measures 17-OHCS and additional cortisol metabolites as well as 21-deoxysteroids, such as pregnanetriol, which are not cortisol metabolites. Changes in 17-KGS excretion mimic those of 17-OHCS, except in congenital adrenal hyperplasia resulting from P450c11 and P450c21 deficiency, in which elevated 17-KGS values reflect increased excretion of pregnanetriol and other 21-deoxycorticosteroids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177133254\">",
"    <span class=\"h2\">",
"     17-ketosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary 17-ketosteroid (17-KS) excretion is an index of adrenal androgen synthesis; testosterone and dihydrotestosterone, the only potent androgens, constitute less than 1 percent of total urinary 17-KS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/39\">",
"     39",
"    </a>",
"    ]. Because of this, 17-KS are increased in patients with congenital CYP11B1 and CYP21A2 deficiency and adrenal carcinoma who have high serum DHEA sulfate concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/40\">",
"     40",
"    </a>",
"    ] and lower in those with an adrenal adenoma that secretes excess cortisol and causes Cushing's syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41319/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15130992\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of 24-hour urinary cortisol excretion is a first-line test for the diagnosis of hypercortisolism and has largely replaced older assays such as urinary 17-hydroxycorticosteroids. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Urinary cortisol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urinary free cortisol (UFC) measures only non-corticosteroid binding globulin (CBG) bound cortisol (which is filtered by the kidney unchanged).",
"      <em>",
"      </em>",
"      Therefore, UFC is unaffected by medications and medical conditions that affect CBG, such as oral estrogen use, which increases CBG and serum cortisol concentrations, while UFC is unchanged. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Urinary cortisol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are a number of assay methods for measuring urinary cortisol excretion. (See",
"      <a class=\"local\" href=\"#H177133547\">",
"       'Types of assays'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important clinical use of 24-hour UFC is for the diagnosis of hypercortisolism. It is not useful for determining adequacy of glucocorticoid replacement regimens. (See",
"      <a class=\"local\" href=\"#H177133931\">",
"       'Hypercortisolism/adrenal insufficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Twenty-four hour urinary measurements of 17-hydroxycorticosteroids and 17-ketosteroids were used in the past to assess cortisol and adrenal androgens, respectively. However, the clinical utility of both is limited. (See",
"      <a class=\"local\" href=\"#H6\">",
"       '17-hydroxycorticosteroids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H177133254\">",
"       '17-ketosteroids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/1\">",
"      Sederberg-Olsen P, Binder C, Kehlet H, et al. Episodic variation in plasma corticosteroids in subjects with Cushing's syndrome of differing etiology. J Clin Endocrinol Metab 1973; 36:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/2\">",
"      Refetoff S, Van Cauter E, Fang VS, et al. The effect of dexamethasone on the 24-hour profiles of adrenocorticotropin and cortisol in Cushing's syndrome. J Clin Endocrinol Metab 1985; 60:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/3\">",
"      Stewart PM, Penn R, Gibson R, et al. Hypothalamic abnormalities in patients with pituitary-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 1992; 36:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/4\">",
"      van den Berg G, Fr&ouml;lich M, Veldhuis JD, Roelfsema F. Combined amplification of the pulsatile and basal modes of adrenocorticotropin and cortisol secretion in patients with Cushing's disease: evidence for decreased responsiveness of the adrenal glands. J Clin Endocrinol Metab 1995; 80:3750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/5\">",
"      Chan KC, Lit LC, Law EL, et al. Diminished urinary free cortisol excretion in patients with moderate and severe renal impairment. Clin Chem 2004; 50:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/6\">",
"      Mericq MV, Cutler GB Jr. High fluid intake increases urine free cortisol excretion in normal subjects. J Clin Endocrinol Metab 1998; 83:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/7\">",
"      Elamin MB, Murad MH, Mullan R, et al. Accuracy of diagnostic tests for Cushing's syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab 2008; 93:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/8\">",
"      Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/9\">",
"      Pecori Giraldi F, Ambrogio AG, De Martin M, et al. Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab 2007; 92:4123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/10\">",
"      Lee C, Goeger DE. Interference of 6 beta-hydroxycortisol in the quantitation of urinary free cortisol by immunoassay and its elimination by solid phase extraction. Clin Biochem 1998; 31:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/11\">",
"      Wood L, Ducroq DH, Fraser HL, et al. Measurement of urinary free cortisol by tandem mass spectrometry and comparison with results obtained by gas chromatography-mass spectrometry and two commercial immunoassays. Ann Clin Biochem 2008; 45:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/12\">",
"      Pearson Murphy BE. Lack of specificity of urinary free cortisol determinations: why does it continue? J Clin Endocrinol Metab 1999; 84:2258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/13\">",
"      McCann SJ, Gillingwater S, Keevil BG. Measurement of urinary free cortisol using liquid chromatography-tandem mass spectrometry: comparison with the urine adapted ACS:180 serum cortisol chemiluminescent immunoassay and development of a new reference range. Ann Clin Biochem 2005; 42:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/14\">",
"      Fong BM, Tam S, Leung KS. Improved liquid chromatography-tandem mass spectrometry method in clinical utility for the diagnosis of Cushing's syndrome. Anal Bioanal Chem 2010; 396:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/15\">",
"      Persichilli S, Gervasoni J, Iavarone F, Zuppi C. A simple liquid chromatography-tandem mass spectrometry method for urinary free cortisol analysis: suitable for routine purpose. Clin Chem Lab Med 2010; 48:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/16\">",
"      Fink RS, Pierre LN, Daley-Yates PT, et al. Hypothalamic-pituitary-adrenal axis function after inhaled corticosteroids: unreliability of urinary free cortisol estimation. J Clin Endocrinol Metab 2002; 87:4541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/17\">",
"      Turpeinen U, Markkanen H, V&auml;lim&auml;ki M, Stenman UH. Determination of urinary free cortisol by HPLC. Clin Chem 1997; 43:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/18\">",
"      Findling, JW, Pinkstaff, SM, Shaker, JL, Raff, H, Nelson, JC. Pseudohypercortisoluria: spurious elevation of urinary cortisol due to carbamazepine. The Endocrinologist 1998; 8:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/19\">",
"      Meikle AW, Findling J, Kushnir MM, et al. Pseudo-Cushing syndrome caused by fenofibrate interference with urinary cortisol assayed by high-performance liquid chromatography. J Clin Endocrinol Metab 2003; 88:3521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/20\">",
"      Palermo M, Marazzi MG, Hughes BA, et al. Human Delta4-3-oxosteroid 5beta-reductase (AKR1D1) deficiency and steroid metabolism. Steroids 2008; 73:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/21\">",
"      Taylor RL, Machacek D, Singh RJ. Validation of a high-throughput liquid chromatography-tandem mass spectrometry method for urinary cortisol and cortisone. Clin Chem 2002; 48:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/22\">",
"      Cizza G, Nieman LK, Doppman JL, et al. Factitious Cushing syndrome. J Clin Endocrinol Metab 1996; 81:3573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/23\">",
"      Villanueva RB, Brett E, Gabrilove JL. A cluster of cases of factitious Cushing's syndrome. Endocr Pract 2000; 6:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/24\">",
"      Burch WM. Urine free-cortisol determination. A useful tool in the management of chronic hypoadrenal states. JAMA 1982; 247:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/25\">",
"      Sch&ouml;nesh&ouml;fer M, Weber B, Oelkers W, et al. Urinary excretion rates of 15 free steroids: potential utility in differential diagnosis of Cushing's syndrome. Clin Chem 1986; 32:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/26\">",
"      Caulfield MP, Lynn T, Gottschalk ME, et al. The diagnosis of congenital adrenal hyperplasia in the newborn by gas chromatography/mass spectrometry analysis of random urine specimens. J Clin Endocrinol Metab 2002; 87:3682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/27\">",
"      Weykamp CW, Penders TJ, Schmidt NA, et al. Steroid profile for urine: reference values. Clin Chem 1989; 35:2281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/28\">",
"      Dauber A, Kellogg M, Majzoub JA. Monitoring of therapy in congenital adrenal hyperplasia. Clin Chem 2010; 56:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/29\">",
"      Speiser PW, Azziz R, Baskin LS, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95:4133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/30\">",
"      Arlt W, Biehl M, Taylor AE, et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab 2011; 96:3775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/31\">",
"      Lin CL, Wu TJ, Machacek DA, et al. Urinary free cortisol and cortisone determined by high performance liquid chromatography in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1997; 82:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/32\">",
"      Taylor RL, Machacek D, Singh RJ. Validation of a high-throughput liquid chromatography-tandem mass spectrometry method for urinary cortisol and cortisone. Clin Chem 2002; 48:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/33\">",
"      Palermo M, Delitala G, Mantero F, et al. Congenital deficiency of 11beta-hydroxysteroid dehydrogenase (apparent mineralocorticoid excess syndrome): diagnostic value of urinary free cortisol and cortisone. J Endocrinol Invest 2001; 24:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/34\">",
"      Pujos E, Flament-Waton MM, Paisse O, Grenier-Loustalot MF. Comparison of the analysis of corticosteroids using different techniques. Anal Bioanal Chem 2005; 381:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/35\">",
"      Taylor RL, Grebe SK, Singh RJ. Quantitative, highly sensitive liquid chromatography-tandem mass spectrometry method for detection of synthetic corticosteroids. Clin Chem 2004; 50:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/36\">",
"      PORTER CC, SILBER RH. A quantitative color reaction for cortisone and related 17,21-dihydroxy-20-ketosteroids. J Biol Chem 1950; 185:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/37\">",
"      Streeten DH, Stevenson CT, Dalakos TG, et al. The diagnosis of hypercortisolism. Biochemical criteria differentiating patients from lean and obese normal subjects and from females on oral contraceptives. J Clin Endocrinol Metab 1969; 29:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/38\">",
"      Hsiao HP, Kirschner LS, Bourdeau I, et al. Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors. J Clin Endocrinol Metab 2009; 94:2930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/39\">",
"      Maroulis GB, Manlimos FS, Abraham GE. Comparison between urinary 17-ketosteroids and serum androgens in hirsute patients. Obstet Gynecol 1977; 49:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/40\">",
"      Yamaji T, Ishibashi M, Sekihara H, et al. Serum dehydroepiandrosterone sulfate in Cushing's syndrome. J Clin Endocrinol Metab 1984; 59:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41319/abstract/41\">",
"      Bertagna C, Orth DN. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med 1981; 71:855.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 170 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-CCB85E928E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_22_41319=[""].join("\n");
var outline_f40_22_41319=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15130992\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H518434\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1622638\">",
"      URINE COLLECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      URINARY CORTISOL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H177133547\">",
"      Types of assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H192363607\">",
"      - Antibody-based",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Structurally-based",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H177133736\">",
"      Normal values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Interpretation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H177133931\">",
"      - Hypercortisolism/adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H177133945\">",
"      - Adequacy of glucocorticoid replacement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H177133960\">",
"      - ACTH/CRH stimulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H522961\">",
"      OTHER CORTISOL PRECURSORS AND METABOLITES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1622789\">",
"      EXOGENOUS STEROIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H177133119\">",
"      OUT-MODED ASSAYS FOR MEASUREMENT OF URINARY STEROIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      17-hydroxycorticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H177134061\">",
"      - 17- ketogenic steroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H177133254\">",
"      17-ketosteroids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15130992\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16435?source=related_link\">",
"      Basic principles in the laboratory evaluation of adrenocortical function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35190?source=related_link\">",
"      Calculation of the creatinine clearance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33800?source=related_link\">",
"      Clinical manifestations of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/45/730?source=related_link\">",
"      Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21913?source=related_link\">",
"      Establishing the diagnosis of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/132?source=related_link\">",
"      Measurement of cortisol in serum and saliva",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/41/21151?source=related_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_22_41320="Fluvoxamine: Pediatric drug information";
var content_f40_22_41320=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluvoxamine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"    see \"Fluvoxamine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/13/6358?source=see_link\">",
"    see \"Fluvoxamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6195103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Luvox&reg; CR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F173600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alti-Fluvoxamine;",
"     </li>",
"     <li>",
"      Apo-Fluvoxamine&reg;;",
"     </li>",
"     <li>",
"      Luvox&reg;;",
"     </li>",
"     <li>",
"      Novo-Fluvoxamine;",
"     </li>",
"     <li>",
"      Nu-Fluvoxamine;",
"     </li>",
"     <li>",
"      PMS-Fluvoxamine;",
"     </li>",
"     <li>",
"      Rhoxal-fluvoxamine;",
"     </li>",
"     <li>",
"      Riva-Fluvox;",
"     </li>",
"     <li>",
"      Sandoz-Fluvoxamine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1014951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidepressant, Selective Serotonin Reuptake Inhibitor (SSRI)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1014987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"      see \"Fluvoxamine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Obsessive compulsive disorder:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 8-17 years: Immediate release: Initial: 25 mg once daily at bedtime; adjust in 25 mg increments at 7- to 14-day intervals, as tolerated, to maximum therapeutic benefit; usual dosage range: 50-200 mg/day; daily doses &gt;50 mg should be divided into 2 doses; administer larger portion at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maximum: Children: 8-11 years: 200 mg/day; Adolescents: 300 mg/day; lower doses may be effective in female versus male patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Slower titration of dose every 2-4 weeks may minimize the risk of behavioral activation; behavioral activation associated with SSRI use increases the risk of suicidal behavior. Higher mg/kg doses are needed in children compared to adolescents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release: Initial: 50 mg once daily at bedtime; adjust in 50 mg increments at 4- to 7-day intervals; usual dosage range: 100-300 mg/day; daily doses &gt;100 mg should be divided into 2 doses; administer larger portion at bedtime; maximum dose: 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release: Initial: 100 mg once daily at bedtime; may be increased in 50 mg increments at intervals of at least 1 week; usual dosage range: 100-300 mg/day; maximum dose: 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Decrease initial dose and dose titration; titrate slowly",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F173577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as maleate: 100 mg, 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Luvox&reg; CR: 100 mg, 150 mg [gluten free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as maleate: 25 mg, 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F173561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Luvox&reg; CR capsule:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088625.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088625.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Fluvoxamine tablet:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM249169.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM249169.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7803083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals. Do not chew or crush extended-release capsule; swallow whole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1014974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect from high humidity and store at controlled room temperature of 25&deg;C (77&deg;F). Dispense in tight containers. Avoid exposing extended-release capsules to temperatures &gt;30&deg;C (86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1014952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: Treatment of obsessive-compulsive disorder (OCD) (FDA approved in ages &ge;8 years  and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended-release capsules:  Treatment of obsessive-compulsive disorder (OCD) (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F173650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       FluvoxaMINE may be confused with flavoxATE, FLUoxetine, fluPHENAZine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Luvox may be confused with Lasix&reg;, Levoxyl&reg;, Lovenox&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F173647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular:  Chest pain, edema, hyper-/hypotension, palpitation, syncope, tachycardia, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams, abnormal thinking, agitation, amnesia, anxiety, apathy, chills, CNS stimulation, depression, dizziness, headache, insomnia, malaise, manic reaction, nervousness, neurosis, pain, psychotic reaction, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, bruising",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Anorgasmia, libido decreased, menorrhagia, sexual function abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dyspepsia, dysphagia, flatulence, gingivitis, nausea, taste perversion, toothache and dental caries, vomiting, weight gain/loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Ejaculation abnormal, impotence, polyuria, urinary tract infection, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Liver function tests abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hyper-/hypokinesia, hypertonia, myalgia, myoclonus, paresthesia, tremor, twitching, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Amblyopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough increased, dyspnea, epistaxis, laryngitis, pharyngitis, sinusitis, upper respiratory infection, yawn",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, flu-like syndrome, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute renal failure, agranulocytosis, akinesia, allergic reaction, anaphylactic reaction, anemia, angina, angioedema, anuria, aplastic anemia, apnea, asthma, ataxia, AV block, bradycardia, bullous eruption, cardiomyopathy, cardiorespiratory arrest, cerebrovascular accident, cholecystitis, cholelithiasis, colitis, conduction delay, coronary artery disease, diplopia, dyskinesia, dystonia, extrapyramidal syndrome, embolus, GI bleeding, goiter, hallucinations, heart failure, hematemesis, hematuria, Henoch-Sch&ouml;nlein purpura, hepatitis, hemoptysis, homicidal ideation, hypercholesterolemia, hyper-/hypoglycemia, hypokalemia, hyponatremia, hypothyroidism, ileus, interstitial lung disease, intestinal obstruction, jaundice, leukopenia, leukocytosis, loss of consciousness, lymphadenopathy, MI, myasthenia, myopathy, neuralgia, neuroleptic malignant syndrome, neuropathy, pancreatitis, paralysis, pericarditis, porphyria, purpura, QT prolongation, retinal detachment, rhabdomyolysis, serotonin syndrome, ST segment changes, seizure, Stevens-Johnson syndrome, suicidal tendencies, supraventricular extrasystoles, tardive dyskinesia, thrombocytopenia, toxic epidermal necrolysis, vasculitis, ventricular arrhythmia, ventricular tachycardia (including torsade de pointes), white blood cells decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1014958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluvoxamine or any component; concurrent use with alosetron, pimozide, ramelteon, thioridazine, or tizanidine; use of MAO inhibitors within 14 days (potentially fatal reactions may occur)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F4007574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fluvoxamine may cause abnormal bleeding (eg, ecchymosis, purpura, upper GI bleeding); use with caution in patients with impaired platelet aggregation and with concurrent use of aspirin, NSAIDs, or other drugs that affect coagulation. May impair cognitive or motor performance. SSRI-associated vomiting is two- to threefold more prevalent in children compared to adolescents and is more prevalent in adolescents compared to adults (Safer, 2006). Use with caution in patients with seizure disorders (monitor closely; avoid use in patients with unstable epilepsy), concomitant illnesses that may affect hepatic metabolism or hemodynamic responses (eg, unstable cardiac disease, recent MI), and in suicidal patients; use with caution and decrease dose in patients with hepatic dysfunction; use with caution in patients with severe renal impairment. Use with caution in patients receiving diuretics or those who are volume depleted (may cause hyponatremia or SIADH). No clinical studies have assessed the combined use of fluvoxamine and electroconvulsive therapy; however, use with caution in patients receiving electroconvulsive therapy; may increase the risks associated with electroconvulsive therapy, consider discontinuing, when possible, prior to electroconvulsive therapy treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution during third trimester of pregnancy [newborns may experience adverse effects or withdrawal symptoms (consider risk and benefits); exposure to SSRIs late in pregnancy may also be associated with an increased risk for persistent pulmonary hypertension of the newborn (Chambers, 2006)].",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1014959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Clinical worsening of depression or suicidal ideation and behavior may occur in children and adults with major depressive disorder",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . In clinical trials, antidepressants increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (18-24 years of age) with major depressive disorder and other psychiatric disorders. This risk must be considered before prescribing antidepressants for any clinical use. Short-term studies did",
"     <b>",
"      not",
"     </b>",
"     show an increased risk of suicidality with antidepressant use in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Patients of all ages who are treated with antidepressants for any indication require appropriate monitoring and close observation for clinical worsening of depression, suicidality, and unusual changes in behavior, especially during the first few months after antidepressant initiation or when the dose is adjusted. Family members and caregivers should be instructed to closely observe the patient (ie, daily) and communicate condition with healthcare provider. Patients should also be monitored for associated behaviors (eg, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania) which may increase the risk for worsening depression or suicidality. Worsening depression or emergence of suicidality (or associated behaviors listed above) that is abrupt in onset, severe, or not part of the presenting symptoms, may require discontinuation or modification of drug therapy. SSRI-associated behavioral activation (ie, restlessness, hyperkinesis, hyperactivity, agitation) is two- to threefold more prevalent in children compared to adolescents; it is more prevalent in adolescents compared to adults. Somnolence (including sedation and drowsiness) is more common in adults compared to children and adolescents (Safer, 2006).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Avoid abrupt discontinuation; withdrawal syndrome with discontinuation symptoms (including agitation, dysphoria, anxiety, confusion, dizziness, hypomania, nightmares, irritability, sensory disturbances, headache, lethargy, emotional lability, insomnia, tinnitus, and seizures) may occur if therapy is abruptly discontinued or dose reduced; taper the dose to minimize risks of discontinuation symptoms. If intolerable symptoms occur following a decrease in dosage or upon discontinuation of therapy, consider resuming the previous dose with a more gradual taper. To reduce risk of intentional overdose, write prescriptions for the smallest quantity consistent with good patient care.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder. Fluvoxamine is not FDA approved for the treatment of bipolar depression.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Potentially fatal serotonin syndrome (SS) or neuroleptic malignant syndrome (NMS)-like reactions have occurred with selective serotonin reuptake inhibitors (SSRIs) and serotonin/norepinephrine reuptake inhibitors (SNRIs) when used alone, and particularly when used in combination with serotonergic drugs (eg, triptans), drugs that impair the metabolism of serotonin (eg, MAO inhibitors), or antidopaminergic agents (eg, antipsychotics). Identification and differentiation of SS (eg, tremor, myoclonus, agitation) and more severe NMS-like reactions (eg, hyperthermia, muscle rigidity, autonomic instability, mental status changes) can be complex; monitor patients closely for either syndrome. Discontinue treatment (and any concomitant serotonergic and/or antidopaminergic agents) immediately if signs or symptoms arise and initiate supportive symptomatic therapy. Tryptophan (which can be metabolized to serotonin) and the herbal medicine St John's wort (",
"     <i>",
"      Hypericum perforatum",
"     </i>",
"     ) may increase serious side effects (concomitant use of these agents with fluvoxamine is not recommended).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F173633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (strong), CYP2B6 (weak), CYP2C19 (strong), CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F173570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: FluvoxaMINE may decrease the metabolism of Alosetron.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Asenapine: FluvoxaMINE may increase the serum concentration of Asenapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromazepam: FluvoxaMINE may increase the serum concentration of Bromazepam.  Management: With concomitant fluvoxamine, consider use of a benzodiazepine that does not undergo oxidative metabolism (e.g., lorazepam). If bromazepam is initiated in patients receiving fluvoxamine, monitor closely for increased bromazepam levels/adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Strong) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Strong) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproheptadine: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DULoxetine: May enhance the serotonergic effect of FluvoxaMINE. This could result in serotonin syndrome. FluvoxaMINE may increase the serum concentration of DULoxetine. Management: Coadminister these agents with great caution.  If duloxetine and fluvoxamine are used in combination, monitor for signs and symptoms of serotonin toxicity/serotonin syndrome, as well as other toxic effects of duloxetine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: FluvoxaMINE may increase the serum concentration of Erlotinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: FluvoxaMINE may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of FluvoxaMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: FluvoxaMINE may increase the serum concentration of Haloperidol.  Management: Monitor for increased haloperidol concentrations/effects when patients are receiving fluvoxamine, particularly when fluvoxamine dose is 150 mg/day or greater.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents.  Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could increase the risk of serotonin toxicity/serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Methadone. Fluvoxamine appears to be the only interacting SSRI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mexiletine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Mexiletine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor). NSAID (COX-2 Inhibitor) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.  Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: FluvoxaMINE may decrease the metabolism of OLANZapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: FluvoxaMINE may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pirfenidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: FluvoxaMINE may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propranolol: FluvoxaMINE may increase the serum concentration of Propranolol.  Management: Use a lower initial propranolol dose and be cautious with propranolol dose titration.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of QuiNIDine. Fluvoxamine appears to be the only SSRI of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ramelteon: FluvoxaMINE may decrease the metabolism of Ramelteon.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: FluvoxaMINE may increase serum concentrations of the active metabolite(s) of Roflumilast. FluvoxaMINE may increase the serum concentration of Roflumilast.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ropivacaine: FluvoxaMINE may decrease the metabolism of Ropivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: FluvoxaMINE may decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: FluvoxaMINE may increase the serum concentration of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: FluvoxaMINE may decrease the metabolism of TiZANidine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: FluvoxaMINE may enhance the CNS depressant effect of Zolpidem. FluvoxaMINE may increase the serum concentration of Zolpidem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4423150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food does not significantly affect bioavailability.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F173572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F173585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Fluvoxamine crosses the human placenta. An increased risk of teratogenic effects, including cardiovascular defects, may be associated with maternal use of fluvoxamine or other SSRIs; however, available information is conflicting. Nonteratogenic effects in the newborn following SSRI/SNRI exposure late in the third trimester include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypo- or hypertonia, hyper-reflexia, jitteriness, irritability, constant crying, and tremor. Symptoms may be due to the toxicity of the SSRIs/SNRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. Persistent pulmonary hypertension of the newborn (PPHN) has also been reported with SSRI exposure. The long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     SSRI exposure on infant development and behavior are not known.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The ACOG recommends that therapy with SSRIs or SNRIs during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1014992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor patient periodically for symptom resolution; monitor for worsening depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased. Monitor for anxiety, social functioning, mania, panic attacks; akathisia, weight gain or loss, nutritional intake, sleep. Monitor for signs and symptoms of serotonin syndrome or neuroleptic malignant syndrome-like reactions.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1014976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits CNS neuron serotonin uptake; minimal or no effect on reuptake of norepinephrine or dopamine; does not significantly bind to alpha-adrenergic, histamine or cholinergic receptors",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F4007575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 1-2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: 8-12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 1-2 days",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1014978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Steady-state plasma concentrations (following administration of the immediate-release product) have been noted to be 2-3 times higher in children than those in adolescents; female children demonstrated a significantly higher AUC and peak concentration than males.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     , apparent: Adults: &sim;25 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~80%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive via the liver; major metabolic routes are oxidative demethylation and deamination; dose-dependent (nonlinear) pharmacokinetics",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Immediate release: 53%; extended release: 84% (compared to immediate release); bioavailability is not significantly affected by food for either formulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: 15.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 3-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 94% of the dose is excreted in the urine, primarily as metabolites; 2% as unchanged drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Hepatic dysfunction: Decreased by 30%",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1014996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/13/6358?source=see_link\">",
"      see \"Fluvoxamine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide that you receive with each prescription and refill of fluvoxamine. An increased risk of suicidal thinking and behavior has been reported with the use of antidepressants in children, adolescents, and young adults (18-24 years of age). Notify physician if you feel more depressed, have thoughts of suicide, or become more agitated or irritable. Notify physician if you experience rash, hives, or other allergic reactions. Avoid alcohol, caffeine, CNS stimulants, tryptophan supplements, and the herbal medicine St John's wort; avoid aspirin, NSAIDs, or other drugs that affect coagulation (may increase risks of bleeding); may cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth. Some medicines should not be taken with fluvoxamine or should not be taken for a while after fluvoxamine has been discontinued; report the use of other medications, nonprescription medications, and herbal or natural products to your physician and pharmacist. It may take 2-3 weeks to see therapeutic effects from this medication. Take as directed; do not alter dose or frequency without consulting prescriber; avoid abrupt discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F4423154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A recent report (Lake, 2000) describes 5 children (age 8-15 years) who developed epistaxis (n=4) or bruising (n=1) while receiving sertraline therapy. Another recent report describes the SSRI discontinuation syndrome in 6 children; the syndrome was similar to that reported in adults (Diler, 2002). Due to limited long-term studies, the clinical usefulness of fluvoxamine should be periodically re-evaluated in patients receiving the drug for extended intervals; effects of long term use of fluvoxamine on pediatric growth, development, and maturation have not been directly assessed.",
"     <b>",
"      Note:",
"     </b>",
"     Case reports of decreased growth in children receiving fluoxetine or fluvoxamine (n=4; age: 11.6-13.7 years) for 6 months to 5 years suggest a suppression of growth hormone secretion during SSRI therapy (Weintrob, 2002). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Neonates born to women receiving SSRIs late during the third trimester may experience respiratory distress, apnea, cyanosis, temperature instability, vomiting, feeding difficulty, hypoglycemia, constant crying, irritability, hypotonia, hypertonia, hyper-reflexia, tremor, jitteriness, and seizures; these symptoms may be due to a direct toxic effect, withdrawal syndrome, or (in some cases) serotonin syndrome. Withdrawal symptoms occur in 30% of neonates exposed to SSRIs",
"     <i>",
"      in utero",
"     </i>",
"     ; monitor newborns for at least 48 hours after birth; long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     exposure to SSRIs are unknown (Levinson-Castiel, 2006).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al, &ldquo;Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(6):579-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/22/41320/abstract-text/16467545/pubmed\" id=\"16467545\" target=\"_blank\">",
"        16467545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cheer SM and Figgitt DP, \"Fluvoxamine: A Review of Its Therapeutic Potential in the Management of Anxiety Disorders in Children and Adolescents,\"",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2001, 3(10):763-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/22/41320/abstract-text/11706925/pubmed\" id=\"11706925\" target=\"_blank\">",
"        11706925",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cheer SM and Figgitt DP, \"Spotlight on Fluvoxamine in Anxiety Disorders in Children and Adolescents,\"",
"      <i>",
"       CNS Drugs",
"      </i>",
"      , 2002, 16(2):139-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/22/41320/abstract-text/11825104/pubmed\" id=\"11825104\" target=\"_blank\">",
"        11825104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Vries MH, Raghoebar M, Mathlener IS, et al, &ldquo;Single and Multiple Oral Dose Fluvoxamine Kinetics in Young and Elderly Subjects,&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 1992, 14(6):493-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/22/41320/abstract-text/1485372/pubmed\" id=\"1485372\" target=\"_blank\">",
"        1485372",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diler R and Avci A, &ldquo;Selective Serotonin Reuptake Inhibitor Discontinuation Syndrome in Children: Six Case Reports,&rdquo;",
"      <i>",
"       Current Therapeutic Research",
"      </i>",
"      , 2002, 63(3):188-97.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dopheide JA, \"Recognizing and Treating Depression in Children and Adolescents,\"",
"      <i>",
"       Am J of Health Syst Pharm",
"      </i>",
"      , 2006, 63(3):233-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/22/41320/abstract-text/16434782/pubmed\" id=\"16434782\" target=\"_blank\">",
"        16434782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 344(17):1279-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/22/41320/abstract-text/11323729 /pubmed\" id=\"11323729 \" target=\"_blank\">",
"        11323729",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grimsley SR and Jann MW, &ldquo;Paroxetine, Sertraline, and Fluvoxamine: New Selective Serotonin Reuptake Inhibitors,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1992, 11(11):930-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/22/41320/abstract-text/1464219/pubmed\" id=\"1464219\" target=\"_blank\">",
"        1464219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lake MB, Birmaher B, Wassick S, et al, \"Bleeding and Selective Serotonin Reuptake Inhibitors in Childhood and Adolescence,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2000, 10(1):35-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/22/41320/abstract-text/10755580/pubmed\" id=\"10755580\" target=\"_blank\">",
"        10755580",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levinson-Castiel R, Merlob P, Linder N, et al, \"Neonatal Abstinence Syndrome After",
"      <i>",
"       in utero",
"      </i>",
"      Exposure to Selective Serotonin Reuptake Inhibitors in Term Infants,\"",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 2006, 160(2):173-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/22/41320/abstract-text/16461873/pubmed\" id=\"16461873\" target=\"_blank\">",
"        16461873",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/22/41320/abstract-text/15156966 /pubmed\" id=\"15156966 \" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reinblatt SP and Riddle MA, \"Selective Serotonin Reuptake Inhibitor-Induced Apathy: A Pediatric Case Series,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2006, 16(1/2):227-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/22/41320/abstract-text/16553543/pubmed\" id=\"16553543\" target=\"_blank\">",
"        16553543",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riddle MA, Reeve EA, Yaryura-Tobias JA, et al, &ldquo;Fluvoxamine for Children and Adolescents With Obsessive-Compulsive Disorder: A Randomized, Controlled, Multicenter Trial,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2001, 40(2):222-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/22/41320/abstract-text/11211371/pubmed\" id=\"11211371\" target=\"_blank\">",
"        11211371",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roose SP, Glassman AH, Attia E, et al, &ldquo;Comparative Efficacy of Selective Serotonin Reuptake Inhibitors and Tricyclics in the Treatment of Melancholia,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1994, 151(12):1735-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/22/41320/abstract-text/7977878/pubmed\" id=\"7977878\" target=\"_blank\">",
"        7977878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Safer DJ and  Zito JM, &ldquo;Treatment Emergent Adverse Effects of  Selective Serotonin Reuptake Inhibitors by Age Group: Children vs. Adolescents,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2006, 16(1/2):159-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/22/41320/abstract-text/16553536/pubmed\" id=\"16553536\" target=\"_blank\">",
"        16553536",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weintrob N, Cohen D, Klipper-Aurbach Y, et al, \"Decreased Growth During Therapy With Selective Serotonin Reuptake Inhibitors,\"",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 2002, 156(7):696-701.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/22/41320/abstract-text/12090838/pubmed\" id=\"12090838\" target=\"_blank\">",
"        12090838",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13025 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-1F43DE5731-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_22_41320=[""].join("\n");
var outline_f40_22_41320=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708808\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6195103\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173600\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014951\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014987\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173577\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173561\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874605\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7803083\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014974\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014952\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173650\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173647\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014958\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4007574\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014959\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173633\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173570\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4423150\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173572\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173585\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014992\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014976\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4007575\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014978\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014996\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4423154\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13025\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13025|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=related_link\">",
"      Fluvoxamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/13/6358?source=related_link\">",
"      Fluvoxamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_22_41321="HSTCL liver biopsy";
var content_f40_22_41321=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F62858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F62858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Hepatosplenic T-cell lymphoma liver involvement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 369px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFxAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCOO0hOrXFxbzysuDCsJJAx9PrWpdWk1xII4AqzMCqvK2AeOfqR6VTkUpclSo+fLAg8465qNNZikhuWhjM5tX2oQoJDMADtPY84JHavVs27n09R8sVy7v8ApjrKeCK9jisbsTyWuRcoyhlkYjoV7AVImmWH2O805tSvls7tzIY5EVvJc5wY2GCFySSD14rF0a5La5ewtapA7/MM4DSAd8dfxrT0vVobw3Pkx70iQlZMYVyCePfHrWjjJPQwcKdRKct9f+CK8AtlbT47h5tQgg3x3BU+W69Bk927/Sp9Ks9dk0C5tZL2KNmjG8lcfvQcq30xkVm6FqcmpSJtilijZDJuPT73KmtbSY57VX0+W+a5ubmUtBvI4yeFH0qZXWnYu3tFrqn8vQSWCSy0i0n1yVUCyJG0gBJdycDao5PWteaFtMmntiVaSIkBc5+boee9YNig/wCE91DxBGkjWtm0t1bMpOJXVfKEOw9w6nke1UrTX7bSYXgmnaYTTO4lkOSM4JAPsSQR2INOVJvRanLh8ZKbvOyXT77HUWwe40Z7u6t7gLGjFTtPJ9Cal8Hh9c0+TNm+cBYwwxuBHJ/DiodJM4urnULe6lK3KIk8fmExnA4IXt2qx4e1uLw/daxZ26PvWP7SfOz5aDHIRv1xWLV00kdNSU4Jtv5f5mVqum22nzHUtWvbqaeyzIbiL92vy+qjr2FaP9oL4ighvtFkDMoUSrcEPGg/jwBjLY9eKHNnr2gpfW1ytxp1xvimEilQHGCykHqCGBBqr4esILXTmi0qSIW7biSrZG73/wA9qL+7rv8AgOK9o+aLXLb5mtNe6jdskf2oQRQXAaJYgAsidWBXtn+dVYXh12XzhP8AaDDKRl+sbKe2abocWoJZwwXzQvfLu89OhZeTkLnIO3BFNjs47MyvBPK7SMZDyAEPtgCpdldGtNK14JW+RYg0SDRdNW5LTXctvbSQfaJpMsVdyxU/3QOn0rn/AA/am2htrhYrezV3MjGBtynBz19+9dJriTT6ABb2ome4Qr5O7BYf7R9Peue8MrNcXFxZRmL+ybeIQKq8tv8A4sk1SV4NsVJ8suVKy2Om1S9tYNZkhH7to9h24+Vg4DAj65pnn/2DNDLEC1tO2J2LfdBNR6rpq3Fro8Ejb30+EQeaR8zgH5cn1AwKqag0GoLd2RzIYCryID0HaoVm7AoScFzbndX/AJdheCO4kRxNEHRz/EhHBp0N2nCmQFV6Z6YrhNc1H7XL4at5QwbZJbj3A5UfhVuWQqscaksCxA+vvWfJbcUcOpxSnvsdbqOqR20qyKSyuVU7ecZ7/wCfWuQ1fxW+narHp8Ts7XJYquzG0Z4GaxvFEF9eWH2XT7kQXjZYNu9D0NbOmw+ZawPqsay3kcYBkVe+OatKMUpPUIYeMXqtO5ZNxeJZMttdFHKkgdgaj0bUNRgs0N5cLJIOrN0FM1O88lQthaGcuCrIWwwyOCvYnvisbxZaG5sLK3uL7yXMMYllT5QzdD+dOMbpKRo4xbaUdfuLl21xrmpzzxqttp/lNDJOuVmOeTtPTGRUHhxLp7SeK7gaNIWKQsW3blA4bNavhXSv7I0ZoSXkRD95vQ85NZ66zaahc6bBYTRskskkUiL3RR1GOhU/oabbldRWgJKErP8Ar/hhnh4Q6Vqtxa6vKbqG/cDMnITP3Vx9e9egwQWB10RPcRblRfMhDjftIxyOv4964jTtOt28R7r13CnlHzjOOw96n8N6hILa6fxNp6QyXNwbZbmFAZoos/IXYc4pSXNqc+ITvaDPQGgudMsrxGmtpUd8QBB88ae/rWObK2v2miv7WOS2U5LMN2Rg5AHarNtcxafeSWF7cC8bbuiuNoEm3AGWHQnPcU6Bora/88mZ5pCFRNnyvnvjt9ayUjijGUVd9Tn0kgsLZprJFe3giCQ2VuvMeOg9ayvG2oRSeFBLdweWLl0VoLlypOT9zK8hvfpxXXz+HLqHVllsLVJPtJBny+0jjqPXFacnheC4kBuxCVjxlnGQT7CqVRJpmsqlLTU5TU7O8sNEgutExG8yxRTLMxYLGnbjvjv3pl1JbS2jQXvlm0nxGd7YBJ7Z7H0rqtPtJIkktbhpGkLsqeYoAkQHgjH4VYistOmspIru0iMLkFmcBtrDkYBqeclV4wTurmRZ/Z9T0e607zGLgBYWQ/MSoxjJ6nH51i2dp9ktBAZftUir+6kY/gc/ypnjB5vD8YGjWk100zCaFVfB2ggOc9sZHFTXZMixmcsm4biR1J9afS500Yv7L0epi3zMIogbaTzryRPtD27lSFTn5mHUdqfp81rq2kpc6PE8McbyC3eb5gsnTkemRmtuyils0tZxDJPBKJFadhkQFcHLe5zxTL7R0v7J7WENbW8rb18o9T1zVKSsaSmnLT+mVNNTUZNIij1V4Zb9V/fuOUyc+vbFNuYpkktRaTRLpwgdHjC/MH/h2t2x6VOQsUbHcAwXHznjgd/ypPCayHQSb24iuZS7MJUGUcEnp9OBQ+rQ21Ba7ES6hBbXUcTFlmAUoxGAx7DPrmqkMDpcX0VrE0e1vNUlfk3MSSPfqfpWjDNpV5NcxvMjXdpIoeEjJiY/yOKteLNVsdP8MXn2G5VZlB/eeWJHB9gO/wDjRbpYl1+WS5Ve+hzMNvpVhe2UtzcxvNf3HnRp5gzABlGmHtn5frSaZc3hs4bywsktJZJnM8MjgkjP38jgk4pYZobjw5pk91pFtfzSSLBG88OGhjJDYwODhhu54rZt1e1t4Uklad13KZWABY5PJA459q0m7IdPmcpKW39f1uZlve31zqummfTNOulhvV86SYt+4RsjfjjPOB9TUl3NrOoQWt5IzWN8sjtPDIuWKhtuMdsYrPuLLVJdWntAiQWVyjH7WrY8pNhJc+4bbj61r+I7u4u9ZmWSJwI4IJYpC2wTcYYE9uQc/Wm9laxmoL2ziuxPKYYFuLt49rS7RIUXLsf7x/rUCyzpq8Mtr5MtjbtmQhuS2fu/h3q/bu9naoxVZLhx8rMdwGOfx9KzbGynh1adFtoYLaaOOS2EI5YuTvUjtzWSejNXq7LY3PFi2Go63DrWmrJ/aK27xMWXGARwB6/NiuTg0yVp9Pvb9jNewweXLKoOGYHkUXurQJqiW0WslWuJXhfyU3FVAKsIyOj5/iPTHFXLKGW3uLSb7fNeWtnp32SeR3I8x/MJDNH2YAr8w61aTjEyj+65YxV1tfyM/VZ3WaC2gsXuHnYYVBwMsBnJqPTdZvZ9V1i0Km6XSdQ2C0AXcY3G0yMTyqIQCMcksRXRW0ZlmtJCRGIm3kbeuOTz+FZtpf22qWt3eaFY/Zvt5N1KzL87nkKWPfA6UKVovQqvB1ZxSdtbs02uYLdIIlD5uXMIbyywQgZGWH3QR0Jxk1hWttpum6xbI+qfZIPmeQzDg/X0GavaVc3IW6a4AYRRk7E/5aYGQMeuelYesPqK+JVih0557S6tB5IuIwPJd0yY398nkHpzRCLva5c2otpbv8OhuahYMt1tuoyHk+8oPUeoPcHgg0y20hbq1vled/3LxmNCcYwCTj8ulVNPubqF4hqEqfZ45Bbxbc/u4xx/KtTWHsU8Rw6fHcEQXhCQlHwTxy2T7HFDTTsi/aSUVzbpX/r1MYRi58+NrUyMj+W/mAjcP8Kqa1BqI1bR7dIjBpsJ8x5kOASDwnpiugn1BmjmjWErslKFscsOg/DisXTJ7jVNLnttSheEpOHCryXVTkLz2PGaqEmncVW8oao19RnEcrCeJ4pAQQwbn2x7VhTalclxjyoYlOdqALyep9ye9TC31C71W6fUhF5SAPA5PKk9QRWPdt/Zd9P9vut0dy6rbwEf6v2+venBLZGmkYpyW34FjX/Nj0WSa2Yme5A5UZ2HOBxWpoNtqGmxQNqMgu7O8AWZZyS6MBxJER69CDwcVPm2utLuLFNRgtLjYA7MMyIfUcVT1SVo79HWc/YUj2og++foTTUnblZjUpKrJPt/mQapBIjNH8zISSG9PTJoqHxFb37i2uLWZo0+WSQ7c70JIx9cg0URi2tGbSqpfZuUdY028g8QfbLjy3itUDwvFIW8wMMgjHBBGMfWrNrqOktcWOoWthN51yfIOyX5I2z82VxjJPWpYtX0+4tizTiG3VY42djhY/lGB+FUtVnttF8iGGObzJNzqsUe5XA5yPr61qouWjWpyc0YrmlK3X5s1VsLa31VWdR9o27CTy6qT+oqx/ZxhnkkaQGL+GMLg57AdqZYw2uoPba1IrRG3QNH5mQSvdWHfmtSST7RCXhBaZuTH3OTxiseZm70eun/AAShbG00CIfar1Lg+YREzKAcMOhI75NZ93ZRRapBqE5czwqWicNwmetXNQSSW7tNPFrb3E92cJBHNG03HOSuc8fmKbeppssC2cmqTWVwjJFI01m7bC5IVSMjk4IGeKtJ6ee5h7ekrtyTsZuklddSPVTAkNykkkfmMSSq5O0+h5Oee9JpugWbabDA0bfZUeRYzOoD3M4GSkY6lmxx2NTSpJdaRd+Hke005kg8/To5H5unVuZJ5kyq8Z2oDj1pmtaTLc6Bp0+q6lFdz6ncRLCLOTfDbywggxxyDGxyoye/1rVb2ueesVzL93Gz2u9L/wBNGtY2MVrbX2p6RI9zHcFEkhdgGsZQozDKvZsH8atXl9pkUNrFqCKLy8l2Igzyo7j05rK0pjpfiyDWNSlnaPUFkbUbGBl8udlQjcVJy25cHuQ2apajfW+nQXd9p1rbX+l28LXlmbmd3uFjZgEOMcLklSOxHWs+Tml6myrypxUam63sdg9lFflTOxdI1Kx7WwPm4YEDrwBWf4QTT49LcaUskC287xGOSPADA5Y89frWhcXKTAxQxrbkxLsAGMMUDEH8cirmkQqtrLLfzJDMF2xh/wDlp6nPrXO3pqehe0eZfd6mVf6XajxcmuCJHv1k+0rOSdzPjGcdMgcc9qoR3Us2p3kWmS28txGm17W4jO1SRkHd/StZ7K+MyzOVFugDBuvy9iaZpjWVp4lvbLVrWSC8eJWt5UIGQwJG78OcemM1Uby13siG6dGKila/bqXtHlupFsrieZFmtHDShBgSLnBTH0P6VkaFJJHq97bTWy2kX2p2R1P+sjJOGxUt7cwyW+jzW9xIsV3D5qqFxvY5BB/Kp7LSDN4hstQlIP2dGWZWb/lmRk/rS2TTKSjb2q2aNGaZZlkRWV3XALA+/Nc34gspLfS3uLCaODWL1mhiWTgOF5bn2FOvJHhu4m0fY0F04l3k8FD3H5VraharqNoIp9vAbawGCmfSlF8jTG6fNCyenc5W3u9QXU9Dlv7dY2lEr+WwDZdV+8pHQEj9a0dJvrm5jjnu4/JmaTJjboMmovDOmajptre2WoSLLp0KutvMTlo2YAr/ACqK6sr+bULK6hnik0x7cEtHyQ/4VrNxd0XQTTSlu+hq2uixza9/aXmNBcXBML2UzfMrqc5X1BHNdA+mNBIzzzpEuQjZyRk9OlUbuKS+8QQXcMUE9hp0BEtwJMOkxX5FK/iao2V9qctnOdS/dszMnXkKeh/KspJuzbM4TnJWgSPp91pj6hNdYuFGXiiQ5bg9RWHfpJcSX8N7Cs9s5EtsWO0FuuPzrQu5prKxt/IDXUvyxszNzt6FqkstPvDqV5HfPGbF9sloyZDDA+YEfWnF2TbNuq5g8LajdXVrrCXNmlncpazXTIrbkaTZuyB6ZFV7C3YeE7XUdIsoINQuLYSLEU27Q7ZI/HGfyroo4l06RCi7nCbXbGdyEd/WkkWKQ3FxZA7pVXChuPlG0KPwFLnvsjPltO62aM5ohNptlPqHlxTGQL12gvj7o/Kpo9Q8m+hS7fy55MokKjlveop0u9Qt2s7+OAyRtFqOnw7wkwlTKurg9VwSc11EyWaytPbRK87ENuzzj2pOyRlKvaTTRNqRtbnTbW6nuWX7Kd67mCYyMFHJ6gkjHvVd9as5dLNwJhaJu+9dx8xFThhjtnpmmeNdGl13wFrEVupjuSqFCpxyrA8+xFc/4OSC98R2uiayVmvYNOWNrh8MlzHnj5ezA4znrikopxv1RxU5c0X2X5ndWN5cxae722ya1ZA8Chz8/qC3Tk1DY6nFcRXEvnsJYSMxdQjddo7HFXo9PsfDtoWizFp9jkyKvRVPJGPr2rmL7V4odO1rW7Qm8SGN51twANqrjKY7HnJzzWaXNsQuSXNLp3L8fiK5vbid7e0WRYcGGcSA7yT82B2qz4Z1e7nvHtdatLOKKVtsLW7Ngg/3g39K0/D3h6DTJ0Wztkj0y4s97LnlZi2Tx6EH9Kp+ItMW1kghgkkDT7tpUZYFRuZumAAKTaeiHGpQm3C1uzNG402GawkhmbPkSEk/hgA+tccml6vY3N+dVeOWwLh7crwUHfJ71oaRdvfhb2wvlnhLgzuMt5qpkZUdmUjn1Fbd5E+pzQPZXVvFbmULcLOhYyRYPCdgxJU59BTXu6MlSlSdm7oxbKbylMSsHLAk85yMenSudj0549dfUUuH2+VtMRJ29eOnTHYVpaLoSaez2NrqBvGFy8IaY4cODkx847Gkg0TxDEF1O70540XfFLY28yylUzxIP7x/2etXdLZm8akItu+5R1Cy0y5xaX73d3ulWcrHMI8D+50yVqlGbDUdKsNO0G7vLTTLQtsuUILM287kbgDGat3MMVhfASgGaUhYyVwW/wAMUi24tLaVLKJfM+Z0RTgFuv6002dnsou0r3ZYksbCC/8A7c2FryKMQz+UhYyKMkHaOpqCXStNENhcxxvp1xq0zNFaXpCSSyYBIUZ647UkGl3Ot+F2tNYlk0u8vJB59tbv80kC8kK/8OTjnnj61JM9tA2n6RHHEEslK2RkPmSR4HIV2+bPqetN+b1OeM6inam9u/8AkWLeN4rx4biB0WP5gx4BOPSsywtr7UDLDcWksaSOUQyEKzHP8IBz6VsBZ96M07ktyATnHvk065nkkWJLmVvMXpjr/nFSnoaKUr6FLVNEZ00qHVpvK8m4MzwRS7mYJ9wuR2/2PoTVLU7mXU9Etp1sXlXzjZzQSYBUBuufQ5BFbL2BtnVAxlnZQVHXrUWj6nCup3ENsiyvGf3ylSUVhwBnpuBquZtehnH3bzTu/uM+5CRpNaWflJf24O0ddm4fLkfhR4Uku7yzU6jOgv7EHzpIxhVYHOB61W1iyhn1TfY3CWmq3W0yyMCTLEjZIHY4/Or5vRHewLZQpcafKjLNNGQcADHze9O10ayk7JdTntPtrKbU7oaZYQJaRu0tvOpDZLHLkfXmtyz0m/j8STXMkscejSW/kiEj53fqp/MdfSs+y0mLRdag1W0mMcESBfsn/LMtn7315q5rrSW9jJqNlbs9xbbrgRJISZCTyOTzj0obu9OpcnK3Itv8hwtbV557uORnkxsYB+IyPQVc0y2iQkvIY42ODwAQOvHpWNoltZol9c2UUtvdTyLczRt6soPHtSeGtW1S61C8g1HTPs1rbkMkp+YyZ/pihxbvZ7BK6XmzfuYYYTKiMDkF4pAoyM9j/OqWnaPJqsjLLPMDOriQRt85XHJz2J6ZNW75YXs1lZTGGbIw3AHTpVSeT7PB5NhK0SZHmvkh5AexPoOtZq4LmlDTdnNXcNvqaSeGtWjnW/t4Eka5t8qitnhQf4iBgH1INbkWl2XnaZOrG4exAj8xh04waiuJvNv5ZH4beG3D07n36VLa2xVr23XdHbuQcjOK1lK5Xs3FK7uZkFy1j4gmi1adfsNzKIYpokLeSSDjf6DjrVnXPMspERAxeP5CFOQ2ehzVtXt1WZkiSSPYA6sck46Z96xNO0eeJrea3uprqBS6TwO4LOmSylT6ryMelNJPV7lKbg+beL6EnhHWL7RYrm41m2jmnUOuQMgL2bnuOtVbXT49d07Tb2y1GOaS1VhdJqCgSuuc+ajDqRkZFb82jC+0dr7RbhL6xkXLYUq8XqGQ8iuUjsJTq1u6yG2sraNjJGOdw7nPpVRkm30ZLpKS56T9Sv4i0uWyu50hby7y+XesvVZFB/hPSr8Vgb62hW8jVxGM4A53DvUkM63elQ+WxEAkDwcZ2EHqM1f02LZq95NNKVt5I0KjcfmcnBwD93iqbdrPdBKbg07Xv2/yGNDA+mNZzYWdpECyJkM+flVCfYk4+tFOu7tb66msFtY0snXO7OZC45zntjrn1orPmtuyGqkdIJW8zFvbTT7yOWH7Pb/Z5cOYhwD+Ht0qdLiIXUMEqsoVflQjgD1FJcaLZi6tr4XLyXEIaPyo1IXB9asBkhguEgtUu77Z+682bYOuDgnjIBzz6Vro9EXJqKcrbdia8U3CzWJffbxoGdehBJ6A1X8NXD6PcXF0lx9olswLgBhnyxu+UEe/Sq2qXk9n9hjWN76cYhnvAAhkOfvEDgY6e+Khsb23t1vo4redbq5uwu114kZV+T/gPX8aOW8bPqEp3jtr1NawhtFmJ0/TU0+3kma4EcQ5LPywLkFse2cCqkEC6vol3HPeXc9raXHms9zhmGDuA3Y5AOSPStqGK5a2hEkBWUjLqOQp9PpRLEYLC5iVURJwVIfgOcdD/KpU+hlLD01H3UtEZ+opYtZILcI8L/OjKQFHcmrUPkRaBEdIMMkS3Md40eAySSJ3z644zWfJJpsGhyQ3Nu1rDFZlzbqfMZVHBwRSeF4rax0qxsrEu8c5zC8h/wBZu54oatG/mV7tR+zk+lyHSrKKaGQTSLNbRXSz23mjdcWpGSY93fk49xXTJ5nkFw4jQqyBAoAC9cfT2rFstNuNdGoaP9muLO6abLXGMJFGvWRj2H6ntU93q0UNpqq6cqas9tHC8SxSbWdWkKSMc/LxgYGdxokpSd1uYutRoLkfkXm0yCKzhiE93AJt8rvC2ZVI+Ybc9QQCMHuaz/B9jqV7f3suqXKyJe2UMqqWYtGUY7WOeFOzg47mtx4xLbKk1wrkKB0wV9B9R3FZ2of2qt/Fc2LgwRQOJLWJcu7AZBFTCTace5VajeSqdv6v8jc0vW4763WG3miewRgGwAflB5z71y0GoaxfJpi67J5txPPLcTo8CmeOHdtjTIwFBUZGctVfw7exXF5pdnHaQ2EF7e/6TFE25UU8tkjgNx07VZ0a7v7nxDqq3lmYLbzWMEmc5AJ2/oBVOPs+ZWJhShVqRab0102ZqzSx3l+ba02LcIAscCjiJenFZurT/a9dm8O6fqS2awWs0dzOeJGnixIMH06Aj0JrX0K5s4/HFnE6osrbZD0BfB6D8a5ptB1Wz8Ta8sclr4gsJ7u6guYLY/vQsy5KljgIykr3xgZpU7J69jPFuWlJba/8MSR6fqWq6babAtqYJnUoMKApbIX8Rmt9fLniuIIbpGltSqOqN8yZH3SOoOOnrWR4c0SO6trC08ZXE2o3EaAnYQqRup+VhgAsyjgknBqWw0Q6NpBjmvpJZxcLI99tCySIjkqjHqy8nOf5UpuL66nTSlV5lHlsrF+IRvbvapKXhcfMmc5PTP1qLRNJn0u3uvJlVrBE3Qwn5RFjqMn8al0mHStNm1DXbhppLRAZniUFiT2CL3ySKr2WtC78+wu3ee8SNZZVeLaWRzkHb0wOmPaod7O2xqpKMuXqQ2t1Y2ejXeoRuUS6kMkztkB8eme3v3qu2u2d7HBamKeJL5WEV3j5Aw4xnsa27uLTtRgk03UGjaIqCY88qOxPcCo5v7Ns/I0lIPNIniVo413C33KTG8nopK8H6UKz1tqXKooaX6/eUJPBy3SaZBc6qbWSBwSzE5kA6jHetR45D4jXVHDW0KwJb2doTl4Vz8zSdtxPp2rCn8QaLqHi+JHWaTVbYNDEBkDPcDtn3rcXWbaK7WCchbxkLmJ+wAyWHtTlz7PsYpc7U29Fp89hup6pbWerJY+YXu5gSq45K1btIWiZXgijmCyKzIz+WApPzEH1HUetTeXpUd9p7IyvqFzG0kDtxhAMttzye2aotHfnUnmaaNrTG1YwuDuB7nvWZonzR5UXvEb6XpQl1qeJ5ruFNisF+cq3HH1BxTp5Rb2omQYDRCUE8YBHQim6PftfpM0ttIht5DGySr17g/SmPJPc3F7HfWo8lHXyznPmgjnp0A9afl2OWEeXT7xbbxidGFjKcBNRkEEcBXdk+/8AjUi6dpqaTfG7Edvf6nLJaw3SphwHPyoMdMde3StbToNOuvLMkURO3bGo5MZ9veuZuE1Sw1i9vFkWW2FvIILTZnfOoypx7kY/GmkntoZ+7Ju2n6neeILVbnwsunzvIuZIonbO1nKKD1+oqx4N0yezmvHEVkul3Cq0SIv7wyZO8t2IPB9a51LS/wBX8H6QmquRrMS/bgvMYEg5CN1IHO2trw1q5tLZJ9UE0ElyyR+Wzbo4DzwPQdy30rFrRpHHNNUXFPrqjsCDnJArP8Rad/aeltApkBDLJsjfZ5u07hGW7KSAD7VpDJwf1qlqV6tpAJJSQpO3eo4U4JBPtxWSvfQ4U3fQ8/8AC5urHxHf6fPpiWCRSLNH5HEc/mDLj67gcn6VraebyOaQ6jJBdIJt8JSERlVP8JA4OOmetRaNdLqt6Z7WTzRGBIWX+JTkcH0rSubT7OSYxJKBIAVY4JyOcfhxWsmelJ+9Z72M2GfWLC6gla0sdQaa4YSyj92VT/lmwBzlgPlb6ZFFzcz6hZQ674bvbuOLT45nfSY4hi8lGRtbPIwQcgVbffZmbTZkcxpteK4JGXUjkY7Y6frUV3dNpmg3GppdrdwQy7mS1iPEecDIBJyO5/GnfW5g4qSTsZAsNV8UaBYazdNDpOqzQr5tgUDLE27lhnkMV7GszxTbarYWV1f2viGGFFTYpeFQsR4xlVB3HPfjrUt14ijOtKLq3JN9CwsCXC+a6BS8bk/dcZJA7ijxMI4LCRILZr6CVwssDD+E9fyrVXjJeZ00oyfuN7EVhFLbW+m3ELQTWs8JMsysWZ3Y5JBbopPbsMUarpkU89tdQwGS8tS0sKZ+YHocfUU6HTLO606DzR5lvBIJYrf7qqVHHHpirDafbvrKayN5vVjKB9xwB1xjuaL3dzXm5HoIL6yURfaA0c6gCXc2AjHnGe1UtVtrb7ZYahdvPE4lEaKp3AknA6etWru2hu4Jxe48qXDHccYIOaNStby4sFXSZ7f7UjoyrMCV255z74ziki3ZbMs3Wp2ulQXF/dTBY7YgyOFJ+XPNR6jc3ryRnTYYfsMsLPLgfMZCcgj2IxVsWwt5w88WVxh43wQ4PUU28tmS9g/s6eOG1IZTGw5BzwR7D0qbGalFSuY+laV/ZsE0RdgbiTzyJjnY+MfL6VM4s9E0uW6v4obdT80qxgYJJx269avLp9/bW93NqNwl0eCm2MKFXGePX8aoadZ6lfG4lma0n0uQf6qZQWPGevbFVe71ZcpXXNF/8OY3jKKJoILNZZFW5YGIqMlW7A1rWiNDZxmd1fYgBPTdUOr6lHbT3YELy3lvGrNbAfNjsV9R7irT2iz6QiLvzOu/ZjJQN1FNu8Ujq5kkkySOeCRCBECGXb8hzj0NUG1m3t7iOymtrhp7h/Kg8h0cSLn72CQeM8jrUel6S+lWTWqtI7o2Q7Hn6e4qrHZzQatdXmoLssWUGBGGAjgctRHluQ4cy0lr5BrianBfW8NnbechYrKxP3APY1e1qNBp9uu8CU4y4OAM+3fFVW1qyTVLC3nuCqzsAHB4IzjcKxtVtNT1LxJNpdxaT2y2U5aSXBMTKOQVfvkYP41UY3tfQfPyySky5ewXVtM8kIWWGBSFAOfMbtz/AEpdW1eez8I3d1cQyKzRqJVh++qscE/hxzUd1rFpP4th8q9RtLMS2FxEFOYZTlkn44JJwD7VnQ3OuXGs3EZtoraMSCEuTuEik4yPaqUdr+pUajmrNWt/VzW8NaHDFZrFb3LSi4BfdI2GbKk4rL0qz1C08MRiW1uLO4dyEDKSVG77xP0qz4mtprCTWLy4v5xZ+ZHHZfYztmYAY2egG4ZLf3aj1SfxA1vaf2XdqrPt8xGJYbMciizet9xwlKWy2RPqOsSeHpbC4hkmMrv5IZec5/ve3tV9ZLPULeZGh8lSWWKeEHZG4HKMO4z6VJBaLbajBNPPDJZxKogtY4wXkk2Hf5sjZwATkBeeOtYeq2Eslzp00FxJDa2Kti3ThNvcn3zyT1NJcrsibyk20rfgU9OsJ7mWzut8kbwxbHtSu1QcnJx+FbD4ursQHcNxIUhCVLY6cdBjvU+grLrEC3OlqklphiZcgBRj5utVpPtcV8xikC6cIgXUEhmYjgkdfwNDleRspJK0XqUdO0jVDdXn2t4YlQF1mTosYPJP060UguHvLC8m064UXKoUWLOMn39qKu1/iM6sZyfuN2JVlM6XARAqQNsZem1uv+NQ6Pf22p2n2nKRwqWJZuMYOCfp0pbj7Wt7GhkL4+ZsknpU0VlbB72+uLSNykIh0/a5GRISZlZBwQBggnvT0sTVlUppOOutv+CR6l+7gkaQ+QiZDuein1/+vVjSy1pajzphcPtyGA+8D0P/ANei2XzLgfblV4VbcyHkMPTB61B4g1FzZR3+mwC4mCBHijyM4JBYD8uKSTfuo0qzUNXsbUuomyYatE8901tbpFcaahzyWOJlHckZ6+lYP2OOxgvLDVJTcRSyuYtrnKxtyoz2OKuaU8o02HU2RoZfJLPC45UYzz9OcD3qO3lttZ0yHUrQlo3BJLrgrt6nb+FC0RhGlBVG31/UW907RPKsLSR722R0OyOKQfvAB8y8jkEVHeypKbWztLV7Wzih22jxjP2cDpz/AHvepkt7LWoNOvjuY2r+ZbzDgHPBz9a0lESRyGIgjOQvr/nFJztZdSo0lFyk/wCkZuvS+TpVlokk+o/brttzXse1UEgB2ecOpU8ZxWEukW7WF5pdtbPJfWaqm65BK3MoG7cB0AySRj8a3tb0+fUo4tWhgb+0Y3CRRMCQNw6sPQY/CjWZ5l1EWOjsY7tQJBcSRFo2XuM/nVxm7JRMo0IRm5y1f/AE8O6ZK7SakJnzcoqSoW3xQzAc7as6daSXmkRprEl/BG6kTWTIIp5JBJlWMgPyxkAYUDJHWm3enW1paQ3NjYtHcafI95bRI5UNKy4JPY5q14cu7jVLCzeUJa6lcBZminbB3E4xg8nnFZuTa5kXKCb9nLRW+/1+dxmh32jyC6h8P2UFtbC5LyiHPMnQsSe/0q14m+0m0WTSFikuONinge4rntbXTtG0iabQpLaM3V02HkYmN5d2H2nuAQRjpkVralHcSRy6ZpVzbTXQtUkaJpDAdrsFacSHgY5wOtDheXMvxCM4QpK/boX/ACEOqypIlvHqqKsZgLL5wGN3Trise+SG81G50+FHgdFEpmQbeScEgjvXLa7Z6pomu3WoX1g1u+nWkVnBcSykQXmXAVfNGWZipI3Z9Sa0LHxnNbq1pb2iTW9vcFow++7muYhw8Ib+FlYjDHgitPYveLuc0cf1mvuO20pYo5Rb5O/B68moPEV1bWiJbahHLJDO/kLsUkZYd/QVQ0S81u7hl1PxFLZRqQq6fGlv9nlQE/MsidMAYxnnPtW7a4nuFjJDRbdzM3T1Jrna5ZanZCpKpH2lrFHS7d7BI7YcWyLsQE5JI5OfTjAFSavJbWGmX2q3DRxiKNQjBQzyNnOxRkbjjPGazvCOsrr2mSXZaITiaWMPj5eD8px7rg03x1ZpdfDmymuNNt9Rmj1dIYopXZFUSjax+U55wPpTUfftPuZV6rVP2lPrb8S1YQ6ROLLWrOxme41OMESAEN5YPBYN90dfyqyx/srVtZM2oTie8hjuJYZEVXSFflBGOSmefal0WbVNP0uH7e6XE/MSmFRtCAnYFHYAYGKz5JY7y/1GaFY7nXo7YxyNcFj5MWenHBUZGRSWrfY1cJWXNbT8xukRWU1/cXHkQ7dwxdlABMpHY9z7Vbv9JU6jFdW7RQTQn55SuWdD/CD2B6VkWNumt+GJNOtnhOp6fIJrOeWMxQtOrAsNv93GcGupu2mFuj3CJPIq7WMY+UEDt/8AXpzdnccZScuTYWE28v2SOcD7ZK8kdphdx3bcuf8AZUKOT7ise2ttRgvL9mkaX97mGFgAkagDO096TStcS/1W4topAY4lAKgEYbuM+/StjS5or2+X7PKCgfy5FU5ZT6VLTj0FrTbbd0W7e8tvIE1wXxGGMiFtqsCOpPtj9aoS3YvGeQuP3g3RrEeMEcYok0gxpqEc250uWYsrHnBGCB7UthY2+nWkEVtEoSGMRxk9QoOQM/jSslsSuVPmjrcpaVo48JWer6ldzTNGzrPIAhdkz0OB9eT6Vg6nqN/qvimw06yO6yurdpZJVB6Hod3bt0roEt9Y/ts3n2lv7IMRV0YZKsejc8GjTNbaLU30We5e5KRb4pZIVRlGeeQOeuMdK1T3luyFGSen4fkaKTX2iyWF9BdTNZylEkhusGO3/hLMwO4k54HTvXQ6+bey2OZkFpM4jUyHClm6D05rivDkifbdVtLe9muJ1n8yVHPEeRkKPbjmtHSNWn/4Ta8truJri0vYVuIo5GMkYYYB2HomCPu/jUSjf5GNSDjJM6VfEN9FqYtTb3PyRhd2wlMdzn1qC7u7htT+zxWM0yXWXlduI416c5/kK6KK5lj1PzHnQWbxDCEZO76+lVtFcO9xLNbzW13PI7hHlEi/LwCvoCO3asduhxupFaqPQoPY6jayZ0adYIlhZAhiBBl/hYn+6Om2ol1uPUIfDNwFec6jP9laSGM7UkQHeW9FypxmtrRJ31TRo5Zf3KzhkeJwVbHIP0Peq2nBbKz/ALK0BTbRW8gCgpwVzzyeue5pt9ybycvNFjUDLqd9KLcqkdlJtZWGC474P5Y/Gs61sotI1e6tXthDpk9ufmR8jL53gj05zn3qRCsviuR0nkguUjVZgATFMp5Gc8ZB/iHI6HirN1Gt1Zalp16omsmURozHlg33lB6jFTsUpOPu9Dn4vD8N1ZiwvLRZ4rWXbFI2NxAXAkQjoSvH4VS1aH7Zqd9YSxXMKQ7LiO4GQk6kZIQ9yMcitOWa30qe0QreMsFlITJksjKjA+W3ffjkHuMis+W9v73RbXW2EqiO8cQeUwYSWrEbSeOhB+oK1om92bU3JzvcLBrbUrKKaBnjRSYnDDBJzUKTSRXksMpUhCdpToFHr71esdf0aa2u7+CZo4LcslzMIyFDA4LYI/Wq39lzLb3Ak2GO4bAaPB+U9Bx6g9afqawabfN+IkrreTvBFBFLaeTuNwsgIdicFV+gwabeTR2Nl5qrIZI1H3R1x2plhpsWj2MdrZxeVHGeUY5xzz15ov7O8KXE+nK9xPNbmMQyk+UxGcE/3SMkZHrTVrgraK+hZXULaXS1lnJ8hkBJU52qe/0Fc74obUbK/wBLutOjllskby5I152g/wATVS8UwppfhaG2MMaTMqwJZxuXIBYGQL6noATW7r8txdaclppt2LaUMrJtXcABwQR64q0uVplQVnp1N97i5Olz3KxkWywYk3nqAeuPxrnfslnrOlJJ9pu7GzEguMeb5TErnhs9jU88yWssl35Fzc3lzp76cZAcRJt/eK0g/hBII3du9Y0c6a3pqtcwpcadLEGmKPuZCvIQ471MU1qEIXUlsdBfxNduJbVYhdFBHHdSJuWLoOfXjtUOsmZbUxwTgXGColiG3aT3HtUMV89xpkJt45UiZvMhhYldnG3GD/nirBsLy5iljkUQ+Wi73LbdvOep9ak1h7jTlsZWgpdad5a3Vw1w54Ky9/oexrb1adZtDt4pmaV7qdiiv0RV4x+Of0ovEikSJ2Rg4AKggZU+4pLxYZoFiDI8dsVkt22ESq5B3l88EHjGKHq7sbmnJSSsYNxpse2S9jsLe7ns4fMtInZVRmyB19BnOO+MVlS3vksljHcrqWoTOG1e5GULPjAGOyAcACurtrl1ha22gLjKMyjj2rDuPKttQle3s4xNOpE8oGAQBxmrjLozTllUnzMwLWwWxure00q4a1TTpBJOHXiaNxnG7uB71u3E5tYZVumaTdcfI6jG0MflXj0rSinsdb0y3hEcU1uGCylUDZ5wOD1IPPPHFS6XZ3ekCZdXljvLq1laNXMYRJGX7jFfpyac5tvUFNJ6b9PyKmtaOfEGlz6dJcCxgijRkuFib+9llJ9zik023a0+3QJaeVboixw3MzLunPdo0BJVfdvyqnq9rquprLNJdynzJVljlkbauM8qc8d8VJfyXkN1b3MNo7pGQkpjG7HbJ9qW8bXBQcWtTO1i01m8v9MbTp44bO2+SaNusgz1B7mrNml9E91Dq0YXDFbcLyHTGDn3rWeaOO1Nxa7XcTMhUHO2RDyp+hxUBuJZrFYJZF8mSQzuqD7jN1AJo5nazLsnLmjs/wDhjE2XVpqNg1vKLezCMhhUAfNnrWqtrFClxJBEk0FycyJ/FvPcn6VHBpiXmw3btDZxZ3SBcuW5wAO5xWXd6kttoDzaFFczQQhkG9w0kxDc57Z5/LFX8RDa5rRXn9xK+lxCaSCykiiDHczudvl46nPYYorPnhe7spXR2tzMivLIeSB3yPTtiiqUL9TSdSppy7FVYtR0zztSYTXlrI4RbaFNzRc8k+i+9aFnezQ3stldSq+9vNshGh4jxzk+tR2Vpb2urCedpW8xBH5H8IAHb8a1JZSNDvZNPmnt7i3ZJYxCwUuAeVyex7+1U5cztYxcHCLnfRdPLW/r3KEd5FNdy2cUJ81FBMxHXPYGrUt1DZ6dM4O8qUBEY3HcTgYAo1P7TrfhJNcazjdN7o6WsgOVPQFhwSDke1c9Amo/2XatYBNLkVwfLlO7C57/AF9e1CinuCqOStHf+vkdJaXckruFEsDhtpS4XO9Qeqr2/GjUPsGoagscDPaXVufM8tGIRVPUMvXBPfnGelVILe6nuIUjQyzx/OX65T69vqaLVtOl1jUrrSrhNR1SK3zcLApKDBwIt54LlhjAziklrdBVcYtKb1/H5HQQxW8NtbgQICfvpEMID6D2qeR4Yo/tZZMN+7xHg+WR2b0NZekPPd2tvJJb/Y5J13ywsdxiOen5U2002OO51KcpIIbpRFPCrYXqR5i+hB5FY8q1uzRy0Vv6RPeJLqV0jpMypFIN4B4lGOn0qXQ9LuRp0cDNKX81yhbgsnoSew7Vl211b6RcWGjwm/uLsxs4up8MpHo3aodW02TVdRspdbmvpQLOGS9uY5QkTPC5ZVSPruYYyRjGKtJ7N2RnVm429nG99PQ0LO6bVbe/utPeONIiBHPeIyRyknkhfvEDrnA7YqPV9Y0ywuZNRit7m/1OzgQoqoEBj3ANt7jk5x1rQs5LOOGS7nbC3chmYzN1Lcjk9MVZvDZQfaLi7kiWO3jRrgn7yRuQASBzg5HSpTSe2gS+H95LUq35tdSu1S6WIyykEbgMZ7bR2PPPvVLWvD5v5rKPUbmNdOTfmBiFMpU8OpzuIHOeMVd13wj/AGvqdq0T+VaWxEz7Gw+B90qa5D4gaJqtx4qvtb1YWljHalo9OlRy5niRcLH5S5bGCckY5NXTipPR2MK+JdPlhCN0djaQanHrcyTG3GmRInlQMu4Fgc5IPGKzbGwh0XUo5dAsy95HLKkszScW6SHezIvQtztB64rR0jUbK3j07TCxV1soxHG7EuAqjgk5JIoMC2eqW0NkyJ9tui8yyyfNI2wnCL1JPHA6DrUXaujbljO0qiMrXvs+o6FJcX6y2dsziOR3yCDntjJyTVrxDcxaLY+GYrSO7uIJZ2lufKieR/JhTd5WByCzFd2e1bF1dz3WnvHpt3FDI0ginuEAkZVB5VOwbtnnFZceiiwtYrXSbq8s4vtf22VRKS00mMcsecY4x/OnGSW4qsalT3UrLT5/8AzYrCa7jhGns+mxPKt1tiTazI3JyhwRnp+FbkP2XXPC9vbxSyyRwaqtzEQpQSsgIxz/AAgnOe+KbNBb6nqjrqtrdRz20QFrq0EpWYZbcY8dGXI6N0yfWrGsQx6jafa4rqRZbVspZCVYxK/YHucf3RS3sVUm5Llktmv+AQjVZdMeO302wS80nlbnzufOz1JPUH6VTaw0HwvearqmntLZ6df28dt5LZcRbmBJDHJ68Vo6TZ3U9vgwv5suC0fZD6A0l9ouuya2bPTLHT9TtWdPtE8t4rQ2YXGQU6hiMkDnmlF626EYj6vC05bjdVL2lkfKTfMiHCqMbgalsZL7+wk/0WSaWeIkQQgEuM4zu6KB3JNX9QGhwCSz8QMt6cs0YikaMSKD90468enWor/xCt5oypptiIbKCJo4raL5UZMY27albLQc5zqO0Y/P/gEWlafp0NlFNaNbvczFvtJt3EiK46ruHDEdyOKlgeTRUlfRooknLmQBVA3sepPvXPRaqLbwrbXmj6cd+4f6IV8tgM84HqK9A0zRY5NMF3qcot45V8xU/j6US01Ypz5F+8d0cvraS6lbRSzki9jYywSEk7ZMdTjqM9qbo80k2nY1GeCTUYQBMY+FB68j3pJUMLafPPdyI0M+TsXCyc9CPTFbc+i2i39wwt1tmusM7liA6460r2VinKEdGrGHZ6vqd9eXY1FFEKyYgjiHyFOxwK0LmztrO1/tjXJobCzBAV5Bl3OcYVQMk59Kr6nbeHL6xS2hn1e0h0wvue0YRhzjJLA8sB1Gah03TdObT7S402WWVRGy2t5eTGSZt/P3j05AwB0qrJ6mbqSVlBcvmWPENlbWMM8NyYI5pn3RGKQoXOPkDnjk9xXO+HJtfN1HDqkUUI8vIMXTdnsOwxWlpelu2lx2+vSC9vImILsmN3PDD3rbuYzD9mkne2gDnbDJcSiMEdOp6n6U+ay5dzRSUGuZk8OqlluLaUhkPyuoPzKT3B7HvVnR7g2dukMVzLcmFSRLKcyEZzgkDHSuSS003SdSmtf7W3Xt3J54RzyQfT2FWvESGTTJdN03VFtNVuFBhlKEDjk81PKm7dDCdKNvdRsFLu6geeO8vre9jIj8xCrq8Ycup2Y2gnJU98CjTvGkd+ZZrFEkMT+VLD02sP4hTtA1D+yLaDRry6SXUpkTO2JmDEDliQMKM9zUemeGbSz+1PbbImvJDucEDfL1IGfam7ap/I5oqCfvLQu23iu2uUaTULeWzyTjfgfNn9M1ZudfNnb2iWsJna6mwWIyEGM7iewrhNf8Pai+sP8A2tcpDpaQ8wtwQwOd+4Vq6Ldn+z4fs7i4tGb5HjOQ2Pek4Rsmjd4eG8Tfk1C3vY/LZzJIyuGVfvOQM8A9T7Vz+meMJ4fCQN7pU9vNFhYSI9keHOIlYE8FhjjtUGs6BO0lv5LQwXhleeB5mYFJMZBAB681neGoZLjw3d6fqsjzzszJPM1x58bSDgMvcFcDr3FVGMeW7G6SdlHU6nRpLrULGH7AiwTtL5dytwnCBTiRdvfjOPXipz4fto0uLC0mvP7PdAIrYNt+zEZyUb7wz3XOPTFUbCK40ey0p7edboLD5MrysTJIVHyv6FugO7tTNKudZ0y3lhuFOoRKrv8AaFky7AnOzy8ZyMkZyai3ZkSUpu5i+J9W8Q2FvNZ6fazTJGY4zfSLvlcNxkLjHAHLetZh1/VxErqNXvkhldV2zqseIwqsWA6g53HPoa9AsdQEd5FctH5US4V1k3KQvHHPBFF3o09xYvHcXGntciZntmS2+VSd20sgOGyjbWHetI1Ut0NtU+mp5W5vNJ0W3vrqGK2WC5jvUubOQP8Aa2LkDbu74GdueRxXeadp2mS+Kk1S0uPOe+hEwgD8Ro3fb2HH4VN4g0ER+GbyykjtbeeNVl0+G6ULbwldoVBjovXGf73NeeaQ0un+J57K5s5ZhHIBG8FsUksGB5UvkB4gR8y9xyMVqmqidtCZycldav8A4c9F1PSyutw3bzzwpCzJ5ceRG5PZvwpbOR4rl7a6tYoYPNIiAAw47MAK5HxX401S58WLPp11G6AwJCPs++GWNztYHnBUtn/aGK7G80qK51X7fEspMZe3VCSxiYk/KQPpx9RWUoOKXN1HCo37siXUYXaCEW7+Qwb5sKJGk5+6Mj5B9OTnrWBBr95J4mlspHha2WEMMvl2J4II9vStTSJ5buykubEzv5LbXd4yuSOGHzAdPUVHd6ckRj1W3tLe5vhKi434+UkbnyOMgVMbLSRomoq27uYd14h+zaldWMlrckRFA0qrncW9K6KSezjtLYXU4UzyiGBmbb5kmM7RnvisTU7ydpb3SdOiaOeOENBfXBMgdien4elPS9jWbTNM8QyG9+0FWgAiGLadP+WiHGQD3GapxvsbVeZLmRn3Bu9N1QRWMQu4LuYm5ecklR02rgjFa11v0vS7y8tnWe3jUNi8O77OP4vm/iHbmk8RaJrF4lza2KFbaUc3URy0L5yBj68ZFaVjImmeHWtp1S7uFYIXnGVLLwWI70nJNJibWnJqc/puo6bo9+jPDJDZMyXEEnllVmaTkBTjk9iK1L+4u10+K91h7eO8aXzpliz5Ibn7ueTkYqzc3v2iJJ5nWXYn3sDgf7PoKzfG1vNq3he5GmENO6ho9p4JP9e1NWk1fQLvnU+th2lW9tFZzW3zXVnLKJT5zlwdxDYGegBFadzd/wBrR6vDbWd0s1mhjY28fE6HlSpHU9sVn+EIfsXhm3bV4d01sgWRYhu3NnAz64z2qvrurtqrTWX2m4gW2ZW8q3BRSOvbr7mk1eTJcXJqUFZop+M7iTT9P0KOPTX3xoHu4rfGVkfli2PvEcAmp1ikIWeIeaSPliAxuOOn1qOL7VqOspaW8fyuwWNpDjzCRnj0AqppM7TS6jc2t5IbaGcxoEQJgJ1C567jn5z+FVb3bf1qbxXs7Qjq7FSS+1SHVNNk1SN2YK0ckMR+SEk8n37flV27gjt7C7l0xUdmYukWf4yPTtViW/n1S13T2MFrOcgQQvuwe2WPJOK5rR7p7LVLnS7C33SGLzkDtkSMeuPpVq8vkVFKnZ7fp/wTTtFdrGGbVYRDdqhUlW5VTgshHcHFFLnVv7RuLRrBjALfKO3V5D94Y7YFFTJ92bUowV76P+tRDc2t1ZW0treQSxO5iT5sMXHJXGMg/piqes6TNqug30NrcRR3fmI4SSfyllAP3S3oOuBycYqTQ71buwuLmLS7a0ad9tw6ptkm28K2BwOM9ACajsoY4tYuLprh55XQIYN+Y0+laW5W7dDk5pVaXJP7X5WNeLS7fZGiXMsempMLiGxtYhDCDsw4ZQSZOckE+vNZ0eoafqOpXGkNbuZoVDO3l4Xb6D6cVe0yO7j06Brh/MYvIAy9BzwM/SpEUIGliCGRgMSJg5qL731CFP2bShot35ljW9MiureDS5pHj08gC40+J9v2rJBHmsOdoxwoIo1b7ZpdsZLe3HmQf6uG3AjjHoAB7etV50ubi/tZUvFR0cmZJMEuccdKtX+pw2SzSXDCe5H7uG13czSsD5aeqgkHmkk7pbkNRpJ1Nu76/wBdjP1WFpxpl3I91ZP5i7Vi6PIVPyuR2x1qxHBcCzZJLtp5X3ZfHHJyBgdh0p627yM15qM3l3PlJC9rFITDbt3CA98k5bqau6Uj3D+X5nysrY4GSVBJ/PH50Sk9jWHKouo9/wBDmvECz2SadfvELoWpAmK8lF9veujS7jh0ueeSHMU7qdzHlfoO1cbpOvaxqWo3AstGadgPJe3l5jhJGfNkbj8hiuoGuXMugXcFzo+kyavaOpFvDcSGBkPOT3BOK0qU2rJ/mYrFKr8MW7+RS8Wz2ken232qya7t2uE2RIuec8flW6l+Li2K2ogSRSsEkhUHMSnOwnrxngdqxZVuNMM8nneVpuXaaCa5V/3b4ZZM4yDG2VA7ip9CW8kW73WlnHZS7xbSIdyzBl++fxNZtJRNotVG+ZfI3NCub3ULO7OpWotbyJzHtjOAyD7p+hFN1KMXUNotuim5jl3Hjl1P9PpT00y9W2037Lc48srG6klzKOm3J+vXtRYaqZre9vtJW2jzF9nt7gxkzuyv8554VcdMd+az3d0Z83J8OrKmpWP2PV42e1ia6t4w8iBv3sSNnAHoDgnJrL8Uyatrd1EujvpcWkMhT7Qq4uIMgb3EnUknsMdKfdfbLHSAsaXOozomx5ZpN00qbicM38WNx/Cr+l6XPYajGJxFDpz2oWMAcqx+Zs9sdgO5q4vl1W45xUknV38u5nXHh+7jtbGPwrcJa/ZmGF6RNzlmbPc8k10lzbtHZLqUs9v5P3A4Y4AHX8Ko6hNf/aYxZSxxRrIrOW4OzuPrSanqqz+IE0qW6ie1ktmaa2aMltgPJDdMd8YqXeSVxuU4yXLsWrOaG5tvM0+RJUILGQHK46k59K5uEaRqcd83hCBtc8Q6fcxCGRWBt4GuBj7QuT84XGOwBrqLx7bSrBJ/DWLi1EaeVsGxWz1A9sdauRX76YsEVjp2nWVrdYa4+xwrDnPHOOuM0ovl1RhX9pVS5Ho9+5U1qW7stAis7a6XWNTtYf308KhFuZ+hPH+eKpWSR6daS3JhSzNwBJcKpxg/7R74JpNPtbTS5rrTbWOWMJIZ3ZySHYnsfTmk8S6jJa6Ygg0ay1KABjexXMrIxT1Ur0wPzoXvPlXU2UfYU9rkKaS2rau8skaSQW6q1o6nLMCMtn6Gptb0rV2trC38NeUJd437j94d8YrX8CXT6qY54dIGj2WnB1izOJI8FfkfcPvc9RWHoM2s2+q3GnTQMbVRmLUDJukmYnlm9M+nAFPW78iPaybtHT+up1kWj3Y8SrBqumaWPDllbrKb+dsStPjJKEHhR0OQKg8QayL7UI5IExZxfJFt/i9/x7Vl6hYNd201vLuayuEeK4wxzg+ntUvheKxs3soopRNYwEKpJDAY46ioaurmdOlyPnm+b+tSfWYbSw/s86tMlq164W1gZS8kjdfuj7qjuTVy+1BX1BdsoDeWAIyc4Cjt7VztnHfwatdXeuITLqE0slxcNMrvp6LxHGo7occY9a3odLhvybxZ4wAcLkfMV9vqaGrbieqTqP8AyD7KCYbiKHZFOCpLDjJ4P4Vi+L0+Sw0mCxN7YySCOR0fYIQOQ+fYirYvL99dvYbhdmmlVEMmeAwGNuPQUWsE80srDLFACBjgChe6zSMXbmm9EaSyWVksZSEzXQUEs5+Qt646muYivDfalfHWvslxc24JVxhmiQjjr938K6JrKVHSORlLP0AbIGfU9qw9YstMhs7+7Fp9onlTZIY1y8q9NoHeiNuppSteyd33MPV9L0yO6tPEkkdxPLbAYaIl9y9sDv1NdXpNrbw2cl1du0yhvNDykARoeSD7YrKstKlsTbtBeXMFlsUJYMV2QKBgKCOp6knvUmu6vPp3hRJ4LCO+N1fC0e2kHytDgl/px3q/iagmKtJ8nMl1LuiNdwWlz/aV8L03EjSQvGMKIzyq+4Aqa4vop3GntOFkj233kgcyKhGUHpnPUVS0K3kktLXUo7S5SynTy4dOmUB7RVOCC4OHUgZBxnFSa1qekaZewSXGYZJSI4pAuSDngfSk03LQytB9GXBKt6IobtGdZI2DB2yTk9wfrVe10+G10250vSn+zIyFEaHgoT3U9jVbUtHvr7WlnkEEVgkLRh/MBeYyYDpjquAAQafr9hDcRRWMstxBHIyyg27lGO3nGfSjRW1BJPRFXT7GWfT7Ka5juIL2yVoYTcE+YCTgtz1+tc5dabdeE/D0n2eKW7u57jLJChbljneR6Curi1oXOtS2k+mmWa2jOy8deYywx8pPf86SzLQRNA887+X8xeWQu756kmq53HRm8IyfkYWq3Bl0+O0uJZoPPKjzouNrjkn2rekN/HPYC1aP7Nj9+SfnbjjHv60kvho+ILbM48iwicSNO7FQCvTB7n2FP0fOrwyCKC9tIg5S3mvIDH5uONwHUA9s0uZNaBVnTbt95Jr+sC30aab7I14jL5Uka/Nvz/KluNZ+wavbq3mYuY3e1iLqkaIqA7WJ5DDnkdR1rOutLHhzTDYh/OuCW8uOZwrFieMeoqhb3ttdXd9bWzp/akUatMzZKo2P/wBfSnGKt3M/ZQaTid9pet6X4gtrC1uL2Gea5J+yyN8ysyj5oy2MP9RWfJpWu2mjsE261cy3zYM823yIi3KsWAZsAHj9cVirbyappUNwDbedC8csEjhmRWDfO20Y+bA4PY59a66HXfJ1ZLS5R40mSOaCSaRQk5PVR33DjjHIqLcuxyVIOD9wr23hzw7I0OqNoEwlDC0MMilFTa52tszjg87h25rXsPDrvPqRkt7a0tXufOtzG5d5O5ZugGT0HX1rRu7iP7BMJHiilHzFGcDao7n2rI0jxhbavo0tz5LxRR+YjlDuQIMgHcODkDOByKzvNnM1OWqKfibQzp2nQxx3N3cwNuSV7mQu+WJPJ9OcCuYiguF0oWdqfswiACZGcrnn3rrPDRh8P6RFo99fz6tDdB5rKabdIShG4q8h4UZ4X2rkzrC2d/aR65pbWt9K7RRxRy+avB7uB6Vcb7HVh6j5GpK9jTtPnkmjaJPNVCo8wZ2j+9gfWoPDllJNFd3+o2XkQ2bkRkn/AFh/hx9av+KPHU/hmxe7k02FoIgu9Y1yzDgdasXHiNtcj051lFtptyh86LZlixwVbd2A9KPete2hfPUWlrX8+hX026vrXWHuZNRm8iQrG1oceVGM/eA9feuX1jW4lvJIdatXtLea7ktQyfPlMcS8dM1My6xH4kELJE+lucO4ByuB1zVwhNksUyJKWbjcuSMehqrKLu9TeEEpOUdGZfhuwsYdTt9PgvJ7y0kiclx82xEGWJ9D0HuSK1tOunu9GknuLIWCQTyRomcl0BG0n3xnNP8ADMdvpmj3kEaLHLM+7C9SoHr7muR1jVdS0fxDbvK7Npd0BHCiR52N3GccetV/ElZD5dfRos+IdeuLSGNLRHkkeQKqldvmc859gOeKuROHEboVjlkc72XofTmt1LS0vYpbvUpTbRW+C+1AxdicAD0zWNqzvbWzzQ2eTGCY1DYz6fSo5r6JHXTlG9o6W/yK/wBkkg1+71SGd5FFi1utuPuozgqW+vJrI8PXEWq6Pf2MyyWM4jWNhjmPsremelbVpqDQeGIWubeBb+9maZElnIaTap3ADGSOuB61St9+s6MJ7XzrBpQJA0kQDxhWBO4dwcYrW+mpnFrmco6P8w0nTLLTZAZ9Rmub90AlUxkRqwHUN6+1V7ewvLrXJceQLQwMPMX7w3Agkn3yMD1puqalLp1/qzXdqYba0KpEy/M02R2UeuR1/Gpfh1fagbu6Oq26IrOs1soPzKVyQWPf6e1O0knIU2uTlSev4FnxBqcXhK7e2e5nuoY3ighjCglRsCssh5MjMd2eQBnA6UU69tvtdtdSEqbiSXq4HI5JIPrRRGUbe8rsmODjKK5ZbGXG81sEljiuZmnIVEt7dpC3boBxjPU1Db2hhubhZYhDIXClI3VmJ/2wPun61Hqmma7rmqRXc2p/2eg8vbb2MroI0UYIVwRyTk5Iq1bG00PU7mIzxIt3D80otiZGk6CSSX7pbJPGK0dkrJ3ZlTq1py55w5Y7eZ0XmsdMfT5IVVJmBXB527ef1/rWFY2clheFbRx/ZioIlgZejk9SafeMZbERW5L6jaR/upZ5NqPu5AJ+uaR/DCXNtBfzyn7dvSVo47htgcDH3c8DvUKyVm9y+ZKXNYvmzhiuR5sitKSSAPvN+HfFVNeFraTjWJNPZpg8eZh1XZ8u76gE5qS31JHvri1mkUXltgSx4zgHoR7VbuXi/s97W7biUZGeisOv14NSk09S5tSSa6bDYbW1fzL2KbdHdoG3bsqR/CQP61Uuft6WF9HaN9nkWMGCcc7T3P5U/V9NB8L2dnZzLb2qxGOMRjlRupbea20vSvIvrgmJvLh3uMlix2r+p5oVrXG22mnsXNPmR4oZZ2UvIFEhUjEvbPvg1ja7a3WjarA+mWokOoyKtxPnO1FPI9vStLSdNWz8QQahJAr6bYRK+lW0UnDzHKvLLjoq9l7nmmatdx2s9qJ33TSNtjiGXZ2P91RyaFpLTUyT9reVuVIp6tDpt1eyXN2y5uENkyM2F9cEd63NNjWztdNtri4t7Qyv5Fss8qx+YewAPXPFZ2naFdXk7XuuRxRTwBlS0k+aNJB/qnYDkAH7wHaqerW9tN9jfXoLa51w3tvF9qnUxxyylhgpjoB0AA6gUOz924TqNRfKkutzo9J1mK6luxYedMti7RSzEbY0YcN8x+XgZ79qSKSCC+1i3t5YWtdPujBGYmOBhVb5s4AOGzxxXHawbbU/Dskd9pj2zaprsum29rZuxit9jkvM6Zw0jHOSOCM9K7W3tbWHRbbT4SZ4IYzHvmALSDoCx7/KAPpgUpwjBGGHrTrS5lst/wAync3yXL6athOrSXcjIsy/MqheSWbtgdu5qbUZLXVPtWkTeaw8oJI6grnj7wPTPHasi6sJpbd9LhQWtj5R2m3G1oWB4IHcGuhhtTJPZMsryFR+8Qf8tSODz24/nSfKlodfLyu89jLsGvrNLtb7bPEsiC1EZBk8sjqykgnkVbFmI7mS+uITDPJFsQXI8sqD0HqMmqdjorz+KL7UtaaK6uY5GhtAEVU+zk7k3Af3Og79c1sanaJqUcn9oKLgOwZsk4yDwcjGMdMUStfRmcKs38SsZfh0aq9pFZXcBmvlYgiEApnPQetP8UwtrOjR2Gl3crLN9oF/e2kSzww+UMGBu5Oc8r3AFaqXGrw69ZW2mRyW2iI6fbLhwu25SSMt8j9UCFdv1NY9nqNveG7t9OU232GUxLbKNqRgkkY9eeSepJzS1T5kZNuu7LRL8SDw34gmun03StT0e40+CbNtZyyq0kzMh+V5h/DGy/xdARjoKnNjqV/elNaksbTw/IJWurpThmh5VUix/Geu/oKiltpbrWoP7VjtntXtBA8uQsk0hfcYzjnAABq1L59xqlzp91Yp/Ypj/dSh8l2P3lI7VTavdaf10CFKSTi3ozasH0u30qLSdFtxZaPAu6OPJPmn1c9yetckW1+016J5HRtLZ1BVB8wXP3hXZafooS0kNxMlv5UamONuC4xwAPpWbZXRmiv5ktnka2B2x53Mx6bgo6CojK19LmkOSndQ2HWOp3j6XdWOvW9vaedc77Xyz+8aLnO7n6D161Snhi0TTZjpdnutrdGkSCJcmU9cD3NXDbxaho63g2rfJNsguJASFyMtx7HA+tR2X9p23lxNPbXE4BDTuCNrY+VwuMGjQIR9mnyvVXJ76COexW+MMaahNbpEDIpPy8lQ3+6SRVbw0dT0/TrWHVWgknDsWS3i4aMA4A9COCW9q3JoWlDvLKN7ILhowAqI2AGCn+LcRu5rGurSfULO6htJ5LeRoWImQ5MWR1pKXQVNxnHXoTiQGI+YzCMtkcZqrJNaan4htrcG6F3bx5ihMmLdSePMwPvN/vdKfcbNFsLGW7uWfSoLcPJJs/e3DYxuHoM/yq7pMMOoWNlfWjJHDIrSSOww7/3YxnoOST68UJW1CU4KPM0ZmvSX2iCzQQXV/HNMscrKcsNx4Y/7P0qwUkke6Nt50UsVzGkheAmJQwLMEJwGOB26Eir2qPqDXtsbWSAacEdbh3Pz8fdC9h65NWI7iCw0jTbOO4drOEko9xLveVmOck8DOTwKHsrIlVZWX4lMbJLiJJCUhLFnwMnaB296g06SOW+1i3v4lltP3b2iNHtS0bHMZPV5Dncx6DgUmt6pbx6pptuHnaW8LBCi8BlGcH0qXU51WyZLu5W1ct8sk2AAT6g9c/nQvzHOPOk3oZ2pLDb6zDf3t88BeM2ojeXasu7oMd61blVukijlWNmiXdkgAFgOOvfpRrvh621PSkF9EJp4h+6VCFIkA++M1kz6XfTnR7GyvCLhJA8iuR5kygHco7Z+lO6aWuo4SjLVaF7zpk0ewuNWUW8gjIuE3ABHyc8/lzUmmySXQuFufLhtxxC4bcCezfT1qhqRgULo+rQSzJclyVYEDA7E9sdqkvNHlFlp1tbzvZwJOm7aTueIA4QH3OMn0pabha0bFrT9P1OSMDVls7e+UlJIoZ/MRvRgcdx2PNSpprSNJHKP3WCGY5QYPXJOD+VQaSb9rm/kv3SFUJ+zlGIBUDjPv2qew12x1TUGsJ5/NmTLZBJwe4/Cly7hOrUWl7obqZjtokg03VpYTbWvkWVpbxqscB7yDdkuwHAJ7nJ5qn4b1/WZ7RJ7y91GJkfywlxKpDgcAkEfrWZrdzp9jdDX5bhmKH7KEiTdyx9B0NaeraausaNNaXQZLeZRubdtYLweO+avTlVxKjBaWuZupz6L4isbnW49NE18Zy8hYEySPEceWAx+VSQPu49auRPby4vNK0kQyyFTfROGyHK5IQgfMV6HsM9ataHbwXFpN9kKSW1uwSZzwVP496l3OiXK3UYFshxBtOdy+9HN0G4xhaMN0bulwxJC6QP9mj2Ek8KPWsmH7RLPFda3bWtkGikiUMUubnccbJo2GQoxnIPWsS5vr621mGHdEulNCDmRvmeVjwgB/Gp5mfUWkGnsJLuJwrnG7afQge3Sps1qRGhdtt6FdfDumLtElxdTMobEt1MXJy24b88MM4ODxxXR6UywK2mWUSxW8QWRWVQI5GxycDgHNY2s2Ed1pE1pqW+OGQYYqdp4OetAGqDS0k8OokkljgtFMN5kTGMDkc07827HUpPl5lsjV1vWk0fSGWcXCxXbi1aSzRWa3Z+FbB9DWnFp8d/aW5M8ZuIlHmNKoGegLDuM9frWXa6VLq/hgDV7MwyTAG6hJ2lnJzxg9RVrUNM1Kzia+0+a3u0422czeXsXODhgM+lTZbdTn91W5XZmhqOgW12gVr23lLjCxk8EYrEu9LkjWKO2RDCcKDK2xfcjHXA7VLaeLkudPsjZWI1RLqHzI5448QAbipHmZ4ZSOcirunWUC363sv2a6kEOzNszFEAPKIpJxyeT6ipSlHcIVJpau6Mi8tp9K0+8Jd9RkiLSqsKhSy/3VHT8zVKyme+06wu/s8ls9zHvMcvBiweh9TXUwPYX1/cRpPKt2sBP9nzoFdkGfm9MNg4BNVdNtLfUZJ9Sli1OFp0RfsrKXWEgfwjoD6461XNoXCtyu72OeitG/tJrhboPbbMCD/a9QRU01wLXTS7SJ5qMRtYbtw74FbA8MmwuzKkrPE+WJZuOfb+lcTrFldarp0ksJurMyFlCv95cMRkj8Oo7U0+Z7nXCVOr1N9J7PUbSa0lhVklhXAAON6sGBPpjFR6jcWtlAkc1xELycEQRONokI/hz6+hrltEg1KK9t4JnU2aqB5pHzM3euje5t7vUrKO8jhle2fdC0gywNU4xTt0K9nJaxEv3gMGnQ+R+7cFkWQDcmSe/UA+lZmpy6iur6fa2Mcf2Ztwmc8kAdhWhqNtDfPbq0/lyKxKjPcentUt1ONNs53nBZgm4MByexAx2xSTsWrqPKjNe1un1C+bULpJopZN0BCZMUYHO/wBce1a9raqlsYWlhDFQonJGwA8gg9xisTX7y0t7aSe6vPKRkCD5tu4kZ2j8KxrQXXiewtpLBhZaXbn7PG0a4BXBJXb+Jq1FyV3ohTe0Ezrb/Tpr5JYNOjE/krnzoz8q/KScfhzRWNd6xdeEfsVraxT3dzBhJIUfAjLd29Tg9O1FChO3u7GTqyp+61cNTgF3qdhemXyngQp5CdCMcDH60lnGkA1JNjZuADkgHyz2OP51VS8gfUbOKPzLqKRthurZldImHZyDxVm30eew1TUbx7p5oZUyA3AX39/pVvTR7mqipR93bUxZl1yz0qOZFj1HUBcEKQMDyj6j1610cF20MQEUI/f/AHtpwV/vDnqAazItZkmluobKyncweWYmzsEyH7xBPTHpWjq1x9jsxeSxtNIg4UU53bV0ZxStpqi1LbpcTzx2yD7Q8WxpIV5YdyD6Vj6IbW40zTbCwvotXuHVivluHlkAOMsv3hg8Z9qmmvJRpMN7uktGixdK44kQgHp6cdqytc1G21fwNqnjDTS1veeUNLniihVFuGkb5ZSB91hlvu9Sc0RTa/rc58VUnh2pK2i+f9X0Na6Z7S9e1a1+zTIu8iVGAPHNReHPstxaXbW00l0wkJn2/vSD9Owqn4ZFzqngvSI5oNTgms5F2xyyGKQ7Tg5L9UOScHmn6zDLo/8Abceoa1NF4avQbdrS0tFWXc3+rdWUALtbnPO4cGpilJWT1Nq9ecYqfKndfoi69zY6hbnTbDUo7e9hZohscA8dVA7njpSWepaddB7i3nuozBMIJLiF/KZmGMKXA3AZ7KQDnmqcuh6hYwWt5bJaXsUU8SK08KiW2RY8MUcfxscEk0+3ns4reQXkb2FqEFzPJIN0ELg8qSuTu79M1Vlb3f67hzKXM6iSX9P/ADL2gxaja+IdVjuDEmkyMJIIVH3GY5bnr+prYbU7W2vUEE/kT5BGSCcjnIB68+lOsdWsUuZLWzK3LRwR3PnlSY3R+FKt3BqC20fTtT8T29/eQEy2e+eLB+UbQW5HcVk3d3krDSSi+XVf8Ehv7bTpPF2l3N+LiI6jAbe2towPKS6hJdXJ7E5b65q1AZUWzhgj3K64ZycCMeuf0rLn8RabqGr6Tc3QkfTYJomgj+ylh9p2u5nUg5IwcDr93GKuw3rx6RC+pT2c8styxhW0YsVhI4Lj+En0NVOMrJsyoVFCUoWtd6ElzeR3umXUNlNcLsA/0hDgllYZ99vGCO4pILmHSLiys0mnae53uknkqglfO48LwDg8D2q7BHuYrDCDAyjbs4xnrn161PaQDzg0RguUhYuCkqyNHjg9DwazTaVjWoqad+v5mLqUmqXGtN9mZbaz02P7VdTMhZZbcDnGASSPStnRriHXrK1vtHKXumSAs09t85BHZk6g+xqOz8S6cdUvNPgmmTULfbuVEKqAecs/+FO1a3urqxVtJla2uILiO5k+zkQk4PPKjk49Qc96b1smrGHPPdbfr6lKbS7y9vr4XcTNpd7amCK3I2edJ1CqD3OO1ZWlx67b3d4t5r8FlLbhIlt9OsFkRCQAEeVx8zKODtyAe9Xr22vPDtpqHiFri913VLmaR7W2kkLfY42JBKAkjODjjt0q54btr2ayS2uBHLc7ciROOSeBj15xVN8q01QRi6us9EipfOq63pFvdafLcxkPIt277jE/+0fU9vSp9M1G30q/httTvHu7mQtLbrKoUHn5Qx9M8epq25ihnFu25pSeS3bBwf60/wAQaVY3Mumi4hWSWJzMp3H5CGypP+FQmtmbyf2V1MnVWNvcSSWVybjX7xZUhlu2JRFJDtGvoM9D6cVFHaS6PaXV5oS/8TOUK7BnO1m6N+HXiuguIY2keT7P9onYAQQrgZkwSCW/hBGRn6U+80iUTxC2WRzA2/ZlQJTjIRmPCjPfvijmYRnTinH5mZps6wRy2lsrbLZclZCSQT8xxnryani1qQ29teIIkgkkw5nOzgHBAqxHqE0ksF7NZWFtbsuGZ7hZlk5x8pXjGeOTUEWuP9v1S1vYkia2t4py5IMbrIxVAnbdkYx60mm3sS5xlFOyL8z21msmpGdQ0cLPEpILSAHOFX6kYzWbMJ9UktJrwNZ28G25Gnx3BBd+u6cjBfn+HgVl6/eappN8r2q208QlEXmn5TFB1zk9WySSfwq9Z2MN14gl1m0gmec2qxllk/dyEtgKB1yRk/hVJJK7JlSSjzS1JIfEI1vSm1aNXlSSRkw8fO4HBG3/ADxSzxw/abe1dWLSMJy0ZKgEcc49Aavr5DtPaw2TwQWw3LJngzN1VR36HJ7cVm6TejVtKvLy2jkzFuWOOdfJLyA4xk9u+fapXkXHlUXfS39I0NR8qS2mtNQ3eVdfucIeTkdKx72PRlfR/C99aahJI0hSGRAQkXlYILt6Z71taazm2i+1iEzxLmVoixUnoCu7n86p6xYzJ4eXTdNKwZKwpIckCMn5hjuSMj8aItLcjlley0ZZtbi01PSftGhNbPGfuSXMchaQg8spUj5eOCOv0q3Na4sYZ7qGCa5jAeS42ZJY91BzsHoM1g6PrQm1K+0pbF4I7FVjR8ALgDHAHSugsbxbvTLnypB5aym3dGUj94BkqM+3OaJRcdDOUZJ33Oe1JJLvWrAx6gYZLWUyPAHwZVxzkelWrm6tU8VaWJ2jkvIma5s41YqQyghjkexIINQ6loiTXz3+myrZ65JD5Ed1Mpby1JwSFHVgOmah0a4026iSPT3FyLAm0aR0/eb14YsfUnJNVpy3Nrc8uVLobN1fRXV3E0wSO7YkxjPPvjPWsS8tdSutJtoxetZ3kc5OWYylk35+YnrkflWhc2EGoQpqdrbJcX1jMsatJIVVAxwxIHXA7dOlMvIxHZTT6cA12/IDnIJHQH0pJ22CCinZdB5u2N47G8gFlaxNFcw5yRKDkMzdsDtVjQ9P03ToZ7lIYy037xADhXJB5J9On1qC90xbTTrSW4063mTU2M2puSNsRVc8r/ExwOvGKiie31jTneGYNbyKPLkiOAAD2ND20FFc602LmiyNp+myW8y217OWG+aa3jX5s5yQowTyOfarGqAOIZbeRgzpkn+6+cfhUENh9slbT3ZPtEe0SKrYdAwypYdsjpWhcQwxJd2McyvcWv8ArI0cM6emR71Jm5U4TTic3p2lXOm+H57YXck0wDH7RKcnPJyfXFP8L2V/eW3/ABMbqGaNWyJkPy7e2e1amoj7NZ3Ud/FK0FvAslwxHykOD+7A6s2Bk9u1Znh+7ji0hZtOiezgeMBYJBxEg54XoD3z1q220zRTlKLcUrmp4tsNP8vQY2tJJp0aWeG6b7qMmBhv9ohjj0rnE1K/8K6JqN9dG3uroyGRhbDywUzwCeucc8V0MOoHWNKWZLpZLd+VfPX1/Gs4RwsE064aGeWdWCpIQWcfTvSi2vdZMIe44y1K+p38Wt29p5lvNLBfBWkKMu2Iep/zzSa1bMtlJaaFKIsRbIpJG5JA4J/DvWvDcWtndW0SxJCiMqkFRt28A/Xg1max4fTQdR1PVrJZtQmuhmG1aTKArwFHsRindX0HGVmo7Evw5utTt4Z7TxEA1tIGMbGTcY+Mgk+oPGe4rS0Nx4s09ENybUJOH8y1n5EidMnHT1FYt/Hqtz4djH2cWGpTRglNvyxP3HvVuwFzp0QuZ7iOK3wFeZjty+BkY9+tKSu2+pLpxcea9rm/9nu7K51YQ2V1bWsai4jCToIbljw6xx8FScbjnjJzXIfD/wAT3evQ6npXhvwvp1sI2MkUiEwor5wxcgnLd+OtdvaX0jRyR3YWeJQCoAwce3qKwZfCd7Y3b6n4a1NbK+AMa7kBQKW3DKdDxkZ96IyjZqW/zOX2e0XZNCx6hrGl6la2Wv6RcC8lnYwXdihmQqMffOMjIzz+FXdZ8SQ3TzLp8N/HK7YkgUGKXyz8pkQdSM8EryK5DxLq+t6te31hr2pWUN1aovkpplzJAIs8sZpBwBgZ25z6VLpV9ceJBbXFndhb+1lYR3yWxKKBw6xqxyQ3GSSfXrVSppLml+BpCM6vvNbef9aHReINVv8ATQ01rpytp1rbCSSQz4fI4yA3bpk8k5rH07x3bX+s2tleWqfa7gf6TbrJ+9ifA289CMdQBxV3XtIv28J6rem4udU1aG/FyImOI1AwFQKf4R19M81q+FLzTvETLaa1pMFnrKGRIJYl++g5GH65x19ccVK5eVu1xNKEeZx0vbToZ3iPQLp/7NuNM1KCG2MpdonYBpAP4Pwz2rI1ZGsroubUmZgOg+77/Supk0pbO8TTtcWC/tEcSW9yyjdHL2JQD5cdODyOtR+I7SW1S08x0kk3EL/sr9fSpT2R1YfEPmUX1/IxLe3dtRjd/La28vJAyWBPU49KbcJPDfPKJY3spMCKP720gc5zVKx0yTR9Rvrm2Zyl4DJNI8m4789FB6Ci6v4ryC5sYbtYtRWJW3xqGaME9SPertd2Rsm3JTZm65px1XxFZW0+ji4mKfaIjbkNGiHhS65yp49MelWvEWjyRWmjaXayraW1uJ7ifyuS0rrtU/8AAR2rVtY4kurXUUgjF9DA0UN7ysqRZ5TI6jOTg9OcVj6XY6jEl5calMl2JZXaMEcBemQO/P8AKr5rddiFD2mlTb8fmGs6fI/i7+0ILsPaXESmbjJMgUKT+Yoq3pFxZ/aF0+8llWNpRD5hX7rcY59O2RRWcm9ExzqRo+60c/pTW0f2qx0iRPtcZyQYwqj8BjNXZtQvDqxsjasbNY1f7QH4Zz/Dt9u1VPDtvDBYC4B4CjliN/BwVb0IPFS/2rGb+7tWgZEt8Sb8bUIPTB710SSbdkNa8vM/61sT2ZknluPtMEdsLclFbP31P8j/AI1WtYGi8x7a8kkCurAXTlljQZ3Kp7HnIJPbFajMl/aArNnzPuhccGufW50rTYbrSryeRzGUWWeRT5ZL5wN3c0o63sDly2Un6HQX+FjMk5LRLFuZ9pIdO2AOuc1T8Z6TBDat4LbyLC0nigvYb3G+QXQPzIIRyFCnr+OalsL5ND8LSeRO8tpagm3VSG2c52g9h1pfCWo2/ieKa5e2aG6tztWSYfM2R0B60kpRXN0RlXh7W1OWi3aXVGhZLZwNArma5uSiiS7uWzJMVXG9gDgHGB3ptvbrBPdtDcPcq8gfZNhgnsoqTUTNYo8TRHzgCMN69uar6JpFsfD8dpqAuVmiuWuILmNgWjdumAeGUHOAfU1mrWvc2d47K6INRm1STw1qkU01or7vMgaYYG0f3vfFZVj4YntfDGpx+e+o3OqoZBHHlNkij5Mt03EHr3HFdBq+nwy6K1jfLNqJ2hJDHGEdv+A7uhHUA/SpNXuhY6ZbGGG7ki8mC4EvklEK5KiIH/nopUZB6cVaqSStHuYVKdObs9L6L5lTwNKI9Nks/s8olbazQvN5ixMsYCwqv8HOTj1qvo+uXen6ZfJffZ4/Ek0Fw9pbv90Ljow9cA1c8Kzwaz4u1RLe3Nhq/kx3V1bFwRvAHz47Hpkdq0vENrp0N1PqF/8AZ7V4k8qWZiPkDcgevOelOT99qS3sZxdPlUYuytr95ysdzp9lpCar9qBu5ooLiFHj3LZgZC7F75OansdTub0X+s6Do9qt7eShriZ42CiZOHLx55V17jkEdDWh9ogv9d1CzNuotIERUbAwMchMe3X8a29G/wCJfdbTGGjlXJjU4yemf51MpW6am8oJxc7akWi3ENzq0djIJZN8Uk+M/LIqgkp/T1xXn/w/nv30vWJtF03T9Ov4haTxvHCEX7O7yfuWfJ3HIU5zng+ldZqyWkWmXM1lcPFqFxI2lrc+bs+yRtzLKo/iIUY47E9Kq2fl+DPAVnpmrLska4lldIF3lULFYs477Bn/AIFVR0g0t20cdV+0xCW0V/TOqfQG1LQ7O8F/ZSX0bIbkWa5LkdVB+vSiyvbU6hPFDdW1zJCgkmS2mV3iVujEDtniqfg/7FoFvHHHMy28zgkOfmOc+v48VU0/w1aeH9HFvbKh2M0sxs08lroh2dF3HLFRwNpOCRmsrb3foaVHNTUL3Ro+H9QtdZmmtrd2eOKRhu6bW9qXXbgafB9mhfP227W1eVMqyQlGMm0jlWOAAfWs3TL6K7s7eeO2azlu0LmGT5XBHXOP51b0nRZoRczX98gbUZV+xR3DqnCj5kjXO5yevFDSTNZxUUnJ2ixzyxRJGspO4jClzknj9TU81pqpvNPa1s5Gsp8m4kdDkY+7tqrHrNlHb3l8tpNqF3YRxkWpjw6SyPtj3xZ3BeCxJxwKwp9I8TvNJeS62nn3N8WvXW6aUQxKPljgj44c7sKfu4HNOMdbydjOpVbahTVzrNSmlt7bZDA8lwzgPngoPfNU/EqXGteFNb0mBpBdzwb7fY4Bd1IKpk9j7+tT2MqQaCtnZWshaAH7ObqQmVR23MeS31rHvdQXRW0nVmQfa73UFhu9xLARgc4HtnNTG/MrF+zUoNTWpJDolgmg2GiyqWs4YhuQfKA5JYnjodxNWUkjuNej8ORwpOyG0nbcoYCJZT+oAJFUI7fUNI0K3imkillt1b7Q5wxYbieMdcg11PhwwBZdSSMBpLXCPtwzcfKD9MninJtXbCokqehga/JZ32qSaVNaXTm7VpBIqHygAc4Ldqfr076Poui2Gl6nPpscMi3d20EZaR49wjiiQnjlyMj0zWgZZGt1jLOQpwQD1+lWpmNxZ2qzKqDBdcgcAev0xUp7aBWjKUVGWxDPcSLM/nfeyVJb1J6iq01neS6tA8br9iWIq0JYBnbPBrRsfJRRJMTICCQM8fnVGDTNOa/nv1tit7KPnkD/AHvwpIamk3psZ9nYX+mx63qOp3K/YDLuBlYIsSEYCbicAZxTWi/4SDUrfSri8TTbeURMmJVM4lzuU/KSNhUcfjWprs9voVpG2pGaWwvnW1FkyB0difvFTTdSklh8y5060t/th2Qkqqq3lDtkDOAOlWn1FzSm/dsaEsXm3M724Ay3QdXA45+tJJdHzJdPMRijhcTrKRyxK88+g6VFBJ5SkxnBxnLetQRadfXGtJd3V39k0xLcTJAcebcyMCGjlX+FRwR3rNLuZzlb4/kLZOupSQCJXAkbYjvlec9Tmqqvpon1I6dH5JjunSYugQvIOr+4Pr3q5od7ay60sUM6yS6fMouY8EGMnpWZqXhy1s4jok0pcyiSSRzJiR97FhyOuM4qrdGaxkue19LFq5Ew8PWl/bvvurO5ZLqOHlXgmwrZ+mFbPbFLJYxpBNDveMHKlweRnjIqlpuj29loV5ozTzR2VxEIckksBuzTptQadrqPSYWvWjG2ExkEMw42Z7Ed6PQ0UJXduuv9eha0zTgJyGmdwY/JxI2c4HX6nvWXq8zaDpES2VkkqiURuqttVFPVia1op5U03TZ9NW1nlN20OpSLJvW3KrkquOrZIFTXVpBfWcsV9GHglG1kboRQnZ6kqp16f5EsdtDcaodSt7iU3VzaRRToCNhCZ2sPes/U7y30XUm1hIUbVbp4omZlz9o2ngMR6DvWmk62TbohHxF5YwPujptqhpfn215ef2xsuECi6tY/KOI4umc4wcHtmhOxjy21sV5NOa2srkWFzOz3d0bh2vWLs2STtz2AzwKYlvfy63EYTDFpgRhciQc57FfX6VuJeefKJii4Vg4TrxnpUfhnThbXNxcXTo9xdyMz/wDPJOTg475GM9BRzaXZXO6UXFoy7WJC2oafpVrItlYBZI2V1kSfdyy7V5Rwc/K3UdKdFoUF7qNvcyZhubeJ1W4Q/vI1I5xnqeePTrUOp6al7qNxbx20cGnQR5tntm8sb2JD5Qcbv9o84ptzb/ZbOyRbgQrAcSNKeWUDGKp90EG3C19zdv8ATkTU7y2iRkgU5QdcAAYxnrUOmkxapbGRjNbuygxN/CQeo9Kime6uH0+4WYxoozhurKRjnPPFRXuo3V3e28Ol+Q5jkBuA7YKJjjgc5JqUriXM1ZnUeJ5BLaNcF0ZlufLCIQSuOoPv0+led+DhqGvXGsWuuwINPS9JiWYbDGoHUc85rrVuo7gvbQ2sEEk85nkZMKHlOAzH3OOa5m+08X3iWOZ7yRTY5EttFyJT2LU6TsmiKdNqHLLoa97Dv1G1khu3SG13xeUhwkwx0OeeO1VNX1Z10F73R911bxTBJHhkBMWOuR3A5BHpTLwSDVbZoJFePADqWG5fQgevapfDOo6aDq2mW8DwRRvtlHl7ELk5yvr0xQlpdmr91JrUuaJ4XsL+a1Oj22keVGDJcxOpMwZsFHHPAwe4P1q/qVzF4MvYIRHLqmpX7OkTFNtvZRKoLbmA4A646nNYukyq000xhdJ7aY263DoFdlPOFI5ZR0zXQafGEuLmZGHmzYLiTkSbe/1x3qZX5veMqtOSvFS93sSajq39iRwR3Ugk0/VHS2iLuGZncfeQDqOhwe1ctqfhfUIfDF1NBqSDxSrRx/boW+zi4CsQoXPCttyDjg1u61NJdX9ppeLO2mVzNK1yhG6PBAMRHU5wD0wM1heNtNutSn8PwSiK9tbeSOWeWIgJE67gwwfmYMGHfjHFEEk0iY8y23f4l/S9Tu5buyl023luGSaW01OfUiVmRo8DKhflPUHPQ1LrF/DJqcWn3qMA0IZJM483kllHrjgHHrXby6WDbGWwcRiaM7kZeHJHJPua51Y7ffBb6hDEzQkpE+BmLPDYPbI71KmnrYmlNS1XT7zjNc1q2kndreM3AEi28iQ8mIjru9RWdq91BZajbmysTcXl2joXi6ttGQDn9PerWsRaXp2oXNqkkMN5cy+c3OCxHeq8V00dtLd3UGwQzIEeME7yTjp2wa6I2Vmj0IxSVi/qyJc+HorZme2jlhKSS7jvj7kn9al8Lx2cfhGKwsL17u6t0Z48tlvKDg7s9+uap61DHJp6rdmR4bkHfEDy3qKl+EAjlnu0jtGsFt4isHmfKU5xgnsDU/8ALtkVYqEVO2xQupLjUPFcWnWVo4eVEZ5NvysxPb396K9S1i+tPDtibsWltHqM/wAkW1Rkccsfb+dFZOUpW5UYuVXEWlTSS82eH6laebpekXFts0q4uXaJ4Y1PkyzM25ST/C27g54ORW5pGmSSeF7uLWxE16I2XEQypOflB+p6mtOG1tLvQJrG8izDJhix/gYHhl9+cEVw/jS4l0+6VNN1y/jQ2y3BHlKAH3bdiSH+LIJ/TrXZHmqWjsFScaClZPV2S/r5nS6a1xCLW0S0tyuzEk7HATGOFH6c028EPh+eTUbKwiuZJiHkjkBfeR0O1uBj26VzJukstWa5S5kvtSMzx3NlCqiRg5HlyN2yAckAZ9a9G0C5024s5bnU5UufKcxDynyMg85Pr7VM1yNPoVGsqsG2tTl9OMOpWLw2LT6VNgnbEoxkncQQwwRkmrrWmt22mXMmjXIkvba2llKeSvmXHAGFIHBAJPHPFaM0KvJO1jG625YlFPJI+tYUz6tb61bG1ULYiMs0zZB3DoF96It30/EqcFVg0nZvQh0HVLeLwzoel6peTSavPHJdosxMjKoP+rLkDB4J2n161tW93cjVUV4iysoZGwcA9+B7Vl/E6cpbeG/FNjp9u80EksNzmRY/tG4ZKN+G457VoaTr0Wl6m/h+wgnjudOt3vzqF0v2gTW4Te0JPGCNwAcZzjFEo8y54rf/ADOWliVRTozWqdjRuTJcxAlxLbSO3zRkHBHBGR6HrU+g210h1eyaUmC8g+0Wkcw3LFdIMBh7MMZHtTPCkumR6JpyaPZwrpkjyz+Wp+U+YeQOvQjvWi2n3OnW8MjTLN8rlUGS6oxO3J9jjJ9Kx0vZHRVk3TUaitc86sWgaW3XVrpnvdVhFm/kII1jliJDbSBnqO5q/wCKNDV/DFrC0jXFvZ+RBiaTnIY7GJ6t3XHXkVo6PYXkejRzaxHB9tklecCJQQhPIye79cke1WLttPu9G8SWOrxTTwJZR3wEJwwZJAAAexzj8M1s53mv68iZqMcO5R3/AKucpo+orqkusW0dheXUN6iieRXWCW3I6RMW43LnGR1Fadpqgh0iJrKeKW4uHOn6dHO5dDLGuXDso+XoQWP4CuZ0vWbOawuC1s9yLFZL4yNJtitWCkxo5X74LLjd6nvXoulwS22sanDYx+Q2pCC+uZXIEdo7RgiCIHpjcxLDn5sVrWioPVHNCtOo1CD9WNWS4vbqwkthazac9uH8xBgtuAztzyB1FI0V5faw8kcxazgBEtq6jDtwQ+T19KmtfD9zqOu2UtnqRhS3hkEvO6Mr/eI9j2rA8M+Lb/xB4ohtNGWNoDKtnJDNkmSIOfOlkwMKzKBtbPB4rnUW03HodVSvGlotWbei6hDrltFc3mnyWrpLJ5MLx4IZP4sen+Nav9r6XdW8t+99bjT7aNzPMGysRVSSCR0/I1mzHVbXUEUCykUJLay3TOTJLGG/d7FHC9ix5z06VLY2ENrDNbGG1aOQ5eDyhskz13KetQ+XcpxlNXXyOW8ReLrvTNc03StPs7PUNUNuGS5lVo4ZnZd6iGPqSVIwCTnHIq5faRcarqmm3Xim5un1tNHiiiddkc1tOxJc4HCuoIAIHGfWuivrm+OvaXNEqw2ghuFnZohmKQY2ur/wgqcY44FZmlzT6lq7Q/2eYY4bjyTcSHC7TyWDemOeKvm928VbQxhh1Kd6zvboX7uVLGDyrEQ2xnkXzFjT553xjLt952x61dtgrBAzwpMysY4mf5pQgy5T125GaS58weJrhHuLVtD2iGC2ghBcH/nq0nX3x6msPSLL+zbu6v8AXNUTUtRw0FkcZ+yRsMEhiAAWXAKgY4z1rOyau3qa807KMI7msYIbni3n3RspXIkxjPX8aiihWO3jszbo628hljaUb2RjwSD7iregaTEJBb2pSCBcyStjO0HkmsrQvE1hr00sdo6rOZpY4ojIrSSBOd3HQkc7frQk3dx6GkqqhLkNNBHNdW1u7LI8pCeW+PmB9BUNz4lGn+JF8PjSJEjMphW7T5gzAZYY6gAD+tFnpsH9ppf7A1xFgRy7jlaq66tgdYlmGnXCXWszILq5tp2jJaPlXOOnocYyKIKN7Mzr80pK2qJre7eBdrMLxZJtkcsUBUqe29c4wO5BqoqS6cbTTryCe6trt5PMniORFu5ZnOeASeAOnStyztobNXjtIEQSlnIT+8eSxNFlNFeKGtyHVmx3GCOOh96LlOXloW5dOt9J0mLyxcvaRIDG6oWJBYAAjqeTyaz9MjvEurpry6t2bcXjwMKFHbPc0t8LtpbMx3U0X2SQ71TkSIQQU+nNTW0QkdA2SCOQBzx71PQzinZuTLt/EuoTXSyhHNvGr25Y/efH/wBeqdupleASRHzpBsxnoTUIdLHUzdyzg2gIG3so6Nk+mKw/EcGrLqaWOlrJeWmoCSBrveALRGH389l2kEevIojFy0HHlitXpbQ0opbfWI7yP7PcwwaPfqI2kIEd6+3Ak/2kU5wueuDVvQ31CZimoX8E9/Ad7lRtUx55yP7wXp61gaNaf2XpQ0fSY5TYwDyWlYgMX/imUHrk84NJ4O+yZm1BYrqPUJWNteNOcnzIxxnHHzqdwI64NW4qza2H7NxVnuzq7d7SK8B8lY2lYM7lcZHoT3NUJYra9uUvFAlljyisG4Vc8AeoqvqerwQaZqc8Ub3psE8yW3gIMmCcc5OBjqSegFT2MDwaJpnmGBp5IvNkNuMRkEkqV9flI579amzSuKKjGSi9yO11by9N1+41ize002yjDeevzFtzADHt3NZl+ht47WTQIb22t4riOQJp7IPtqyAFpGZhlVHTjluelbOt6ZLrXhHVdMgu1sXlMUpc8B0R8snrkisXVtavdN1TyU0uWaxSESLOh6YH3R+FVDXVbhFc8pRLltFaeG7q00jSLfzYJ0e5uCSFdW3klioGCMkDI5HFV5ddbT5501VfMhR/3bxxFRGuM/OxOCR/s/lVq81uC1tNNvp1nH20hYY1j3Ow/iJA7DIzUU1rp2m3AGrR+fBczI8f9oN5kaPn5WUH36ULe8tS0ko8sVqTeHb7TNTXVNU0rULrUbZXjVYJYDEIn25BjyMsrDjPYg1Y0n7WLnUbi7upWtrja0dnJ0t8dRVXSZtZvr1oZraOLbO8MkI5JjByrqRx/SpdcvLnGr6fotpO11Y+WFuni8xZy2DhQCCVAyCe1D1bSMbcq97VlfxKtvNosRhvpLCKSaOMSLxIzbshVU8ndj8e1SwXsWosNX0u5mubadBCtu42KhViC20854x+FWj4bt7LUP7ZTzbmSSNI0+04eOJ1JJkRf75PO49BwKkXzJCsoY7i2GOB8w9qTkrWQ4OT1ey0ILkTN4gtrvfdsjRsnko37rORyRjrTNWu9P0Wa71rU4GnLNGqGQBhb87fkAH8ROTnNOvtQtri8vtMF/HDqMUBmlhjOZI1I27uBjjIOKitvstvoljpmpahHJ5aqj3NyRhwSAGPtnAp9NQjZq/Qke4v7m/maaJBb7RtdOo/D06VENP8tLx9KWGPU5wSQR1fsWrUhltvtGsJZzOZtMmWC5DxkIzEcbT3FZNxp/8AxNk1W2nfIGNqt8u4/wAX1pJ9zWElPRbEOmRXp02GG8lke62kSXCAA7snPHYVHpthZa3q99Fa3TjVRH5E7xEowGOMN3I61u2UiXE+owwnLRsEkUDlGxnI9sGqdvfW+m+II4Cx+3PF54CR/KF6Dc3QnHahN6tBzXi4rdGJImn2UL60bszS7Ps0tzj5W2Ha2B6k9x1q/FOsiLMk4WCQBlYrgn061t2fheA6dLZPcAwGVpIUuCBsDnIUE8Ebug61ja5ZXGj25uNSidILeNiwIz8o7jsaHJSehpQqRnHkvqZcFzYadqEGgyPPFPeiRom5brnLbu3OfpW3o0TaVpCwi5ubiS2iJUv87vjPGe5qlaajZXn9nymVIjIuYQ4AdhjoB1p+m6vNqUki2dtNaR28/ltJOmPNUdSo/kabTZFRPboW9A1t31S2bXlmSK8IeyQxBvsq7fmSVjyuT+FdhqVhbXSrsQ21yn7wLG+6F8+v8+K8/wBUs7S78UWZnE6NZH7Qq9I33cHPrWxqmuPEbdNKgVxK5SNQchPqe1TKPNZownTfMnA3ofG9vaXyaZq2WnjVTLPFH+7G44WP/e6fhUB1GC9u55bYCRGY7CuCFI4KmqGmNHeNcPPax2kscnlSzH/lrgD5v1x+FWtNYW9oYpRFAfMdljyNxGevHY/1qGl0QlRhT1juchr/AIWtdbv3GoW+XKhkkU4OM+tVrTUpYIblDCYYoS6SB+d6qPvD8K7LVbi4t1d9Ntopr3ephinJETAnnOOcYrk/FPh67Wa21AW8ytbsZWsbUiU3APG1cHn6VrB30k9DqjWTeqIrTVotRstMVIXe1nTdFJjnPatLQLGefQfEjXUlxZySK1vHcgYdccgqPatK10SOO3tk1VPsMWzcYujIMcBvQ+1Jr3i97e1l0TQNOitlV0i+13rAxyxE5coo5Jx0Jx1pN3dooU6jnCMYLm7tbHPeLfJ8Q21qLi4uQtukaxmNtr5UDknvk9aKztZEt9cS2OlzSWSQOjNMwwjDqRn07UVrCTjG17GtWlBWSjdIpNe6leS6lb28ASS2ZJEllOEdS2GAx3ArQFja3Fs8F0iTxIXmVJBkKeuB6HvUQtpJ9Nv7aNUa7u7N7USsMBiVABPtmruiJA7taSTKIbdBEJdvMmFwW49TnGKqT0uiI8ylKD10Tv8ANkUVpZNfG5it4o5jGN0gABJHQE/j1qey0m2t7e5NhCI2nBkeJSADIOnt+NZC6xZ2dxes1pKpSdIpSwJWRWGFkU+nYj1qa5sr1tZtJLKdobGIguu3JkPcUNPZ6Di01eJtSazDY6PYz6lB9gfcI3jZt20k9yOMe9ZuoaWUe+t7SS4S2vSbppfNLMkh42qD0UZ4xWpqclrHNo8M0f7y8eaNEblRtAOCP6VPMzXERjWDBXBVycc5wRn1/Ss03FprqNKMlfqm/wDg/oZttZaevh5NC1aNdRicrNaNMx2faEBZRIR0DYKn61j+ErTV9ettathJPHFqE6OmoXBO0QnDSLH6rgKBjg8CtS20K7+w3X9qXpLR3Alt3A/1SZ6HHUckH61seF7rSNJ0OOxvtU+ywJcSWliJ+SrZz5SAdB0xWnPaLUdXc4q1O8/abK1n+RFZz2z3U1pYILaCG48vYE2iP/Pf3qfU9L1NtRsbm2v2tYoHLSJ/eB46/j3qC1vS3iDVBeQ3IWKMOJiB5ZB7DAyT/jVDxZdpe+FbSTTrqzmhvLoWkKPMwLORnDFRwoAyc44qIp82htWkowXN0LXiexl1jRjYQ37WLFlMc0fOQDnHHr7VJNDZ33hLURFeSWsMiR28l25CSiRWBCc5wWI6HjBrk7/VdNj020j1j7PqUljffYX+xRyWxDldzOo6SoDjgDPTgcVp6ek97H4g0i607T38y0nurmygSTY8+VMDOxwWkIB4HsK15HFLy/zOOVeM4S5FqSeHLUDT9OfUxaWMcFvMdT0uC2WRZ2SYuvmE8AEcke3GK3fCQh1OzvtTuL/7VBf5cmMHoM4IB54HGPasnS7XT7XTRdWP26W2uYvP3TpsOM4YlfU8rj2q5f211LZWEGgm10uOW2NxFfSEr9mmEmAvlgc/Lk471E3zNo2VKNKnzRvqP0OTRrjw74l0eCe4gT7HOZpYZf3yhRuLD0ztx+NYeh31hpGhyXlxHchA9vIb+3hWKKUeW0olcLzgKdhB+84BrootMglvtXt7r7M+lavEbRE8oQMpZQN8jJglWYfUA1h+EbS/trnVNN8Q6hpO4xyzavpSgv5KeWI4j6bFKg4ByN3NCcbS1OespKqpW3S/M6JbYTm2mtLhznBRAw+YMBj9K276GxsLy9ht5ZJHtolglt5IMKJWG4SBz1GDjArmbnUrXwv4dh1Sd4hPGpWzROFndYy+AeQuFGRn6Vct7mNtDtJDfXNzGbeK4NxdyBnw67/nYcdSenAArBxdr9DulL2lRU09Fqw1PUzPomuLZ2yai9rbEpZMvmLKwYDBUckc5x6VbNskDNGiokQAUQryqD0xVLRra3Nrcz6XJGkkymRZYjw/XkHvXPpf3nhTwrdS+JJZby+Eu1FjXJYMflHT0FUo8ystwkuWbttZf8P8zeWwjuLz7Gbprd8i6BIJLhTj8u1Y2padqt34sWwlsN2lyIZftSHARlHJY/Xiun1HXpZNGtnuttlFHCr5xjZkd/eqGh28l9a41S5FxHHLHNaeSxHmBlKOsgH3h8wOKItrUpzqRXMw1K4Ym68I6bHcSX+p2yQNdR5At1dSxJOOAFAJP+1isfT/AA3Pp2i2zaNerb61CVP2qNFO+RRgZB7EZHPODWr4dUSapqOtW5uEjvGFtEjvwtrGNqgD+EMQevOAK0dMsrCxm1O5gLia6bzWDkkAgdRVOXL7q/pmNPm1lJXbM+08Tx3h0salp9zYardh2a3SPdEWQ44Yfd3dQDVxdS06YWl3HNKba9uPs0ZWB2IkxnB4+X69KybC6D61bXul2ZFvqFsXmvEbaflYhRj8D71f1jWL+0v9Gjiu9sFy7eakxzkduKTSb0RqqUlaKfkXNZkv7aKFNLt45ZRIFfMnyiPPzHI6060dGuHltQrMh+c7s9Owqrc6pdGCzl+wlGnn+zvH2VM4347irEcN7DDd5MPnbmKZXaoHQZH1xmotpZiS5FZ2H6X4g0/VL+7sYneK6icZEwAEwIByg7qCQCR0J5q5ZzlblkLeVuOJGcYGBz+lYDWN3a6TGIbuD/hI/ICtqLW4JX5s7VOPu1sNtvEKzBpW8oysicbio5Az0JIokktiI0/uK3iYia4tNMvI5rqyu7cz+YqBY41DcISOp/nWgk0QjaABkVQvl7BkAAcAf/Xqna6p/aWkWF+wk8uWPdbo4OQg4YH3BHHrWV4DihabWbj+1tQvojJu2XUHleSd2Pl9Rz2oS92/YcouMeWXQvWlvJY2JlvbuLECF7i5lOxSBk5C9ScdgKxfDuraNq3iibU9OviqXSvF9hZPLN6Y9rLMin+JMsCODg1r654Z0yz8VQ68J73Ub+/ZbWG2KqyKMZBZh91QF5z24q6thYWbh7extY7hGLRNDHsVMn5tncAnmqTil6kOo6upFOmnaPFcXDwxxRXcnlsBHkztIMAMO/v2wKr67dTywXDaJasZrWc2ccMyeUu1AMFOxXB4I9Ktam89xp1xHYSeVd7SolzkxtjrVOKG7ZNNikuWlu4VVZJCfvn+lStrm0Yvm52WEM5CL5ZLNjKjP3sdBUsshAe1WM3U1vIsdzBGwBg3YPzE9OOauz3Opprvn6XPZwaRGdibYv3srj7+5j1GfTArD1HWrqDxFPLd/ZYrW/KBWhXa8sgGPnx149aSTYozlU6E9rLfS+INXjmslTT1tv8AiXXIXlRnkZ9+tUNOt4tb0KG11+Ke9glmyHeIJJEAc5I6AD179BWzHq8UGvWFi0ZlkudyugblU2k7j6DjANX5LtVeOGOLYWyVbOSRVNtdDN3T5UtfyMqN79dZumMiWekxRiO2ig++44y8zHqfQDgVbWJjIiQx+a8qlVA53E/yqt4hUJZKs8NzJHdSLbgW6ZOeuT6AepraV2sbi0aBl8oLhsclvTnt71L11Fz8q06nOJ4hd7xNCsLSbUEmV91wgAiQo+2UB24+Xjp17VclREunkUCWWMmMFTgYz/8AqqpZa1cavdTxixm0yC3mZFiICRjBzlfUH+dVbJYdN1ubTLW1uD9u8253jLJu/iXPY57VdvIuEGtWyppPhWw0y+GoNGbi/Ny9yszHBVyMHIXAOc9+K0/EUcseky3dpbwyXpj+TzlGMg5x/XFZ9prOmadDf3N5qUMcCXRtUiVSZDMq5ZMewBJJ4qr/AMJboOsXFnomoR31vcX3lmMhkcLvb91naeNwAPHY1SU5O71Jm4U3aL0OggSe5sGFwoFxdRg3CpwJHA5Oe5qtFItnBb24SQpI2xDgkADk5NV9ZlTTPFOmzPczzXNs0ls1tDgoobH7yQHpipfFVxc2um29rpTR/b7pwU8wHa6g5Y+2BU8t2vM2i/svZj9ST7ZZTWkjSLZ3BCyiOQqXAP3cjn8KuG3S3SERhSiqEQEcAY4A/CqnlC7EBdQxGHAX+BvX3qGbRw+pabcw6pOYbOJ0aJWysjEZyT3x0qVqhzVmjpLK5hvLJbPUoYb20ikRyrLkxsDlXB9jV241LV9X1cwmztYtFga4guxcR73lYKpilj7bDkg/SuUNwbfVNPt1t53e/kaIui7liYLu+c9ga0dO8QXENndDSp7O8ZJGiLTkmMMOGQlfTpScWtTkq0FKV4bjLz+zbPxX4elutCge0v4jB9ujYs8M3IESovQAZZmPAFYHizTNVub42EEyW1kAyvcw8y/7Oztjvmt3XL7Sre1tb99FQ30TSXPlWkhYvJKuyQhON2Rjr0qzoY024mtNNnvFt7u4T/R7bGMhRygI4BA7ZqoyatKwUnKmpSqbHNXV2kuqRWUs5NxDGCVVcnYehJ+orc0GxKWEv2yNYZY3O3DZCr1BP1rtrPSvD51GQ2lpbzXIHkzSowfYV/gbng89K57x5pGg3CpGqX813pw81tP0qYLJIH6GQZBxxkZPY0lU5vdJli1OShFWRzmtawNIuFa4WH7G+C7ecEYszAdD/CMkn6VrR28N5rF5eHTXju7GAxNeXETJGIuuVY8Ee61lR+CNHm0k6VJZzXKynziLufzJEYjONw6Y9BxXUaE0qwtBqN9cSJanFmCuEjTy9hSTb98dxkUpOKXu7mlWcrKUV/n9wlt4dvJdEkuv7Stb+4lBdGgXam3sqkk547muFsdLaDWP7RF1IxMZik2y5VF5BwR0Ndp4Wms/DWjXGkWI1G7Alkma5u1CIS5yQvcgdsCuW8Q2c9mZBZRxwyOC6KV2rv7lhTi3dq5phJNtxqL0Me+S6utElsYrmdPs0fkwTSMWYL2JJ6mq+raINegsElZ/OtNroY5MGQrxyK1PD0F42hT2uoTCe7B3DYMBgewrnwj+FVvZbeO7vJ7iZC0QbmInvjqBjmt47tJ6rY3bstI+vl1O30zw8kuh6rM17DNLcScQPgeXGEAKD1JOTmisHUQ9yyKvmrKzBlCj+Lrt96KyV92zeHPC9ndPUxk1i2eFJ0ZJ7SFGiu5GBXbx2x15qG8stQM+nFXFuLcBpoh1OedufTFbEF9ax6qdO8iNbZFH7tR0HHzVWSVLyKS4t2kcJIyE98gkHNb83K9jK3Pq/wCrGV4lV7a9j1C2V0uEtWePOWhePzVWRXH94KwIrp0upHndTE8UMZJQP1+p+tZN1qcaaYupx3JksrGeOZxBht4LeWykHjHIz9Ks65p51VXtp5JowrEl4mwdyk/pxQ9UlI56aanPl1vrb1LWoTRahr1rpazLDrV3bvJp6uhMZkXnLMPuEgEZq5aapc3mlizurJLa6C5nhLBwx6ZHY9M5riPiBf3Fhb6bfWMy2VxsaJLtIyZlZSGEYbsrY7+4PFdl4qvLY2NtrEqm382xja4CDGx9nIwMgc9hUyhpHzIhUftZ05bJi+Ikv1sdQ/s7TklguraO2S381gWkPLnAI2jaDhs96j02zRNNhsJpDdR21w0ySzIoKAgbUH+5gKD1NbiTJqXhy01DTSjQmCNFJJDKVXuD3PODWTpzvH58ctwknlRl3O0jnP61mpPlt2OiNKMp88t9in4i1PULaG1utMs2uYYnH2x1XMvlg/MRnoAOpPauYiSKPwWmo6Mdn2vVHYE8w3N1JmJIwMfcSPcfTLZ6Cu38L2kWnNeRyzSyW9x87lvn+9wUAPQY7VxMeg3mp6xf6Xpl7Pdx2U00epLPAsNsriMiN8qdo4IXjB710UXH7vxODHxfPy9GvuZ3EVvZ6RZRaVpu37DZu3k3BfzZmyAGZZeoDYH3ccCuU1eS6tPCfhxLh9RvbDWrlxeXdxKUliiEqiNQ+chvvEeoNX/Dd/B/wj8LSrI32O1EMrLDt88xA8xjvnGBVm3vNPtPH89hdNdX1rcNDqLW1zEFFinkEgqcne235cAAkiogpRk79CsRyezhGOl9X+Ztxm41CCOVIJYraCeeGDzFw8iBs5x0xjgfSszUdSgF9Lp97fW62lxGIkQNtlExOUYex6Yrf0hdRk0ize5u3vHNk0gla28jYrksgMZyQVUgEVwHi3T7WxuY9a1Jb55BEEgu9MKPLhCCTKjDbGMcA9amnFSk0zR1+Skmlf8Ar8zqP7U0f+yPNub5HtLe9gtFkbcm925ID4w23DZA6kY4zWFpeitb+Lp9fsrhtNhs9TP9pT3l8pN5Yy8mc8Y2luAo9cdRWXqGnDUdG1BIlhk1WSc33mKAkNwFX5rWKPIInWMhyQuMj3q94T03SIdH1NtTSa5sYba1gkkdNwlfezggDp5f3ffqa15VCLszjk5V5XfT8DpLrUJtV8NPYXVrapqMl68kUmnFJHsYSwVXKMfmBj4Psal8QSOv2qOO3tE0diFkaRdqQxcAjA654wB0qlbJbaDrq3Rmsra1vozGpZFR5mIH8fU9s1p6nqGnf2Xc+HtcvI1knm8uSMkFkDY27gOQM4+YdByawa1Wmh6EVGndw382Jpn9m21vHYWUklvvt3W2EAB2jaQHGfQkEe9VWsLnTDDJarPq5lMMUnnMAY9iKhkJPrjJ9DVq+tpdG1bT7U26JGyNAs27fsx0QEfh1puq6e2r+RDJLNB5M4m3Qvt347N7e1TF232ZcoxlPnga97o1tqOny2lySWYZCD7p98+tVNGiurHUrExMiWluMmFE5OOlaYKSRSBGVRGmMd8Co7hrWARrAqtkFGcttJOOfoPSpu2rGUJy1jvcz4NUs5Ne1aH7RYm2juVSJbRiW/eAmMOP4CSHH4CtOzSD7Sh53qTgk9sHrXIrf6ToWvW1tN9ohMShJopCAlzG3AOcfvHTgqxPHNdPdWrwahELNZpYpkyJIgXQ+pz7+lOcbWJjGS91sL6WK4tzDZ3FqmoJDu8hIvudwABgHPbnGTXOaxrFlYapaNqE3kWlvbRXNxcXlqS0cj/di2g5jfPqCPet2409LTUJ5iqi6lRd5IIOOw+ntWfqlpZzzz32rWFlMsEB8q7uULNwDw+PvIM9Dminy31KkpLWnLQpaHrOpeKXdreF9Ls7K6aK9LMjyP8AKCkSjHAYnJI6Adea6uacy3MkuAImGxBnoAMZPqcCqUt55dol1dC1hItxPMbVAInfb8z++QB+FMtdQt/7OE0UivBIvmqzcHHr9KUvJaDjGTjd6sNet9Qm0q5OnsFuiu2KUrhQT/I1lD/R3tNYOrmZNOiKzRwNmN5F+8Wx1PatKz1WC51i9t4L2WeV0SQwsR5cEbD5VUDscZ7k1Pb2ljY2DqwtrO1DkINuEJLYOfTrmndxVmNScVaWxLaize3VrBZhbODLFFKxYRliW2juBk5x2rBtfEq6RqusfbHXbZqjEbSxaKTgZHfn0q/ZyXFvqV5bXE0TXkT5WFTgpH2yO/FJq1/BZNp00lgJ3v8AUYNPKN2WQk7h7rjIBpxWttyZNU4tvY0LvVGgs1tbSAXInm/fCOTAweOW9vT25q6luElEd3PkqpYBFJZlHGQD0Ge5rl7aTT9H1J9LjRokWdyCQcSSM+SR6knmt+e7kTI3PuwS2Ty3vUNDdNr4eotha2tvd3awq8ckrGVlmOM+4J4/Wo90UV8bd2Cy7d4XOGP/ANb3qhrOmXGrWWp6bdSx/wBmXlqY8AnKyHlX+gOKkTTobe5jupcNeLbpBvA5VQAMDPPanp1YRTbfmaU7PNdGQybSBt2gDAHX9aoag1hAJDdQpI9tGt0UC7jGCflPoGOCQOuOelVL+S603RXeyia9lLbUikOSST94n2rT1PUVSyE2pvHCu1TI7EAbiMYJ746UJW1E4yuorYo2V1pFiiaoIVtXlhWF7q4lLTGMsWEZZug5PTtgdKvW/mzajdzxyPLDgBVYAKhx1B9Md6zdX0jT77SJk1coljEPPnkbgADjPHYA1Amoy2Oj68rxJdQ2hNtFbGJlJRQPXkggg5Hana6utxOMNeUtX0uqPqlgkcRk0rZILhm6hwflK+xrTuIrhrBriGJniSPfjdjJAOAPr61Q0fT7TVtGlvWsBCs8aTTW7TPsJXoAufl49KvQ3CppbwRW6w25XBiXgYzx+ApO2wPW3KtmZ3h29Gp6A2oLaeZdrbNJDaJOAJpF6IH6DPr2qbW47w+E4Lf+35LC9mlF1efYIFRo49uTAJMkjB6tyTjtUFnpUenvBDZYgs13bYY8BMsc5+vWqlney6pDHNY2sgh8545RKOcKSvQ9iRTdr3WxXsVNpzkJDd6fdLp6xQx3Ec8bSpcrGCCQMFmJGdxGQT3p2qS2egwXOtwWEL39nbYjWJNrOMABfoM8Ht2qLxAmkaNaaTFfXsOnMtwGhtbZTLM+e3lrlguTya2b+O0S3uVlW4kMcZDIxUBgOcZzwPc1TeqfQOaElymZ4X1C01u1Go/Z4JbqSM+YwPK5/hb1INS+IxcjxH4ElgjMunTfaLS7AT/VE8ly3bjp64qn4ZsrLRLaNNItHjt7rM5czByrkfdyOCB2I4NT+GjHDZ3MZ1GW9CzsztIflQ919sU3ZSbjsTOMpJSej8izp8KlWsrV3RmZ8SKcZxnJJ7VDoGkx6HpKWqOziUmWMtyQpJzn61rIE3wXVoym0mG6RwQQEz82D78VlyvrTeKLi6dbWbSZYlCIfvQkdvcVEb2aNJzUpXRe+xajqVlcxaLcQ218hVxcOCFVQQSPckAgVzmr2cNzayado11Bp0hlW6ljhxvwWyxx23HvXTywppK3d5bMYru7UKYeD5gUY346qq5ZR6liTXMaBqGi6nf3N9pqILpT9nmm24YkdAc9Vpxb1fRBTTk3JvfRfqPW1hu9fju3jddQt7eWKENwhzjLgd/rVjwHo1zpOkW8crKb1JGnMm7cQxJJOT6e1aukWtqmnzqsEdpbWOSgZ8KVLdiegJPSseznNvqupnUNcQKxCQxKo/cZ6D3Jp8zkmkKa5n5r9TVXVNG0rW5b7wzpqR6zqaNcNLKZBCXYDcxjHAJxk1B/xPb3UZNS1TVbVJZl2/Y7K3WJXIBC+Yx+eQLkkKTirVjZwWEMUaXEt0wPzTSD5mPrVrVIrENZ3twGMtmNyhQW8vccE8e1K6Rzezpwa5Uc7/atv4TvXnuru/vLiQiLyGQAsSc5XoAPbvVzXJ7sWcs8GonfdgHTiIWRonb+GTHVRxyeR3rT+32KalcWd5AymJ1MEsijZccZwh9QP5VQ13WIPDc2mia3la01OdlEqEMsbEAktn2IoV21ZanStXzPQi8MXWv6X4durTxjbrNe2rh7a9eUMZyW4iJHXrwelT6ut1qdvHcz2N5puotH5bW104xHnuMcHnv6VSl1PXy81lPpqQxu5EdvcTgecAD/AKkkdc7TzxzVVtZ1W70mP7PcSXerQ3CxSi5UeZCN3Kuo9BkZ71TTvfTUzpU+R3T2v+n/AARFmj0u0hhvrhRNO4iDHKl27bff6Vky2F1FqQudKUNeXk6reSTMSQg/uiuou20vUNWubSWNG1CwXzzlf9SScA5965qzuLVftuuWSSozEtMzZ+facZC+/bFEbrU64y9pp/SGXWqzzlv7C23UjSm3M2dvlOBgk+1FaNhcWMdhcSwRw28JPmShsBlyM5PpRTcnHRIpy59W7DJ4bazlN2USW8kQKqgkDGe5rLtpQE1JoJIzdqNzW0ZyFbrycdev1q55sstu/wBm5lWMAHGTk9TjuKfp2nW8N0yWbwvcyn9+U/vgc7vwquaydynBKVr9zPedtGe4sLGyspL+ezW58iX5LaKNZVaRpGz14BwcfjwK1dF1L+21vNQKmyuzclgisGjngbpLEOuMjkHvWPqbWjaF4puNQ06+I1Nre3itlPzzCJwfNAGSqhfvKeela3g+/wBQgfWHe0i3O4ji2jAWHHTHbHpVTS5fP/hjzqTnKtOontt6a2X3DPGP9k/2Fcx3KvuLAF/vksxwCOw9qg8JxRR2cvhhL6OXVbC6nQWcmC08eFfKDuVOTt5JGfSnJZnUmYmPzHOGVMn5yvOQvqMVg+LzHDrmp3tjqWnRXuovDNbGUvFImRtJ3kYWTP8Ay0XI55xTglJcnUeJm6MlUOw0i9Nr9oWUuTPDskGMBiDxx29h71jaLaB5b7UrS0vVubqT+zT5ThyrMQDIAeBtXk59Kv6PeLr0eu3Es7tNHbxTpfCLYN4zEUY9GkDKcsBg4qfwHruoNocUeoWKWt55xI28GU/89CPXioalC79DVVY11enu0/Qr2FldmVjfytKssZge2aQDYAME5GPmI5z70aUloLTUHNxeSeGo7c2c2lvFkM4wqybwN7EdzyTW22izx3ks0PzuZDIWcDHqRnvUGmXk9zr+oJNJKqWrbHBQqiqR1B6flUc7aZpVo06lr2dkZWjaRbWcdkIfOs4HldYLdyXHzA43DqF4yKt2tlZQeJbXUbwTah4ghhEguJ4lWHzQSBKqjkuAcAMccA4rXvTO+oF3aRt45C88f04qlrtrdXukxW2nXixMWLz3UYBeEKQVHl9XBGenpTU23ZvcxqQjJKTW3Qk1XU2sLG4nuLtIxy8kkrZJBPXHcmsZxdaZca1cpDp0+rx6YGsdO88PJOHIIeWM8DH3tpOTjpVm4fU7qzMdkbKKy80p501tIL5kCjDAEYRhICwUZB70tk2jwa7aXCQGTXliyL29bdcFFG3djoZNvG/rjpiiKUUTOVSquSmrL7jD8L6LqMi2N1e7oXsNUOovqEm0LcySRkSRRA8kbgATjFal4lz4Z0a9l06d77gSC1uWyANxyV2jcxJYAD261u6uhms523StIV3Rbfmk57KP4j7VXTVPsV02mxxywaslp5Ml4E3G3dgriJiOj7TuIpuo5O7CNNU48sX7zMq68ManrOi6g114euZ5rv7PK9hf3higRASWljIw0cnAymenrSpaXX2+4vmtNVXW7q0Rbg6cm62DLhI3QyDcJNgG5c7eD3NbOmLdyWcEF1cCS62NunzxkDkn/DrV9JI3sHCMN0Z2/KSGbPt2NT7R7CeGtPmbu2YWhWz+Htaeyvb61vLe/kaS+ku7mJJ/MC/J8vYk7QOc5qlp2q6rfXdxY6zot5p5aSMxqztBjDZk3zdPlXJHQHGK2NE+y6hqFzFChXYd0m5RjPY4PfNMtFN5q2tWt3FazW0zJKymQsz5HO9D0zj6GnzXvdGjpuDspdOxycvjWe68TSW1nZzR6hDeC1gsJy7pKgfAcEAEOQQcdMHNd74p0y0v9YS8lVozaSkxxxuFXgAHPqMjrSzFX8TNrBjtpp4wqWIWAKbMeXsbBH3sj16CqFhpjW1zf/aLma5tLxtwilbKx54IHt7UpSi2mtCKUaiS590RvDDfXQsL+CG6ilDz2jABtqRgF2LduWGPUmpdNmtfEFneadpt/cgWl0khNu5jYOnBQdnBHVe9Om36X4eto9H00SrbXItvIU42oxyXJ6kf4U3SLtNRa6FjA0aRyFd7J5auQeW+nvSe10bayTTIvDkl5pNjJB4lmeaBbm5nkvOZI4oWYCOMs3zIdx3AHoAa3b6G3dZIZWNzEeMrwCvp75FYc2saUNYstReE39rexnTL2aJt8DxHPLL0JB7/AFq3dMum2NncaWw1HTp8LBNC3yeX0ySemOlTK7d7EU6dlyt+nmOEVzDrF3Di3OhvaRQQweXwpAwSPQ9B6Y4qP7PHJHLDOUitBGyFQO20kqB64HAFS6hZXmp2cFvpt7PZXdndC4byMN5qFcbCD1UEg1i6Za2ketaXdeLv7Ukk0shJNqFbKOYt8s+RyzDIyOgpqN9Wx+0dNNRWpf8AD50S/imu9DaCUxFLZpEJLEKmURsgYO0546VHqOn6rL4b16KG5E9zPEZrZWQAR7SDj3OM81S8PT3lrZalpuufaBfW8sty9w7BleN3K7g44+XaOOwbFdBY3W23Yw4lhki8oNuzuUjBIPuKc7xloEeadLfUr3F9DL4pkihtJGmuoQ63AjyJFUD5c9aranrT6br1nDZNNutJfLucR71NxNERBt/vlTnIXoT7Vakgs1kPhhFvY7X7MsguIpWUhM/d39R6YqVNPltNStLrTPkhSRPOFwfN8uJQR+5H8Dc9etJWT1JqNSXKloiS3stQtWtP7WktrxA4SQyR7JI5McmMj35wc/Wodd0qG58WaM/2y5iePcyIEO1l77j0FXbto5JknspRJaECRXPO4HowNRXNzqVzqulJBFGbQownkY8rjkEVKbuWr/Euo+506Se+T7bdXLWak7Le3YQrt9zySfcn8qp62YJNXktor6S3gsgt5MUXLCEDG1/rjqOtdPoL2GqWlxJcvPEbZmSRZF2HI4yM9QeoIrl9Yt49R1+1iljVdMgRb2Jo3ImuZI2I2SgdYxkEe9EHrZmUZy5ttUTSXrrpCTtayI7qzRwjl9mflPsSOcdqq3KaXa2+m3uuJJIb1kt7e1lTeiuTkSOOigHvWtb5ub4bvvu43HHJrMvpDJ4on0jVbUzaViOWMGPKqUbO7PXdnnFEdWaTdvcXqSaxZNcz7Lvz4io2bY22hcHNaEc0WqxC78twZQVdtpX5h8v64qla6I1jaousX9/9rvHaTbayb448Mful/uA8cc81B4pudQBs/wCy42khU+RLAj4wh/5aE92HWhatK47qVuX7zbvmutL0T7RaWc19HL+7aK2w0yr/AHtpIyPpWPpySP5TvZagiXUrh1n2qYVx94jJ4PQAVFp8TaXp8UE9wZzv8tXbhmYnIH86tWP2+PVr955RLZSsphjAz5IAwQB9aLKzItKF9S1euLCO0t9Pa088kkG7DSZUddqqQM/U0svi+20u6snYxR+fMIIx5XDE9hjofeqeteXYpbXd6kzB2IjeJC5jDA/MVHIXg80230aRLqMLLCdKW2WaNTHucyNyGyenX680WTWoctO3vale5Gh6TBd6x9liN61wEkIBZ0L8g5q5CFu5DDtXDK6uSDwmCTx9Kks7Kaxinj1ieKaRixTygAFGcoHz6VmeHtP+wROp1G4vXeRpkmdumecL6AdqHtuaRtZ8rNHwlewQ6Av9nQTCzjZoIxcxFDIgAIfB5288ZpLSAIvlB49rKc4TGT3z7Z61Xg1B72FGuhMl26soikOTtDYyacl3bJd3ggLzPaQmN1AIG4rnA9T2oFGG/ct6JLZf8Irps1lB5Uc8e8QqCAigkE7T0+bPrxiieXe5iDiMlcBiuQpPRiO4HpWOurahqH9k3dpbAwzIRcRy/K0OB8px6DBrTjvrRpJIkuYHljRZHUODgEHB9wcHH0ptPclQtpLcq61fxWk91qQWW6a1tEhlZV5fyxzhe2SS341T0k2TabbXWnWsWnXl44uZ45YQXkTkY2Z4JGPm7Grljc2WpW0k1vcAWzHy5JR8hQngkZ7+lRS6Jp+ka8Z83FzeGFYkk3llMQAIP1PUmnsrPcpcrSil/XqZtoZNQ1fXIbma4nidFge1kTbCq5DZUdzkDmrVhYJrOmJLqenLbyrKx2uRklThWJPerg1nSJGM8cc0xhvIrabyMtgswU/l1J9qy3jn1Vry38QwGCTTdTnESDKgxq37t/8AayOhqr91YfMnLkjo2bOj6lBq8UkumhnSCRovnUoDKO2T78ZrL0rxZvN39ss5rJ4ZliuknwBFnOG+nHXgY5qxcxSXASNnZUjJI8tsZyOv1rXllS5tIre+hiuJHiWCVpcMZUHRmXHJ6danS2wOLjp3M/WRp1jrkMlpvuDqcDXU0Mk+Yo41+V5k4JJ2kjC9Ris+O40tYR4S1C8cx2t00kCyncLy38sYUkjkAN9flrppoXufD8D6G8e6HbHIxYbDbt8rFSOm30FcFqOk2q+OYdWt7K+FjY2pgvWuxtZHRMLKMnPlsOrfnVU7S0fQ576pN9f1/wAtTudSfQbn+z4tRvPljnhisJXG5GmYfJsboRwRkdMYNYa+fY+KtdtnjgjmVUkkvUIJjZRwJVPqOQRXD6Pfwf8ACDSaRHDiYXvnaa80RkjWRyD+6KjOPQ4616rq0LanpzPeLFNO9q1reqybWlbGQSPT27UTgqWny/IdHndoy1RX1T7NBBFexQwvdXEW12QbvM3D1746j0rnZZDE0KfZy4lXYfl+6feqekjWdT0nTY0WW0utLmNvfxsoBnwBgoRxtwR+Vaeoh7xElkuGgEMhZwg4lIA+Vvahqztc6qGkL2MV9Lils74xW2XvZN1xGzdezUVLdre3fiQLDJAmlvAQ2w4l830oqnK3XcrlUtH0KWmahp8yz6bp2beWOPZaJIDibaM7geu3B7fSr+naVDo2+7togL65+a5fJKg45wD6Yx+NaPh+G3g1Az3FrG0EQEUQj4ZYx/Dv9z2HT1p+sX8oDQGRJFRm8tyio0aE5CDHUDpk8miUruy2Em+ZX1Zj2Go6pa6/qOpLqTfZpQI1hVQqg4wwx9O/WtiJljlQ2+6MyLuMbc7TjqTWRpFxDZ6tZw3QWQ3EuzDKMnPp2zz19q0dYEWi6S/m3c9xbwI0D3Mi/vcqTjp1PIGabV2EnCHupf12/E0Euk02yD6SdmoZfcWHXdjI54561hS/2Vc3ESKkd/buQZ7dYw8MEynO9cklCehAIFWNKlgvtKuFtonju4WDYkOVOQOvfn2qKe1+xytZ6WttbXLWv2poVXbu3EjP4N1pR0bRLpxjurj0Ef8AauoQqwmi1e3EcodsSRbHDKFAGCuGbnGfUmrWlWOn+HLS+s9Lla5uYEZgGbcwY84yx6cVWjjMDWMhVH1SNQpnCjcP7yj2OMGtKOyi8yW6SPLyAPK7JlZM8bT7ihyvoyFTVL4dE7mJa6vrGt32nX+k3P2fSkURyRD7wkB/eLLH0bOcKQeK328QxWrXOoyPajRhEUlQxMJN+cMTnggDGAOtUvCOlrpsl1amSeaOWZ5eFyFJOQo29hWhdOk0lzay2sxSN9r+cMh884APOB61M3Fy02QowSjytasxlsbs6fpX9m6zLbxW5dpZLePCzKxJQ4bJ4BA571HNYXE2gWt5c6xcPbpIWN2qiEuoY5D4wDjGM1W1C8jXxnolrFNdF7YMtxBAPlCsPkLL0K9vaptd8WvH4j17R2t7aDR7KymS2k+zeaJrgKuzJPBJY8IBjiteWbat6mcq8aMdutvuOkt47DVbXT7y0uFkVpTAkkL/ACbj2PrxyfSqWo2Ni2vxKxhN/bIUTDDJXPzEeorDg8TzT6tb3mnwPFaraWkl1HfjyILWPaUZoh0VzIGyp6jGPbYGkW0niGw1LyhDM+be3mmbYHZgSETP3ieTx25rGUXHd9P6Rph6yqR53pr1IPD8Opt43hmNrbRafHcFIZxl5Ydw46nHJz+Fa7ajplmuualNZ3bC41X7LqISNTJGxbZG7FTghDyD12nmp7izc+INLvI7i4jEQASEHETNj7+O/Nef6239nw+K1trLy9Lu5Y50RrkwyS7nG+WRuTsJ5DAcDiqilVZjiG01KKO61vT7lL42q+Yslm6tMIWBbHUN6gHrnFa8cWm2lwNUlf8A02WMJIwHygD1Hc89a8k8SGOw0CHV7a5j+3amH0uB5JWklaPcWkXzVPKjcFU8Egiu5mtJNc8KaPHcSiCe6sYDOYpAWjcAr/48Fzz15olT5Um3psJVnVfJL8OpqybpL2N7OEyLNJFAyJhQoZyDKvGS2COpxgGqGjadZ2893eWZEj3cx3yb87ypK8egyDUoltvD+mm4sI5LhLKIKSCWclfT1OWqn4ZsLmKSS2cWxhG57byyRJsPzHIJ5Oc5qNbM1ilr2L9/IIxDAkkY1O4ieS1s88zKp5dsfdUE9T1wcU/UJWsbff5S3MqgE+V/EenANcTFJNqXxTN7PKLW5SxDfYlbeYokjKGMsOwLbsd91dVqNna31i1lqEsvkyEKzRPsYfj+lOcOSyYUnKa5pd9httdTahq4ht3+zWlgizXilfmnmkJxEw7YUBgw6c+taOrK0Vk8trEJwEbdBuwZD3H5VhapCmp6hDoKRXSNJElxHJHwrFWwELdyAB17Vs6TrFnrX2qxsZEnntH2faFG1GYZDKpP3ipGCenNDXVIG+V6vrsZMiam+lRW2n6dZaHa+ankpjc3l7QWUjsdxIrWt7I2vhWa20W2SWZJXmW0Z9qeY2CVUnoGGcDpu471V06+1CSG4i1SBYj57hOM4QHj8a0bvzbd7SGCJCjKRcsfulewA70pPWxUouKS2fQ49JdFihiiXUJra71e5+0uk4ZWLRHBQ5xsOeMflmurummS4dJ2cNwRGScYx0981U1jwlomt6ra3+p3F9EtvarbG2ib5SUbcjA9Rz1FV/Fs8PizxTFFDNNbXNlEJJYoztDJ0BzTladrCozlOVpL5jdbvptKTU7qe0L6Ylnvdim5JXlIXacdMEfN6A5rm/Dniy2hnOnHSHto7S3ctA1x8xlAyI0JGOfU9K340htfEUsA1CSNbaAtJaRoXBVhyXY8cj+GqGreCdP8T6zH4h06/NppF/EklwI+WMykcKB0DqPwI961p+z2mTWlOm/d1TNXwx4xn1rSfPk8MXBnVkCiCbbFtYkfM7dxjJAra1bVzYtF9milkR5ETCDdtOeuT2FUb+zXVDDpkcItdOQKYEgbYI9p/n3J71p3dq8KiCR1K4BWQHIYY45rCTi3dIqFOMOVS3Zn2drDYWQsrRiLdXkkRGJIQu24gei5PTtVfSNZlsZbKDVQkGoTSOIkTJXaRitD+z7uZ7Ga2nSOJXImjK5Mwx0X3FLa2VtNq9uJgsh83ahI+YZ9DRddS24uLilsUtM0q6tJbpPt1zeJJKXUXBB8oH+Ae1XtaWZLOG20eW3WRWKvNODnaw52AdMH14NXtRvPszQhQsO8MIwvUDOAfqcVhadYXzXd15032hHYGNNvKAUk76sE3JKUtEWUimVYgJAzKmJGUYy3qB2FWdJuUmdv7QjkKQBpAFOWbH+NZnhY6i4uIdYKSSI0mHtsOirnhSw4DH061qWEcF9JeQaa7DULVgk0cuAZFIyCjdD796UkE6kbOL+8q+JHu7rxfA1vJGunLD5RtnB3seoK/nUkUrWl45mhEtuIg6hW+djnnr296sTslu6XV0N8SMqsGU7gc4x61l2UTtrGpTXsXzOkckeoOVG8DI8ggcgKDxx0FNEprlSW1jRsjb6sUkvbaazRSZETAZi38OfT8KfZXM82o2ltNZlDdSTCFww2Okaglj6ZyRg+lRtbXZLfZkDLIvyOp3DOKyrH7d4d1Bo2vDfS3tzDOloWHyRqdk8ifTcucelCVyaiSWj17F6cXsca7cXheYGbzDhVh6YH0GKfb36R2Km7WRXUvKHk4CRhsKp9OKg05befVZdRtr97q2LeW8KnKIVPIAFWL/8AfWky3EatFIdrqP413ZGR9McUeTCybsyLVLO+1KS2l029WJDOryb1yJI+dyD65q/qNqlhoDzaYltNqIYLDaTMRFjPJYrz0z0qGB5EgWPZtjRSVO3ouKS1MqQbGYBBz75NLyCSb67GHrlw8d7byqIrWIvuW3SQl58J86AnoM8gDsKu3cY1LTkggmlt3lKTDbw42nOD7HoarR2ejq/n37ITeXYMLy/MFnUdE9DjNT2mnW1rqN1fRo73UpPzu2Si/wB1R2FXdI1027CaZZXsenyR3/lyNdF1lB4Qxt1B/wCA1ny6BZLfGCSzgSztiDC8TEblxg5GecYGK6QODE6Mw24JXPXp0rH0fVbbV4JpUR9kEhiJYYyR1x7UouVm0F25XkW7k266ZLHKV8lmR3JXAAU5DZ9ain1WBtLTUoebOEBCiLyqg4+76VQ1CW38X2d5pdq3kXumLI8UmSIXLrt+Yc7sc49DTNNkey1D+zbfTnt9Mt7aNYrh5NzSkDkN79etVy6a7ig3KWqNW6uLXS9OubkqsNoB50jIMHPr/KoYZY/E2lJN5sj2txAV8wcNtPAx+NRanPapJBp1yId10P3aFsK4A6YPX6Vnl5B4htVitZorewiHlFJNsTMTjbtHoKOVNX6l8klsdHbaY2k6BGzCS4EUJWNCQWk2jp9TXPQXa3Y/t2DTriPWHhEaQSSYVAOxX1GK3tJ1W012C50yU+Wy3TxoZQVXzAu7bn0IB59RXN3epebqdxZvazWcFkVD3D/Irn+77jFOKd2nuRSi5S97dHV/DXdH/aulXUUaWN3ue3G3bktyyfgxPPfNUDFH4f0a3TWZWnOnO225WBpZVhbIZSoOWwGHqDjkGsa5urSHxLZO1zdtf/Ynnt4g58lEB+82OCTjFbkXiz+1IbfVrJJbS/lWP+0tIubYksDwQu4DcCOcqScfjUSUr3WzM5Rjzcv835o5e2ttV02x07w/4W1e2vb4JLcPczN92F04EZxmJgOQOvJNdp4YhjbwdHNazvc2kcIK3Lvva4J4J3Hlh71z/h57Sz16G+i0TU7C6sZj5cMym4kWCQ7d3B+YDnGSSoJ7Vp6h4hafxTZ6etl9ltbpZRcJP963IGUVSnyjJ5x0Oaqd6mxKvTdraK3ruN1m5uNL0Wea2jM0xQOETG5z6A+pFYNtfSXlqj3MIh82MuYnGQp9z/Ousk1WzGg2V40g+wXEgijZkOGY8dOoOfWuR1e/iFit1axi5hYkpJB8wIHB56cc1NOLtax3QqXYFZ4tLJt5lvr4RnyjKuFMnJGfQAUVBHK1/a6fcWUXnXCfvLaJXx5gztLehA5orW3czqWukaenPHbiZroOsO3OP58f4Vk3MsEyiZJcb32ojqVdgCP4Tzj371Rvb/VJvtMVnPbxyQzRlGA3lx0YMM5FSPpcV3rlvf3crMIY8onRVOfvf0pxil8RpNPnUorT+tTZ0+SCwukv4o0e5jQojMN3lt/eGe4qFb+x0rTDpDASiRWmiiI5Ynlm56mr32VUhlnuHgSFcsu7qxx2X+prMt103VBbahFJHLPGGEcgOQo6H6Ulrv8A12FKMJSclv8Ap1GWt7qFveoLG1a6ivNrRmM7SsfcuW6MOcAZJqxJp0VqY7vT2a7uLPcu6STLSIzZYE+oyTg1X1jSjeeHPD1xIFLzD7fHEz5VZNxXJI6hQMj3NbUhjnE1w6xG7YjfdBQrNxznH86JtaWM6U3L3lt07mNGby+1eXTLW1dEuYW8u83jbGfUnsAO9aU/inS9B8LNfxmTXJLeXymHm/Z451QfvJlBG50UsgJ77s9Kgt0tdMOpXT3LxRvaSu0r5cRsFyOO4OOa4x9REGhXceo6Jafa4JUmgniumC3IugPMCEjoyhSBjA5q401U9DkxtWUWoJ2v/mdVYaprGuyLretGXTdJxH/Z+iQfulMw53uRy6j73J5yBjirJm1x9egdriNrOZT5qEYkaTOc5rC1DXtDvluvD2qabf2lpaWEVx5+mTmeaMttL784G0HA3DFasd4dU0Nh4VQreGARvLqN8sD28nQo23J3hQDwf4uaTi97W/IdCvRjFqKbe/m/8lc0bU3l34oWA6eE81UP204VWG77hPUYHPNcj8R5LfSvEHiCOyX7bYx6nDNd3EgObSQoVCRJxk4z85JGRxiux07TLf8A4Rf+zdYuDdS+Ttn8jO2Rj12k8kD1PJrA1vwpeppGnJp+ugWmno6gPGfNERG7JzkSHcABu+6BRQlFT3Fi4VKijZaf5kGrpd6Vr50ybSotXsYJFt7ea7d5pPJB3AOScbgTnOOOldc+i6VpNvZnSUupJrtJJ1kkuWdbZzwwAJ4yP0psuoWs+s28DyRf2tdWi3CpwfNjwAXBHGDjP51pwWYEqINzw7xvw21m+ntWc6kna6t+pvTo04RTv/XYx/BC6tcW99NqGqX9gllDcRsRGrIgUBhNtI+8ACB9a4jSln8R+KdI1iyiudSdbp4A5k2tdWYw2HUAqgQOF2nr+Fen69a6g/nWWk3L2ENxHJAwIAkIZRsO48AZGD6g1ytho15o/wALpbLT3tv7WmvvPuI7K7LQNs4VQRwAe6juK0hUSTfVnHWhKrVUlsZMXgfU7rXz5OhSaXYRXc93+4ulmjTbwoEWcjeBgY7mtj4faHdW+rT3X2e7stKS1bT7iO+wJZnU74SmOoXcw3YHQ1qR2/8AaEEIti0F2jB5vIYFgAMkfjzUXi3WBolmlxeFi0zCOJeWO4jIB7j/AOvTdWc/c7mn1OFN6StZmnZaNZ6PBLa6eZFEjNJtMhY/MeeTVi00i1h1tdVQD+0ETZHOxOFAPTGcfjUfhe7k1W1gnv4JraUKTLGeuAOmffipbae6Z4IdV020i80usslpcF/sxzmM4P3wR97GMelc7vrdmknNe6zB1Dw/Y282ta5ZC4h8Tair8TYkgXcRuQAYIVsdeorRghtDq1pDJdot+1oZBZGT5tqn5zgj5tpyM9xzV57dSpMz5APz85DY9PasLR2u79jqMyW63UE0qW7bDhFyRgnrgjrjtVczkrtlxpKEbQ0NE3J1bTdYgsZZdOl2m3jugmGVs53J7ds+lczNpmoWepXmoIYLWa1tR9jnR/kSZkxLI6AYcHk4POa0NRutev8AQNOl0a2gtb2Z9t1b3LbjCAxBAPdTjI74Irfv0jstJluNQB+yxqPMyORuO0DHfJNNNx0XUi0XrL/Ix0+1izVtJFndTzlLqeHzWjWU4G9oychSeuDx2qvpfiG1iWR9Y1a1iS4cz2TSqYX8ncV2up+6ysCPQ9q25T/Z2nQS6ZbLeNKipEY8EbCcHkcADv6YqhrGiaTqesQtrt28sshURwOQBGIxllHGSvcjNOLi9Jf8EcpPeGxtXClUt8SLLFKgkSeMhklBHUEdRUAhj3PIVBdl8suBhsemazZvseiaGbQ6jNbaP55e0eGMH7MG/gT/AGCecHpWvFd6VK8kMd9CZoGVJI3O1gzLkdfWs7WGpNR1Ipo3g0ea9uiJpASyRxL8zqOAv1qrPaSWvhiz0m2j+zz+Y00n2Q/LEWOQoJ64HBPTOcVf1DU7ayv7WNxiSZCIgvzLnvu9D7VZUJdFGMpjIKqR3Y9vxPpS1QlJq0nte5Wvnj07Q726M0UEywNFbyTcr9ocbYwfqabdR6guh25lgC3ghQvG2MeaAA65Hoc1pXiSLDOgkCTbSikAMY29R7j1/KszStQu1uf7Ev5Lee5trBLi5nTK+WzNhDt77gCSfahLQyUnfmFvhdy+G5oLKWO21VU8yOVjlFJwSpXv6Zq54fhljNpcXbw+bEBJKQcLkDBx7ZIx7ms6Bnv9Q/cOktqw2qyDLb8/kfpWddyQarJc2pvka20a5jk1MofkeYZ8uEY64xuIHGQM9KajfRmtR8q5Y7voW9SvJodXEV0Y0i2BYY5Pvgjkgn6VYXVI3sYfKlKwSSK/nQuBvHI2nPVT6VUSax07Q4raGGOb94Y7NLtmZiz5IjD4yFPr2p8cUUdjp0Uuj2wnJC3EMU7SRQYz0JxuwaVuqNnKPwSjsXzaGy0KDTNIiitbOKQzNxkvnkk/7RrnNXfW4b+GfSVieLGGjbjn1zXTXLXQt90dxCZ4wMZi+THuAfTil0MweItLS+02XzIMsrFx5flsrYYEHng00+X3tzKFRU42ewXl9Pe2Vs4uZLS8iZJDMiBt5U5wwPUEcetZt+p1G6ulnhHkzZOQeRnsKderdx38cMHkmMOfOdjzx0x61Sk1DU4vEljaW1h5ljNkyTn+A0JX2NYwUPeRo232ebS20p8syJtBLHK56bsdsiuYWx1WztNDvbqG3efSruSALZRk7reY/Nu3HIAbB4rr47yxi1u3WyRbj7XavKbqH5oiVbaU3DjcpI/OrOnM8jMcrtOQwfuP6U1NxOdtPXsR6dpUOlx3FolsLOXduZFXlix6j61X069hurWV5YJoXWcoqy9wpILH8RT7qSSHRrl1vY2vxMPsTN+88/blmj5PDsvA56gYFYlpqE+v6NHNZSjS71Zh9ptroZkVc4IA7Z4pKLauxxs277mjPcxaLc6hq4Mm67AS4IGcjAAwD0/CuWfxJ/YGqxaPBDNd2QEc0lzdMXdIZmwHGPRmGM11ur3Fpp9jZ3N1bz3kV1dpZLHDgYLA/Mc/w8cmuIvr9vFel65bW2lnRdevUENtLKHfz4IeZY+n7sjbx69q1pK+sldGVapFR5YbnVM9xBosD3+mC5uBMs/2aFQDC5OCQfzOa17K0ea/jWLAeZ8E5rmNFSTxBHo+uaZqUyI1qonhUfLKQMEHPeugjMk7otpcrHcwSq529Qc9KiStobrbRly/itoWjW3nWeORcrIvIByQf5Vjw2HlCfzDGLYklNi4Iz1z9eeao63rWmeHTLbarcu4ld5bZbSFnItnfg7R1KsWBI9uK17O1/s2GbT4ijW8eCjFixIPOcnnv3qXFpDp1NLJ3Zn2qQeHWu9DhsJjfXGmzXFpkfLKwGSC46HHIpbW5srSOyhN4GvpI8okp5f1+uK05Yml13w5qhWaVES6s5nQ5TYIiVDj3yefavP4pr201O71TX7C1vpdN/484bWIGYIzYDluBtA/hOTVxSnq/wCnsRGUlf1X/BOxvbq1l8Xadot5pLyv9mNzHqBUFDNtyVQj+IKQD0+lUzqsUulR3ukWp1BGnMLeUOQykgk+wPpTvDN282taxefZTbyxOjFmBPn5TCyjsNvIwP6VX8NG4trG+iuYobK03yAeWVUxp2kU9A2cmk4pfI1gpJPW+pe052WOS2ukiu4pw0chA2/Mc9D14zjNVfE2mwXumQ6W1s0kNvCkOxn5KoAFG7ueBWpetDKiXFkA37obi3R2H8eB0PfisTQ49V1SO4Gu2qW0KyEI8bj96Byp9jSW/N2NVyqSk13Rg6Jcwa1oKSTwXGlR2Fx8yycZVOi59D0Na1vqVza6QmmO3/CQJeSvc232tcpC3VQrKcoAMcgip9WvLa6FroFxpnnX91GxZUVooJADyFc8llHJOOe1Wo7O2sIIrayVkjiUIEHPIHrWjl3W5EYxqLlluvl+C8jofDc0GvWrILaayvItz24M4mIwPuscdetcvPPB4gv445rm1ms1mP2pY/kmeWM/ckAA4BAPv9Kbrepy6ZpN5Bax3Fnei8R3ZRsbyVIYuG/hDfd3HqAcDmtPw1qek67BPqMdo1jqeoOZdipxOQoHmZPTt7cVCjy3mjK7jo9Y9/66XLOsvo2nwXlzqAt7G3lmF3cXG7dulVQqvg5+YDGAoqzZ2tjF4Lknv9MkghkvCqw6au7zt2DvIxhd3fHFczfvNZ+JxYzwSX+j28a7DOEljlcj72MZ3Kxz1r03wfqAtLX7LdPC8RYtHJGpC49GHbFTL3Yp7mNWMoxvBbf0zk7HQrWDxfBNHHqFlpWi2cdxBDEVAkuJC2Y5QPmyBjC8DvRUniS1l8M6PfW3hmYrHeXPn/aZWNw8ksh+cseuBwAKKHB1NRUKKceeb1ZwWnXHlXs+oWT+VDdxhTB5abM/3umSfqa1reK0vbFHuzHFlNs8ZZlc46kY4H0zVOC0umtmFxbSWz5MZiBD7ccjBHGSOcdqtaLpd14j066i0W4syVcxk+YH2MOSD2ORWzet2d8lTUNHZblG31L7dI8XlJ/ZhTFuwfIZfTHt61U1CCLR7CZkeOx0yFHMpVPmeUrlQo74zuPrxXRx6DH4ft7dbCKCW4BZktsErv7E+2e1YetWPiC6sLRJXW4v7SNpZrdHj23buTlMMRjaMVVNpy02Ma9S0Lrt0/E7HxCIo9K0SyicstrYQLlgNzBl3FiO1c7Yahp1815A8wgitP8AXuFJZExkn3qedrh7XSrnUYguqtp0UV9GBwpjZgo25ODgjJ9KWB1XM0CCCVc9AB36+9YxSS1NMPGXslGPmYv2fU9ftdTtVWHw9a+QLe0ub5jM86FgWK7eMFcdu+M1D4y8N3F/IPEE62t5pOm2KWb2y3JibagCrM24fKeSeM44rYSG6ufOiV1aSVWDOo+dmONoH061my2X/CPaffafrM95qc2uumnraW+GlRnHB28gDIByefSt4zu9Pu8upw4jDKnBylJuXntf0+Zj6pc3Nt4P1eDQ/wCzDBY3kRurW1XfnTmXCRyMw3sGcknB6nNdTpesxajpVlCdIi0bURbi6NsEIWWHcVVzn5t2AM556U6y8PW/hjQtQt72yMl9q1sLa+jhnLMpXhlR+oAOOfXNVtfY6JoDa/DI2ozKbfTLGPUIvONuPusMrhmJGeTSk4z0XyIo05UP3z+F/wDDGhfauunWsM07r5HnCLeiknLcdKsxyrLfyWc4d3KFTuBUMh4/LrVHWbyxsrEWkMqR3ryKkFuI/MPJHzHPQY3HJ6YrpBqdk95dpbPDPAuIiTguMAAfn1rBr3b2PUdSXM4roWdfj0fStMsdO0iGGS/061EUfQyRwnqmfcisS6tb7V7CWDT2mtrto8CWP/lnn36Aj1JFSy2E9xq97rscTSGHT2iubQAA3DrgQ7ScAc9fauE8R6rfav4UOn67rE8DabdQkm1tB5E0zHaE2qdzojDO8jB6DNXTpuVrM4JVVh6bpqN2dVYX9vdyado02pTS6rp9vPMq4J8xkUq28nvw2B+NGpH7P4Vurawt3fzkBUQvsZMnJYN2bPNcHD9usvHl1qVvO+sX9nfqGT7ilmU7xIMAoGyyg/dDdeteiaZPZ3niJ7G1vy0CwrMYfJJ3o33QGH8QIKkDuDWlWHI01qtysLXjVUlPQ0tNt7awuILrSvJFnLFm7OP9Iu7wABxI3QqAQeMYNZMl/nWoLCe2mZTmZZiAUz7571c0sFotVCIWSDVblnmjZXikMmDhSOhXbtIOORTztVii7izkOQw/zisG7N3N8LG8eZf1qySzvZtQZkkE0axOUAOMOB0bjtUN7A9rpUltYOzXKhpI5JCWBc9M/nWb4ouJLjxDDo8euR6emsqrW7bGV7cAYPl7QdxyOAcDGSa09L1iz1fxTe2drf3bQQmO3EVxEAISFxuBAGdxGTn1p8rS5kZqopS5Uti54WmzYJa69E5njgE094gwqMOGP06VHaNci21CJ/MtQbloVZcHzoh0lX0Ddu9TaffSz/2ppthPG0kLmO6kQAtDgcqx7dsetV7ma3s0tledRLLmJdxxvYckD3qN29DRRak7PRlq51KCS6t7GNbeK68gmBQuWYKfmyfWnyxHVLG4tbg+Zb3MbLIjcqQVx19R1HuKytMsbTTBqGoyz3F0ZcPAEi8x4snDbR1x6j2rVkt7maJTpo3ucNslPl59Sc9PWm7J6GMkneLZxvgO1n0W01Lw5HdRfarW2e7tnkfadwP73IP8ONrA+oNXhE9zaWV1d2MeoahDmG4+zyjdEsowXx6EY98VPc6QX8SXGsafBu1C1McdrPc4+z3O8YkXAOSFGevBJFa97JJbXxeytYPKd/3iZ2/LjAIx6Y6e1aTld3W7/MKTcbxW3QjtbO30+CC3UCS1RQgVxu2gdP8A9dXb63jna7nWNGeZVzhQAdoO3HueOaha9uH16e0fT3SFBGyXBcbJAwBYEdQRzmoGkklTVnkWa004FoIo3bLyqB/rQo5UZ4Az0FZlSb0kywLY/ZYpGV3uQm7y5eCrY5UuARx64q3BClyLS4+zmO7tg08dmZVKNKBwd3c4zjOMGsHUJ7nRPB8B0sTX0sCgxJISWcZGc4+pqxo+pPfx3lvJbvE9q4XDD77EAkD2GaOV2uhSTa3NLw2RrTOVintnjLb4phiRCM/e9P61yPhm+Gq+OfF+rTXMxsBAIfLJBQFdoKjHPGOM9ia7zRrZIrq3uoFjhcygSkcblxjn6DPWua0o6deXevRaDpbafbx3QzGQAJ1C/wCtUjgg+xPSnGVlKyMnyyqJdC54fntYSken29tFpxxJBceaR83X7v4DnPOayJtMuLHTrmDTLmPfcTm4kM6qQ7EkseB74Gc4q8bLzIGXZHIoJaHevypIBlePY4rN13R7afU7XXb++ls4Yot0qKcBePm/DOacWm9WdKShO8dSxeS3NjbaVfReXLp4kMc7R/MYpmBVGP8AdUcjPqatGG+lmsXtFxaMxE+9CCVxxt/GpPBtrp2l6aVtpWl0y+VjvZt+Q3RgPY4qCPSLCwv2uNXuWvLoXQubSZLyQAs6bSrI3yoDjhRmp0vYPay101Zq3Nu4tlMbAFWwMHlvUH2rE02+Gg67HcI91cRalILbZEA8UWerY6Y9z6Vo6g1xPFdOsaEyI3yNkLyMc+1VdKtptN8LyWULR2l75TCK4gjDrDk8sFbjOKFa3qU0+Xleoa0k+la/DZaZZRyaaWImlVtoi4znHck81diniZ7iKG4gee2cLPErZeAkZAYdsjmsFM6/oNnLpd/NDZQnlxHtnbYcdz0yCPyq81xMmv26WzwrFNCXu18ob5CMBGJ7nAx+FNrp1BKXKkvmUdCla11m+0u20pbKzQ+bC8KkK7MecjoSfat944LS6nthdwjVTGJ5bYud4h3bd5HQfNUdhf2lvrtjYzEveyMbhEwTiNTyxxwB1rE1XSdR03x5da94bh/tC2v52t7+2uCA6ROVG5G/uAgt6g+1FuZ9tDGrOUPNEuox6RpWmzWesZe1vZ0DKcsTIx+UgjkH3HSr7waXaa/q9nazxSa+bYXzwkHCocKm5vXOCR1wc1WGpXptby/1jwxdTW1kyBILaSGd7nk4ZcMflHUnGccVx2hWOqR6ncapL4fvbvV7a9W5ncP5MN0JCyuF3YyVUg9wCK0jDmi9djGdd89099zo9AfxGmp2kmq34b90RNaxIfLDbvv59hWvousvqeomawWVZYLvErS/LsCnlj7Yz+FLdyTXkFlqX2260O0sWd7i2uo1MjRjj94QSBjGQRnIq++s6bFolrf2lxFFbXjNHCTx5/bqcZ78984rOTudKnzfDHVnn1jr1/oHjbWLSG0W+0S4kae2MBXMqM58to3HyA9fw6811Wk3H9oT309hbTWaRXHl/apUUi44ySoB4x0yaytX8OaX9h0yPT4r6EXmqr5dpaOBBHceW2ZNhP8Aq+QzKP7vHWte2Fxa6UsEJS6uoYgu/wC4txIByc9sn+laVHGSutzGhGd3GXQj1DTUs2h1IrLLZ2AJjsYsMd7MG8zd97IPYHGKqa5p11ey2uo2F21vfr/BvOx0Y5wy+vNWkl1CM22qam8Ol6cbQpdQ3LBSr5BBB703xIbuLT3k0+KS6mGyRYY38vzhwQNw5A5BOOTjFTeV1qbU0leyN+8slMFuY4Xe8slkEJViMySjDLx1+Ud+hrnhd3Uugm4l0eQX20oLGFhI0jDooI6+vtzTLW7vtU8ULNpepCaG2jb+07Q4H2V8Z3bu2OR6GnSXba3PPpOk3MkNhboJNQ1KHBW7VhzbRP2HI3MOTyKlJrcV1DbVv+vwMjXr59Qsf7K015U8W6JEt4FglX7NN5gAlVQOXaNDj8WNR6Nbw+JvDE9vfXXnzxgSXtox2SwpuwjLj70RIPX5hnntUelaDpuppdxHQV0z7NmO2uoSUfPQFWH0BBFbHiHQ9eg8QrqvhtbSaR0+yNJHMqO0ThWYOjADfuVsdq2bjbkWj3MPfoS5r3/Xo7j470Saxc6Z9le1jtYUKzkYRsjgD8Kvwy+ZAm5gAAdgHO0DqT/OsLQJ7vxP4DmttXme31NXeHL/ACuUjIDnA6csvT3q5odr5FnB/ZMsiGBNil8gjHXr1z+tYzjbR7noUpqrDmRQ1TUWPibSkGnSyxwyeaLjoIiOjA+uD+tb9rPpVzqjT3l2bK0KPEUlXhi4wM+/tTNc1CeVkRrQy3G1c+WnyqD0YgdF4x7VzWptBdaJc3GpILSCGXzFluFypcfcAx1yelUle2limlKLk3r/AMAqWHhGN5I4/E2r3wFyrSyWdku9SEGAjseFGAMD9K6p5LeQxR6JCsC28f2dcMNzDrsPoM84rH07Wb261e8hms2S1jYCCVjkyAj7xHbH9a6jQdH06yM+oyxMZJ2ZpDkgZC8ECnUk/tmKiqfvrX1/yMy+vZNOtbZ51lNwjlSiDOeOM1zdy093oclxcXc+hm4uNkkQJcMzfKEXP3d3X0zXTNqEVzI8sRjYggSBiPlrE8Qai1rHb+dbtcJNMvlBF+6QcgsewopPVJo3nTfI2nsmdlLpeh6T4Y1DTbfVjDfaZ5K3mWMbRSSY2EH1Oe2eaKd4q0+GCw1G+hnaRPEEkV6ySDcIWWMLtUntnJ9jRWcbO7uc2DjVlSTb6voYWm6n9itZpYLcGWdwJCzHYWHcL64796pax4hkhlis5c2n22U7JbOJR5bYxuIGAe3FQStAVeGC4kjlH7xYQocoT1PP9ailkS3htJGt5rkO+1hHjdHn+Ln061pGKT1OiUYyvJKxY1rxF/Yt7b2tyspinCJ56L95jxhsdMnnFLcErK0lwMxQybR8uQSf8DWTpF7c+c8V/dwXdnp8Kz3VzNFuMu5iqCNum4Hr6YNXNGt0a+a+jvJbk3c6YTIZeuPlH41UoqK8/wAyMPNzu0rr8V699dDW1Wa1truztZ5EhuZ4mdEP94jIH171g6gl2bey1G4dEMXyTxq5CFNwDOe/A5wMkk4FauqparZ2ms6g8TLEZ7cyeZv8srIQmT/eKbaZdalJdeFrc6TfS2jR3sMl4bWMGaWFsKFyeUAOCfUGiOjViHUboOcd/wAtSfw1qOnQ67PqFtLevJbXx0y1tppI1i80pkSNt+ZRjsec1m6Hf2/gOwltrh7abVby4dvtsMbfuFJJK7mySck4Yeta0+n2ej3M9hpFstrbyTefcz53STS4xksf4eTgD3rG0W5N3f3un3tooEC70dl37o88Z/pRdNN9P6sZUsM2lOq/e89u50enxxyRBIW82Z0yTnKhR3zVXUvst54U1XTpi6webH5Uq8uJBklk99uRn3rLhudbTV5DYolvpvl5cFCGb2x6V0OjLJfF44kWWERl55HXakWBkyFv4QMVDXJrc66iUotz2MSxvbCTwd/aMsawW9iVihkmwHnfPyws7dmwcmorCbSYBe3GG0fVrs/6RDOv7yGQj5MjoQRyMVo3zRa/odlpvhK8lEuVvfMubUfYpojkbXLd2xkfh0zRewzXWoXUGsTW8hv4lk0y3kH7wmFT5rIR0UK2OT24rRNW1ON1U536NpdvmVZV1HXPBul6fZ3rXN1Hf/ab26kbyWeGONsSCPgyKDn5fUD1rP0G2fXdQi1vSLON9OSyk8rU7jEDCYArh1XOMMcgc4OK6zwvplrZ3+m3qRNDa6UrGNi56uDlMnkg96oJq0Aik8PaXFHE0DvdNEkYiWQufvYHAH60lPdRQpUH7Rxvo9/ut+hz0nhS3l8O30Gj319Nqklv9n1AXgbdfAEPiA5+VsjIznOMVY0WPUdc1A210txZWRsY7uK5lURXCRLhZYFAwS2Sx3dic1vaDfy3OveHbS6gZb+adJJLZW3+Ui5JkJ7Lgd+5rB8L/a2v31rSxNdWd5cX1uLadWDCF5NxmiY9uNuO5zitFOTTb/r+rGNSlGlUUYN67/18zpItP0+21G1u7FGtXgd3ZInI8wOAHMn98nAJJ71janrn9ha7fy6yZ77R4bhLdUgiWOQu0fmJuY8bSMjIq94e1a21i1+0WittBaNklXaykHnI9q0r+JNXP2HVglzYoAYoCAEIBBX5e7DB+Y8kHFYqVn+8X+Z1VaclFKi9zKsdYurjXNG1uztze6ZqE6WcNtPagXOlRs2JixHVOu1xx1qe4u1h8W3uj2lo7rBLIk1yRjyyv3QfUkEY9qq+LEht7i01IrbR6lbsi2jXAK7jniPI6A9B2FXxr841a1sdTltbq+uZmu3kuovJljtNuTH5qDDNEQeSORTa59kYwVTDO97pm5HcLJG0DPHJJwX2kAg/7XqcetcYmi3upXnm64wNta3YnsoYfmkgfOMtj+AjBPpWl4Z1C11CRDDaxxaheiWeN7WcXUEqxcHMgA2tjsRV6ytyb+9a2tJEZ/3jyE58zPoKlN07mkOSorxehYvL9LS7SWUO0UjLFGqKWVfc+5OasTo0kDxbuzFjnIGOn5062WCH5tUn8uziUvLLg4wPbrXPf8JKsBtotSsH09NUu5TZM0xZVjTja7HAViw4Udue9SouS0Jc0pKK3Ne+055dIRDNIpjlWQlODxzUheGS8trSR/LllKMCwJUbm2gDHfJ6fWk1LUPsCCKaCfc4ypVTjHdmY8KB1JPFTaRq8L2GpXkELNLastrbsuCkhZQWeM9SBn7x6npU2dvIpyl136E3iEyzRahb6XOlkzErFMRuCkcE4P0NRosgswrXG+TChpWAJfH3j9DTrNI5Y4Umj3bzhcc5Poalm05ra8jnacMIw0YhC8Ak5yT0JFK+ljJJQfKzM1bTL+9kluLPVLjTkBjdAADGuBhlPfDD8jTr6f7IsFjeXBilu98FtLECzBQM8se+O5qxqMR1LStUsPOZBcwbA6ZJRgwII/KqGraxBpcNsb9yfMkWEgJk78YH/wCurWtkXFSbsS6JdultcWMP2pfsTCMXFx/y39W/pViyIsYmVY4Yk5EahANuepAHrUqMipG0oKiR1VQe5PAH1PanfK948DrunjUbgR90fXpUvfQb7NCBGS0jONu9ywH0FZmpxx37pDcSgRtlmhOCHTHQg9s+laFzukUIr7lx94nqfas+60q3fWLbVAhe7tYzGrZPG4cg00XTaWr3LtvpX2h7RImEMMJACKdqqO2R/d96z/FGladfWtil9qcQg+2x+VJBG0mJckAEqDge56VW1mTWE1HTjpDxpAJCbh26gen8632unCI4QEk4ZVG0H8qNVaVxyU9iTVvK06wNxdGSRIzhhbRmU++VHOKyfHF7d6NpaXSWU97CxVYjCpIYHo3r9aVNSN/dalZTad5EVq4jWRpHAlBXJIIPI/Gt2yv9gRJWBjxgqowvTj8aXwtXRkueHvLc53QYNatvCOp3zxWI1Yrus4rk7I8nkh+mO/PaoftmvWOk3GqxWGnahJFEs8kFtuyOx8t8/Mo68jPJrW1SA3kMluWIhmQjI6gE9M1Hoq6f4Tt9Ot/7TjsyI5Zoklkw7xL95snjbk9/wqua99NQm7e+3qzB0PxXD4h8SXcEUel2N1ZQmJgshdrhnwQsbnGMc5XHJq3BcW9lqKWIllkvbxnlAdep7gemKt+Jr6006wutUudKs7iWNvMcJGqktkck44xwc1o6T/xNm0u8tYAUvFE2ZVG+NT1+h/mKcrNcyVkOEnTupamPqMv2B7b7Bp3myz3CRziJQvlrzukOBz0rSaZpWEe5jt+SPDcD/Crnia7lmsrhNJlW0uXAihlC5IwcEn1yBUF0moNpentpUVnc3PmpHctM/l7I/wCKRBjk9eKjdIr2jUeaRLHFaxx3NpdNbsJ45Ioln5SSTyyQhz1HHNYWnaLFHoWj6VqtvA72VnHuiL70V2yxKse24mq+s+HZdU1GbU9N1fzbu2SSKHTrpwLZ9wwy5HQkcHPNR3SReJdL02F5p9K1Ww8tLqxSTDEJwOf4lwOtWoq2j9fImLfteZ77HQzaQX/sWe2YbbCaecmUkMrvFsAXHHQ8Z96rSaZ9ouEKTywG3O/Yhwjgdd3qOKpT3F1cGzu72K4gg0yZ1YJKU3RkEK8ij74Uk/L3B9q27eGWSwUyzxGbAztO0Sr2Zc/yNS7qw4twbT0uzhviVDLqMdlq+mTtc21n/wAS/ULFl8w/vZQVfb3ByQcY+6K6CO71H/hG4pbixU6zBE9vLawyqf3kXy8bScZXacdRms19P1+TQtUgW0WG61C4FuHsmAkiiLA+byRyoBOa2raCLRXvvsL/AGf7XdefI+M732hS7H1YDJPqa0k/dUexEaTVV8j0/wAzJuYby9+wWF1G2m2mpq/2+OGMGSVtnyK5POxTkk+uKi8ELp+iQJ4W81zcWpe4nyuAPMORzjkdOK0NOm1abW4pbmDT7tI5pWglYFpIIynGD3YmpLu6MGsWtvLDKZLgbVkWMnbjqHPbPak3pymsYJybdr9/l0L0qtMkjWxVJFjDZwcKuewrOSW+fWL5ZYIlsYY42jld8mRu+R256VseIJP7J0G8udJslutRkZUx5mPMjQLlV9OTj6isO6sV8QaeYdUEsNpOEd2D+W6sDnGfrxUx/AcZtq6Ida8qzm0/W3tHTM5iupkyRCGTHz8fcbA+bpuAyam+2ypqdtbQWkrLcIX+0KRsA6j6g8YxSRajPd3mrWt7BLbaYkDQxTK+DOCPmAP93Hr3qhoE+m6L4XR7G5V9JsyVnupZC3lFjwM/3SewqmtNdzSHMm1pb7v+HFcacvhq7g+33a20NwZppLSYmUuv8G4/w+o5FL4fvrm6iit47Wwa28je/lAqYU6R5Uk9RkZ4q9a2pg89zFF5NwRJGsYAXaRyR65rLmt5INSFxYJ5URAW7XBDSqudi/QZJoUk04mioq/PHcz7O4ubnxmwR5IrO0xFNF5eN7t0IPetu/1S7u9au7AJcWwi2R7CgCg/7Pr7ms7S1uNeh16x1YCxt5QIrOaFS7Jhshj6kgfhmumvy0OmrIZI1nuMAO4G6R+mB/hTlZWQe0bqN/i/67GR/wAIlbG11jUGDA3E6RTrA55Y/wAX+yKV98U1rpsUTcEb/lJQJ7n1qaGW4sr+ytJb2WKS4US3Xl8eYEOduOmOcGqv9rx2moG1DKbgAyMmeQM4H51PvN9y4J2f4fM2/F7z3OkxQI3lbYvKjIx8oHOaKydauJtQsQLY+XOw4XHAI44op01ZDSjCKi0ZVzaGC5knaHF4mfMG35gv9329qjN6EW3leGZpJ22qpTDKD6+1Vm1HU9NuIZrdIJ4x87W8py0mPurnrjNXYtOvZdTeXT2k1I3jvO1nesqzRFhxGkucYU5x64xWjWl5ESqSg7JXS3sSSRWcFhBZzJHb2wlbCp9xy55GO5z396vWFnp9o0K6fKLOOLhf3bOVToxX/axnB7GufR/7WltDZ39oVSQiSKVlWTKttwoPo3HFaUlncXsGoHTtQs5JlR4nNtJv8lhklSP7/XjvSaasmxOdJRdvw7Emh6ZZW9lcaVbzSyWDymVC6BTtzwoGTnGcknmkhtbDQ1vo7VSGmO64TBJck9T69B9KreHLK9giglvLK6axRMyXt5NHEyjBLYhB3kjjjqa3NR+xXlpbvp4uIpJYleX7RHgjBxtPoT1x2pSb5rN6EU5U2l7NX6CXaWurrIkyJJYyRAFHLK+7+LkdBjB/OpbOxlsbm0n0+e5gitEO1IJiqHK4+cfxY9+lYdtd3V6NWtGWCMQDy4n3hgpx39DWzpK6mJYI7+dY7KVo4xOEMZ3YwwJzhuO1S04qw6kItWuYeimG/v5tZne/ha0RortZCSCoPBVf4mOcD3NaWna1dR315FDc28ui2t7LHKShhVUaPMQwf9cdxIY9OwzUcDXhN3b3Nr9jizLALeOTe5TJAkaQdCw7CotM0lNQ0t9PuomNoT9mWNs7olH3Vb8sg1cmtbmLpOolK9la/r6lK6u2sdVe9inuUtbe2QTWgTMQI+6Yx/QdK6PToo7201SG4ZrP+1bWSK2aRdz2csi4z7Z6ED1rLvrqDRbyWMrbSLBa/wCiRIzNJNIgBPJ46cAL/Otnwherf6npWrSRmCE4maKTqPQY7HOKVRu3Mi3GEqcoeXzM+Max4f8AEWk6Nc6UbjTZrMRPeSTqGZ/KIdtueNrDnvTdIVr7TLkLNFDq3kBZWGGaJsfqKqaBoE+m2KXGrRyjVbi7u9n2grJJBG7AsA44Ab29T61smC6m1S0GnWcEizfLducIURcncx7qACTUysnZGeGc3T9pVe/4IhkvH0r4c3mmwwLqOrTxND5+Skk0eclQV5HfjNNudSu4NIXU5i0xS2WTyE4PA+79RVEw+G7i8tbx/HumyfZbhjuwyhyTwq8fMBkDitSfW7OOa+0/wrZNqes27oWudSiMNmi55dO8m084707X2V+vYhYilC8o6t+X+YumG0h0xPEQ02OC7YDfbkbTG0gDMWX1YAN05xUiEXd1Bcpt23H3hg5x0GKl0m9tJdLlupjulkuGku7h4yhuJwNpk25OBgYA9KzvFF5qC2tk2h7ktL2X7PdT2vNzESfk8vPCpgElvw4pJc0rD5nRjdx18vM29ae1eFLa4sne4hXfGko3FynoCODkjk+tcvp8uoarZpceJEn0e5F0J7e2s0w7Rj5XilZs4DEZyOSParc9xc2MsunabcXZupI4hJNdTmSMiP5TjPRiDye9Tax9qh0yGbRrJ7y4kdWlU5+U9GY/hTi+VJLdjVHrPbt3I4jp2j6nCTbFHvLh4oPKXbFbiXllAXAwdo5Oa1Jbe7fWrfUxfz2kETESKANsy9sn0FV77SrfVoFhuDMACCUjcx78fwlhyAe+Oas/2ZZ3Gl3Vjq7tJ5uPtMsbGNSw4RFXsijCjuep5qeZNJtjmvZyahHQfvnt/wC07uS7LWktnJDFFGoLrIw2hge5+aqHhwWMmiRaYs4vrfTZBG3mjzNsmOpz3zWnDaW+nacbXIjs4o8K8ylhEAOGPcgHBNP8P2Mk2lRT2sNpmd98v2f7jv8A3snB9+eealtWFok36GFp81o3hPVrifRkktpJpDJaXDu/nYYZIQnhSQCB0rdkt7u402xvIY0jtP8AlrCy/MCR1479qwfEUlxZXFjd2t9pojRnaeCW4RWdGGF25PHzA1q+HtYl1i2v7ePbustq3Lqx8qOcniIZA3HbzuHHWrldrmIbjGzg1e5Npt5e2muytcGFtKBAVkOZM4wWI6DHamW3laVqV5oCT31zJKp1GCeYlkbkDy1PY7Rnb9ah07UrPUNUurKOC4ja1fZM0sZQFsdR6jPetS4ukXTL6C5j82ySFmLLkuoUfw456DtUvezQTezSKthMNNuGa1tztYFyf9o8HPvWPqhe0sVl1W80+YQhfs82oQvxJuwvmbT8316+tO8P3vnfbGS0uo7NGEkNxO24XAK7iQOox6VetoI9W0xZtTt1jtZRkQXY+9g5BA9e9NLleppNR1aLmmWkttLqIupo7q13pdWbq7eZ54B3B8jhFJ+UCnWN/cT26/ardY5iNrqrZAI9KZEHtLrUna5aSF2SHynQhUwASV9eo5ps8tnpOg3Wo3rSCwtZFjxHy2XOB164qHqZxUbNy1v1LMNjLdTFU2ogALsxwsYHOSay9RvtWv3eHw5Zx2+npFIbe8vJRDJeSqODtbgRk5wTzxVfT7u913VNTTVJraTRtIlUWtvaqUV7rOVWRwf3hRfvA8AsK2H869uVaU+bLIdqpjGD2+lVblepMOarrskLo+ZdHii1PULS7vYwBNPGQSG7r8oAOOgp15b7I7dbK4s5EMoWbz5jEUT1X5TuPtxVYWlj9iKRYll8xizouEJB/P2zTLhJ1ltWLReS7eWFPJZguQR/hU7u5rGK6SaLMsy2elrcX6WNoHdU3iUOEJz8oP8AFniqVvbQDXre4vtSnIKEfZVXCyDPU+4qvcT2ury3ugXtkzJCY50lYcOeeR+Iq1PblTbOcuRlVYJlhzx9KLcpcUnHlbtc0Le4E9zcqRbboj+5WNjny/Vge9YtidO1zWL9b3R7eaSPNs8l0m7zEK8j2H+FaFpoq2mvSX7pJDc3CKjJISFb0IFWLmC000X/ANmiH2mYgTOOd5HcZ/lTTS2MZRV+VLczr0nVHGk6hbz29/dxKpSNcrkjBAboOmfpS2k11odpodl4cure4020EpvNQmGRKy5RYVPpnJL+g4qpY63d6V4LfVFtZLG/vNRFvBHd/OVB5kdR/uKcfWtS+sI5GOnrDN9nmiG1VBCEMMlc/j0pvTR7Aoxm1FvRfiOg8mRLVrz7PZ6jdplLdbgOrEdVjfo4GeO9QXd9Jp+s6VZNDKkd+5gMirlUYDhiewzUVnb2cE+maNd2bGxgLlJm+cxlBznI45IAPetq81O4l0+7hs5Ht3mDLHc7Q0sTdmUkfe+tLRMPeWkdTGOhDStMv4dODRTXLPKsj5YeYeM//Wp0M1xZeD5v7RMmpX9hZSPFPCuJ5D0ZVP48emKyDpGr6beald6BrH237Yw3WGoA+XHwCWGOrA5wRjAJ61rQ6ymnWNxqdzBfebaOiyw20O9grNtZ/wDdHJPtVO763BO8G5K1ti3ot/HHpNvHB5rfIuWnO5jxwCTyTTZZzG21ipBztV0yvsB/9asnxJ4qsNHRm0Gzm1e3+yfaYb0YNuzM2FjCjljn8qS88WvY6Fp0/iOGSG5usI0AXeYifft+HIpeyk9UtyoThfRabkZ8Q3L6udLvUiSeaR44fJXJESjO5h2Gat2tlq95p8D3ksMF7HLmVQNySLnheemRipNTsdPuLC4h1JmhtWTM0iPsLL3UuOcVaW5sLDTX2RGaJIVELhySEC4XHr0obVrpGjk72gjJttONxZ6rZ3G+KC7lZUeGYiQopxnI+7yDgdcVc0a+nu/ESab9hn+zQQqwutvDlR9zJ654qidaK6dBcRxTzCZlDMIwHUN/Fj0HfvWlZ6iNP17UdBFtcfaDaRzw3vWOVJPvAY6EDj86LvsOqkt37zGajLN9iWC0kiWeGLCmQbkLnJJOP9o1x+uJrFxovhiz1OWWzu7vVgtxe2wJiVOFCH1JycDtitaPRpTryzM915cybWTcTEAPT3rK1iLU/EWkPYxFbPVtDv1vLaZ3KRAE42BsfMcDJxnmrhaLT+ZOJg/ZOMGdZdzQ3QndoN6F2CoBnjPt7VgWl0NMvDov9jxHQrzH2l8fLuzxx65rS0xNTg1+aG5tYJbB1e5tru2k+TjlkdTyrc8DoaZqqXN1Z/6C8GCGCmRer9ufTPWoj7rszq9yorR2Xl/mamtiS1jSGCBla1XYNxGJFyensK524vJ44LOTWYbaGW8uBbMqzEIqnJOCByx4AHT1q/qNrqd94lge9aH/AIR+C0ikEkb7W+2BcErzlucgg8YPrWfHokWdSuZVaVJyJTE8m8RlBwUB+6acUkrsilOU48trdP1Ohv7eQQqYFEW1hGdvBUgdfTpVfUdPt9X0yFL3mOC4E8LPJs/eD72COTjgkViaff3NzB5+sy/Y9KvIlW1Vxtl35xsPqSeAabrd7cWT6RE+muk8cIimVG3G0DHO3Pc9Nx9eO1Cg77hdS916/wCRcvdJtz4ij1sahIJY49nlZIXOerD09qXUdHs7HUH1by0+03IQZBJEinlSMduvPbFLLFHqcEthvjSWSASmMvtk8kn74Poaq6hZXT6Tpum2VxKkVo6tEAwJYZ5XJ7HOaE3pr/wxpyXfu69X6mr4dga81GxEqQ2xLbsxtlRGOWzn2FFXPBGnWkmrxTa3IVkvlltLODfjzcoRIfpjIHvmisaklc8vHVXGryJ7HFNpUq311qmnyRzXUsYgg88H9wQcsNvRvY9/Tip5bO5uYci4ltpUYEOgwQfX86bp91cNPqUFyBDaNGFieJtshk7MD2xRp+orrempLCW8qUGNnB2kMPlJ578ZzXXJytc9Kmoxk4Lrr+JYumtViMMdpbnVZNzWKmMBXm6nBA4JGTn1qjYzxtZPPIgW4UbmjQchx1APc1bm00WXh1buLfNqlnzp4lkJ3MTgs/8AeAGT+FJpV5Zyme2jUteQsPPIjwrA8lgT3z2pfZutR0pJVJLbt936dQSwN/fWl/F9omhhTL+YSFDEcbj7VNo+nw6Ur2Ut08sylpdsrbnbdySB6Utxdmea4tFjXZEA8Me3CqRzn3J9/wAKy/D999u1S/dx5f2cIY7oDcW5yykHpnpQ03FlPSV31/4f06GjG0lj4gMNtYmGC9iM890ehYcAVpaikOrXttJqEgne3bMMkhztIHUe9UdM1KPX7KWdLt47uGUkDIGF/ukHpxVaTUbrRUmubyztb+JJIwN5dRyxDkKgJOFwR0yaXK2/MxnNU4ttXttp/XU0NM1K3v7WyvIZVt4J+D5gOWGcHcKZF/ak1/qVrIVjsZ7JilyjFHRwcI49BnpWcdEnubsT61bSmyhcyWOraSVMcueRut2IbgEZA54Na1xrMPhGwMfiK2uxdRSqIId0Rl1BCeZgBkIgyODz+OafLZ+7qc88VDl966+X3+juUrvyI760t9chM+safALp2CsiyAr95OOp4yOxrU+1pqujwWMf2rTEvVDCS3GyWMZ+6G5xn86yPDHiqK/vrDQVeNPtEt7FJBfF3klv3O+Ih1GFBOM8YHStDTXmktLaS+8lJJnMYjicMEmU/NEpHUgilPTdbDw9WOI92e/5/wDBOhvLiW5ukimRFFsBtViPmzwWye/Ga52LV3sfFP8AZtwlwFu90QMrcTblO5EwMgBSfm6c1pa9qVoyzDVbJbizntmRoSeZCo4Xg57VS0S7bUdQOpzsjQ3MaG1hMeBAgG3aD26VnGNots31fuWVrf8ADmZa+FzotnZrpEFlDLBNmO4mUzMinuA3R8d8e9aLTajZa6zy7205IC5upH3EPnp+tXbrU7NPEWuwNGYoLB41eR/uMWX+H14P5UaBDpcNw11BPO/2phLln3BxtIAXPAX2FXKcmveFStCF4aX/AKt+jI2ubW1gil1G8jhtVYj5vunr+ead4cupb/R1ubqKK33/ADPbrJuOAcrtbuMYqteaSq3Wmb8G1slLJEfmSRsYBb6ZzVKyGoyeL9XRjKNNjgQRDbiPeSOQfXrS5U4u3qDd2r7M2r6UQiKXyjKJnERZedpPrWR8RLeNrfSYrO9u49YjjuLuytrYH/SigXIJHfggDnODUtvBfeG/Duq6rfpLqsdvmRYkbyyylgMA46jPbJxVjVdIGr3pk8SXltBGunstrb2SGO5gimKsI3yTtbAO5upzVQShLm6HLi5up+6p77+hQ1WHWfKh1WE/Z9VuQsaWsjAR2yZGV29Mn1rcT7VcairSbkKD5Qn3ZCR82R6g/wA6x9ZtRcLbrdWNzJYzRpaxwpNmKEJ0b1ye5zzWmtpDJELoyyxyaROY0hAYLO5j+TJP3gudxxnnaDSlJNI6tYxXNuS2OoXa6xcQTWDTW0IVjLOu6OU/3QO4FTXunadeTNNPFcQLOVZ4oJdkYdRgMg/hOOD2NUdQvLy1sY7m2i8xdxadpHA2LjO78PStC2miudLiu45PNhnUOm5SuCPY9OanVWa0InFN67nPP4Z8Gatf/wBn3Iv2vLOMJLBE6DdGclQWxkfePI9a6XUdRWztYoSsdjpFmgjjUE7YlUYyxPLHHc81Q3aXZ+JQduzWL+EPtXq6oMfTipdYnsNllb3YluBqLuI4YI9+Qv3ndvuqoPc9T0pybk0nexmoQg+drUs/bAlrJcQxPcExNJiMb2bAzgeuRTdEv3vNNiupIHtGlUFYjkMhz/PFU9c0+W80caZpU8mlIjRyCaJyJGCnJGRjg+nSpNbtLjVLOaEXVxBJOMPLCcSKw547c45qbJofLdu+xsQMrWsouNxJywY8pt+nc5xWTqWlwale213NPKPIC+XCD8qlelVrTUL+DRzcahZTxiCFswFhJLIw6HI4JOP1rSDyw2tu9xBJA8iqPKZcmPIzg0rOLuNLW66iXmuWX9rw6fLdAXu3McHUlQKTVrTS76Gx0XWislzcXcN0lrk7omyyxyMB/CeRg/WrEY021vLbVJNJa8vEfy4/KUbk4+85P8PtTtIi1JPErX+s29hLO9s9u+qJLsM0eSUVYj8wGTjPtmnotV/TOerJ25baFXWp7bRYf9DtHFnLOzPHbjcQ7nJkP1NRjS54ZNU1KC4uluJoAIoEbJUAEFkHZiOA3ardtazrcJGQ7O7dAOc9gKsNq1trNjcXekSQmW02WiPF2bk4Ye3OaV2jTSPuxMnS4WeKyuLu1ltLiNMRwE/PbrjhSe9aV5bb5LBlMIht3aWcOmWfjCqvOF5OSeeOKPD8V2sL/wBqNC0yjLyKDtGegA9TTpptOuLlrZWEt3bne2Tjy9w6kd+OKHvoNy5pJGCt/eQ6leXbpZXVlGoFutopM7Nn7rZ4OM5x7Ve1BtU1KEaY81/ptwN8y3tiyjz0HAVnI+UknIXilKWmj2E0sVuzrHJvaOEfMxPp74rRnkdrxkaNl2RBxD/ECRnn6ZovbVDklL3UjL8LiPQ7uS2urv7Vd3M5u4oZJS5B4DnLHnkdBxUXiy9utOv5o4IWKmJ5jfynFvG/XDH17VdtbayudbsbmeBWvoC4gJ6jI5/HmoNVuZ20+5i1ezjuFSXYIYx5jGLj/Wdic56U005X3C3JP3RqxQ67onhptS865NnOtwLiyBKIx/vDume46fStCHUdUuNeubaS0VbFWVrWRZDuZzwQR6gVLpFxJbWtuIbWYWt28dsNijKBuv0CgZPpWeo1KTUbq6tL2M2cEIlWHHIZWGefcZFLfQz5VzPyBNXRde/s/W4ZdNkluSbCRmHlXwPAXPXIIOR71l3fibN3oP2azuZLW/mmjkQITKoViocAZ+X5Scn0rN1Gx1LWrixN3byyNpafa2DKFXzZJiI1En+wAGZe+BV+KxvbCGZtBuGk1dHWKa6uRhpU3bivHGOcjHFaqMFa+4R5tWtEjd0XW9Ia/R7W/t72UZlSIggsuduORjIPUVT1XUJdO8RX/wBouLay0cEQo+eXduo+nUc1avLO1k1C2ZrODzbRhJGwHMcmOWA9aV9Oi1S9SCWGGaCT985lG7Zt+82O+B096yVkzdLlTk+xlXWraR4Wv7K1ugtlZMEW2lZMQA5PHH3QOpJ9apb9A0yZ9E1rUkl8hjfRz3YJhMbncpWUZBXng1NbafpetXFz4gFpcXj3MarZWWoqAtukYIVtnQl+Tz0B9aJdI0+7S0utTsLeG68oRMyOUKqeNmM4247YrW8Vve/6mcVVqaqyWm/b8jp9P0caxYtFdtHNBfR4Fu06/vEHIkXB5U8HNZOmzR3QurWzmCfYJBbSK6lfLYDhPmA9D0rAj8N6ffIbvw7qc8iSaYNKgmljLZjDfMSeDk/MufTpW5p2iwwGzZppzDpsBSGGScuACeWweXb3PsKzaitLlU5VU3KS3/rQslY7ywF1DIrxSJvidfutnOCPb+dZ/hN7m+8PJBqclw8kbyK8kw8tzhs5Hoo5pniK8W58UwNptzOkMUQMlg6fJIG4zn1B9Kn1eKR7aztL2NfsmqrLDIwJWRTxtUEfQ0JaW7m7TUU5blrT9Xs9XtJZrKctbiXyDIgIG4HkVUii1GCbWf7UaF7ZX863IAHkwbeS/p61o6Pa2Vnu0xpVgsgmxSoCsGxwWPt61zHifw2rPquoRakn9o3jlEDE+TJb4x5Eqn+Eg4yO4BFC5XJpaXMnKpDSMW3v5CWGq29rf6RoGmyPezPcxxTPgsqJJlgzMPQAn8qkbSETWZ9Vt3le52+RHufKFc9QvQGqPw9f/hFfA3ia/uLQRtJdrC6W8pkkAAPyMD0PPB7g1saDrL392Vks3toY0WQSuuARjgD3zWk4uLfLt1ZWGrOd3VVtdF6XG6TqiagtndwoEjlWSAKcDcUbBbHbnFSaGliNVvo7cLc3jvxArEK7kHCn8euO1UtemsNHEeoSrHapCHAeNMffbcxwO5bk0zQtds77XvKsvN/tSwYT5VMAkjj/AHuDUWvdpaHRK6goya5mXri83arNLJGG1K1hW5lt+JUjZVKCPGPkVHPBHfr1rDstWuJ9Dk1DWrMrMquzxA5YkHOfc1dl0PzNV1uea7nzfWyRQmFzHNbMGBcxyf3WKg47nOaR1vbPVZb/AFe7tIvD1nEHuJZV3SsRjI4xukboMdzThypWMueVNuUo2W3r5/qQWeqP4k0k3trDO0ogMQEUOZAq84JHOM9ulaO6+t9Ge4WDFxJEuxJvkZeOAfTNZU2rXeuyRR3Mq2umTA3MelWq+RCsRPyCbHzSMcZPODTNWmvL2CcR3EaXrELGzpuUDt06cdKbjrY1oOo4c01bTp1ZLZ2uram/h37bHDDNpU7XTyq5zEACcqR1HqO9FXvD8t3D4S1dEmtJ9Z8oxcOEEjn+HnhTjrRUzbbsuhyunTk+aS19ChPMItRSxjB+1MJGaIMHZCFLEPjOzj+93pdP8o6YIbeGK1I3YEY6Ejg4+vrVfU4JQjpaFLeS+UCWZcDO08Bj/FnmtKCzaOBZdzSws21pEB47YPt15q3otzrhdt+0tddv+CZ/h631JIruDV5DM0wj8qdZNyIFGGU8Zz3rIsZrGe91e3tYbyOaKJ5ZmCnL8HlO2f511F3PFpotpX3LaOSm4EYjA7uT0z0zUt7ZefbSPpLIbkIWVC3DnGR9apTd29r/AHGXIoxtF3te/fYydE0zNvYqLy6aTbGcMCGYY4L56e468VsmKy3T2xto42EgaOVZQJWH8RwPu+meT6VmWr3lrpa+c6z6gsRDqi4JYdSO3tUC+UNTtdTuYjb6ncoLZUckgnOcBR1NTZvqauzSXTr0Ce6g0+OVVKXWoyZMVvjb5jnO1CQOB/nPNQ6hPLeQ2elaxi1vLkJ5v2QEIjA5Kbux9a2tXabT7kXKWYkWGJpJZ8DKHoAPVuc+wHrVPQYprzToY7u4jujOxkV4024UZIXHr/WrurKRlG0pcrenboa7G0s7WzNzcPLJdlkhVR9zAxuJ9arW0l1HdWU9hcxC2ileRzNMWZmH3VVf7p7+1Goz2mo+Dln014bOeW6eztnlOcbFHmbgepGQKhsC9naeUm2eVIiHeIcscckZ7ms7aeZUX7Tmb1X4ehYm0jRxq1rfaXZ3cFrZzDUJoobraZLjIJkViC3GMAZxj606BoNJ8S6tpKNavuEus6Z9mgZfJjmHzNNk4VsnAx6HpUsMrPo0UxiIEYCuhODjOPzqtB4jk0+71N9cS0j04wCwgWOFBLNz8sjSD5sAHG08UJykrbnLUwkaMoypK2v3oqy6fY6xc295E4m+yyANJHLlQenOKuaXdS3MV01zYtaW0MjKhc7d4X+PnoDUWmDS9FjCW9pb28Esg8thnlyeOp5Oe1acxuHi8ooDDIdzKx3Fj/tE9valKWlunQ7oxlzbWfUS6VL+5ura+ktTZtAsgibmaZwRhvddvy47dauBba1hto7RYd6AqFTnCkY4/SuevLaQ6naXZlEEdrvj8uUgGUtgZBPpz+FaU2nfZNWhuzNJ80LIuGAVfVcdScc56UnayVzP2ai9e5b0GCHRNMlQSS3F0rs/mzNkLk+nf0FRqINYjub2O6uImniNsxt5cKnOS6r0De9ReIxLqugzNpc8VrMsWwTMdqqAPvMTwBwST25qhcvN4f8ADFpBpcSX08zrHviyEOcb5MnsecetVFcyvfW5zuyly2JNZ0+4VvD2pQyzX11o8vlhC+FmRz/rGHcjocdQah8W2sNnrEGrXN6I0hYrPGBlnJAxkDJ4BHbpg1vaZcS2z7njV0b+CRflYen196ptE1td+INUm06O+t4oUvLG4a3UNBKPlZWZeWYKeM9R9KITbdn0FODoSvFbvfzLtpbymJzcMi2TLvUhvmz6AdcY5zUGuXrX19DKl3D+7QJFp5b50jHTvn3PrWH4hmfxVYaeLe5lsp5reKRXjJDLjJ/I1vrbxwXFtfT+VNeRRBGlCAknGB/jipaS1e5suZS53uZ3lm/jey1m18jT2mMLNK+Hu5QN6rGByFHVmPYY71Z1uystQ0yW01RnS0ONxWQruOeADV27aO5+z3gVYyqFYtw5QEgng92x19qypLq5n1u207+y5ZbO6dFWZXyBIxwAy9gD39M0Jt/D0J5UryqaIuXsOkX17dWMd9JHdWNnGWRYvmAclSvmdc+wrLk0y6sZLC48P2tu8lgRBFbyytn7Pn94TuOC2fap7i4um8TR2Ny0anUoXaSQMpEMqx4EUR6lAQcHuSTVHwQ+m2Ul9aW1/d3l1E2Zo7g4IY9OD71ak0rp3M/ZtxtLd/1Y6fV7eb7ZaXUc7QxWjNLOOiSqV5Vvp1p9tcR3yxSw3EMqqindbuHwrjKnA9QMjNTKkV41rZXEIMgcMrFvl3diR7Zx6Vi39rbaL42u0ggla71FQjzJzCgjA4wOF4rNPmViVBqXL1Nlpwkm2ZyrkkRAty3Hp69elQyeJLH+w31C5uolssmP7Q/A3ZwB9eKq28Vr4juE+xL9oubWRngL5GyUDrn09c9qmSxiltYrW+itJFRF87yV/cmTqxUHqN3SlZddy5Jdd0O8R3GoGKwt9BjhkdIIJbp5vu7HLcr6t8uKtu5s0AKMyt95fx/oKztbu7+KCNvDyxyv5kayrLgYhz84Hv0NSajYte6lFfNdvsjt3tjAG+XJP3+O56U7aIhJ7S2L91rn2a3vGlnkVksbmWNkXe3yRHDDHU8jFYXw2uLePwTbx6fbGGUOv2sFfmMgQck/8CrX8I3dto+mhdKg8yIo0StIMsDnkjP9etUJ7u4sby2jgt7c2+obhaMWbdJcD5n8wAfKo4+b1Io6OKM+Rc7b02RqxShWBkV2GcYByah1HTIrzz980NobhMmQuEdgoz8vdiPYGpwyHIiiAdVy6bt3Prn61XvjG80V3JBGbtE2LK6hmVT1UHqB9KlGqi+bTQwLfxpZm/lstNt/ttrHERPfPKIVhmAIWOQMBgsQAD3J4rbsJNVvfDga98mx1l1O9Im3pE3YZ7np3rJn8PDXIJbTVvIaee4TF1FCEZ4w2VRgPvAZOCeQec1P4Rmkt/C1hbrAyKiuhEhyU2uwJP5VpPkcbx3IjGoptS1OiWTy1UKv77YFM2NzE4wTVHR7LVr25u3vBBHZeblJ1/hTvu/wq1pskV6Ekt237yFUr3PpWAWstX8SWd7ZXV6ptoJrVZopB9lmXeQQYzyTkH5hwcD0qEtxJyTtHc15r64u4Hlhjls4zbmGKFzgomSTnHQscEn0wKyPhVpl3p+lXdrq7PDPOXIEr7uA2QM9uKt6nFfNd2slrdxJYI2Zww3M6+1a0zfa4RPBhfIAXLH/AFij27HFHNaPKupo4JRtsMgi08X15dW0Ui3E4Vrja5ZJSvAODxkD0pk811b6fcy6bFDLOU/cxynbHuB6se3GTj2rH02Sz0/TJdV0cz6pZ3VziK3gcNK7M2JCgPJC8k4B4FLHNf6v4fuLvSJV0+4umKwGZxNH5aORvXAxllH4U+V79DJ8l+VMS5tYtdEBurpo57OVZZBaSEL5g/hbvitPSZm0M6nJaM0k14wZ5ZSC0ajjap7LSwlUnAby4i/33VOXOOuKrXem2+oHV7EaskE/liK5jjJ3W5YZ69ATnNTe+nQ6ZctrTIbCKWza8nub9rmGZt9qnk8xD+7kdRVa4tbbXNOivfssovFLMlvOcASD5fmx1X+daEdp9l02K0jlkCW6eWDnnA9/fuaz9U1C40iwN9qbxR2szxpD5Q3EMTtKk9znmqTu7ocU7LUbqFjLBNaapFfNb2lhDI1zbxr8rLt5IA/u9qTS307RorC017UZbu6A3RhiFkk3HcCc8gAHGKni8QCz1e5s7Jpn1G1txdsoGRtyOCcY5zUXijRLK81qS8uI990JN0bjnGeQKaelp7FcrlNxT/H+uh0ccsMm9Le2ijkVC6Dhip/vHPX6dKyYxMumlLrVFu9hYG6KACMepA4yvtWlptpd2sUclyAiynZEWT5SMZOfb3rKktLay01rPTrWGS2lLvJGHI3swPGeeufwrO6IirTtHVFa2urXV7TVLa2uJotSsphayyvGB5u5MiWMDOUbqPwqmnh5r7QRpV7PLds2A0pfDfLyGJ9sc+gp9hbyW0d28yJFFF5aWgQZKxhBlCe5UgjPcVcTWIkvIreQFjKn7l0GH6ZJyP69a0d07QLhGXs/edzL8H62dTu9c03RtMtpNAljlubrUZMl3nRQI3XtsOAoGM9TnmrNzFqCaKu+5jiuJBlpUh+UD2U5/WsyW9vbWW6tPDtjDYQrdIt0xQAXUO3IIIHv+daOvfbnhspdPMSsSv2iO4PAU8HHYnpTkryVtmPDQdLn5uuv4EsCLc6Z9nupEnSOItJJNjGxRkkk9QBmue0TVTe+dc6LpSrZqjbrqYFWnI/1SoR/AR1Iya2r64lhs4p7JlWG0DtdwumXmXaf3S5Hfv7U/Q7x73SrEwQMyyKNsOMbR2XHQY9OlCdot2uVKL51rypa+b/4Bl3Drd2uk6l4j2aTNazYykxCBzwUPqDweelVPEmpXeoQS2NtLdSWlzLFY2gjiV4oboNvEobqxK7hkcda2odOt9OstYt/E7/2lZTz+ZESu77NJ0Uhe/XB9ap6IkmnC2tLvN9fQq94l0VCRQOBtUKo7gE8Y4q04p37GNSE6i5Ix3tr+H5FVtP1SbxBql45tEshOI4UI3OyBQoIOcL0yfUmr5t0totSvNQZk0+ysnuJJEADA9Ag92YgCqGmWkqfapBfyXDXJ8xBn/V8cj2FL43Wf7BpuiR2++3uYDdTTvuKtcr80SEDqAAc54y1T8Ukjeu5YehaN7vuTA2lhZWsNk9vHZz2wuoEjO/CuM/Mx5Zz3Pr7UVitJayadDc+JI4LPY4EfljftP8AdAXgfSiqdJzd0XRxEcNTjTl2XkWdO1OV9FF3cwvHMxX90oyR82M5+lTadq9z/ahttTRLaKebyY/LbIfIypNXNYuHGlqulW8PmbFaMTcBvUseuTVSO3S7u7b+1JLaHE6MJC+AjdAT6DJxRHlcdiJucG+Z/wBW/pmrqiobJ0uQWcjqAGBHoRVRDBa2c+p26m5xEFaJQWzjhVC/X0pVimstSu4dTlUeRKY49g6IPUn+LOaozXh1K+n07SZZor213J5bDyopw3zMVOP9aAMj1AxRGL26EVKqUVNac33mraWlydPikvZ3urxi589gE2lu2BwAOgrPMmrWWlNY28/mahgyLdSkAMC+1k46HHcHoOabc6jfW1pZ21lEbuGPERLMFdvVj64rS1Iu9mps0826t086bIwq7uFAPfpz6ZoTa3KnCK3fl8iPTVa2jAt45ZbiRgrKuTub+7j+lSxNdstyl3EbeWKQjy+49PxrF0mC9tLO8vrzzjezw7W+yux2pksQo/vZxz7Vb0aW8msZHvnvrme1to42uJztSdD8ytsxkPhgnJ/hocdHYJ4hqpG63DxAqWek21rf2HzxXsl7poiTPmxPGhlfjgEScc+p4qP+2Y7L7LHfQyRQXsybJo5gkoIOVQDBG3g7unXFalmhSBonkDO5wDI/CN1AwOMdKpt4c1bULOzl1JUSW1fzpWCARsoOMgnoehppx+0RGk6UHTvo3f8AHU0bY3V3qK2ccKB7pmKwjgL6f0qnqGjOdPjstWvLZLhwpj1spmymkd8CEOM4cEYOR1zViK5S2unlt51W7eNlhMjDBz1C/hWfp1rf2KaNaWlnbrpvnTT3JRcqHYjHHTPAJPtUx7oeIVR2UXaO3c2tG0+1n060SWe31NInzDLbyboy44PzY5wc9Kfdu0qeVp727XcEnlTSzkyLEe6CNSPmHqT+FZ2tw6jD/Z0vh68hjggmxPBL8odM4AA9M59OuazvtVvZzTLfaZPpdxrF7IltNE5JlZR/rdp6jJAPpngUKLl717kOrb4nb8L+hoa/dRz6YZrKC1utRt3CQx3K7kSVuA+09/TPGcVmeFbxW0dLK7mmutRkuGkjaOMsycbZF56AsPzGRW7oui29rZ3VzdQlNQuNrSSOWAypznnr0Bq5Ne2WmrBFEsFtc3gYyXBH7xkyWIB7Dk9KiSS92J0Qd3zSWv4eo+y0cPdwxvLFHp5gZHsj92RiONzHoAOMd6k06CZdNQyRzCEEpFMV27CvG3A444x7UxpFm09Xs3heEgMrRnO5s9j36ViT6x9l8cGS41FbfT7vTDYyJOrLFHNHIPLbcAVBdmOCexIpJSloc1eqqTU33t6HQ3UflRxK7hpBglmPA/8Ar1Ru5rvUNJ1ix0ySOZ/JyVV9qEq6naSDwcZ5qtFB9u19Y2v5YhZu0U9kRjL4x8/fA7HpWjK0GmhNNthBCJw80u1B+/CfOVJ7DAz+FUtGu5UkpQav/Xcy/F2pq8GonRGhl1PSGFqYzCyPgkkDbjDDrgrVrS0uHlWS8cLbPbIwtsYmMufnOP7vQAe9JA9z/wAIk58O3RuXuXaaJ7p/MBYj1PQDn5fSrOmG6l1SFtV0yC2n/s3zRfRnLq5IzFjsp602ko2/4czjOdNWb18tipbahb3Vubu6trzTVil2AXXOVzjJ2/yrUi1OK70Bx4clliFyxjnvZo2jZ0B+by1PIU+vepkaWUsXQnd8sS7RjPr9KbNcQ2zR/bJAjyv5UYPR2IyBWbtLYu9n739M5uaSGzFlLHu1JIJ2tpryPDTQ7+NwHZRx05rZs7YvEZp4l8tl8tpygTzQO/scVUfS724vreDQbeCCJ5vPv5NvGwdc+9SeILq/v9cge2ngGjRo0Mds68kqRtYfU5Jq91ZFtuU+/c0b2OWDT3KRs0/BiVZApI4wpPb39qTxJrFt4audLtNenJ1PUohKohT92jk8hvQc4FZot7qS8tJZ7xkmhdhNBjIlyMdfbrmrusafp+rXWmXN7FuvlVik0jZLDpkDvjHU8ZqVZOzMatOTaaZNFdR22tNbW0k2biEt5yLhCehH15/GoNCiu7iRrefy5JoWZlY4RQoPDN7DjnpTrXUd17Jb/Y5oxGAqXHBjOeeK1LqCC2svs0YIub/E1044bZjCJ7Dvj1NJ6aMq/JoupkWdhJpkupXH2k6qZJTNb2pk8uNXx93zMZ296fpt3f332f8AtHSrOyMqsJnhuCREw+6VGPmU988iorGzTR7G304O4tyxijZiWJJG7H4AHk1ZUrdW8sUpx5gKsB0OeMCm3fcOTmV03oMs71UuLrTIYp0ubbvKnyY/2WzzVK/XVbX+yooWiuxbzOt5I/DqGHO0DoemfpUqRXQ8caZeQF1thZKtwyINnmRbkCljySwKcf7PWprCC20yGaKMTOR5lw3mOWbJJZuepp6LVEQlzNpmhFbSSq8kDKgiVppZCRtjQD5txPakW6hnZpIyJIZFBgYrgugAwxB6EnnH0rJsZtO8QxzLHHcLFAdjGTKLIHAypx94YqTUIS2oiQ3E0QTIMKjKyA+vHGMcVLjbRjSc5O+yIvD8v9peJPtml3sty1u32drU/Kvne+enrmr8Ok2+jW32C0lach5GneSQtvZyS4BPbJqLUbjStG1hZruaWFIIVQzxgbGeUck46kAAZ7A1Y02w1KfUdSZjDLZKoe2jX76rj5s+tNt202JbXMpPQntHh0Symh0/EaRwtMqhfMdWA4Kr/F1qDSrNLbTbKIbCwgUvsTbnd82QvVQc1CmlLNqttqNwCk8ERWLDnChvUd6sXdnejWdW1jTVtr2S6SEPbKwint1VduMnhgSCRS0asJtQlvv1K0ASe8a4tp90UeYzEDkZzxu96de30FpLFZMSbu8zshbptxhifTvUkdzPY3cMMVkEYjzZg6AZb+6/ufaq/i2w/tJB4j0xf+JkWWyniV8eQjtgzR59M5/Oi13ZmzlytSlsV9Yt/D+kPpWsrIr6rJIbLTwH2w26p8shiQcAkHBNXLSDybdFhYxRpGYY0QYESgcBR6jPaua0W5fWb250e90ieS10KX7TY30oySnCsX7AuRux09K2dJvrS8WW606c3CozxE5PD59+euBnpVTTWj/rsTh3GUW49W9f0HwwSQ2kely3uoySTAFrwOFnU5B4bGB6Y9M1o2UcdldXV1vluJpXwWmA2kjoSRyx9M+1Y3h/WLfUpvPhcpKzND5b5A3L94jPb3qvo2oyX1pqpN5ArW10YlZo9ghBICK27g89/ek4ys0y+WDaZ0T3cXksbucKD/FkDcT+g+lZM2nrZIllaiJ7BAJXWUF5ROzbsKW4VQuMY5zmq1qNOS4mWdbqa4nkYtFIhESNFjdIM8ldxwMdTnHAqS41QXk32uyk+RG2OpO4/ielHK47F0lGbTWxFa3I0NoJdavBczXVx9midLfG7ccKhA7e9S2mqJdXV+YJgtypNvNIhw6sOntx2NWry9ij1b+y9yveRQia4VhjyFZNyOCevXGR0JFUdJ0i00PS5ktpt0McLTySsC7FVGWYnufWm7NXe5cJJvTVdybUNSv/AOzo4orsPcwhVAuTuZxnBz9R0o8PwXOkxCPWLtJ5GYmFsBC5PIXHfisywvbC98S2trGftsxieWaRHH7hVG4bh6HIwfereu3txFco101q8Dvjcw+ZWbhVU/mCfek017ttykoS92L0RoG4825n85Bt3jKjkZ7YqsI7W01KOC5PlS3O5053YI9D6Y7VlaLJp+mMuj20jJNADO8DEswBP6jNaeqa/pktxYQ/N/aAnCgocbeM4PHTHanytS0E78v9bkrTWEWo/ZJroNdxQi4kt+SwjPIP5VVvkg1G+tL9DJGYw2xS2I3B4wV71dOjqniG/u1vWlE8ccBj4HlgZYfMOTyTwfWsS7uzYxXP22NikDb4VhO55FJxkqeQM8Z6Uo6/COCbXNN/13Ltv4dM+rWtzYah9ns7Qtcaj9oZnVrc/fVR6+h7VkaF44srq9MVvZXmmWDP5NlczSAyTuc4UqBgZA7HjvXTWEkJS4tn3LFd2jQXAJIwj4zkjv16VxGk+D1t2srG71VXW2vjPaC2jJypGAHZunQdj3q4KMrqbOOu6yq81O7X+SN7U9YSXTb5rBUW+t4y7LcyAiPuchQTXO+L9cttP8W2+o295PeaUkEM62dshj/dSRAl2dvvZO7oMgjnFdJptvosd/d3KWMMc8K4uSXZW4+8SQa5u80jw3Bd3eowm/8Asc6vKl3JdBvswbPCgj5hknGfWqpxgnqGM+sVLey89maniDUtH0uUXFvqMl0xWIxaWImWWQSDcokJ4U+uCfpVPwpq39qapFZC8mu7zUGnF200GDYkoSiqw4YHaBnsB071j3Wi32manZvDNY6p4e1eVYI7qf5j5ix8SOTzHIM9QcVFoHhbX7CystY8ySO/02cKtm+Y2Kj5XkGOC3JxnqBWihG25wPFYipO2t1qaX9k3ulpPZ6unn2UcyiNNm7Z6DPrz3orr9Rs4dN0zWYob6SWfVLrzHu42KSpHgBFJ7keveis1Uv1PXjGTinyX+f+Zj6nY3b3JkeVvssLEEgBlbA45HasvTdLsLqa4vJ7G7R7ktHIsv33GMbgM/Qj3rQD2lld2WsXjzLHbfuJACSHjkO3OO+Cc/SqsMc9prd3L9q81RKqJHnhSpxlcdc+tPmdtAfvT9m9f+D1+ZdkubtLv7G1rcS7oknMxx84IByc+3Jqx5s1za3LWEsMdzbMnlSGIngsAwIHfbkZ96dqOpzkwjV1h89pZBaLAu1ltMjYrevO4jPY1R1W8e11jSo7QhbOeQrLIBlyeqj25pJNvRExnzUlz6XdvS7NHU7eBNba4too90A8sM/GE69u/wDhU0E8i3sjpKFZ2JHAwcjpxTJI4Li98qO5OZcsuRuJ/wB0dTj8qxpp49IngF6qBJ5RG4SVszP0JHHyAccc9aSXMrdTXnjA2jqZ0+9trZoo2lusrEr5IU854HtUaicaLPp4W3gds7DuZo8ZyM859e9Z2raxZLp002i2q3d1byCMtPc7FBJxjGOfzFLe2Iu9YtJvOkgijXf5S5CFyo3Ajvg5Aqkrb6ErlqS5bXf6eRa0TThZabG16JLa5hLCxjEgeZv+mzDkKo/hB64zVPwzdsllJbSCSP8AftPJE0nmGWQnmR/c9cdOabq0MsVtJqFgpaVV8qJJXwsrE559cAGr1n5qAvGltFdbM+asQYbiPmznrjoKbfuvzHGF53erWn9fcM02ytNd8YLGbOVnsYzcIFQhchckKf09zU0ba5qGrW9ze2Op6FpmniEpHLEFaVgT5hJz82Qen1FbpuFSD5BCZJECs0S7A5I9PfnisK1s20qG6ghfbDCkk+JWIRWPI5J6k4AHvUc/N0MJUJcylJ2ir/MXS5Li6nvkurfyLeFybco331J7+9aUn2eWM2dzCl1aCQOkMnJRhjDq3VX47dcc1TgvZU1eez1WK1twyFoS0hM7thSCVHyqnLDLY5FWZfK07ySxMssrogReTuPTb9cilNNM2hOFWF5arbX8zJ1TSEm1ALbSX8ml6vM93JE9yXSKZH3NHj0Ynt24q1F4hvtQ0a+ggieKdHeKMTICDxyenA9qn1JZdK8PXdvpFnNdaleXRt7aQFiLc4LSyKccbQM88Vg6HrFx4l0fVbW/1SygazEaQ6omEE25sEyEYAZu2a0SbjzM5Y1qVOfsUvP+vS5v6VNLY6HYWs9lNcTxME32SKgTOOdp4IGT05rZfUIptKJWS5ZrOaWJlljCksG+8q9CuCMfjUOtWt6mlDS5TPZzCLC3OMPv/venQVSjjudOtrCW3hTUdRhUWTtNKVV4WILOwH8XGR71lo9eppPWzWy2M7WpdWMUV413eXF20ijyLa4KgqDwGB6j19q0p73N1aJcxW0UNwz27k5BLSLgL6L3H5VPY6ja3movJ9kmtJSxTybnG7aP4+DwD2qtr+ntexRWyPGsC5e5d+CFHI2nscjNVe7Seg7JK6W5V8LzWxudT06zsDYiym2PFg7XI/iUdulbGoanDaNbm8L/AL+ZLaNkjLZZugOOccfhV2J7BrCz1CC6hkcjc6jJLZHBBHWudvNcnTTAkNysVu9/Il3NLEqSsA3yxI3RVHdhyfaptzyuJTaSUVd/h/VjS1mW+a7mis57aNBF5MHykkSc/M/sO2KaqodOhk8QPbzNaBXnkT7ile4qnHb2sV418Nzu+IwVkJwOxx0/Gi08M2Z8L6wLC9lvrFrpvt6OpV4yQCBg9vQjihWS7FVLRsv6udf/AMJTIIzDpkFulhLFt+ZR84xjJI7c9a5aHSJbLUJr99Qe4heJQtkqZEB74Pc+9Z1pc3F9bi20u3a0jgkSIPKoIcAdB6DFbmnvqV7cxJFCsNo8Z2u/DDBx92jlcLoXLCHvQdilql5d3vhq91CyhmjeMtEwI2ybjhY0Hpljkn0X3o068s01BbFjDDfPCshWMYMgXAJB9B6Vo3+DY2MdsGfbIZiDj5pDxuPbgfqao6dpFhpmoZdw0t1KfJ8w5cORyq5/E4oTTjZgrq8v6RFpc+m6X4n1K2iMsV0dk0vnuWjct02E/wAq3bi5R7hSJGeQgg5/iPp7VmanYzS6w6MlvJZxrmNyvJcHqB0xU09uJx/okn2e7jTEVwUDrC394DoTSlZtMEklzGtFZO/hS6sbl2ml85Z2lVSrBey/h61zemanDcWlzqF0XtILNvJkkuhsVeQBn3OeMcmpJtEmOp2E9xr19MftKLb2UW7Dny8MZW6EEqW/SrGpTW93qEdk6QzLGWZwxJcjtx0P9KElsZQcve5S7JFeW11cvOnlujrsXoenOfUHr9KsXkcMeZ4rYTzRwPKF3hEGMHBb+Fep/CoxHqL6g6XC+XAYspI/39/oR9MYqZtItb5NVh1cvPZyGNYbSM7VYxsGyzdSNwGR36VN9dQqyaje+qRy9zqN/qegWR0qG2tNRu40nW1kHyhc89eemOvNbaXTOlpBO0aTBGLtjgbQM89MZ6Z9R3q1JBDKEkLx+aXOVC4KHtx6fSpJlshbpHcQiRElEwjcZBZOV3eoBwfwFDaehTlaKUVdmDJPpt/q50SW4jlvSnmSWqruOOvzdhgc10N7rE1pHaQaXYT3bNLtEsIGy3ZcbTJkg7O/HXB71ltY6fb6iJC0EF7fnDSr8sk3cgEc81a0u6dZx58USxxSfu9pyzr1+YdM03bTsTUi6iv/AFYm1aC6ubb7TBLCL/5o5PLUiLzh1KqedpPQGqkM+o2xsoJvs0gMWLgqnzSyZzu+g6AVq6vc2upeG20u8SVJgytE8LhGyrblOex4prXUNi1nNIyM1x8sSSOFct3wO/Q1KeliNbKMltsVp54rjVTA88ceoOm+OJ2AJz0G3rzg4NZtpf2dze3VnJFJJGuIrtGjOxg3BUHvkZBxU97p2n3OrjWWsVbUowoFxuIKdQAB7AmquiXUV5q13p9o0099CN7xkE7M88Hv9Kdla6N4J8r5tEc74d0bUPD/AIj1M2NgltpE0UlrBIbx5tkTHdG0gOBhCB15AJA9a66ySB7W7tLD7PFewKBJtXau5hkOB/dY9D3psN1FqOnCR4Wis5t8cyzZDbRkdPqKSaIQR2lzZSWqR2xAvBj941uFOxOPujcc8+lVKTlpLcxp0lSS5OpKlsIoT9pCvcgBSyJtBbHNZdvFqMmham9xp9vJfybjb28jAo+DlWb0weauStNLfW0oaNbRlIm3DLMD93b7+9TvfW97rF7ts7y2mt1igEspUxTR4zuTHIwc5zUp21NpN2Ue5nfbJLnSo7nUAJJ40HnBVzkgZO3157VF4PttGk0yTUtHWVdMGZ5i6n5cHkAHnr2qtJrsD6jcwrbXW20ufs7SbPlLdfMB/ugDrT9fsP7ZsFi0+8kiEkThEgcosiSAZY49ccH3qrW0elzW3NH3OhLc2Nl4gudQ1mNpQmor5RLgoyAcBMH7uPT1qho+jjRdWtb22vLiZ0AiKs5ZNnOSQevHBHvU3hXSJdGV7O91p50uCh2XchYxIOHKt1JAxit+4hh0yRo5XWZxzG6n5ZFP3SvbB/nRKTj7qd0RTScVBxs+3c55fs9nNdzXNlDpmq6rLJGwjPLxIcKVHQHGMgdcCrthps76RLZ6vPFqD7t0cioAVUc/N9Kik06W/uzd3kkEsYfzLSH7zwtj5vwPvUtxJFHptxYiUfanTdIin5/KJIz9M8ZolLsaUqaWi01/MdLcaPpVudTuMPGkG4SRruZv9nI75qlbWlvdTRamluy/aUF0XAyFboAf9r1qhoEl6uq3FrqES/2bcxmKIIMbMjjj2qdtHv8ATbiwttLu0g020Ijmgc5MwPO8n8arltpfX9Cr2b0LOpJqB1Lfpk0EcbRjaWjJKtkE59sZp2s6fDYX2pmSW5lvtYOwuFH+iwDPlxp6f3j+FXJdVOnLNJNbp8pCjyxuYdun9aydPFxFr95cSSPcLK4aCLkmMd6mLdhVKTc1N9Pz7lPTb+LSjaabdLcN57eVHIQXBI/vEeta0VxbGcv9us8WsuyRmfLh8/dIFGt3tvpmtW6XT24s5CQgY/P5jD7vH4Gsvxmtta6RaXktiLp5rj7GzLwAdu5XYDk/MADj0qrKbWm5U6vs4OTskXYz4dtvEmpmK5ur6+vrpLC7ihRUghdhkEljll6jKg8isLW9F/tSS2iR5rfRhuiS2lQxyfKccg+hrLufDN/Lfaal+6Q392G1GMwx4S2YYAf0JYjOzPvXUmy1Kwkimsrn7dbNBLJLHdH7lyXLBwO4OccVs0oWaep5uHlUneM03GX9fiWo4dHtPDkema1bNcWM0vl2kC5AM0K7w5x6A4I75rHg1HWrq5v1nI2IzPbnvJF/jUdlaa35dj/aN+Vljlea6j6rk5+UegHHStYXdvptrYXlxHNdG+uzbCCMgbVAyzZ64+lYtdN2d1NKk3Vty3t91tvkZ2l6gNR037UQVQyGHD8EkGiq+qXt19rgltLWAWKzrI0IHyhd3y4Heijl5tUb1KtSm0uvoU572486ANG025tuMjGPpTog1pfxx3YF9I14PMjtXCfZojhi0g9TngD0p0treSS20lrJHFFFkOCgyw/3q1LmC3hiZzAyCRPKM4Aznr949qu6tbuZ1ISlK6urfiin4n0xdevJbgXa28plHktjlFHAA9BjFWrWC4isLaAXlrcvGzNcLcIUeRQuEMbgYBz61V0+zmub61e3vYvIDbGKqGDg9Mn1+lWNPt/PfV762mW/S5nG50fKJt4wB1xn2p8zStvYznSjKVo3V/Ptt/kOtrhrq+09p9ObT9SMRj+0o/mwLgZwzj7jEewHvTf7PvI1lfUDYyW8Fw0q3GR5cAP3Rk8bq56F7rQYNY1CTUZkmlcBSoyU5IChTwfoeMCti8a/1HUIGaUSWCwr/oxXCpJ2YL056+1Npr+vyJpKd+W2vptfvb0IoRaPJdWf2ApaORJM+zIfvlQOrVtkXEkN3HeJLpg3lLJl2yySx9pNn8P/AALr2qJ7lbWxn8qBpLhYmCtGuT+HpVfTIr2bThcS272bFN7z3Py4z061DbaubuklKylZJff/AMMT/atL0xdStby4uFa78tppZ2JCNHwrrGBhByclfWtOHZfTBrUsyOgkSccwEdgrd2PPHWqiW1pY6nDd6s32vUkjMe2NPlVWHRieufSsVNZk0W0vbCwlZrk/6Q6tjeVJ6IMYRfZcUOLl8O5nCPs9kkvzNnTktba6vbZNUFxc+eZEic/NErentmo7rxGv2JZbaOW4gnmFuwA5G1sbyD6EcGqUUsv29G063eOaaxMrX7IGMLryFxjkZ4IqS3v7iA3FxLpabZGVlSaVY1lO3JKD/lnzngk0+VXuS5fY/S/9aFmeOMzzR3Jia2niMbiNeWyO578VqG7tdAtdHimd3u7x1hs0ILSuOnmN6Io/iP4VBe6nYWguL6832enaeAJisAmN2ZAArR88IjdW6VnaXO0rpJqUg+0Xd5PNaMDmSaH5SpU8/JwMdvaly3V5GbrxqVPZ0lZ36ljXtQsLmRdGvbqSIyEmGGKRkw2eCNv9axm025tfFsUenTCOSUw30diV2xyrEvzSSEDaBnua19UtYbrWdPuFsY3mU/8AH0U4Tnuvfk96as2o2GsXcGoXb3dlHE8jyEAFmBJChR2wOFq4vljp22FVpe0dmrW6rsW9KvkttINxcW87/abxlnC5ZGmY8yDJyEP8q2lkZpxDJtWHblSBjLehHesZL5LzQJJtOT97Kq3EMUq4Byv3T6HNW7W2t7zRGn1oMiAbiEfb5TntuB7etZNdTW/u+hUtdMe1vLa/1YxtqUgaLzI1Iym7cFI6HirFvdLr1nNm3ltknZ4hGy7fkHB6+tXNL1x9QtJA9luS1CwpPNy0sa9HHPOcnrVC5s4dduLa+hnn22jswRJDtlzxkgdcDjFF+4QjJboRIoNK0yWHT1ElvZJ5ccMQyxf+6Peo9YWDXbGHTLiwdppGXztrr+4G3O4+vPHHpVm2aKycy+WlrHG5cmR8AjPLH61Xuooba6vNS06MPeyKFL7iAQOR/SiLd79SpQ93la0LtjpUWjWUFrD80Qg2bWPOB1JNWdMuwdOvbS58yODULdreV1bDgcgMD/eXqKzxcTalp6m7AtL14tkjJyob2/nVJ7Brm2g0eS9aSe2ZJ5Hj+9IAcgk+h9qVubd6ilD3bSV0x3lXsM5gW/WCFZI0QumGuU2gZPbJOelbOu3cWkRtNdkmBINssg5YAEHHHQc1Q8UXUulxRXpsJr1I3QLFGPmGTyR9DXQ2el6V4xja3eR7bVbdWVVmO5JkYcqR0JXFEmtJSWhlKfIuZu9t/wBDEv7u4fSVl02FZGdd6KTgYIyCfartvbM0GmXF5Gkd75XmruOQjNwQDT0srnTNSkj1dI002EIii3O5mx3HbpXP3Wt3PjBr0vYTaHb7BawmRvnVlz93PX5cHPrRFN7bdxynGUku51MblzOmMsV3AluB6/pWNayamusNGyQyaYEyk0bryc9Mjjimx2UcWkSadLLLKJrZoXLjlgRipNG01bbSNFOlFYLC1SWO4gRMebKWBEnuCAR9aSskxy5oyVlozTtdStYNYRZfubsxkNyHA4I+lMvpNN0uW6vr+BRNbqSzZ7DvkVnurbpFslDXXzLEsg4JxgE98d/wqk2lXUOlXVqmoW0t7MQ7zXSF0T5QG2qv3jxwPeiKXcKtNXvbobVteW1xLFrBjSaW4iXE+MBh2X2+tZ2jXMh8Q62/mXbsrpHIkgxGhI/5Z+oI/lVvxNpX9o6LC/hy6MM5VFgMgAEbADIYDjbgfhUumTSzRZhuIi0kbRJOy/IJcYyD0xnNCtZsSs1otev+Q7SSLnWtQtBFJB9nwfPf7sikZ4+lZl7r8MNzP9r/AHaJIsMkrjAkLjjb29qg0/WdUj1HUJtWhEOmWjppjRNCPMluyeJI27qQc+mKsyzWMzzWc9okkVq+5mlHyLg53A+1DjZ6oqlLmvJen3GpNY299badJdtbo9tcZtJJHEZdj/yzXPUkdqzI9P1LStPvXLyalfxvLNCrNgkE5VPw6VLf6jZyxaDdS2X26Ke7eO2kRQUgwB+89s+vtU2la/a6rNdpZcvZSeW64/M/jg0Wkltp/wAEmDd3yuxLYSSXkEMt1GqOY1dkBBKv6fUVX1ee2m1A2RCyarpkLXkfmI2yAFScFhzuYZwoBPtVnSobHRJbuTR7RIp5/wB5M+S7yP8AU9B6AVnrNFqWts95pG+13JL9tjwJhKARkHuVyaFa9+hLVSSukbdlPHc6fZzyZ2XKrLHIAQHBHAGetZXjWaXRtIEmg2KSX+ozfZ9znAECjMrtghtvbd261ykFzqHgbWIYbi4N7JrM0sJae4LIVxiOZM/dkBwD0FaXhvRLnT7yS61V5LyG3tVt7SeV97uzndcdeuWx7c4FXyKL5r6fmc95ztFKzbszpUu4JbSGCURxLPGqmNZfMXpjAcgE8VSigbS9Rm+w2yNFfY+1s75PyjC4FSXdtZ6jBIkvlSCOQMFI/wBUw9fcUrPdyGKUNb20CSsvkAGQ3EIXCkk/cOck4rLvY9HlUUlYtyjz4byIxtagxBIrkMDl+h2r22g8E1l6Jqemm1ksLZp2Nn+7kecneWH161S1n7Vcaxpuo6S6X80bNb3ECzfIImI5AH8Q/pSavZabYeI9Pk1G5W01LUGe2iWYFY2VSCzsPbgD1JqlDSz6/mTzQi9Xr/WxvXV1bPevYukMty9sHuocY8uGRSEJx1LenvWff+HbgSx6jo86i5t41RI8/IsYxlfpiiyli1DVr3UjpdxaziztoHmkk3GVFZuCg4GPlyQTwR0p2p6s+nXsFta201zNcPh8JhYV7lj/AEqY8ydokwcnG70d/wADOtftM+r3supW8G2KQpauDlirDn6Yp82hI/hryFvZRCl1ujG75wrAFkDem5c/8CNVvOsvElvqEGnSy2V6XFpLOPly3YrnqeoyO3Wr09ymiaMi3PnSW8KcFgXeTHBYgdSattrbfsbNc9pdru9/lYjg0Sa1sb2HVLmQwXaMiyI+11U/3SOh6c1leGYXm1bVtRhvEvoZYBHb7SSVjjHEfvjn65rdivY9WsbS5jYL56mRVlHAH+RWb4VsxpV7fS2+02sKs6RquFVjxgn0JNNSdpX3G6S92b1/z6Ffwn4im1JEuZfLeSSMtsjhKrCORtLE/ePcDpWjq+sz2MZmispb0SssZSMDMeRjP4CixjG4BI0WQAOUK7VUegHSm6jNplkLu8gk869hKLJbBuI1dlBb0x9e9K0efRDknGnaT17le4jlv9TthZ3ksMllLtmRU3B8AfIxP5j61avtMn1S48szNaaf/wAvjLnzU6MoT/exgnoAaDqjx+JTZR2E6xyMPMukHC7Mjn1I9Kfe3tykVr5c0aM7nzSxwGTJGPx4pc0k4uxUqbqKcL7/ANfkYWo6zoeqRC6u41jEV1sjD8FSfTPtWrDNYw2MN1q0yJBb3r/YRjdPdzIhUrD/AHdu4ZkPHasS3Nte2l2dTsFgtrWVlleZR82DwwxV+0ubHU9fkhWLFvaQJHHK/AhQnd8v1zk9zWr0VlfQ5atOVSKimknb10Cza50fSvPS3lu7qdvPJvpNwRioBRQOFHHUdetXZ7xo/EsXk3ZhmNgZp9MbkBduSc+g6mqd/fPpdreS6qySWiSsYWhJP7voPxFQahrUF3p80mkRBvEUiILd7hRiSGTiRsHqu0YPbk1CTbvY0qRjTglD7ur1uRvrmmaz9qj0pZL+NI0NzNDPsQyseEQEZIGDk8e1VdYulS80qaWKZpLJgLO3UDCPjnPchzgHril0tDaPYW+kva3VrAWW/cR7WWXsPcKDge1Xb+ytoNXS9jd5pIvuEjhc9h+NU+WD02FRp1K1F+0XvP7l/wAN+dypca74fgtPMu4dTS6SOOU2KxKSgkJAXeTjj+RFFVyLXVp7y/8A7PgnvJIxbPvyEdVPdQcZGBg+1FCjD7TMakcde0GmvU1L/wD1Vv8A9c61PEn/ACT+z/66z/yFFFZL4l6jqbHP+F/+PPTv+uo/9CrW0j/kKQ/9tv8A0M0UVc92T1j6fqc38Q/ut/12T+ddFb/d/wC+P/QaKKJfAi6f8SXov1LVn/yL95/uD+dZE/8AyB/+BJ/6HRRUGU/iZoT/APHxe/8AXT+tc9cf8j2//XtRRWtLZ+hrV+OHr+h2x6P/ALjf+g1h+I/+QZD9V/kaKKxjui1/kZsX/HprH/YsTf8ApUlZnhX/AJGPTv8Arg//AKEKKK6I/B/XY8ml/vsvU9Ah/i/6+KoX/wDyF7r/AK6f0NFFc8T05fE/mX/+WU3+4n8qztU/5FS//wCuL/yooo6oxXwlvw3/AMirpf8A1yT/ANBq18Of+Qdp/wD10uP/AEKiiiXX1Nanwow/it/yBNT/AOuaf+h1paZ/x6Qf9ck/kKKKPsocfi+Q67/1Mv8Av10Pg3/j9n/64j+VFFLoyMR8KJ737tr/AMC/ma5vQf8AXD/rr/Wiij7Jlh/hn6F+x/4/7n/rmn86zvE/+u8N/wDXxJRRTW5p9hE9z/x9wfU1b0T/AI9NP/65yf8AoRooqXsWtojtH/5Dlp9f6GuV8b/8ell/13T+lFFOHxCq/H9x1Wlf8gfUf+vZv/QazPCn/In6f/uj+ZooolszGP8AEfqbWvf8gm1/3k/lXJeIv+Qdqn/XpL/IUUUR6D/5d/eaHgj/AJEbTf8AfX+VZXw2/wCPjxF/19t/OiitHtP5Efyer/I6yH/Xy/71Msv9VJ/10b+dFFYG0/8AI4D4r/8AIy+GP+vST/0Ya7hv+QBo3+8v9KKK3n8ETGh/El6r8jkvD3+p8Uf9fr/+g10Hh/8A5GXVP+u8X/oqiilU3f8AXY3Kfwl/5GjxP/12/wAa5pP+Rm0f/r6u/wD0OiimvjfocGI+z6/qepaT/wAhKf8A64v/ACqj4g/49V/66xUUVhHc9Cp8Ziap/wAfulf9f8X/AKC1N0P/AJKEv+9c/wDotaKK3l8fyJqfwhbr/j9X/rnVvQ/+QRr/APuxf+jBRRUM3n8EfVCW3/H+/wDuCuX8Mf8AI3eMP+vQfzSiinT6mOI+H+uzOxm/5CF79TXn/wARf+RYf/r3X/0cKKKS+JG1T+FL0O88Uf8AIPf/AHI//QVrFsv+Wv8A10X/ANBooq1szGj/AA4ehP4g/wCRZvP91q54f8hzQv8AsBr/AOhvRRTj8DFW/jQF0b/j3v8A/r7/APZRWrrH/H5N/ur/AEooqXud1P4fv/Mg0f8A1v8AwGT/ANCooopdSZbI/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Liver biopsy shows sinusoidal infiltration by lymphoma cells, whereas the portal areas are devoid of tumor cell infiltration. Hematoxylin and eosin, 10x magnification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry and Immunochemistry for Hematologic Neoplasms, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_22_41321=[""].join("\n");
var outline_f40_22_41321=null;
var title_f40_22_41322="Cystic fibrosis: Antibiotic therapy for lung disease";
var content_f40_22_41322=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cystic fibrosis: Antibiotic therapy for lung disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/22/41322/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/22/41322/contributors\">",
"     Richard H Simon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/22/41322/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/22/41322/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/22/41322/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/22/41322/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/22/41322/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystic fibrosis (CF) is a multisystem disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, located on chromosome 7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39095?source=see_link\">",
"     \"Cystic fibrosis: Genetics and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary disease remains the leading cause of morbidity and mortality in patients with CF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. One of the major drivers of CF lung disease is infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The approach to treating infection in CF is multifaceted, involving antibiotics, chest physiotherapy, inhaled medications to promote secretion clearance, and anti-inflammatory agents. Undoubtedly, improved use of antibiotics is responsible for a substantial portion of the increased survival that has occurred in patients with CF (",
"    <a class=\"graphic graphic_figure graphicRef61930 \" href=\"mobipreview.htm?25/23/25981\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of antibiotics to treat CF lung disease will be reviewed here. Treatments other than antibiotics for CF lung disease and the diagnosis, clinical manifestations, and investigational therapies for CF are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=see_link\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27351?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations of pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32167?source=see_link\">",
"     \"Cystic fibrosis: Investigational therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic bacterial infection within the airways occurs in most patients with cystic fibrosis (CF) (",
"    <a class=\"graphic graphic_table graphicRef55018 \" href=\"mobipreview.htm?8/33/8732\">",
"     table 1",
"    </a>",
"    ); the prevalence of each bacterial type varies with the age of the patient (",
"    <a class=\"graphic graphic_figure graphicRef74073 \" href=\"mobipreview.htm?18/0/18447\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9942753\">",
"    <span class=\"h2\">",
"     Pseudomonas aeruginosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;For reasons that are poorly understood, the CF airway is particularly susceptible to Pseudomonas aeruginosa (P. aeruginosa), with infection occurring as early as the first year of life. The prevalence of P. aeruginosa increases as patients&rsquo; age, such that more than 73 percent of adults are chronically infected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/8\">",
"     8",
"    </a>",
"    ]. With prolonged infection, P. aeruginosa converts to a mucoid phenotype by the production of alginate. This mucoid phenotype is seen infrequently in populations without CF but is manifested by over 66 percent of the P. aeruginosa isolated from patients with CF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27145?source=see_link\">",
"     \"Epidemiology and pathogenesis of Pseudomonas aeruginosa infection\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Chronic infection with P. aeruginosa is an independent risk factor for accelerated loss of pulmonary function and decreased survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Conversion of P. aeruginosa to the mucoid phenotype worsens prognosis. Transmissible strains of P. aeruginosa have been detected in CF populations in Europe, Australia, and Canada, and some of these strains are associated with a worse prognosis compared with non-transmissible strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7028176\">",
"    <span class=\"h2\">",
"     Staphylococcus aureus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staphylococcus aureus (S. aureus) is the bacterial pathogen most frequently identified in respiratory secretions of CF infants and children. It remains a significant pathogen throughout adulthood. In children under 6 years of age infected with P. aeruginosa, co-infection with S. aureus has an independent and additive effect on airway inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7028183\">",
"    <span class=\"h2\">",
"     Methicillin-resistant Staphylococcus aureus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methicillin-resistant Staphylococcus aureus (MRSA) has become more prevalent in the CF population, increasing from 2.1 percent in 1996 to 26 percent in 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/8\">",
"     8",
"    </a>",
"    ]. Regarding the role of MRSA in patients with CF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study reported that acquisition of MRSA was associated with a slightly greater rate of decline in pulmonary function (as measured by forced expiratory volume at one minute [FEV1]) in children, but not in adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/12\">",
"       12",
"      </a>",
"      ], while another study reported that MRSA had no effect on the rate of FEV1 decline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of nearly 20,000 CF patients in the United States found that MRSA was associated with 1.3 times the risk of death compared with individuals never infected with MRSA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/14\">",
"       14",
"      </a>",
"      ]. Multivariate analysis showed that MRSA was an independent risk factor whose effect could not be explained by its association with other known risk factors including age, sex, diabetes, pancreatic status, FEV1 at baseline, and socioeconomic status, or co-infection with Burkholderia cepacia (B. cepacia) complex or P. aeruginosa.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H902257\">",
"    <span class=\"h2\">",
"     Burkholderia cepacia complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in bacterial genetics have revealed that Burkholderia cepacia, which was originally thought to be a single species, is now known to constitute multiple separate species, each of which is a member of the Burkholderia cepacia complex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/15\">",
"     15",
"    </a>",
"    ]. The species most commonly isolated from the sputum of CF patients are Burkholderia multivorans (B. multivorans) and Burkholderia cenocepacia (B. cenocepacia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic infection with B. cepacia complex bacteria is associated with an accelerated decline in pulmonary function and shortened survival in CF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Lung transplantation in patients infected with B. cepacia complex is associated with recurrent and often severe infection, with poor outcomes, particularly for those carrying B. cenocepacia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Infection with B. cenocepacia is considered to be a contraindication to transplantation in many centers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12778?source=see_link&amp;anchor=H1627022308#H1627022308\">",
"     \"Bacterial infections following lung transplantation\", section on 'Burkholderia cepacia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7493970\">",
"    <span class=\"h2\">",
"     Other pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other pathogens have been identified in respiratory secretions of CF patients, with varying prevalence (",
"    <a class=\"graphic graphic_table graphicRef55018 \" href=\"mobipreview.htm?8/33/8732\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef74073 \" href=\"mobipreview.htm?18/0/18447\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/25\">",
"     25",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Non-typeable Haemophilus influenzae",
"     </li>",
"     <li>",
"      Stenotrophomonas maltophilia",
"     </li>",
"     <li>",
"      Achromobacter (formerly Alcaligenes) xylosoxidans",
"     </li>",
"     <li>",
"      Nontuberculous mycobacteria, including Mycobacterium avium (M. avium) complex, Mycobacterium abscessus (M. abscessus), and other less common mycobacterial species",
"     </li>",
"     <li>",
"      Aspergillus species",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other species identified in the respiratory secretions of occasional CF patients include non-cepacia complex Burkholderia species (gladioli and pseudomallei), Ralstonia species, and Pandoraea species. Although these organisms are identified more frequently than in the past, this may be due to refinements in microbial culture techniques and the use of molecular genetic methods that separate these organisms into an ever expanding taxonomy of bacterial pathogens, rather than increasing prevalence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/26\">",
"     26",
"    </a>",
"    ]. Furthermore, non-culture-based molecular genetic techniques have identified microorganisms in respiratory secretions of patients with CF that were previously unrecognized as being present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/27\">",
"     27",
"    </a>",
"    ]. Both culture-based and genetic methods have revealed high densities of anaerobic bacteria in respiratory secretions from CF patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Investigations are ongoing to determine which members of this complex microbiome are important for driving pulmonary exacerbations and disease progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7025018\">",
"    <span class=\"h1\">",
"     CONSEQUENCES OF CF LUNG INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once established in the cystic fibrosis (CF) airway, many of the above organisms are difficult to eliminate. However, definitive studies have demonstrated that P. aeruginosa infection can be eradicated if detected early and treated aggressively. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Early eradication of P. aeruginosa'",
"    </a>",
"    below.) The same may be true for methicillin-resistant Staphylococcus aureus (MRSA), but this will require further study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although chronic infection of the CF airway is sometimes referred to as \"airway colonization\", the presence of many of these bacteria is not benign:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic infection with P. aeruginosa is an independent risk factor for accelerated loss of pulmonary function and decreased survival, and conversion of P. aeruginosa to the mucoid phenotype worsens prognosis. (See",
"      <a class=\"local\" href=\"#H9942753\">",
"       'Pseudomonas aeruginosa'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Infection with Burkholderia cepacia complex connotes an even worse prognosis that may be due in part to the behavior of a few particularly virulent species within the complex. (See",
"      <a class=\"local\" href=\"#H902257\">",
"       'Burkholderia cepacia complex'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Infection with MRSA is also associated with worse survival. (See",
"      <a class=\"local\" href=\"#H7028183\">",
"       'Methicillin-resistant Staphylococcus aureus'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The persistence of bacteria despite aggressive treatment is thought to be due to one or more of the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poor penetration of antibiotics into purulent airway secretions",
"     </li>",
"     <li>",
"      Native or acquired antibiotic resistance",
"     </li>",
"     <li>",
"      CF-related defects in mucosal defenses",
"     </li>",
"     <li>",
"      Biofilms produced by the bacteria that may render antibiotics ineffective or interfere with host defenses &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT OF ACUTE PULMONARY EXACERBATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course of most patients with cystic fibrosis (CF) is punctuated by episodes of acute worsening of respiratory status. These pulmonary exacerbations appear to drive long-term deterioration in lung function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/30\">",
"     30",
"    </a>",
"    ]. Although practicing physicians have been recognizing and treating pulmonary exacerbations for many years, it has been difficult to arrive at a precise definition for these events. To determine what information clinicians appeared to be using to decide when to initiate treatment for pulmonary exacerbations, data from the placebo arm of an inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    trial were retrospectively analyzed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/31\">",
"     31",
"    </a>",
"    ]. The following characteristics were associated with initiation of antibiotic treatment for pulmonary exacerbations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased cough",
"     </li>",
"     <li>",
"      Increased sputum production or chest congestion",
"     </li>",
"     <li>",
"      Decreased exercise tolerance or increased dyspnea with exertion",
"     </li>",
"     <li>",
"      Increased fatigue",
"     </li>",
"     <li>",
"      Decreased appetite",
"     </li>",
"     <li>",
"      Increased respiratory rate or dyspnea at rest",
"     </li>",
"     <li>",
"      Change in sputum appearance",
"     </li>",
"     <li>",
"      Fever (present in a minority of patients)",
"     </li>",
"     <li>",
"      Absenteeism from school or work",
"     </li>",
"     <li>",
"      Increased nasal congestion or drainage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reductions in pulmonary function are often present during pulmonary exacerbations, but chest radiographs may not show significant changes over baseline.",
"   </p>",
"   <p>",
"    Surprisingly, the evidence that antibiotics are beneficial in treating pulmonary exacerbations is derived from only a few studies. A small randomized study of patients experiencing acute pulmonary exacerbations showed that the rate of clinical improvement was accelerated in patients treated with antipseudomonal antibiotics as compared with those receiving only bronchodilators and chest physiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/32\">",
"     32",
"    </a>",
"    ]. After 14 days of treatment, patients initially receiving antibiotics had greater improvements in several pulmonary function measurements than those initially treated with placebo. A similar randomized study showed that addition of antipseudomonal antibiotics to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    improved outcomes as measured by forced expiratory volume at one minute (FEV1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7028282\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of patients with cystic fibrosis (CF) includes routine cultures of respiratory secretions to identify infecting organisms and guide antibiotic selection. Because CF patients frequently carry the same bacteria for prolonged periods of time, past culture results can be used to guide antibiotic choices when a patient&rsquo;s condition warrants intensifying treatment. The current recommendation is to perform cultures every three months so that relatively current information is available to guide treatment when a pulmonary exacerbation occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4200798\">",
"    <span class=\"h2\">",
"     General considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not unusual for CF patients to have several bacterial species identified in their respiratory secretions. Selecting an antibiotic combination that covers all the isolates is occasionally difficult without resorting to an impractically large number of antibiotics. Unfortunately, too little information is available to rank the relative importance of the different pathogens if only a subgroup can be reasonably covered.",
"   </p>",
"   <p>",
"    Our practice is to select antibiotics based on the culture results and the following considerations: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We target at a minimum any mucoid P. aeruginosa and S. aureus. Attempts are made to cover non-mucoid P. aeruginosa isolates whenever possible without sacrificing coverage of the mucoid strains.",
"     </li>",
"     <li>",
"      We also treat Achromobacter xylosoxidans if present because limited evidence suggests that some of these isolates can be particularly inflammatory in nature and are associated with rates of forced expiratory volume at one minute (FEV1) deterioration, similar to that induced by P. aeruginosa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is more uncertainty regarding the importance of treating Stenotrophomonas maltophilia (S. maltophilia). Some studies have shown that identification of S. maltophilia in CF sputum is not an independent risk factor for accelerated deterioration in pulmonary function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/37\">",
"       37",
"      </a>",
"      ]. However, another study reported chronic infection with S. maltophilia was associated with a higher frequency of pulmonary exacerbations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/38\">",
"       38",
"      </a>",
"      ]. It remains uncertain whether S. maltophilia is merely a marker of more severe lung disease or is a cause of it. Of relevance, we have occasionally seen patients with a deteriorating clinical course in whom S. maltophilia appears to be the only delectable pathogen and which therefore warrants targeted treatment. Until its true nature is resolved, we attempt to treat S. maltophilia but place less emphasis on it if doing so would sacrifice optimal coverage of any of the above organisms.",
"     </li>",
"     <li>",
"      Aspergillus species that are identified in respiratory secretions are generally not treated because they appear to be an unlikely cause of pulmonary exacerbations. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Aspergillus species'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      When in vitro testing can identify no antibiotic to which a bacterium is susceptible, our practice is to select a combination of antibiotics that would otherwise be chosen empirically for that pathogen.",
"     </li>",
"     <li>",
"      We generally avoid using two beta lactam antibiotics simultaneously, but some CF physicians are not as reluctant, particularly when other regimens have failed. Our decision is based upon in vitro studies showing the antimicrobial effect of adding the second beta lactam is unpredictable and can sometimes be antagonistic to the first [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      We continue administering oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      during the acute exacerbation if it is a component of the chronic pulmonary regimen. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=see_link&amp;anchor=H12#H12\">",
"       \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Macrolide antibiotics'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4200806\">",
"    <span class=\"h2\">",
"     Susceptibility testing strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed below, the value of antibiotic susceptibility testing based on conventional in vitro cultures has been questioned because the correlation between test results and clinical response is poor. Therefore, alternate susceptibility strategies including biofilm culture and antibiotic synergy testing are under investigation. Nonetheless, currently available information is not sufficient to recommend a change in the current practice of most physicians who typically select antibiotics based on conventional in vitro testing results, rather than performing in vitro synergy testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/41\">",
"     41",
"    </a>",
"    ]. These perspectives are in agreement with guidelines published by the CF Foundation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/42\">",
"     42",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7028289\">",
"    <span class=\"h3\">",
"     In vitro antibiotic susceptibility testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In practice, most clinicians select antibiotics based on in vitro antibiotic susceptibility testing. Of note, special laboratory procedures are required to adequately test many of the gram negative bacilli isolated from CF patients because these tend to grow poorly on standard media [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/6\">",
"     6",
"    </a>",
"    ]. Many laboratories test multiple morphotypes of the same species. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17591?source=see_link\">",
"     \"Sputum cultures for the evaluation of bacterial pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the value of in vitro susceptibility testing for CF patients is being questioned based on several pieces of information. In particular, a retrospective study evaluated whether clinical outcome was dependent upon whether patients received antibiotics to which their isolated bacteria were susceptible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/43\">",
"     43",
"    </a>",
"    ]. Among 77 patients who were chronically infected with P. aeruginosa and treated with parenteral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    for a pulmonary exacerbation, improvement in FEV1 did not correlate with whether the isolated pseudomonas was sensitive to the antibiotics. Furthermore, there is concern about the reproducibility of antibiotic susceptibility testing of pseudomonas isolated from CF patients; considerable variation was found when the same morphotype was tested multiple times and when a single isolate was tested by multiple laboratories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7028297\">",
"    <span class=\"h3\">",
"     Testing bacteria grown as biofilms",
"    </span>",
"    &nbsp;&mdash;&nbsp;One possible explanation for why in vitro testing may not closely predict clinical response is that bacteria in the airways of patients with CF have diverse phenotypes, with a portion growing in self-generated biofilms. Some investigators have cultured bacteria isolated from CF sputum samples under conditions that induce them to form biofilms in vitro. In general, bacteria grown as biofilms are less susceptible to antibiotics compared with the same isolates grown under standard clinical laboratory conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/45\">",
"     45",
"    </a>",
"    ]. In a pilot study, 39 patients were randomized to treatment with an antibiotic regimen based upon the susceptibilities of their organisms as measured under biofilm or conventional conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/46\">",
"     46",
"    </a>",
"    ]. No differences in outcomes were noted whether antibiotics were chosen based on susceptibility results from biofilm versus conventional cultures, although the power of the study to detect clinically important differences was not very high.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7025060\">",
"    <span class=\"h3\">",
"     Antibiotic synergy testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multidrug-resistant bacteria are frequently encountered in patients with CF, particularly in those who have advanced disease and have received multiple courses of antibiotics. When such bacteria are isolated, combinations of antibiotics can be administered in the hope of achieving activity via synergy, despite apparent resistance to each individual antibiotic. To guide selection, studies have described in vitro synergistic effects of various combinations of antibiotics for many isolates of multidrug-resistant P. aeruginosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/39\">",
"     39",
"    </a>",
"    ] and B. cepacia complex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the only large clinical trial that studied the effect of combination antibiotic susceptibility testing in the management of pulmonary exacerbations failed to demonstrate any benefit associated with this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/41,48\">",
"     41,48",
"    </a>",
"    ]. In this trial, 132 patients with chronic multidrug resistant Gram negative infection and pulmonary exacerbations were randomly assigned to have their bacterial isolates tested by standard clinical laboratory techniques or by methods that evaluate combinations of antibiotics for synergistic effects. Subsequent antibiotic management was guided by the results of these studies. Combination antibiotic susceptibility testing did not improve clinical or bacteriologic outcomes, nor did this approach prolong the period until the next acute exacerbation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H902786\">",
"    <span class=\"h2\">",
"     Number and choice of antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical antibiotic regimens based on the species of bacterial isolated from a given patient are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef59661 \" href=\"mobipreview.htm?37/31/38398\">",
"     table 2",
"    </a>",
"    ). The selection is then modified based on the results of susceptibility testing, renal function, and clinical response.",
"   </p>",
"   <p>",
"    The standard of practice has been to treat pulmonary exacerbations in patients with P. aeruginosa with two antipseudomonal antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/42\">",
"     42",
"    </a>",
"    ]. The rationale for choosing two rather than one is to take advantage of possible synergistic effects and potentially decrease the risk of developing treatment emergent antibiotic resistance. A small double blind trial provided some support for this practice. In this study, 76 patients with pulmonary exacerbations of CF were randomly assigned to receive azlocillin and either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/49\">",
"     49",
"    </a>",
"    ]. The time to readmission for a new pulmonary exacerbation was significantly longer among patients who received azlocillin plus tobramycin; other clinical parameters were similar between groups. Unfortunately, larger clinical trials are lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/50\">",
"     50",
"    </a>",
"    ]. We agree with the conclusions of the CF Guidelines Committee that in the absence of more definitive information, there is insufficient justification to change the current practice of using two antipseudomonal antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most commonly selected intravenous regimens for P. aeruginosa combine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    with an antipseudomonal semisynthetic penicillin (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    ), an extended third generation cephalosporin (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    ), a carbapenem (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/36/38472?source=see_link\">",
"     imipenem-cilastatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    , but not",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/36/41542?source=see_link\">",
"     ertapenem",
"    </a>",
"    , which has less activity against P. aeruginosa), or less frequently a monobactam",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef59661 \" href=\"mobipreview.htm?37/31/38398\">",
"     table 2",
"    </a>",
"    ). Tobramycin, rather than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , is selected because it usually has greater activity against P. aeruginosa. Oral or intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    may replace the aminoglycoside if the pseudomonas is sensitive to it. If an organism is resistant to tobramycin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    occasionally is efficacious and is used (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27145?source=see_link\">",
"     \"Epidemiology and pathogenesis of Pseudomonas aeruginosa infection\"",
"    </a>",
"    ). When the P. aeruginosa demonstrates in vitro resistance to all aminoglycosides or the patient fails to improve on an aminoglycoside containing regimen, we use intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    (colistimethate sodium) in combination with either a fluoroquinolone or beta-lactam antibiotic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Intravenous colistimethate should not be used in combination with intravenous aminoglycosides due to potential for additive renal toxicity. (See",
"    <a class=\"local\" href=\"#H346244780\">",
"     'Colistimethate sodium'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although we routinely use in vitro susceptibility testing to guide antibiotic selection, we recognize that the correlation between laboratory test results and clinical response is not high for Gram negative pathogens in patients with CF (see",
"    <a class=\"local\" href=\"#H7028289\">",
"     'In vitro antibiotic susceptibility testing'",
"    </a>",
"    above). We therefore are willing to modify an antibiotic regimen when a patient fails to show anticipated improvement. This may include selecting antibiotics to which the organisms demonstrate in vitro resistance when no other options are available. Antibiotics that were found to be effective during a patient&rsquo;s prior exacerbations may be selected in preference for those favored by in vitro testing.",
"   </p>",
"   <p>",
"    When methicillin-sensitive S. aureus accompanies the P. aeruginosa, treatment options are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/45/42710?source=see_link\">",
"     ticarcillin-clavulanate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/36/38472?source=see_link\">",
"     imipenem-cilastatin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    PLUS one of the following:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    . In contrast, we treat methicillin-resistant Staphylococcus aureus (MRSA) and P. aeruginosa with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    PLUS the same antibiotic combination as for P. aeruginosa alone (three antibiotics total) (",
"    <a class=\"graphic graphic_table graphicRef59661 \" href=\"mobipreview.htm?37/31/38398\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Pneumonia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/48/21258?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\", section on 'Pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Burkholderia cepacia complex bacteria (which include B. multivorans and B. cenocepacia) are often highly resistant to multiple antibiotics. Antibiotic selection should be guided by in vitro susceptibility testing when possible. Treatment options are often limited, but some isolates show susceptibility to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    . When no single antibiotic is effective, combinations of two or more antibiotics sometimes show in vitro susceptibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H902257\">",
"     'Burkholderia cepacia complex'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7028321\">",
"    <span class=\"h2\">",
"     Route of antibiotic administration",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Oral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral antibiotics are appropriate under some circumstances. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild exacerbations due to methicillin-sensitive Staphylococcus aureus can be treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/11/3253?source=see_link\">",
"       dicloxacillin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/56/43912?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/37/37462?source=see_link\">",
"       cephalexin",
"      </a>",
"      , a macrolide,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      when in vitro testing shows susceptibility.",
"     </li>",
"     <li>",
"      MRSA can be treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      when in vitro testing shows susceptibility.",
"     </li>",
"     <li>",
"      For more serious exacerbations, oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      , which has good activity against MRSA, can be used.",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      is appropriate for P. aeruginosa when in vitro testing shows susceptibility.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, in patients treated chronically with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , S. aureus resistance to macrolides is increasing, causing macrolides to be less reliable for the treatment of S. aureus infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=see_link&amp;anchor=H12#H12\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Macrolide antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7028336\">",
"    <span class=\"h3\">",
"     Inhaled",
"    </span>",
"    &nbsp;&mdash;&nbsp;Practice varies among clinicians regarding use of inhaled antibiotics in conjunction with oral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IV antibiotics for treatment of pulmonary exacerbations. In general, we do not consider an inhaled antibiotic to be an equivalent substitute when systemic antibiotics would otherwise be used as recommended, as shown in the table (",
"    <a class=\"graphic graphic_table graphicRef59661 \" href=\"mobipreview.htm?37/31/38398\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/54\">",
"     54",
"    </a>",
"    ]. This is based in part on our concern that the distribution of inhaled medications to the lungs of CF patients can be very inhomogeneous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/55\">",
"     55",
"    </a>",
"    ]. When a beta lactam",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    either an aminoglycoside or colistimethate are indicated, we deliver them parenterally and do not rely on their inhaled versions. An exception might be for a relatively mild pulmonary exacerbation when an inhaled antibiotic can be added to an oral medication, eg, a fluoroquinolone. Furthermore, we might add an inhaled antibiotic when the best systemic regimen still leaves a bacterial isolate uncovered. &nbsp;",
"   </p>",
"   <p>",
"    There is insufficient information to recommend whether to continue an inhaled antibiotic during an acute exacerbation when it is part of a patient&rsquo;s chronic pulmonary regimen. Our local practice is to suspend the inhaled medication. Others would continue the inhaled medication during an acute exacerbation, but generally not use the inhaled medication as a substitute for one of the two-drug intravenous regimens for P. aeruginosa outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef59661 \" href=\"mobipreview.htm?37/31/38398\">",
"     table 2",
"    </a>",
"    ). Similarly, a guidelines committee of the CF Foundation could not reach a conclusion regarding the risks and benefits of administering the same antibiotic by both intravenous and inhaled routes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/42\">",
"     42",
"    </a>",
"    ]. If both inhaled and intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    are used, one needs to be aware that the inhaled drug can cause a modest increase in serum levels, possibly interfering with pharmacokinetic analyses and causing errors in IV dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Intravenous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous antibiotics are indicated in any of the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe exacerbations",
"     </li>",
"     <li>",
"      Bacterial resistance to all orally administered antibiotics",
"     </li>",
"     <li>",
"      Failure of oral antibiotic therapy to resolve the exacerbation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Care must be taken to dose and adjust antimicrobials to achieve lung penetration and maximize the bactericidal efficacy of each agent. As an example, with beta-lactam antibiotics, efficient bacterial clearance requires prolonged tissue concentrations above the minimum inhibitory concentration (MIC) through much of the dosing interval. By contrast, for aminoglycosides, bactericidal effect is proportional to the peak antimicrobial tissue concentrations.",
"   </p>",
"   <p>",
"    The pharmacokinetics of many antibiotics differs in patients with CF as compared with normal individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/56\">",
"     56",
"    </a>",
"    ]. In general, the volume of distribution and total body clearance is increased for hydrophilic drugs (such as aminoglycosides, penicillins, and cephalosporins), in part because CF patients are generally undernourished and have decreased adipose tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Thus, higher",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    more frequent dosing is required for many CF patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. There has been some interest in prolonging the duration of dose infusion of some beta-lactam antibiotics to better maintain drug concentrations above minimal inhibitory concentrations, although the clinical advantage of this approach has not yet been proven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/61-63\">",
"     61-63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Aminoglycosides",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with CF receiving aminoglycosides, the volume of distribution is increased and renal clearance rate is considerably accelerated as compared to patients without CF. Therefore, starting doses of aminoglycosides for CF patients should be approximately 30 to 35 percent larger than those recommended for individuals without CF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/59\">",
"     59",
"    </a>",
"    ]. The dose and frequency from a previous course of treatment may be used initially if serum concentrations were in the target range and creatinine clearance is not substantially changed, but drug levels should still be monitored. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13783431\">",
"    <span class=\"h4\">",
"     Once daily",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients without CF who require intravenous aminoglycosides, once daily administration appears to be as effective as conventional dosing (in which the daily dose is divided into three separate administrations) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/64\">",
"     64",
"    </a>",
"    ]. To assess the safety and efficacy of this approach in patients with CF, a multicenter trial randomly assigned 244 patients greater than 5 years of age with acute CF exacerbations to 14 days of treatment with daily or three times a day intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/65\">",
"     65",
"    </a>",
"    ]. The treatments were equally effective in improving pulmonary function (for change in FEV1, adjusted mean difference 0.4 percent [95% CI -3.3-4.1]). Once daily therapy was associated with a decreased incidence of nephrotoxicity (mean percent change in creatinine -4.5 [once daily] versus +3.7 [thrice daily]).",
"   </p>",
"   <p>",
"    Based on these results, we routinely dose aminoglycosides once daily (known as &ldquo;consolidated dosing&rdquo;) in CF patients with normal renal function. This approach is consistent with the guidelines endorsed by the CF Foundation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/42\">",
"     42",
"    </a>",
"    ] and is supported by a Cochrane systematic review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/64\">",
"     64",
"    </a>",
"    ]. This practice has been adopted by the majority of CF Centers including pediatric programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/66\">",
"     66",
"    </a>",
"    ]. Of note, most of the data assessing efficacy and safety of once daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    dosing are derived from studies of patients greater than 5 years of age. The starting dose for tobramycin is 10",
"    <span class=\"nowrap\">",
"     mg/kg/24",
"    </span>",
"    hours for children and adults without renal insufficiency (",
"    <a class=\"graphic graphic_table graphicRef59661 \" href=\"mobipreview.htm?37/31/38398\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    We do not use published tables or nomograms for selecting and adjusting aminoglycoside doses and intervals in patients with CF, because the pharmacokinetics differ from those in non-CF patients and may result in suboptimal aminoglycoside concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Instead, serum levels are measured twice following the first dose (eg, at 2 and 10 hours after the dose) and pharmacokinetic analysis is used to calculate the peak serum level, with the target being between 20 and 30",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/65\">",
"     65",
"    </a>",
"    ]. We also use pharmacokinetic calculation to extrapolate forward to be certain that there is at least a six-hour period prior to the next dose during which the patient will have low serum levels, (eg, less than or equal to 0.5",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    at 18 hours), to minimize toxicity. Slightly higher 18-hour levels (eg, &lt;1.0",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    are also acceptable provided the patient&rsquo;s renal function and clinical status are stable and the 18-hour level will be rechecked within 3 to 4 days. If a dose that achieves the target peak level leads to too high a serum level at 18 hours, the dosing strategy is changed to the &ldquo;conventional&rdquo; approach (which is described in the next paragraph), to reduce the risk of toxicity. Directly measured peak and trough concentrations are not accurate for assessing whether the consolidated dosing regimen meets targeted levels in CF patients. Because of higher doses used for these patients, prolonged drug distribution time and rapid clearance rates, the time of the peak serum level is unpredictable. In CF patients with normal renal function, trough levels are often below the lower limit of detection of the assays, thus precluding accurate pharmacokinetic analysis. Consultation with a clinical pharmacist skilled in pharmacokinetic-based drug management may be helpful and is suggested. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13783453\">",
"    <span class=\"h4\">",
"     Conventional",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with delayed aminoglycoside clearance due to renal insufficiency, we do not use once daily dosing for aminoglycosides. Instead, we adjust the dose and interval to achieve a peak serum concentration of 8 to 12",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    and a trough of less than 2",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    In this situation, the dose and frequency from a previous course of treatment may be used initially if the creatinine clearance is not substantially changed and serum concentrations were within the target range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/69\">",
"     69",
"    </a>",
"    ]. If there is no reliable historical information, we consult our pharmacist to guide dosing with a pharmacokinetic analysis. If pharmacist consultation is not available, it is reasonable to use an empiric loading dose of 3.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (if patient is overweight, use ideal body weight or dosing weight) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/42,65\">",
"     42,65",
"    </a>",
"    ] and select an initial maintenance dose and dosing interval based upon the patient&rsquo;s creatinine clearance (",
"    <a class=\"graphic graphic_table graphicRef57375 \" href=\"mobipreview.htm?30/61/31707\">",
"     table 3",
"    </a>",
"    ). Serum concentrations should be monitored and the dose and interval adjusted to achieve the above target peak and trough concentrations. These steps are detailed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/34/24104?source=see_link&amp;anchor=H22#H22\">",
"     \"Aminoglycosides\", section on 'Monitoring serum aminoglycoside concentrations'",
"    </a>",
"    .) &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13783476\">",
"    <span class=\"h4\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful monitoring is necessary to limit the risks of aminoglycoside-induced renal injury and ototoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/70-74\">",
"     70-74",
"    </a>",
"    ]. The renal damage can be manifested by elevation in creatinine; patients receiving multiple courses of aminoglycosides may develop a syndrome of magnesium-wasting without azotemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/75\">",
"     75",
"    </a>",
"    ]. These adverse effects can be limited but not prevented by adjusting antibiotic dose and interval to avoid exceeding target serum levels. When clinically significant renal damage or ototoxicity is noted, efforts should be made to minimize subsequent aminoglycoside use. However, the antibiotic susceptibility pattern of many CF-prevalent bacteria may provide limited options for non-aminoglycoside regimens and require further use of these antibiotics.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If a once daily regimen is used, we monitor the treatment course by measuring an aminoglycoside level several hours prior to the next dose (ie, at 18 hours following the previous dose). The goal is to ensure that the aminoglycoside level remains relatively low for several hours prior to the next dose (eg, below 0.5 or 1",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      at 18 hours (see",
"      <a class=\"local\" href=\"#H13783431\">",
"       'Once daily'",
"      </a>",
"      above)). An increasing 18 hour level may be the first indication of renal injury that requires dose adjustment. We believe that the 18 hour time point is preferable to a true trough at 24 hours because in CF patients with normal renal function, the drug concentration is frequently below the level of detection at 24 hours, which would prevent early detection of renal impairment as manifested by increasing drug levels. Interpreting these low serum levels can be confounded if the patient is also receiving inhaled tobramycin. As an example, serum levels one hour after inhaling 300 mg tobramycin are 1.05 &plusmn; 0.67",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      (mean &plusmn; SD) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/76\">",
"       76",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      During treatment, serum levels are measured once or twice a week. The appropriate frequency of monitoring depends on baseline renal function, the concomitant use of potentially renal toxic drugs, and whether the patient has a history of prior aminoglycoside toxicity. In addition, we suggest measuring two levels (eg, at 2 and 10 hours after the dose) following any substantial change in dose, to allow pharmacokinetic calculations and assure that targeted levels are achieved. Two time point measurements are also recommended if large changes in volume of distribution are likely to have occurred during the course of treatment, eg, sepsis with capillary leak or right-sided heart failure, although these scenarios are uncommon in CF patients having a typical pulmonary exacerbation. (See",
"      <a class=\"local\" href=\"#H13783431\">",
"       'Once daily'",
"      </a>",
"      above.) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/67\">",
"       67",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      If a conventional dosing regimen is used, we measure peak and trough levels once or twice a week to ensure that the target levels are achieved (see",
"      <a class=\"local\" href=\"#H13783453\">",
"       'Conventional'",
"      </a>",
"      above). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To monitor for renal toxicity, blood urea nitrogen (BUN) and creatinine levels are also measured whenever aminoglycoside serum levels are assessed. We also monitor serum magnesium levels in patients who have received multiple aminoglycoside courses within the past year and are therefore at increased risk for isolated tubular damage manifested by magnesium wasting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346244780\">",
"    <span class=\"h3\">",
"     Colistimethate sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    (colistimethate sodium) is a useful option for P. aeruginosa strains that demonstrate in vitro resistance to aminoglycosides. It is used in combination with either fluoroquinolones or beta lactam antibiotics. It should not be used in combination with intravenous aminoglycosides due to their additive renal toxicities. There is potential for confusion when choosing drug dosage due to variability in how the antibiotic is labeled [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. In the United States, each vial of colistimethate sodium is labeled as containing 150 mg of colistin base activity. Using this designation, we administer 2.5 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided into three doses to a maximum of 100 mg per dose. Obese patients should be dosed by ideal body weight. In other countries, the drug is labeled using international units, milligrams of colistimethate sodium, or milligrams of colistin base [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/52\">",
"     52",
"    </a>",
"    ]. Careful attention to the details of the licensed prescribing information is advised. We suggest monitoring of drug levels during treatment for patients with CF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23031?source=see_link\">",
"     \"Colistin: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Vancomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    does not appear to be altered in patients with CF as compared with other patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/79\">",
"     79",
"    </a>",
"    ]. When vancomycin is given for a pulmonary exacerbation in a patient with CF, we use the same dose that is used for treating a serious pulmonary infection in a patient without CF. We start with a weight-based dose of vancomycin of 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (up to 1 gram per dose) every six or eight hours, measure trough serum concentration before the fourth dose, and adjust the dose and interval to achieve a trough of approximately 15 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    Drug levels should be measured earlier in patients with impaired renal function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/47/15096?source=see_link\">",
"     \"Vancomycin dosing and serum concentration monitoring in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Vancomycin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Ciprofloxacin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    in patients with CF are more variable than in patients without CF and may be altered by disease severity, concurrent drug therapy, and patient age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/80-82\">",
"     80-82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with CF generally require higher doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    than other children. As an example, in a group of children with CF treated for severe pulmonary infection, clearance of ciprofloxacin was two times higher than in children without CF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/80\">",
"     80",
"    </a>",
"    ]. We use oral ciprofloxacin at a dose of 40",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    (up to 1.5 grams daily) divided every 12 hours, instead of standard doses of ciprofloxacin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    By contrast, the pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    in adults with CF appears to be similar to that of adults without CF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. Therefore, for adults with CF, we use the manufacturer's recommended dosing (750 mg by mouth twice daily) for severe respiratory tract infection, although higher dosing levels (eg, 1 gram twice daily) may also be appropriate based on theoretical considerations of pharmacokinetics and the level of susceptibility of the bacteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Sulfonamides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic clearance of sulfamethoxazole is increased in CF due to accelerated acetylation, and renal clearance of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    is accelerated by unknown mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/86\">",
"     86",
"    </a>",
"    ]. For these reasons, the dose of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    should be increased by approximately 50 percent relative to that used for patients without CF. For example, trimethoprim-sulfamethoxazole (160 mg TMP-800 mg SMX) should be taken three times daily for an adult with CF rather than twice a day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7028383\">",
"    <span class=\"h2\">",
"     Duration of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic treatment is typically continued until the signs and symptoms that defined the pulmonary exacerbation are largely resolved. In practice, this usually entails treatment for a minimum of 10 days to as long as three weeks, and occasionally more.",
"   </p>",
"   <p>",
"    To provide a more objective assessment of response rates, studies have monitored improvement in FEV1. In a study of 95 subjects, peak FEV1 was achieved in an average of 8.7 days although treatment continued longer for an average of 13.5 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/87\">",
"     87",
"    </a>",
"    ]. Another retrospective analysis of 492 patients receiving treatment for 1331 exacerbations showed that most of the improvement in FEV1 occurred by 8 to 10 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/88\">",
"     88",
"    </a>",
"    ]. These data have been used to suggest that the current practice of treating for two to three weeks may be longer than required. However, in our experience only a minority of patients with moderate to severe CF lung disease report that their symptoms of cough, sputum production, anorexia, and fatigue have returned to their baseline by 8 to 10 days. This observation leads us to be hesitant to reduce the duration of treatment for these more severely ill patients until a well constructed clinical trial indicates otherwise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7025134\">",
"    <span class=\"h2\">",
"     Home management of acute exacerbations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concern over medical costs as well as the preference of many patients have encouraged home treatment for pulmonary exacerbations in CF. Some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/88-91\">",
"     88-91",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/92-94\">",
"     92-94",
"    </a>",
"    ], of the currently available studies support the use of home treatment. The largest study to date retrospectively analyzed data on 1535 subjects treated for a pulmonary exacerbation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/88\">",
"     88",
"    </a>",
"    ]. No difference was detected in long-term FEV1 change or time to next antibiotic treatment for pulmonary exacerbation between subjects receiving home therapy as compared with hospital therapy.",
"   </p>",
"   <p>",
"    When considering home therapy for a pulmonary exacerbation, resources must be available at home to replicate the hospital program including provisions for rest, meals, medications, and physiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/42\">",
"     42",
"    </a>",
"    ]. Children require greater assistance than adults to accomplish these goals, and adult supervision is needed even for teenagers. In considering home treatment for children, one must consider the impact of lost work hours, the number of other children in the household, the number and competence of available adult care-givers, and family stress before deciding whether home treatment is preferable to hospitalization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT OF CHRONIC PULMONARY INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once P. aeruginosa or B. cepacia complex becomes established in the airways of a patient with cystic fibrosis (CF) for more than a few months, the organisms usually persist for years despite aggressive attempts at eradication. Although it has not been possible to eradicate these bacteria, antibiotics are frequently used as chronic suppressive therapy to reduce the bacterial burden and thus lessen their impact.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chronic oral antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;In recognition of the central role that bacterial infection plays in the progression of CF lung disease, a variety of chronic antibiotic regimens have been tested in an attempt to suppress bacterial numbers, reduce airway damage, and decrease the frequency of acute exacerbations. Despite the lack of experimental evidence, it is the practice of some physicians to administer oral antibiotics chronically, particularly when sputum cultures demonstrate bacteria that are sensitive to such drugs. However, chronic use of antibiotics frequently induces antibiotic resistance, which does not necessarily abate when antibiotic treatment is stopped [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/95\">",
"     95",
"    </a>",
"    ]. This is particularly true for fluoroquinolones, which have a high propensity to induce both reversible and permanent resistance in P. aeruginosa. We believe that the potential benefits of chronic oral antibiotics in general do not outweigh the problems caused by induction of antibiotic resistance and side effects; we therefore do not recommend their use.",
"   </p>",
"   <p>",
"    An important exception is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , a macrolide antibiotic that has been shown in randomized trials to have clinical benefit, despite the fact that P. aeruginosa is routinely resistant to it when tested by standard methodology in clinical microbiology laboratories. Possible explanations for its beneficial effects are that it alters pseudomonas phenotype without inhibiting bacterial growth, or that it has direct immunomodulatory activities. Because the benefits of azithromycin do not appear to be due to direct antimicrobial effects, its use is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=see_link&amp;anchor=H12#H12\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Macrolide antibiotics'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Intermittent courses of prophylactic antibiotics have been advocated as a means of conferring benefit with less risk of subsequent resistance. However, there is little clinical data documenting the effectiveness of such an approach. One study of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    administered for 10 days every three months for one year in a small number of patients failed to show benefits in terms of forced expiratory volume at one minute (FEV1), the number of hospitalizations, or the requirement for intravenous antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Periodic hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic hospitalizations for preventive therapy, including intravenous antibiotics (referred to as \"clean outs\"), were utilized more in the past than at the present in the United States. To date, only a few randomized trials have examined the practice, and these have failed to show benefit from periodic elective hospitalization as compared with patients who are hospitalized and treated only when symptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/97-99\">",
"     97-99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the strongest advocates for the continued use of periodic hospitalization for \"clean out\" are physicians in the Danish Cystic Fibrosis Center in Copenhagen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/100\">",
"     100",
"    </a>",
"    ]. At that site, all patients who are chronically infected with P. aeruginosa spend two weeks in the hospital every three to four months, receiving intravenous beta-lactam and aminoglycoside antibiotics and aerosolized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    . After this practice was initiated, there was an improvement in survival compared with a historical control population from the same institution. However, the lack of a concurrent, randomized control population makes it difficult to determine whether the periodic hospitalizations are responsible for the improvement. &nbsp;",
"   </p>",
"   <p>",
"    Contrasting results were found in a prospective trial in the United Kingdom, in which 60 patients were randomly assigned to receive either regular antipseudomonal antibiotics every three months (&ldquo;clean out&rdquo;), or antibiotics only when indicated by clinical deterioration (symptomatically treated) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/98\">",
"     98",
"    </a>",
"    ]. After three years of follow-up, no significant differences in spirometry or survival were noted between the two groups.",
"   </p>",
"   <p>",
"    It is possible that the discrepancy in findings between the studies described above is explained by differences in the total dose of antibiotics administered in the symptomatically treated control groups. In the Danish study, patients treated with periodic hospitalization for &ldquo;clean out&rdquo; received approximately 1.9 times the amount of intravenous antibiotics as compared with symptomatically treated historical controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/100\">",
"     100",
"    </a>",
"    ]. By contrast, in the UK study, the patients treated with periodic hospitalizations received about 1.2 to 1.5 times more intravenous antibiotics than the symptomatically treated control group. Some authors have suggested that the UK study did not adequately test the role of scheduled therapy because the intensity of antibiotic therapy in the symptomatically treated group was relatively high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/101\">",
"     101",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    In North America, the practice of admitting patients routinely for \"clean outs\" has been largely abandoned. Lack of proof of benefit, the high cost of such treatment, and the disruption to patients' daily lives have decreased the enthusiasm for the practice. Furthermore, there is the continuing concern that frequent use of intravenous antibiotics will prematurely select multidrug-resistant organisms, making treatment of inevitable acute exacerbations more difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Aerosolized antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most classes of antibiotics that show in vitro activity against P. aeruginosa are ineffective when administered orally. Inhalation of nebulized preparations has been studied as an alternate route of delivery that is less cumbersome and toxic than the intravenous route [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/102\">",
"     102",
"    </a>",
"    ]. The evidence and other considerations for different types of aerosolized antibiotics is described below, followed by a description of our approach, based on this information. (See",
"    <a class=\"local\" href=\"#H24831331\">",
"     'Our approach'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Inhaled tobramycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with nebulized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    in patients chronically infected with P. aeruginosa improves lung function and reduces acute pulmonary exacerbations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/103-106\">",
"     103-106",
"    </a>",
"    ]. The preparation does not have preservatives and is adjusted to pH 6.0. Prospective studies following patients for up to 2.5 years on aerosolized tobramycin show continuing benefit, although at the price of slightly increased bacterial resistance. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pivotal study of inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      was a 24-week randomized, double blind, multicenter trial in 520 patients with stable CF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/103\">",
"       103",
"      </a>",
"      ]. Twice daily treatment with 300 mg of inhalational tobramycin solution (TOBI",
"      <sup>",
"       &reg;",
"      </sup>",
"      ) was administered via jet nebulizer in cycles of 28 days on the medication followed by 28 days off. Compared with a control group, subjects receiving tobramycin had a 10 percent higher FEV1 at 20 weeks, a decrease in the sputum density of P. aeruginosa, and a 26 percent decrease in the likelihood of hospitalization during the trial. There were higher rates of slight voice alteration and tinnitus in the treatment arm. The tinnitus was mild and transient, and there was no associated hearing loss.",
"     </li>",
"     <li>",
"      In a two-year, open-label follow-up of patients participating in the above study, ongoing use of inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      was associated with greater improvement in FEV1 and with an increase in body mass index [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/104\">",
"       104",
"      </a>",
"      ]. Importantly, patients receiving placebo during the randomized portion of the study improved their FEV1 when starting tobramycin in the open label phase, but their FEV1 levels did not catch up with those attained by subjects that began tobramycin during the randomized portion of the trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/106\">",
"       106",
"      </a>",
"      ]. A trend toward increased aminoglycoside resistance among sputum flora was observed among patients treated with tobramycin during the randomized portion of the trial, although the clinical relevance of this finding is unclear, since the need for hospitalization or intravenous antibiotic therapy was similar for both groups and did not increase over the course of the study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/104,105\">",
"       104,105",
"      </a>",
"      ]. Peak serum tobramycin concentrations averaged &lt;1",
"      <span class=\"nowrap\">",
"       mcg/mL,",
"      </span>",
"      and no nephrotoxicity or ototoxicity was detected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24831257\">",
"    <span class=\"h3\">",
"     Inhaled aztreonam lysine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the success of inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    , investigators have considered a number of other antibiotics for administration by inhalation to treat CF lung disease.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"     Aztreonam",
"    </a>",
"    , a monobactam antibiotic with antipseudomonal activity that was approved for intravenous use in 1986, became a likely candidate. Because inhalation of the IV preparation of aztreonam induces airway inflammation, a lysine salt formulation was developed that circumvents this problem. This preparation has undergone large scale clinical trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial, 211 subjects with chronic pseudomonal lung infection were given either inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      lysine (75 mg) or placebo either two or three times daily for 28 days. All patients were older than 6 years, had had FEV1 between 25 and 75 percent predicted, and had received 28 days of inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      prior to the trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/107\">",
"       107",
"      </a>",
"      ]. The group treated with inhaled aztreonam had a longer time before needing additional antipseudomonal antibiotics (92 days) as compared with those given placebo (71 days). Furthermore, patient-reported respiratory symptom scores, FEV1, and pseudomonas density in sputum samples also improved in the group given aztreonam. There were no differences between two and three times a day aztreonam dosing.",
"     </li>",
"     <li>",
"      Another randomized trial compared inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      with placebo in 164 subjects using a similar protocol. This study used the same entry criteria as in the study described above, and the drug was administered three times daily for 28 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/108\">",
"       108",
"      </a>",
"      ]. Compared with the placebo group, those receiving inhaled aztreonam had better patient reported respiratory symptom scores (primary endpoint), better FEV1 percent predicated levels, and lower densities of pseudomonas in their sputum. &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      An open label study enrolled 271 of the subjects from the two trials described above [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/107,108\">",
"       107,108",
"      </a>",
"      ]. Each of these subjects took",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      by inhalation either two or three times a day for one month, every other month, for up to nine cycles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/109\">",
"       109",
"      </a>",
"      ]. Without a control group, the level of efficacy could not be quantified, but the treatments appeared to be well tolerated, and the frequency of adverse events was in the range expected for the study population. Importantly, those receiving three times a day aztreonam had greater improvements in FEV1 and better patient reported respiratory symptom scores than those receiving twice a day aztreonam.",
"     </li>",
"     <li>",
"      A randomized, blinded, placebo-controlled study evaluated the efficacy of inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      in 157 subjects ages &gt;6 years who had mild lung disease (FEV1 &gt;75 percent predicted) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/110\">",
"       110",
"      </a>",
"      ]. Aztreonam inhalation was associated with a modest improvement in relative percent FEV1 predicted (2.7 percent, p = 0.021). Those with FEV1 &lt;90 percent predicted benefited more than those with higher values.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on the results of these and other studies, the US Food and Drug Administration (FDA) approved inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    (Cayston&reg;) in February 2010. A clinical trial comparing inhaled aztreonam and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    is underway. In all of these studies, aztreonam was administered using a high efficiency nebulizer",
"    <span class=\"nowrap\">",
"     (eFlow/Altera&reg;)",
"    </span>",
"    that delivers the dose in less than three minutes, which compares favorably with the 15 to 20 minutes required to deliver other inhaled antibiotics using conventional nebulizers. However, the time advantage is somewhat mitigated by the need to administer aztreonam three times a day compared with twice a day for tobramycin. Also, to maintain the efficiency of the nebulizer, the system must be carefully cleaned after each use, which adds additional time to the treatments. The FDA-approved drug insert stipulates that aztreonam must be administered using this nebulizer, which is provided to the patient together with the first supply of drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Inhaled colistin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The polypeptide antibiotic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    has antipseudomonal activity, which is preserved against many multidrug-resistant strains. Intravenous use of colistin became infrequent because experience from the 1970s found a relatively high frequency of neurologic and renal side effects. However, some CF centers are reassessing the intravenous use of colistin for patients infected with otherwise pan-resistant organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/111\">",
"     111",
"    </a>",
"    ]. To achieve benefit without the systemic toxicity, the inhalation route also has been used for colistin. The renal and neurotoxicity of inhaled colistin appears minimal when 150 mg of colistimethate sodium is diluted in 2 mL of sterile water and administered by nebulizer twice per day. However, bronchospasm may be induced, particularly among patients with a history of wheezing, atopy, or asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a small clinical trial, 40 subjects with CF were randomized to receive twice a day",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"       colistin",
"      </a>",
"      or isotonic saline by inhalation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/113\">",
"       113",
"      </a>",
"      ]. A high dropout rate compromised the value of the study; only 11 saline subjects and 18 colistin subjects completed the three-month treatment period. Comparison of the groups showed that those receiving colistin had better clinical symptom scores and preservation of pulmonary function.",
"     </li>",
"     <li>",
"      In a randomized trial, one month treatment with either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"       colistin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      resulted in a decrease in bacterial load; however, only tobramycin therapy was associated with improvement in lung function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/114\">",
"       114",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An open label five-month extension of the above study showed persistence of the superiority of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      over",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"       colistin",
"      </a>",
"      relative to preservation of FEV1 percent predicted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/115\">",
"       115",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    appears to be potentially effective but may be inferior to inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    . No studies have compared colistin with inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24831331\">",
"    <span class=\"h3\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until high quality comparison trials become available, uncertainty remains regarding when to prescribe the various inhaled antibiotics.",
"   </p>",
"   <p>",
"    We agree with the recommendations of an expert panel that all patients over 6 years of age who are colonized with P. aeruginosa should be treated chronically with inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/116\">",
"     116",
"    </a>",
"    ]. It is our first choice of inhaled antibiotic because of the extensive information supporting the efficacy of tobramycin and its good safety record following many years of use. The level of evidence and clinical benefit is greatest for patients with moderate or severe lung disease. Tobramycin is typically given as 300 mg in 5 cc by nebulizer twice daily for one month, on alternate months.",
"   </p>",
"   <p>",
"    In our practice, we offer inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    instead of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    to patients older than 6 years of age who have chronic pseudomonas infection, under any of the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient does not tolerate inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"     </li>",
"     <li>",
"      The patient is deteriorating clinically despite inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"     </li>",
"     <li>",
"      The patient is considered more likely to be adherent to inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      treatment because it can be delivered more rapidly than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"     </li>",
"     <li>",
"      The patient is or may soon become pregnant, which makes aminoglycosides relatively contraindicated",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"     Aztreonam",
"    </a>",
"    is given at a dose of 75 mg by inhalation three times a day for one month, every other month. Alternatively, it can be given for one month alternating with inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    for one month; this approach may be particularly appropriate for patients with deteriorating pulmonary status",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recurrent pulmonary exacerbations despite taking just one antibiotic every other month. Data from well-designed comparative effectiveness trials for tobramycin and aztreonam are needed to better inform the decision as to when to use each. There is no reported experience for using more than one of the currently available inhaled antibiotics simultaneously.",
"   </p>",
"   <p>",
"    Given the less robust data supporting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    use and the suggestion that it may be inferior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    , we prescribe colistin only in those patients who are not doing well despite tobramycin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    , or in those who do not tolerate them.",
"   </p>",
"   <p>",
"    Antibiotic resistance as measured by in vitro susceptibility testing does not preclude a response to inhaled medications. This was illustrated by studies of patients participating in clinical trials of inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    , some of whom were found to be infected with P. aeruginosa strains that would be considered antibiotic-resistant relative to drug levels that are safely attainable by parenteral administration. Subjects with these relatively resistant pseudomonal isolates were just as likely to show clinical responses to inhalational treatment as those with drug sensitive strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. This is probably because antibiotic concentrations that occur in respiratory secretions following inhalation of the FDA-approved formulations far exceed the breakpoints used for determining susceptibility when the drugs are given parenterally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4202024\">",
"    <span class=\"h1\">",
"     CONSIDERATIONS FOR SPECIFIC PATHOGENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other strategies against pseudomonas aeruginosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several approaches have been investigated to prevent P. aeruginosa from chronically infecting the airways of cystic fibrosis (CF) patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Prevention of acquisition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because S. aureus was often noted to infect CF patients prior to the appearance of P. aeruginosa, it was hypothesized that damage from S. aureus might cause the CF airway to be more susceptible to P. aeruginosa. If so, chronic prevention or suppression of S. aureus infection might reduce the frequency of P. aeruginosa and preserve airway function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To test this hypothesis, a randomized trial of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    was performed in young children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/120\">",
"     120",
"    </a>",
"    ]. Cephalexin or placebo was started at the time of CF diagnosis and administered continuously for seven years. Cephalexin was successful in reducing the prevalence of S. aureus infection, but the incidence of P. aeruginosa infection actually increased, and there was no evidence of overall clinical benefit.",
"   </p>",
"   <p>",
"    A separate randomized trial evaluated the effects of treating children without P. aeruginosa infection with cycles of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    and inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/121\">",
"     121",
"    </a>",
"    ]. Three-week courses of these medications were administered every three months for three years. At the end of the three-year trial, there was no difference between rates of initial or chronic P. aeruginosa infection among children who had received this intervention as compared with controls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Early eradication of P. aeruginosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Cystic Fibrosis Center in Copenhagen, Denmark has adopted a policy of performing monthly sputum cultures for all patients with cystic fibrosis (CF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/122,123\">",
"     122,123",
"    </a>",
"    ]. When P. aeruginosa is first isolated, oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    and aerosolized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    are begun. The treatment is repeated and prolonged if P. aeruginosa is not eradicated or if it reappears after treatment. When the clinical status of patients treated with this protocol was compared with historical data from the same center, pulmonary function tests were better, the time to permanent acquisition with P. aeruginosa was delayed, and the overall prevalence of P. aeruginosa infection in their center was reduced.",
"   </p>",
"   <p>",
"    The results from these and other small studies have led the majority of CF centers including our own to use antibiotic protocols targeting P. aeruginosa when it is first identified in respiratory secretions, regardless of the patient&rsquo;s clinical signs or symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/124\">",
"     124",
"    </a>",
"    ]. Small studies have shown that the permanent acquisition of P. aeruginosa can be delayed, and one reported that eradication was associated with sustained improvement in two biochemical measures of inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/125\">",
"     125",
"    </a>",
"    ]. Nonetheless, the long-term outcomes from such efforts to achieve early eradication are unknown.",
"   </p>",
"   <p>",
"    Although a variety of antibiotic protocols have been used for early eradication, current evidence supports the use of inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    alone to treat patients for newly acquired P. aeruginosa:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial 88 subjects who had recently acquired P. aeruginosa were given inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      , 300 mg twice daily, for either 28 or 56 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/126\">",
"       126",
"      </a>",
"      ]. More than 90 percent of the patients in both arms had negative cultures for P. aeruginosa one month after the end of treatment, and more than half of these continued to have negative cultures when followed for up to 27 months. There was no significant difference in outcomes among patients treated for 28 versus 56 days, suggesting that the shorter course of treatment may be sufficient.",
"     </li>",
"     <li>",
"      A small, uncontrolled study of 15 patients who had new infection with P. aeruginosa showed that inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      (80 mg twice daily for 12 months) eliminated P. aeruginosa from throat cultures in 14 of the patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/127\">",
"       127",
"      </a>",
"      ]. The authors concluded that this treatment had a beneficial effect based upon persistent negative cultures at one year, absence of serum antibodies to P. aeruginosa, and maintenance of stable pulmonary function tests for two years after therapy was completed.",
"     </li>",
"     <li>",
"      In a multicenter trial, 304 children with newly acquired P. aeruginosa were treated with inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      for 28 days, with or without concomitant oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/128\">",
"       128",
"      </a>",
"      ]. After the first cycle of treatment, only 13 percent of children tested positive for P. aeruginosa, and there was no apparent advantage to including ciprofloxacin in the treatment regimen. During the subsequent 18 months, the rate of pulmonary exacerbations was 16 percent and was no different for subjects re-treated with scheduled courses of antibiotics every three months, as compared with those treated only when surveillance cultures again became positive for P. aeruginosa.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Supported by these results, we suggest using a protocol to detect and treat P. aeruginosa when it is first acquired. We perform cultures of expectorated sputum or throat swabs every three months during routine clinic visits. When P. aeruginosa is first detected, we recommend treatment with inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    alone (300 mg in 5 mL, administered twice daily) for 28 days rather than a regimen including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    or other antibiotics. The therapy is repeated only if surveillance cultures show recurrence of P. aeruginosa. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Nontuberculous mycobacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontuberculous mycobacteria (NTM) can be isolated from the sputum in approximately 13 percent of patients with CF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/129,130\">",
"     129,130",
"    </a>",
"    ]. Mycobacterium avium complex is identified in up to 59 to 75 percent of these patients; the other frequently identified pathogen is M. abscessus, which grows rapidly in culture and is found in up to 16 to 41 percent of NTM-positive patients with CF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/130-132\">",
"     130-132",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24089?source=see_link\">",
"     \"Epidemiology of nontuberculous mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/35/5687?source=see_link\">",
"     \"Microbiology of nontuberculous mycobacteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical implications of detecting NTM in sputum samples of patients with CF are quite variable. However, on average the rate of decline in forced expiratory volume at one minute (FEV1) is greater in patients infected with M. abscessus than a control population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/132\">",
"     132",
"    </a>",
"    ]. The impact appears to be less in patients with other NTM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/130,132,133\">",
"     130,132,133",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinically important invasive mycobacterial disease occurs in a subset of patients, causing systemic symptoms, deteriorating pulmonary function, and the appearance of nodular infiltrates",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parenchymal cavities on chest radiograph or high resolution chest computed tomography (HRCT). For these patients, we recommend the following approach, which was suggested by the NTM CF study group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/134\">",
"     134",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once NTM is identified in respiratory secretions, serial studies should be obtained to determine if the American Thoracic Society microbiologic criteria for NTM disease are fulfilled [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/133\">",
"       133",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24759?source=see_link&amp;anchor=H5#H5\">",
"       \"Overview of nontuberculous mycobacterial infections in HIV-negative patients\", section on 'Diagnostic criteria for pulmonary disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the microbiologic criteria for NTM are fulfilled, a HRCT of the chest should be obtained to detect nodules or cavities.",
"     </li>",
"     <li>",
"      If nodules or cavities are present, or if the patient is experiencing deterioration in pulmonary status despite intensified treatment for non-NTM bacteria that commonly infect CF airways, treatment directed at the NTM should be seriously considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unfortunately, eradication of the NTM from airway secretions of CF patients is difficult to achieve, particularly in those infected with M. abscessus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/131\">",
"     131",
"    </a>",
"    ]. There is no specific evidence to suggest that NTM in patients with CF should be treated differently from NTM in other patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/135\">",
"     135",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24759?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial infections in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2441?source=see_link\">",
"     \"Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infection with M. avium complex appears to have no adverse impact on patients with CF who undergo lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/136,137\">",
"     136,137",
"    </a>",
"    ]. However, M. abscessus infection can complicate lung transplantation causing soft tissue and mediastinal abscesses that can recur despite treatment with surgical drainage and antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Aspergillus species",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cultures of sputum from patients with CF often yield Aspergillus species. Two studies suggest that for most patients without allergic symptoms, the presence of Aspergillus does not seem to affect the clinical course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/138,139\">",
"     138,139",
"    </a>",
"    ]. However, a third study found that persistently positive cultures for Aspergillus species is associated with reduced pulmonary function and more pulmonary exacerbations requiring hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/140\">",
"     140",
"    </a>",
"    ]. It is not clear whether this association is causal or whether aspergillus is merely a marker of more severe lung disease. Therefore, we recommend no special treatment except when criteria are met for allergic bronchopulmonary aspergillosis (ABPA) or an aspergilloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/141-143\">",
"     141-143",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33545?source=see_link&amp;anchor=H12#H12\">",
"     \"Allergic bronchopulmonary aspergillosis\", section on 'ABPA in cystic fibrosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31529?source=see_link\">",
"     \"Treatment of chronic pulmonary aspergillosis\"",
"    </a>",
"    .) Also, some transplant centers recommend suppression of aspergillus with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    for infected patients who are on the waiting list for lung transplant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     INFECTION CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burkholderia cepacia complex organisms are occasionally transmitted between cystic fibrosis (CF) patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/144-147\">",
"     144-147",
"    </a>",
"    ]. Sporadic outbreaks of infection have been linked to contaminated sink drains, nebulized medications, and soil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/145,148,149\">",
"     145,148,149",
"    </a>",
"    ]. The most appropriate method to prevent acquisition of Burkholderia cepacia complex bacteria is to limit patient-to-patient transmission by minimizing physical contact between CF patients and scrupulously adhering to standard isolation precautions. Highly transmissible strains of P. aeruginosa also have been reported in Europe, Canada, and Australia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/150\">",
"     150",
"    </a>",
"    ], and infection with these strains is associated with increased health care needs and antibiotic use as compared with infection with sporadic strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/11,151\">",
"     11,151",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    General and specific infection control measures have been proposed to limit the spread of infection within this population (",
"    <a class=\"graphic graphic_table graphicRef53301 graphicRef63038 \" href=\"mobipreview.htm?4/55/4990\">",
"     table 4A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/22/41322/abstract/6,34,152\">",
"     6,34,152",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=see_link\">",
"     \"General principles of infection control\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PREVENTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammation induced by viral upper respiratory tract infections appears to initiate exacerbations of cystic fibrosis (CF) lung disease. Thus, all patients with CF should receive annual immunization against influenza beginning at 6 months of age, unless a patient has strong contraindications to use of the vaccine. Administration of the pneumococcal vaccine also is recommended. Although patients with CF become infected with Streptococcus pneumoniae only rarely, the availability and safety of the vaccine make its use advisable in this population. The role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40371?source=see_link\">",
"     Palivizumab",
"    </a>",
"    for prevention of respiratory syncytial virus infection in young children with CF has not been established, as discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=see_link&amp;anchor=H19#H19\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Vaccinations and palivizumab'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/57/20371?source=see_link\">",
"       \"Patient information: Cystic fibrosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cystic fibrosis (CF) lung disease is characterized by persistent bacterial infection; Staphylococcus aureus and Pseudomonas aeruginosa (P. aeruginosa) are the most prevalent pathogens (",
"      <a class=\"graphic graphic_figure graphicRef74073 \" href=\"mobipreview.htm?18/0/18447\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical course is frequently complicated by acute pulmonary exacerbations, superimposed on a gradual decline in pulmonary function. Exacerbations are treated with antibiotics, given either orally or intravenously depending on the severity of the exacerbation, and on the sensitivities of the infecting bacteria (",
"      <a class=\"graphic graphic_table graphicRef59661 \" href=\"mobipreview.htm?37/31/38398\">",
"       table 2",
"      </a>",
"      ). Current practice is to select at least one antibiotic to cover each bacterial isolate that is cultured from respiratory secretions, and two antibiotics for P. aeruginosa infections, if possible. We typically treat P. aeruginosa with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"       piperacillin-tazobactam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/45/42710?source=see_link\">",
"       ticarcillin-clavulanate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      , imipenem-cilastin, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      , PLUS one of the following:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      , or a fluoroquinolone (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      ), depending on antibiotic susceptibility test results. (See",
"      <a class=\"local\" href=\"#H7028282\">",
"       'Antibiotic selection'",
"      </a>",
"      above.) &nbsp; &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      The pharmacokinetics of many antibiotics differs in patients with CF as compared with normal individuals. Patients with CF generally require larger",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      more frequent dosing for penicillins, cephalosporins, sulfonamides, and fluoroquinolones. Starting doses of aminoglycosides should also be larger than those recommended for individuals without CF, but dosing must be adjusted based on pharmacokinetic analysis of serum levels because of considerable interindividual variation in clearance rates. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of an acute pulmonary exacerbation, we generally suggest",
"      <strong>",
"       not",
"      </strong>",
"      administering chronic or intermittent systemic antibiotics to patients with CF (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ), EXCEPT for the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend the chronic use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      for patients 6 years and older who have clinical evidence of airway inflammation such as chronic cough or any reduction in forced expiratory volume at one minute (FEV1), regardless of the patient&rsquo;s P. aeruginosa infection status (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). &nbsp;To avoid induction of antibiotic resistance, azithromycin should not be given to patients infected with nontuberculous mycobacteria. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Chronic oral antibiotics'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=see_link&amp;anchor=H12#H12\">",
"       \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Macrolide antibiotics'",
"      </a>",
"      .) &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      For patients older than 6 years with persistent P. aeruginosa infection and moderate or severe lung disease, we recommend chronic treatment with inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We also suggest this treatment for patients with mild lung disease and persistent P. aeruginosa infection (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      lysine is a reasonable alternative for some patients. Either inhaled tobramycin or aztreonam lysine are given for one month, on alternate months. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Aerosolized antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest",
"      <strong>",
"       not",
"      </strong>",
"      scheduling elective hospitalizations for antibiotics and intensified chest physiotherapy (\"clean out\") (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Periodic hospitalization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest using a protocol to detect and treat P. aeruginosa when it is first acquired (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Cultures of expectorated sputum or throat swabs are performed every three months during routine clinic visits. When P. aeruginosa is first detected, we recommend treatment with inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      alone (300 mg in 5 mL, administered twice daily) for 28 days rather than a regimen including other antibiotics (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The therapy is repeated only if surveillance cultures show recurrence of P. aeruginosa. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Early eradication of P. aeruginosa'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to antibiotics, optimal care for pulmonary disease in cystic fibrosis includes measures to promote airway clearance and to reduce bronchial obstruction and inflammation. Airway clearance therapies should be intensified during an acute pulmonary exacerbation. These approaches are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=see_link\">",
"       \"Cystic fibrosis: Overview of the treatment of lung disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/1\">",
"      Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/2\">",
"      Ratjen F, D&ouml;ring G. Cystic fibrosis. Lancet 2003; 361:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/3\">",
"      Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med 1996; 154:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/4\">",
"      Goss CH, Rosenfeld M. Update on cystic fibrosis epidemiology. Curr Opin Pulm Med 2004; 10:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/5\">",
"      Brennan AL, Geddes DM. Cystic fibrosis. Curr Opin Infect Dis 2002; 15:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/6\">",
"      Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/7\">",
"      Sagel SD, Gibson RL, Emerson J, et al. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr 2009; 154:183.",
"     </a>",
"    </li>",
"    <li>",
"     Cystic Fibrosis Foundation Annual Patient Registry 2010 file://www.cff.org/research/ClinicalResearch/PatientRegistryReport/ (Accessed on September 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/9\">",
"      Rosenfeld M, Gibson RL, McNamara S, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001; 32:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/10\">",
"      Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/11\">",
"      Aaron SD, Vandemheen KL, Ramotar K, et al. Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis. JAMA 2010; 304:2145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/12\">",
"      Perros F, Montani D, Dorfm&uuml;ller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/13\">",
"      Sawicki GS, Rasouliyan L, Pasta DJ, et al. The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Pediatr Pulmonol 2008; 43:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/14\">",
"      Dasenbrook EC, Checkley W, Merlo CA, et al. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010; 303:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/15\">",
"      LiPuma JJ. Burkholderia and emerging pathogens in cystic fibrosis. Semin Respir Crit Care Med 2003; 24:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/16\">",
"      De Boeck K, Malfroot A, Van Schil L, et al. Epidemiology of Burkholderia cepacia complex colonisation in cystic fibrosis patients. Eur Respir J 2004; 23:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/17\">",
"      Jones AM, Dodd ME, Govan JR, et al. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 2004; 59:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/18\">",
"      Coenye T, Spilker T, Van Schoor A, et al. Recovery of Burkholderia cenocepacia strain PHDC from cystic fibrosis patients in Europe. Thorax 2004; 59:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/19\">",
"      Speert DP. Advances in Burkholderia cepacia complex. Paediatr Respir Rev 2002; 3:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/20\">",
"      Fauroux B, Hart N, Belfar S, et al. Burkholderia cepacia is associated with pulmonary hypertension and increased mortality among cystic fibrosis patients. J Clin Microbiol 2004; 42:5537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/21\">",
"      Kalish LA, Waltz DA, Dovey M, et al. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med 2006; 173:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/22\">",
"      Chaparro C, Maurer J, Gutierrez C, et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med 2001; 163:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/23\">",
"      Aris RM, Routh JC, LiPuma JJ, et al. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med 2001; 164:2102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/24\">",
"      De Soyza A, Morris K, McDowell A, et al. Prevalence and clonality of Burkholderia cepacia complex genomovars in UK patients with cystic fibrosis referred for lung transplantation. Thorax 2004; 59:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/25\">",
"      Emerson J, McNamara S, Buccat AM, et al. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol 2010; 45:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/26\">",
"      Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010; 23:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/27\">",
"      Harris JK, De Groote MA, Sagel SD, et al. Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci U S A 2007; 104:20529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/28\">",
"      Tunney MM, Field TR, Moriarty TF, et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 2008; 177:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/29\">",
"      Doe SJ, McSorley A, Isalska B, et al. Patient segregation and aggressive antibiotic eradication therapy can control methicillin-resistant Staphylococcus aureus at large cystic fibrosis centres. J Cyst Fibros 2010; 9:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/30\">",
"      Sanders DB, Bittner RC, Rosenfeld M, et al. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011; 46:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/31\">",
"      Rosenfeld M, Emerson J, Williams-Warren J, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001; 139:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/32\">",
"      Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990; 141:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/33\">",
"      Hyatt AC, Chipps BE, Kumor KM, et al. A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis. J Pediatr 1981; 99:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/34\">",
"      Saiman L, Siegel J, Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants. Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control 2003; 31:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/35\">",
"      Cystic Fibrosis Foundation, Borowitz D, Robinson KA, et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr 2009; 155:S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/36\">",
"      Hansen CR, Pressler T, Nielsen KG, et al. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros 2010; 9:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/37\">",
"      Goss CH, Otto K, Aitken ML, Rubenfeld GD. Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am J Respir Crit Care Med 2002; 166:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/38\">",
"      Waters V, Yau Y, Prasad S, et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med 2011; 183:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/39\">",
"      Lang BJ, Aaron SD, Ferris W, et al. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med 2000; 162:2241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/40\">",
"      Sanders CC, Sanders WE Jr, Goering RV. In vitro antagonism of beta-lactam antibiotics by cefoxitin. Antimicrob Agents Chemother 1982; 21:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/41\">",
"      Aaron SD, Vandemheen KL, Ferris W, et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 2005; 366:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/42\">",
"      Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009; 180:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/43\">",
"      Smith AL, Fiel SB, Mayer-Hamblett N, et al. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003; 123:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/44\">",
"      Foweraker JE, Laughton CR, Brown DF, Bilton D. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother 2005; 55:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/45\">",
"      Dales L, Ferris W, Vandemheen K, Aaron SD. Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis. Eur J Clin Microbiol Infect Dis 2009; 28:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/46\">",
"      Moskowitz SM, Emerson JC, McNamara S, et al. Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection. Pediatr Pulmonol 2011; 46:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/47\">",
"      Aaron SD, Ferris W, Henry DA, et al. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000; 161:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/48\">",
"      Waters V, Ratjen F. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev 2008; :CD006961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/49\">",
"      Smith AL, Doershuk C, Goldmann D, et al. Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr 1999; 134:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/50\">",
"      Elphick HE, Tan A. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst Rev 2005; :CD002007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/51\">",
"      Beringer P. The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med 2001; 7:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/52\">",
"      Conway SP, Etherington C, Munday J, et al. Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis. Ann Pharmacother 2000; 34:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/53\">",
"      Phaff SJ, Tiddens HA, Verbrugh HA, Ott A. Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis. J Antimicrob Chemother 2006; 57:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/54\">",
"      Ryan G, Jahnke N, Remmington T. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Cochrane Database Syst Rev 2012; 12:CD008319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/55\">",
"      Laube BL, Links JM, LaFrance ND, et al. Homogeneity of bronchopulmonary distribution of 99mTc aerosol in normal subjects and in cystic fibrosis patients. Chest 1989; 95:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/56\">",
"      Rey E, Tr&eacute;luyer JM, Pons G. Drug disposition in cystic fibrosis. Clin Pharmacokinet 1998; 35:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/57\">",
"      Bolton CE, Ionescu AA, Evans WD, et al. Altered tissue distribution in adults with cystic fibrosis. Thorax 2003; 58:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/58\">",
"      Touw DJ. Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis. Pharm World Sci 1998; 20:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/59\">",
"      Massie J, Cranswick N. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis. J Paediatr Child Health 2006; 42:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/60\">",
"      Lindsay CA, Bosso JA. Optimisation of antibiotic therapy in cystic fibrosis patients. Pharmacokinetic considerations. Clin Pharmacokinet 1993; 24:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/61\">",
"      Zobell JT, Young DC, Waters CD, et al. A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients. Pediatr Pulmonol 2011; 46:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/62\">",
"      Prescott WA Jr, Gentile AE, Nagel JL, Pettit RS. Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis. P T 2011; 36:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/63\">",
"      Riethmueller J, Junge S, Schroeter TW, et al. Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis. Infection 2009; 37:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/64\">",
"      Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 2012; 2:CD002009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/65\">",
"      Smyth A, Tan KH, Hyman-Taylor P, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial. Lancet 2005; 365:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/66\">",
"      Prescott WA Jr. National survey of extended-interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations. J Pediatr Pharmacol Ther 2011; 16:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/67\">",
"      Coulthard KP, Peckham DG, Conway SP, et al. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations. J Cyst Fibros 2007; 6:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/68\">",
"      Hennig S, Norris R, Kirkpatrick CM. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study. Br J Clin Pharmacol 2008; 65:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/69\">",
"      Bartel K, Habash T, Lugauer S, et al. Optimal tobramycin dosage in patients with cystic fibrosis--evidence for predictability based on previous drug monitoring. Infection 1999; 27:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/70\">",
"      Al-Aloul M, Miller H, Alapati S, et al. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 2005; 39:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/71\">",
"      Tan KH, Mulheran M, Knox AJ, Smyth AR. Aminoglycoside prescribing and surveillance in cystic fibrosis. Am J Respir Crit Care Med 2003; 167:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/72\">",
"      Bertenshaw C, Watson AR, Lewis S, Smyth A. Survey of acute renal failure in patients with cystic fibrosis in the UK. Thorax 2007; 62:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/73\">",
"      Soulsby N, Greville H, Coulthard K, Doecke C. Renal dysfunction in cystic fibrosis: is there cause for concern? Pediatr Pulmonol 2009; 44:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/74\">",
"      O'Donnell EP, Scarsi KK, Scheetz MH, et al. Risk factors for aminoglycoside ototoxicity in adult cystic fibrosis patients. Int J Antimicrob Agents 2010; 36:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/75\">",
"      Green CG, Doershuk CF, Stern RC. Symptomatic hypomagnesemia in cystic fibrosis. J Pediatr 1985; 107:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/76\">",
"      Geller DE, Pitlick WH, Nardella PA, et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/77\">",
"      Li J, Nation RL, Turnidge JD. Defining the dosage units for colistin methanesulfonate: urgent need for international harmonization. Antimicrob Agents Chemother 2006; 50:4231; author reply 4231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/78\">",
"      Lim LM, Ly N, Anderson D, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 2010; 30:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/79\">",
"      Pleasants RA, Michalets EL, Williams DM, et al. Pharmacokinetics of vancomycin in adult cystic fibrosis patients. Antimicrob Agents Chemother 1996; 40:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/80\">",
"      Payen S, Serreau R, Munck A, et al. Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections. Antimicrob Agents Chemother 2003; 47:3170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/81\">",
"      Montgomery MJ, Beringer PM, Aminimanizani A, et al. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45:3468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/82\">",
"      Schaefer HG, Stass H, Wedgwood J, et al. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. Antimicrob Agents Chemother 1996; 40:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/83\">",
"      Treggiari MM, Rosenfeld M, Mayer-Hamblett N, et al. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemp Clin Trials 2009; 30:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/84\">",
"      Christensson BA, Nilsson-Ehle I, Ljungberg B, et al. Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. Antimicrob Agents Chemother 1992; 36:2512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/85\">",
"      Steen HJ, Scott EM, Stevenson MI, et al. Clinical and pharmacokinetic aspects of ciprofloxacin in the treatment of acute exacerbations of pseudomonas infection in cystic fibrosis patients. J Antimicrob Chemother 1989; 24:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/86\">",
"      Reed MD, Stern RC, Bertino JS Jr, et al. Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis. J Pediatr 1984; 104:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/87\">",
"      VanDevanter DR, O'Riordan MA, Blumer JL, Konstan MW. Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respir Res 2010; 11:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/88\">",
"      Collaco JM, Green DM, Cutting GR, et al. Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes. Am J Respir Crit Care Med 2010; 182:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/89\">",
"      Donati MA, Guenette G, Auerbach H. Prospective controlled study of home and hospital therapy of cystic fibrosis pulmonary disease. J Pediatr 1987; 111:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/90\">",
"      Wolter JM, Bowler SD, Nolan PJ, McCormack JG. Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. Eur Respir J 1997; 10:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/91\">",
"      Balaguer A, Gonz&aacute;lez de Dios J. Home versus hospital intravenous antibiotic therapy for cystic fibrosis. Cochrane Database Syst Rev 2012; 3:CD001917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/92\">",
"      Bosworth DG, Nielson DW. Effectiveness of home versus hospital care in the routine treatment of cystic fibrosis. Pediatr Pulmonol 1997; 24:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/93\">",
"      Thornton J, Elliott R, Tully MP, et al. Long term clinical outcome of home and hospital intravenous antibiotic treatment in adults with cystic fibrosis. Thorax 2004; 59:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/94\">",
"      Nazer D, Abdulhamid I, Thomas R, Pendleton S. Home versus hospital intravenous antibiotic therapy for acute pulmonary exacerbations in children with cystic fibrosis. Pediatr Pulmonol 2006; 41:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/95\">",
"      Diver JM, Schollaardt T, Rabin HR, et al. Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy. Antimicrob Agents Chemother 1991; 35:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/96\">",
"      Sheldon CD, Assoufi BK, Hodson ME. Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa. Respir Med 1993; 87:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/97\">",
"      Breen L, Aswani N. Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis. Cochrane Database Syst Rev 2012; 7:CD002767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/98\">",
"      Elborn JS, Prescott RJ, Stack BH, et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax 2000; 55:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/99\">",
"      Brett MM, Simmonds EJ, Ghoneim AT, Littlewood JM. The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis. Arch Dis Child 1992; 67:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/100\">",
"      Szaff M, H&oslash;iby N, Flensborg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 1983; 72:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/101\">",
"      H&oslash;iby N, Koch C. Maintenance treatment of chronic pseudomonas aeruginosa infection in cystic fibrosis. Thorax 2000; 55:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/102\">",
"      Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003; :CD001021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/103\">",
"      Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/104\">",
"      Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002; 121:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/105\">",
"      Burns JL, Van Dalfsen JM, Shawar RM, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999; 179:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/106\">",
"      Bowman CM. The long-term use of inhaled tobramycin in patients with cystic fibrosis. J Cyst Fibros 2002; 1:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/107\">",
"      McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/108\">",
"      Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009; 135:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/109\">",
"      Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010; 45:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/110\">",
"      Wainwright CE, Quittner AL, Geller DE, et al. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. J Cyst Fibros 2011; 10:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/111\">",
"      Conway SP, Pond MN, Watson A, et al. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 1997; 52:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/112\">",
"      Alothman GA, Ho B, Alsaadi MM, et al. Bronchial constriction and inhaled colistin in cystic fibrosis. Chest 2005; 127:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/113\">",
"      Jensen T, Pedersen SS, Garne S, et al. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987; 19:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/114\">",
"      Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002; 20:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/115\">",
"      Adeboyeku D, Scott S, Hodson ME. Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis. J Cyst Fibros 2006; 5:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/116\">",
"      Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/117\">",
"      Saiman L, Mehar F, Niu WW, et al. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 1996; 23:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/118\">",
"      McCoy KS, Retsch-Bogart GZ, Gibson R, et al. Relevance of established susceptibility breakpoints to clinical efficacy of inhaled antibiotic therapies in cystic fibrosis. Pediatr Pulmonol 2008; 31 Suppl:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/119\">",
"      Smyth AR, Walters S. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2012; 12:CD001912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/120\">",
"      Stutman HR, Lieberman JM, Nussbaum E, Marks MI. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J Pediatr 2002; 140:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/121\">",
"      Tramper-Stranders GA, Wolfs TF, van Haren Noman S, et al. Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Thorax 2010; 65:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/122\">",
"      Frederiksen B, Koch C, H&oslash;iby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/123\">",
"      Johansen HK, N&oslash;rregaard L, G&oslash;tzsche PC, et al. Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success?--A 30-year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection. Pediatr Pulmonol 2004; 37:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/124\">",
"      Treggiari MM, Rosenfeld M, Retsch-Bogart G, et al. Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Pediatr Pulmonol 2007; 42:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/125\">",
"      Douglas TA, Brennan S, Gard S, et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J 2009; 33:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/126\">",
"      Ratjen F, Munck A, Kho P, et al. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010; 65:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/127\">",
"      Ratjen F, D&ouml;ring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001; 358:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/128\">",
"      Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011; 165:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/129\">",
"      Olivier KN, Yankaskas JR, Knowles MR. Nontuberculous mycobacterial pulmonary disease in cystic fibrosis. Semin Respir Infect 1996; 11:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/130\">",
"      Olivier KN, Weber DJ, Wallace RJ Jr, et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003; 167:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/131\">",
"      Mussaffi H, Rivlin J, Shalit I, et al. Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy. Eur Respir J 2005; 25:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/132\">",
"      Esther CR Jr, Esserman DA, Gilligan P, et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010; 9:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/133\">",
"      Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/134\">",
"      Olivier K, for the NTM in CF Study Group. The natural history of nontuberculous mycobacteria in patients with cystic fibrosis. Paediat Respir Rev 2004; 5(Suppl A): S213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/135\">",
"      Waters V, Ratjen F. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Cochrane Database Syst Rev 2012; 12:CD010004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/136\">",
"      Chalermskulrat W, Sood N, Neuringer IP, et al. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006; 61:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/137\">",
"      Chernenko SM, Humar A, Hutcheon M, et al. Mycobacterium abscessus infections in lung transplant recipients: the international experience. J Heart Lung Transplant 2006; 25:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/138\">",
"      Mroueh S, Spock A. Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Chest 1994; 105:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/139\">",
"      Kraemer R, Delos&eacute;a N, Ballinari P, et al. Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis. Am J Respir Crit Care Med 2006; 174:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/140\">",
"      Amin R, Dupuis A, Aaron SD, Ratjen F. The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest 2010; 137:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/141\">",
"      Skov M, Koch C, Reimert CM, Poulsen LK. Diagnosis of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis. Allergy 2000; 55:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/142\">",
"      Nikolaizik WH, Weichel M, Blaser K, Crameri R. Intracutaneous tests with recombinant allergens in cystic fibrosis patients with allergic bronchopulmonary aspergillosis and Aspergillus allergy. Am J Respir Crit Care Med 2002; 165:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/143\">",
"      Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37 Suppl 3:S225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/144\">",
"      Holmes A, Nolan R, Taylor R, et al. An epidemic of burkholderia cepacia transmitted between patients with and without cystic fibrosis. J Infect Dis 1999; 179:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/145\">",
"      D&ouml;ring G, Jansen S, Noll H, et al. Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward. Pediatr Pulmonol 1996; 21:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/146\">",
"      Pegues DA, Carson LA, Tablan OC, et al. Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. Summer Camp Study Group. J Pediatr 1994; 124:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/147\">",
"      LiPuma JJ, Dasen SE, Nielson DW, et al. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet 1990; 336:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/148\">",
"      LiPuma JJ, Spilker T, Coenye T, Gonzalez CF. An epidemic Burkholderia cepacia complex strain identified in soil. Lancet 2002; 359:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/149\">",
"      Reboli AC, Koshinski R, Arias K, et al. An outbreak of Burkholderia cepacia lower respiratory tract infection associated with contaminated albuterol nebulization solution. Infect Control Hosp Epidemiol 1996; 17:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/150\">",
"      Scott FW, Pitt TL. Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales. J Med Microbiol 2004; 53:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/151\">",
"      Jones AM, Dodd ME, Morris J, et al. Clinical outcome for cystic fibrosis patients infected with transmissible pseudomonas aeruginosa: an 8-year prospective study. Chest 2010; 137:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/22/41322/abstract/152\">",
"      Jones AM, Dodd ME, Govan JR, et al. Prospective surveillance for Pseudomonas aeruginosa cross-infection at a cystic fibrosis center. Am J Respir Crit Care Med 2005; 171:257.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6371 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-1201EFFE29-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_22_41322=[""].join("\n");
var outline_f40_22_41322=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9942753\">",
"      Pseudomonas aeruginosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7028176\">",
"      Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7028183\">",
"      Methicillin-resistant Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H902257\">",
"      Burkholderia cepacia complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7493970\">",
"      Other pathogens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7025018\">",
"      CONSEQUENCES OF CF LUNG INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT OF ACUTE PULMONARY EXACERBATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7028282\">",
"      ANTIBIOTIC SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4200798\">",
"      General considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4200806\">",
"      Susceptibility testing strategies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7028289\">",
"      - In vitro antibiotic susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7028297\">",
"      - Testing bacteria grown as biofilms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7025060\">",
"      - Antibiotic synergy testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H902786\">",
"      Number and choice of antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7028321\">",
"      Route of antibiotic administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Oral",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7028336\">",
"      - Inhaled",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Intravenous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Aminoglycosides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13783431\">",
"      Once daily",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13783453\">",
"      Conventional",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13783476\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H346244780\">",
"      - Colistimethate sodium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Vancomycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Ciprofloxacin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Sulfonamides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7028383\">",
"      Duration of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7025134\">",
"      Home management of acute exacerbations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT OF CHRONIC PULMONARY INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chronic oral antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Periodic hospitalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Aerosolized antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Inhaled tobramycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24831257\">",
"      - Inhaled aztreonam lysine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Inhaled colistin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24831331\">",
"      - Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4202024\">",
"      CONSIDERATIONS FOR SPECIFIC PATHOGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other strategies against pseudomonas aeruginosa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Prevention of acquisition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Early eradication of P. aeruginosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Nontuberculous mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Aspergillus species",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      INFECTION CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PREVENTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6371\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6371|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/23/25981\" title=\"figure 1\">",
"      Survival of CF patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/0/18447\" title=\"figure 2\">",
"      CF colonization by age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6371|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/33/8732\" title=\"table 1\">",
"      CF microorganisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/31/38398\" title=\"table 2\">",
"      Cystic fibrosis antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/61/31707\" title=\"table 3\">",
"      Maintenance dose aminoglycoside",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/49/1821\" title=\"table 4A\">",
"      CF infection control A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/44/37580\" title=\"table 4B\">",
"      CF infection control B",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33545?source=related_link\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/34/24104?source=related_link\">",
"      Aminoglycosides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12778?source=related_link\">",
"      Bacterial infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23031?source=related_link\">",
"      Colistin: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27351?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations of pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39095?source=related_link\">",
"      Cystic fibrosis: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32167?source=related_link\">",
"      Cystic fibrosis: Investigational therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=related_link\">",
"      Cystic fibrosis: Overview of the treatment of lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27145?source=related_link\">",
"      Epidemiology and pathogenesis of Pseudomonas aeruginosa infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24089?source=related_link\">",
"      Epidemiology of nontuberculous mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/35/5687?source=related_link\">",
"      Microbiology of nontuberculous mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24759?source=related_link\">",
"      Overview of nontuberculous mycobacterial infections in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/57/20371?source=related_link\">",
"      Patient information: Cystic fibrosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17591?source=related_link\">",
"      Sputum cultures for the evaluation of bacterial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31529?source=related_link\">",
"      Treatment of chronic pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2441?source=related_link\">",
"      Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/47/15096?source=related_link\">",
"      Vancomycin dosing and serum concentration monitoring in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_22_41323="Neonatal AED doses";
var content_f40_22_41323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dosages of first-line, second-line AEDs in the treatment of neonatal seizures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Loading",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maintenance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Average therapeutic range",
"       </td>",
"       <td class=\"subtitle1\">",
"        Apparent half-life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Diazepam",
"       </td>",
"       <td>",
"        0.25 mg/IV (bolus)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        May be repeated 1 to 2 times",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        31 to 54 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.5 mg/kg (rectal)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lorazepam",
"       </td>",
"       <td>",
"        0.05 mg/kg (IV) (over 2 to 5 min)",
"       </td>",
"       <td>",
"        May be repeated",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        31 to 54 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenobarbital",
"       </td>",
"       <td>",
"        20 mg/kg IV (up to 40 mg)",
"       </td>",
"       <td>",
"        3-4 mg/kg in 2 doses",
"       </td>",
"       <td>",
"        20-40 mcg/L",
"       </td>",
"       <td>",
"        100 h after day 5 to 7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenytoin",
"       </td>",
"       <td>",
"        20 mg/kg IV (over 30 to 45 min)",
"       </td>",
"       <td>",
"        3-4 mg/kg in 2 to 4 doses",
"       </td>",
"       <td>",
"        15-25 mcg/L",
"       </td>",
"       <td>",
"        100 h (40-200)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mizrahi EM, Kellaway P. Diagnosis and Management of Neonatal Seizures. Lippincott-Raven, Philadelphia 1998. Copyright &copy; 1998 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_22_41323=[""].join("\n");
var outline_f40_22_41323=null;
var title_f40_22_41324="Ketamine intoxication - Rapid overview";
var content_f40_22_41324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ketamine intoxication: Rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"        </span>",
"        <a href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">",
"         www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"        </a>",
"        <span style=\"color: #ff0000;\">",
"         ).",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical presentation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impaired consciousness is the most common presentation, although ketamine intoxication may cause a range of central neurologic symptoms, from mild agitation to hallucinations; mild tachycardia and hypertension often occur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Massive overdose can cause coma or apnea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laryngospasm and heavy salivation may infrequently occur during intravenous use, even with standard doses; laryngospasm is rare but occurs most often in infants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vertical or rotatory nystagmus may occur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnostic testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diagnosis of ketamine intoxication is based on history and clinical evidence; no readily available definitive laboratory test exists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain fingerstick glucose, acetaminophen and salicylate concentrations, electrocardiogram, and pregnancy test in women of childbearing age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Secure airway, breathing, and circulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Laryngospasm and respiratory depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Generally resolve with noninvasive support (eg, bag-mask ventilation; oxygen); endotracheal intubation is rarely required",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Salivation that compromises respirations or interferes with procedures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Treat with",
"        <strong>",
"         atropine",
"        </strong>",
"        (0.01 to 0.02 mg/kg, minimum dose 0.1 mg, may be repeated every five minutes) or",
"        <strong>",
"         glycopyrrolate",
"        </strong>",
"        (5 mcg/kg, may be repeated once after five minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Psychomotor agitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Treat with",
"        <strong>",
"         benzodiazepines",
"        </strong>",
"        (eg, intravenous doses of",
"        <strong>",
"         diazepam",
"        </strong>",
"        0.1 mg/kg or in adults 5 to 10 mg, or",
"        <strong>",
"         lorazepam",
"        </strong>",
"        0.05 mg/kg or in adults 1 to 2 mg) until the desired level of sedation is achieved",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Butyrophenones (eg, haloperidol, droperidol) and other antipsychotic agents",
"        <strong>",
"         should not be used",
"        </strong>",
"        to treat agitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disposition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with uncomplicated ketamine toxicity may be observed and discharged when symptoms have resolved",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_22_41324=[""].join("\n");
var outline_f40_22_41324=null;
var title_f40_22_41325="Contents: Hematology calculators";
var content_f40_22_41325=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?39/57/40861\">",
"       Hematology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Hematology calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Hematology calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Clinical Criteria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/30/1505\">",
"           Calculator: DVT probability: Wells score system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/24/35201\">",
"           Calculator: International Prognostic Index for non-Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/32/4609\">",
"           Calculator: International Prognostic Score in Hodgkin Lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/56/23425\">",
"           Calculator: MDACC Myelodysplastic syndrome prognostic model",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/14/9441\">",
"           Calculator: Myelodysplastic syndrome international prognostic scoring system (Original IPSS)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/55/39792\">",
"           Calculator: Polycythemia vera diagnostic criteria (Original PVSG diagnostic criteria)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/54/42849\">",
"           Calculator: Revised International Prognostic Scoring System (IPSS-R) in myelodysplastic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/34/30241\">",
"           Calculator: Sokal score for chronic myeloid leukemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Medical Equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/1/12305\">",
"           Calculator: Absolute neutrophil count",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/21/24914\">",
"           Calculator: Mantle Cell Lymphoma International Prognostic Index (MIPI)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-95ABB3C2FD-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f40_22_41325=[""].join("\n");
var outline_f40_22_41325=null;
var title_f40_22_41326="Cortical trabecular BMD IHH";
var content_f40_22_41326=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F65580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F65580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 616px\">",
"   <div class=\"ttl\">",
"    Bone mineral density in men with IHH",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 596px; height: 333px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Initial and final cortical (Panel A) and trabecular (Panel B) bone densities after 12 to 31 months of androgen replacement in men with idiopathic hypogonadotropic hypogonadism who initially had fused epiphyses (shown in red: Group I) or open epiphyses (shown in blue: Group II). The solid horizontal black lines represent the mean values.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with modifications from Finkelstein et al, J Clin Endocrinol Metab 1989; 69:776.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_22_41326=[""].join("\n");
var outline_f40_22_41326=null;
var title_f40_22_41327="Time course of calcific aortic stenosis";
var content_f40_22_41327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F83004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F83004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Time course of calcific aortic stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 416px; background-image: url(data:image/gif;base64,R0lGODlh8gGgAfcAAGZQSay3y/7k5u7u7tS4wX1WjdSSoUU0MfzkxryNhm2Lxdjn8912eJubm7TQ6P7FyGW12JhSU1hpp4G40/++n79yj//b4oGoycyUkP+svd3d3Xh4eFVNj3x1pn+Dp8zMzKzFyv+XrFVVVRVSqvy2ov7Z2T5Wof7z5q2IaNd0kJ6Iq5l/bKuetaqqqjMzM/3t2b+Xr7xneGVlZf3VzPqGdN2gnqarjSx0u/+Ambu7vPuUej9Fkz1Jic2obJdXjgAAAITJ5u20t//J083V6fySi86GZJdokv2uqI6krvjKjSMaGH+xti9BmHtcffzItR9Dmd63usyqk0GWzN/As/unjREREVdae8+gsbF2UfrVpv+2xf/29f///3xje9KVSyJOp4hxYfyck9+osqp4d/758jcnJK6Oqy8+kv/t7vWyWuvW1n9qnP+Ii/+5tpCWvP+JoTiIxb5Wgti8rve+dPqhfLp8a/22sc+mXvTz9/yqmvqNbpxkefWsTubGxhEMC2phcoG2zi1Gi9qmrR5gsPyGg4tpd/t/eP/2+KiWpR89lrqmvFtfmxFBn6l7aw45lL1ffP/UtuJnd/zAq/3Owep9avSmQf93kubl7QAzmbOer/+hn1e23fSfNA84lv5bfv5efPWONPaKN/aHOfahU/adVv1ieveaV/eWWv1md/1pdviSXP1tc/mOXvxxcfmLYfqDZfqHY/qAaPp8avt4bPt1b4iIiN24nkRERCIiIvjEgPvbs+6tqohjYe7Gqva4Z/nQmplvbVVFPe5/gndcVdbMwJqt1cCsr+3x+JJ+prtkZk9doW06PPyLf+5ykQ85mi5On+WfR/2/u+/KtJy3ze+DjOWNmapbXfS5uOrQu+twc3ZtcJjBzgg/n/TSuEym1FKu2cNucc+2sf14e+WQceeaV+qnS+mFZeCoVe2YYuWYOvmTbPfCfY1bgJlnXeWblWu/4fXbuvveuNd8RcHC2NTJ1PT6/Zl1b5qhveaIOpawnnbD4/y8ruSvoj9SmuZefa9ojSH5BAAAAAAALAAAAADyAaABAAj/ALkIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3rt27ePPq3cu3r9+/gAMLHky4sOHDiDsOqFJlAJccjQfWcsHlh+UfGxhq+KFh5ObOiUOLXtgAV5UWAqs0GIirVuUcXD78QK3ws2fOo3PrHiii1gYRAjfcEijb8Q/YXHCtJljrsgwuty4jD24Z1wcZwx9zluGiyg8XGyxn/8cV/cfw8sc1uLD8fPP6H9wtT99Nv+6AHx+Kx/7h+LfA41w0gNtBm31gG0GydbZBAwVyIcNz3H2wmAsabIYaeVxooNqBtwynIYOYcdGca9zVZyJdkwnUmkAuuKbaf5ZVMZ9AOaCXw4EDLXaLDB8IdMsG98H2oI+uJbeacgI9eCCAXPxmWw4/CFTaiVTC9Z54Ak0GmWOvfVBFkQRVAdxrODInw5ePVSFcks9BVySSSHIhwgZLIuckblBKiUuVfK51oG3utfmadssJdB9qAuYQZEENiODYjyr+sNyQbqp4pGteKspkh7FtiGeUAe7Z56hm1ZIdi0VGNx2TLUjKnHgAyv8g30AfvEdhlqI62OYtbx7p3Q9Fypree+19qiepyFK5YkNxJuvsswk1EBmzhUJr7bXYZqvtttx26+234ErUbLjkjjpuuejmlQMulq22WXmuDVCeC/1Z5sIHzVkGZrr8zrWYa61WGKKAA9Syp7wamBrccOf26/BbeaIKKGdQPvjoZT/s2fDDHKsVMRctTtzZAA/iBylBG3escln/BsiZyDLEe1otVfTYwHMtrqxzWuu2myFun5Vm2ZjCoikgsDsnrfTSTDft9NNQRy311FTDWPXVZVmG9dZhac3111x5DfbYV4lN9tlSmY322k2pzfbbSLkN99xDyR3XD2zkrffefPf/7fffgAcu+OCEF2744YJrorjibTTu+OOQRy755JRXbvnlmGeu+eaUU+C555CELvropJdu+umoQ8LJ6pxU4vrrsMcueyWVRWnJ7bjnrjvuoIQiyiikmHKKKqy4AssrscgyCy2trJIKKqV84olTeCNu/fXYZ6/99n0vzjjn4Icv/vjkl//456Cnrv7667Pe+uzwy147F7vXr3vvvwc/fPHHJ79888+L3vTaxr0CGvCACESc9zRhvgY68IEQ1Bz6KMC+ClpwdO6LnwZfNz/7edAS+AOe8IhnPOQpj3nOg570qJfAFrrwhQVcYARnSMMalm+CF8wh+zK4QQ128IP1C6H+/0jYvxMCUIUDZEr1YMjEJjrRbzK0oRSnSMXI4VCHWDwdD3sIvx8C8X6+E+H+Sug/FAZwhQR8ohrX+MIoVvGNcIzgFbNIR9FtkYvy09oXdyfEEfLPhP9LoQBZsqaBlOdUh4zIEtnIyEZmz41xjKQkwzfHOtLxjniEnRf3eLs+jrGIgTxjEk+yGfNIBhcDGMCKDJbKZTnkByxgQSYMQEtaVsORuMxl97w3yV76EnOVtCQWMZlJ122Sk54kIiDNiESWKEwgvckScKIpojG98gZwkII2N8HNbnbzAuAE5z1iGUsY1NIAt9SlOrcHyV+6853BFGYOiVnMY+4xmX8s4xEHuf+SZxpJSpSJUwMo85AfYOKgCD3oCBY6iBs4VJtS+IY3J0rRcIKTnLI8JxHWyVE2tPOdIJ1kPOVpQXpm0p5fxCcZjShINKrEnwIN6HIGapDwYOymCc2pTnXKjYWOwKHYhChFh0pUi46TnOdMZ0cR+NGQOvWNIyXpDllXzDzajpO8C+MQ88lSUTrzVNT0T1it2RCD7vSsaE2rTxv6UG16g6hwLapFMTrLWip1qVDk5VP3CseoSlV9JsUjSoGoUlAyk58vPRUrVemaxbqyrAXYgWQTkdbKWjatPV0oULO5zbh6Fq4QsOgF6HpOAzCyqXxNrRzR91cdBpaLg/1gYZe5T5f/khJjqcKSj3RbUL9RowLANUIBCrAIye7gsshN7kEzy9agSuGtn43uZ0M7V4yW9q6GQ61qt2s+v7ZWi1Stqib1iNVOatWPKw1lM9N4vRQA9x9rGK5xKavc+qpVs0AVqnT3y99NiPao5aylIASxOO4aGILe/W7pXtvD2Hpwtvps6SiVskgXArcCwpWvZO3L4Z1m9qcO5awU+ktiEkNgAihGcQBWvGICuJgAUDiwjCWXYAVjMLziNSZ5ywvhrq5Xiet0bwX+UYD4cmCyHU4yQr/A5OZCVKIljnKJT5ziabA4AC+G8YzdWWMbh47BG3Sw/XqsXsQupcJ45duFMxxZyTpD/8lJZsQz5iwBCdxAAXgGBASkzGcpp1jFLM5yELaMYNZ6uX04zrGYg3jeT9JWwixMc/aEXIEiF+DIO2ACnDks2UUMFxnIqCVGWWBRPff51NL9s5Vb/OJBE7pzhj506sDswx1jlcyHtS2FJd3ENQ93DcZ986Yt2wnJDtcIwM2bDIOQ5RxceRp/3jOqpz1RKgOa1Vrebpe9TOv4LZqPjVZmhL3KXl7j8rfA/TWmNT3sszKhH4tYgxFgAIPwQSHLz442taltbUBc+cUxjuS2bdztLtoameHmapl1nRQ0m1vSQs5wcY/b7oQ+wwQS6AAy6A3Ba+CbxdBOsbT3zWdrrzoAOf948TUcOHAFF3x23wZj/tBr2NpOuOEPz/nghFxkTFccoc/oRwc6oAIYXKGKzH7xlfVNcj+n+N8udjWsPydrwCZavDHPHa5tHmmde/1w7iVyAfqxA/q22xkmUMbQOe7Le7v4yoAQedOjrGoWy+HucqBg1VH3cqvSr7wgTHh6c33zuH398NujhhkSsIY1LMIEz/i5CUyw9nrvNekEcPaKmT53/r4jxdsAgeiJQXpsEPzqVc16Vmfu6HH/+MyIjz32IElvZHRAGSZ4QsUnX/kZu50AS09x5/v7Z9GD4AOkJ0Y35on6eh78noKvOaTLLfvqD067jgsCvYc+eWFvOu0ah4H/GF79OI+7WPMBCPkERj78z4Le+MgnvR2bf9LnpzT6jyY3kK3P/8TpNXxXAAMq0AES0A+6t2lPYAJr0AFmYHnkVzkfl36AMIHs136gtQQYaAMaaAM90IHlIFj2R1j453pmtmv9d4J5VWAQJAYCSIC5t2lop3ZFJ3UPODlXlHwfYHzbIHcW6FkYuAT5sIEd2AN3oHrmxXri5mMliHMo2IR6g30PxIIDWIAHqGTgN4M16Dgt1w04aHx/1oNENT/hFEsNWEtjNoJKyHCG54ROCIVSxIK2h3vfJ4MOOGMtlzq6MDrYkHw6yIPUNj9D9Q1Qxk3UNVoamABDiA5JuHCFdxQO/8eG1eeGkQQDZjB0BqhkaJdxRsddd2hJeTg6dxCKPbCBP7gE+wWI01aISIAIrJgCrtgMauiIkNiEkihJdvA4AWh7kKdkCRh+NMhlsbZ3C0Z/rnMOQ7iB+fCDEICKYNhNQPCMQOAA0rgA1HgMQvGIs4h4tbhXcNgBu9hhmdgB4udLnfhXfRc780NLZsAC62hRzUhU+gCNDrAA9YAT2JiNX7eNBgaHa/CCHfYMamcGRwdVwSiMN7Y6OcZBIag7KVBLZqCBSPCDYKgPOXGP+Khz+ihjK9c4AUiA/eB99dWLRWdD5ShV5zheV1VevoOErDAOGPCSrIgI9xBOFdhfQFCRF//JfxmZhW2gfQP4jfb1BEK3cb84PiVJUiepkCl5a2gYSKiARPVAjQsgjdIIje9AVA6AkzkZif/Hk+PTkQUIjpS3ceNHSQVpkF9GjLC1kA/WlIRnEPVQjwYhlVO5AFq5lbG3k15pOdqniyCpXP2giWV5OUcpT0mpY0uJcCw5eFwHEXG5ExaJl5Kml3t5ObfYky3oj/aFceI4mJBTmMJ0mLTDlme4mNKnf7AnmdrYlZVJRS2oDJHHYYHJgAMJmpYkmkYYeKaZf69ngqqZj6zZmnF0BZUIm/+odohQA3qHlgf5PgmZm1s3ffv3m15HmcI5Q2BpAsfpAZkQDsyJm6TJaLv/SYKxaBSRSZ0cZZ3X+YYw4JH/KAEeYAxTIGvgmZjQN55p2IjmiZ7VGZzryVcs6IIdhnHxOZ/mqJaykwRJwAdK+XeWgAMZkAH3h5+M2HX8aW7q+Z+TFKCPN6DwKZ+3iaCxkwZcQAZZkAajaTtv8ACHwAVvMKFitIhvSX0XmmYZqqEi9Tn8YAweIAHayWEEagzSwHwIWUwIoA1AggDzUwLHsAHaUAL3GaMKN6PTWaOT6Z84yokFOQU86qMchnYd4AbGgGhFmklzACXwIRv4ISw5EAJRulWMKZ2paaVXqoJZaodnSTpc2qM/Wl8AGZ9DSjrneALsclPVgQaKKaVxipq+/0mneHWjd9pXeZo6e+qlIfmhaVmmmZQER2OoDSChb0pzvLmEa+ioj4qlkcpXoFmpsZlcz/AHWOAFzplJfLAYhuoHA4ADiQqnp9mbTGiqSwWpqUpFtkk64ZAJHqCZlpUIVrAC0FBM8SAsGCMDQsCUFEqlcwqs6Ymqw+pUxYo60tClrVpZgfAHKMBFaVBKGKMBL7qrokqe+lkU56mtaiSs3UqSk6pg4eoByvAFluUIzfqs8fMC6GEeFsBjbtmYVUqvumSv90pD36pDU4AIfxAIlhWws7MOrXIZLQCq7tp6+WmhDJtLDvuwq0V1zHlj6YAFf1CFZ2UFjSA7hHqogBedjP/6qyNLstxqsr8UscMUXl6wAlbgCGjlCH/gBa+TBTZVC1pQswkrp42as45UsjzLcvm6d8SEAlZgdjrFAytQCbVqGbnqtNeqsNkqtY1EtVXbXVdbdYHlBX9AtDuVCNoQDyJArYCnm4raq6Qqi2iLS2q7tuTjs64lolp7ViaQH25Ktns7quUpr38LuDsruALXtvQpoq4DDWDAtQe1AENQAM3AuLzquPFKFPMauQkUuJRrliibspk6q1yEAn+QUHiGCc4AutbauPAqsqj7RKq7upxDuEQKu3jkBUOrU87gAx8ro2Ybtb3rRL8LvBJkuYd2mNCgDZ2gUzuQAjA6urtLo8//y0TRK73ARL3chrkaBA0FkL0J5Qz/IIJlC7U4G75NNL7kaznCe0Gi6TqWkAIcoFMcIFtPe7OlSr/1O7n3K0X5W1Loq0G4UwHshlA7ELriqbshC74G3EL2m8A2aL6np6kJqTsFkFNMQMEyZ8EVisEZzFQIzMEQ68Eu18Dxszv/wL4HVcLgFr8E7LcrDEMb7MKfCcPftb+VUD8pcAYJhcNaN8C+WsA9rMEtDMSF1rquS8T20wwRjAlMcMLee8EL+8QsbKdSTJBUnLJWfMVZHMCrh8LYyhKpxBGnC8YKFMVj3EALXEFnjMYJpbxHyMbNixItcAu/ggsi0CMYEcdynF10/1zHNyTErZXH9pMCNuwM3Ku3XZzCKSEv1eEC3cEeh5zIUCzGjKzAjnygIJxjX5QCSdzHl9zGJhEehUwQgTwbF4HIoHx9izzK4nPHU3XK4rVHPpBQBWDJ7+rFKFELtGEQyFzLtxzG36PLpFzG3ynD8MNJFGe7KWCzTczDzcw9P1zHvEymxPvLe5QC3scBocDEfWsSLoActQIazNzNMZTL0By8pWyS1Dw7WDXCCIUF6vy4I3EoqWQhGWHL8pyCz1zPLyzNaAnJX2R2PPDPpRsSV4IxM0IRBn3QfPPNYxzOVufLVVVewdzPOrzNJFHRnlzQGs1O9KzQmePRs5bPsgN4Zv9nBSW9ziQxAO2cSlyi0iv9SC3t0oR5z0gp07EDeCN9UPLgx/KbyTzd0/H809fD0VIM03xn1LCTt2b3B6TQyn+MEtIqtj4t1dZD1UBs1eAF0sWUt0ndCUy9wyWBphgD1RWR0VJt1i6M1qZjUgxaCWmwoA4MeM2QUI3g1U1tElBSC0+tEXb903jNwXo9jL7MB2SQBmlABifwAoENeP97UFZg2HBdEi2y2GNN1ofz2Akc2YLafEmAAJXwC66NALkww3n7DwjVCaBt0jltqHSN0aZd1kEt1JWj2s05O61dCQiQBZWgC0lA23lrw41QzJisEvdxU709EY290qh9v8Q9f5P/fQK6QAZzQNlz4NyAZwUIZQXS7coo8dRvXNq/TTjbTb7d/brw4wvMXQm5oNzmXV5YgFCJsN5fzc3xjcuiLNx2TNSGidWvk7e3gw8JVQQgO93UzR2+cSpRXeAGntAInuAMbZAmhd+6MOK60Nf67OCgwAMIVQgTzt4n8R4bACWGnOEaHjjzLb31rTrN5wtkgAAkXuL9fWvDgFAcYArMe9gl0SqTASS0/Mk1vuEM1OEPlOP0lAQnkEkObgmh8N8H5QgtPuBJzh/gIRvJbBHZrdE3DrxU3nyUjaJclOW9E+FHHtq3cQvkYRqM/eRQLuVTruChSX/hfQKCfgImPtMoHgoW/3tQjUAHTmA8OlACaGAHLm4S+aIvea7nNh7cfH4+fh6ivjwHZPALCqqgm+20s3tQXQAJM8AKsFACM3AEkQ7mcd0CGxDjF+3bmA44ab66a+7LuXDleATnotAOCMUDJyAJrqAOW5AHsmAHAiDrtzEm4QHPZp7ruq7pm944vT7OlXACuWDZll3qCMvlmOAIJ0ABrkAFXKADsgDr0C4SrUIb8Q7f1v6E2J7t2z47JFoQbn7ieYs/CTUDk+AKkoAGyRMNz47kJKHkWdLkNF7vynbvm57v+u4LCuoL/e7vZJvomJAAmM0FJBALNLAFdvDuIsEYD8IYlw7xe7PrlEvxsvMLmP99AqEu7taK3gdVCHRAAlSAPMxwBIRg8iFR6UhD7xDv8oIL87Bz2bOt35Ud5IqpDQjVBVxlCEGv8HFd67eO6yxv7wee7eCj9K9j5bBzAs1dzYcuCvZQ7PyjB3kwA1sQDUIPEi1A7Svf9R4l8Xwu9q4D6m5+2eWN9v/uOyiAUIHAClTgBFvABTMQBpNeEmriEWd+0Ei/tp0YBcMQOrZwAEoABllkUghABiPe4zavmOSAUApA8zOQB2hwBBSeEhsgA6Tt5Hif918P9pvTiQAQDKFzAMGwAp3/s2qdCyPe9FAfpQhVDFvgBHTwCq3/+idR3XNt9PVe+VXbicHfC1WAApD/AAZlIPzcXugZb+iD/zuJzghyUAJkIABk4PqPH9C8Tf3Wbv08i/0rAAkJ8AO2AAnADxCQBA4kWJAgJ4ScKi1kWCnNiYYncjWkaMniRYwZM4IKJWoUD0whx7jSI0nAlhJhWq1KharUJ09cZM6kWdPmTZw5uQzg2VPnz5o/2AwlWtToUaRJlS5l2tTpU6hRmWqiSrXNVaxZtW7l2tXrV7BhxY4lW9YrBbRoDa4tGAyALjBKBA4rw9auwIQKKfLxdSLNX19kklBsqBEjDosZQmzsOOpPSExNXMF6FYuIHTsrW76MCdTzZ5sDZLioteEW6J9Cpa5m3dr1a9hHq1o1W9v2/23cuXVnTav27lpbfpT8WAGpVxUwv9nmJXzCJgI+hBkatvhAiCUhhw5lwMjRYxfIXSZXljWLlmaXMFGv9+zix48NOX58YH9TdWz8+fXvhzpb024AAxRwQLJ6o0A54FZIQCBbVrAFQYOY28sXBHxJIglfpCuMOjRCwOGQEEIQoLvG7IGMh/FiKe88ltLrrD4YaWrhh1pc2GCAH1qIkab7+PPxRyBf849AIsPa5aoxEihyya0MhPC3Xh58ciAJCUOAjBNOIOMXDReizpIOQzgEhzfQINGjOk5McUX0ONvxzRkHsPGDHN+Uqccg89RzT6OGZPLPq4YBoA0A/PADGECZdP9yyoKkQSGYKoZhFK+EpMuFjDQWunSOLr/UwgJQLfn0zFGKgKwTkirLIwwWN1PPThg1+OEWXGitAlYu8ORzV1738zPRJZXAYBc/EkigDGCLXHTSBIap4odgEtBlUkiqbCgXiBg6YTANvxT1gTcseWCxi7wbhRTIMHFiklcm2WKLI9p8FVf2annvvVpw1bVXfvtd7ddkCRQ2AT92qUGJgAlc9skVcKkiGBSUKI7aaiuVTqK/0iBjjkyl89Zbc9GFDA069NgijDAEkPdFetdrABdccqB3X39rtjkpgBMOkJcDem6DZ50FXBjCQoeJAhJcJqbWWobSwInbijwVYmohuCv/tzFSAoFsADqo2IIGZtBYuWX2ZLi3inxhpflmtm/OOejdeBmmhjaGURLu3YZGsBcwDqiiDD+UnpTppjM2vFvqSkCD6qpJJQWkkKAoYXJZ7ChhbLJBk+8HF9yrYgC12xZ99Lfxrm0X1GtQXfUjTc9N7yf5BvwAaQe3uEvcp+PQasNC5gCyQiRxQgdZolGpRTcz/0y+BmSyV0c71x59ej5Ld50sALK/971Br78NdkajACM52xHS0Bdd0k8/OsQNs+5Lc0cBL6QmKFPRPMyVb68WnmbUAPQ3SY96AwSS9bxnpNStrgatO6BZwEex8umFIoFBgPp0wT6PUecNh0BDB9Gg/wXHzS8ykphECR8QL+TNS386wdH27gW9GAmQgDPUjwEbaCQk3e2GZXkgBKdEuEokIVu58xJ1LFCCDCRRMY4zUUjmgYYSTuKE+VthTlrowjrtSIY05KKQZrPD2giKUIZCFBjH0kMfQgiIfMAUEYtoGAHwTiMhS1NILkEC8uAvhSyrIk568kcAarGLg/SRDc24FWERy1jIOmRY0PgbW/TCOBQDYiV0gaUsnQCDhPlSBizwBlC+ATFX88go6oiJYrDrfq1yUR9daR9CxjI/hmwkVgZWsIPVEiyPZIstDvADuQRDUhGUzhy2dKEL4e5LQqjJdUh5LlOF5Blk8CAaMrPHV//apBYwrMk2AyhLcHqxKroMC898BjRydoWXawlGMOICiXcSkzDYcuMbNUKmUIrScaaAjANmQAISHOEIRKBiNrmwgR+IgD4zacEtshjDcEb0X19M51fkRje7VZQr6zSIxFYgl48u7XYUwVjGlOmtECyRMR4hBT9DMgQ8rrKg2RyAQ3+Ai8496wcyiJ5EffoUWpLTDgkAhg41qhWOFuQAYAgpAIIhUvMRxmk16VgGDfMGAXDwEAII1zNbChkFlEAHOmAGMwwxU4M2FBfvcYFCQ/dTuColqLWsAeCU4Icy0O2ovOkNxaKAVz/47WjylKrhqmpVjQihBIjBgQWcaZGQmQL/csWoyQPQalCZ8KRlW4xrOOfaSKfuwg67OED39nqVpBIkSmAAABiiIEnCUuSwufsSGniXATN5VbIhYUQCxlrWs2ITs6/kbGdl+dlDKqGMbQAGwk6L2r5SCwBKA0NdYts0MiCAU0T8kgUecBEhWGCfkMMEOKhAgjDo0VV8HK7+imtcQiLXjAcYBlYAcIDnQjct1LJFa23x32HI5boMQR8ZXvCLTXKSOmJyrAVA5DhS/A4TX7jEFtCwBQEQ4rLt3Sx8PSxfMGIgsPf1Awby24bUQmIFWKyC4J5UyYXwIQtk2NJsdWcYMmlBCFrw0D7nVwx66CEWNCiBZYXL4RW+18Nc/wTxDnnxZADwQq/5TTEkbDEMB/0XtgNu2i9o/IsrTUTBhmmcRbQwIt3ObwGZIM8RxHbk4QLSJ29dclybfENB2eHEfN1vGn24xiu9IAnsm0OGxpyRN+w4lA/ILWSxZor5OcAY5HnA5eBsUIRi8QeBFGSd7UzRE2NAWKtj4GmrLBDWZm+6UJVgQ/igXYcM+qQZyYBNtrPPQoTEBHgowSRKsAWCXjqbmcYipyHqaTZYw6d3biAAXGhaU0d3UgEugwsAgBxWS4eNf8HSC2aN6AdkIJSj1G0dGaEMEu6DCMFdL5LlrFk6x3UZySDKAZaxbFDn12AKLPVeT62EVMMTANkmTP8SEFAJMFcCAWJG7D2TSK591rEYbiCPHVQmbMxqYAMb37i+4JsMP9D7AErIBr7HueerLLAN/fa3tBnlUZAKmFFATEI8FJ4FS0Lt0BkRUwe32lVHs9QUafpCMe7x22i8ud1I5sJat2dsGCmZiyAvgxIY8FNmH7AGv0SYME98amHa4mFKGDiX+XCCS86BjdttOEYE8F1L4KAE4i23AmwCrw27Uj4OFYEIXODxuDJA8AyIgB8iwABhmJw2J24nLxDm+K+7fErjg0QUWkvJkTYEfYPJBc47RZ04XgS3+zzFhC+ggN8agpXJ43Cc0DaAz8VbogzQ9A/uLdGse0+5zWWuc5//e2pB+RnG9axEJz8JSi2UQJ+WiGzpeZsH9Kq3lUj2X+fMxs1jw3Xw4BB8BCKQeNzn+7kH4AXvnRr5Pk8qCkqIwn8jSXDitx28N8lt80MigWN0EMMaxjhNaWSvH4i9njKuZVgGQlgGQ4kAxfuPPROx2Skx9PONSXG27Sm7mcu8+Luxe8qncQu6czEF5xuCC6gMGpgBS1s6d3OeDdAAwOssJQAHYQi5ZFCCBUS5NqgBXoiyKfs9yYsd99My+MvADfmY3nm0U9CaIVCAGFARN8u7PpKTWmDBDussQnhBkBMGBqDB8Du551IgfovAA4Gg99uyC4wqbbuQBNu5jNAxqpGj/+YDCQWYB99iBjuYAUIQBxRsrysSgeZpwbiKgDIIRDYARELYwsXbqxqoPWhrufRjFF8CJkgQpiBsCC/Lki35toxQHMZxQyMECcqyCTTIw/bSgFqwKVzww58iBEKIgGW4unmrwfzyQlIDQ4ppp3eKpzJsNewSs0uxMQ3MCNuCn07EBEb4ggogK2ZQRTycPqbjghwQgfeAuvqQugESBmscPMEDv4jKvetJAF7ACl4wKkaUwJdbgZAKKS4ToojQuahxn8eao2EMiT14BTbpv2ySAadLKFSMqAMsQBe6vW0Uv9MiP3DELyrrQQhZqqZ6Ki4zpo7RGLZTw4vYoGoCId06hf/5UQACMCEUEkXMaiHSkELZkyhrxEJs1EbPEsi9Ui6s4L2DbMQp+avZqYLBykUNuZL0yS5MxIgjUiKV8sCWwkhMCIAFmAeOdMI+kgGZIRtqJKBlUMDO4kbXKS37MkgehMkpsQXWAgMp4TJNSR+Gax+NCD3qaD7wWAAFaAKZsscn3AlA2kefKsBC/DQuzC8RK60DgMCXJEc/80qHOJzPMwxPyidyYz4jBI8LKAa1rEePfCWEkhUXkkb2aMoBAocXHDyUBCepdB0c1ME9S61eUALRHE3RJB+blA4EoKrATKxmIj1gmLBjuAQPuqbGdKXHLLaRjMt/hMU9a50k+UyE/A3/czyAYDDHFSgD0/whDKyETQFMseQ5DizM5ksTBwgANxCogUJK/QEdOYNLksRGxOPN/BKjQjkUWqQWiRmIvplETRki7qIOIfigwrzINElCHljL2nwlKBRJ70S2WNpMvEmkYjmW85wU+lJPmVNOMySpXHBO+bMIHMiArBICiANKEEyTOFQGZGQ3ZtTDe+HDmfFPrFPJo7olg/G9aMNKBNEFDKiC0goGP0jOF1vOqaIJX7SnBRMALrAA3mk+U/nEmTCy/HwlUjTF/hTRLgJQuDEn/EKnq+TLrGStYcCAafFKw7pRHNUIT9pRLTgEums+VcAEE/iCL9hQ7eyjZ4zG3CTJ/6KwRvHMr4uqG3E8qlODBBZdARuAoOGrp06aUHKJUAs9hTAtBrSkAcbs0PbCxw89UnB6SqKIAC0MyLq0wTbQs70Mw0mxBbvCq65UUF0UwuKjDi3Qgvm8yDBlBAUYAjKYBFY5U+UBySgM0c5igKccvGWI1JScVEotUEZxKknqhdJiTyH0llH6yUANU8hwBx0tAU1gS1dSysyhzNGJACwyvDfd1UulmPQUCHQ8TVD9RYx4n+y4NVOFHAlQAy4oATtAiSF1pRbgT0aNJVo9vGwcUV3dK28ExznVqFM7UIG4L2HNwNryEBAREdJTBR5I1WPoAyIwD3E4gnbtoyrYgGhFNv8svNa9IsircNIUhVIIiQIXvS+aDNiGyAJYe06MCJMxKZODTVgFYARwOFTW47ANkIE/ildwEgZryEuAzNVDfC6WvAqXfFJMzdSt7FRPJaI5CLQ0DFXD+JRQGRVT/R1GwIQ9WJXVU6E4w80B7KxkQMAfOAB6w9ijosqruC9eZZRUyx4XU6Pl1LaIHMKnBRdxqVAw7YLExAQCOAS8c9YquqJ7kcz1kFbRgdTAsgYlgEqy1ai7JDETy1ZqCQZcULVVG7BfELNfOAEEwFKnJcKV+kBBbYIFMAFGwAOUubiI/du3XNNG9YNliAQ2SFy4UlK46UwpA04VRZD0TB89zTynyRD/Y/qFLNCk1fRcU+2C0b2BQwAbpUPUOFvdrvUpQhAGQBQOa7XXnz0q1Nm3WYTcabPA3l3QIMqWLPC2SpCI4jVewxS6U2CFMVAAB5iHIaicE3RegwJcNY3eVGQD6r2rMhhbSc1ejVK1Z0vbJxE70pRRtxVfdVQ4XViIbUnfiQQZI1QFDL2ARZgF43HVzMHfTWNdfhwKcPC+xSWn7VWgYTHghCxO46zJpNU8TGGjwWCjsGzHxJLPImRfVjilHZBZrX1enqgRnOXHuQxgBjwxAFguXmAkoqWYMmjbAZsxA1sIL2vaLL2ICPXTzw1KVYgmTOgEH2avj+wJe1nKb0JSI96z/xrQQdUJMBVGkBU4gB8kwxkVX02RNeasYRvO0R3t0QpmhXQJY6bzYDPuNDTWTBJNJ2Co1uXq2KKdEgq8F/Ct40+VDkNDWVqzAC710mMF5AljBFlQPQ4mG/zlKRA+ZAKi3YSpgWEAhu71XkaJkjkm2UrwhV94ATKw4s6lNS2OO6sBU1YwAQfggksAhxmIhlEmZZ74AOwzZFSOr0SuqCfb1To1Djr2VlcDMy7YEl3eZYwY1VLt5HkIAAVYgBiwg+ad2faa2BnZqSF+5rZR5YQRI0qt5uz5s8x7NQP7hcx9T0TjQFCSzj++BAVQgEuIgSb02xWakQ+ARveA16iD5/+M5v90EjUMeGVH9qF7Dl9ddJoXyAU+aOCdfAOceEdgTsJyLoBJmIFkppc4cYHPeShnlmgakueAiWTueeMV3WjMs+M5GF4Dc09MBuiAPlhWQIZjGAI8oAdga2lcoROHxpFmnkaaHiSbThbuZR2dRpAocGG/XFos8TxMNjOLzGHQVQVW6IIvUIBiUARmyFoxNiibqoUG+AGIpuqqZjKKriii2lc6Dc6+RJA95YN1gA4Jro533GIQRGtjUICQ4ADpU+c4q4V8oex3zut+uWpgqSvrzautXovQJM3RVGDBftv4+5IQ6JAONFVWmIJiCIkdiOwfbsbLxuxe0exECa2VM9smZpT/4WTh4yRt5dhTN1qm1mRtDBjdL1gEs3Jq2k4N254h3AaUoO29z7aLbYWnA6BlPqUOfFrtTu6DynLu584Jwo3uH5nuP6GvqrxutvBXeEpQSu4SPuiYbvYWNpwaTmRftK4DMl3u5lbo8kaN80Zv/lBvJmncvHzc3maWkIUU4f6NSvIyLsCQXD5scUEDARCA7Cjr9T1rVjCHT8YEURbw7RyN0jiNUzZwfkFwJrHdi3bvtdAFrQQAu+npSg4MbBmMCB5rMGFDUTHpP9aBYV4ATDhm8rYT94AP+VioM2Zx0XFxJtmFMYDR+oJlCPnBWU5HiIjgHn9QMEkiMxk91p4Bcr4E/0xA5yTfkRmpkRuR6eyDcraRciJpFj+AFr+uqNSyBUUUVmM6uyTQmEuWSIsQAnA5BE00ajQoaCNP6NTVn5feADqZ6smU8yjf60ZqLj8IhjFQLkvFcgTRcve75tK244VAAFy+koPDcBxAjBDYMcUWVFYoATcoZ0zogxlYBRPPHFmhFVupbUtPb0w/pKIxseoGdeXoBWXXclIfbtPOBbCkLS3ljhCwyCQyajpI6mNwgKbe9cwBQHwB9mA/8GE3o13gGcBq5AZ/EgKuQGE9u26WW/C6DjKfGqPWAQlgawVIgVlY8zfJgY0r5Ccfd3+hcyI599nJc3JKMWWX5VF/9zYq7v/EovfcsndTVYVJIAMF+AJMiAG4HuSQZEqCtxmDXxIMmGZk/40oME6W9+oFruSbc1CJtPd6F3L+ZgV1cAMHwIN5MIOPd7cP7cMVH/kCKndsbaQUKxTRBjhhrdGZwFIyE4I30AI0ACWL72RXaALT4wJk9nayKdL3OMWhJ/pCMvqjN6MUi4IDeGLhe9s08IWMGfSZvwmbB/Gsl4BpiM3jefQqStMP1l+yrx6zP/sdqjJdSICRi/BSh3kKt3BdxjGiFuibJ4FLOIZiUIYC+HkkU9T3EAFxD3xxEmDC13PAVo5HRAGOtmQy2PHzZUd5V19glgRjqFpM4ADN91DOidXPB/3/1ij50c+b0reL/nJRDMBnU1dHL3d9cDVeYHYFcPiCqu2H209UgR973scP3//91wn+tQCDTc8yIGzIXN4WQcfwjwFmHUBXI5+Hrud7UnbLm7X+64eN7Nf+7+F+g8BpSQ5YVAcIMggEVipo8KClhAoXMmQIKpSoUaRMnVKlaoYaBQsw3UPTalUqVKU+eeJi8iTKlCpXsly54YeGHzJnDmhpU+UPNjp38uzp8yfQoEKHEi1q9CjSoZqWLm3j9CnUqFKnUq1q9SrWrFq3cq1K4etXSGLHki07tpettGpt9TLr1iynuJwO0s2lS1cuunob8uX7MOLEiqxO8FNwCZMCjyBF/5K86fixS5gzaUK+mTMp5syaN3Pu7JNp066iR5Mubfo0VLBh37Ju7dqt3Ll6K/mabbsvboV/JVK0WGKfRkzFZnwMObJk5eSOaw5o7lx5y8uep1Ovbv0oaE2ot3Pv7n2ragqvx5OHLXd2Gi4I8tpGmBv37sCqWNEhM+TYvGNEijNGDv3/Si7kYNIHLmgAYErSXbcggw1ylt13EUo44WnhlXdhebHZ5ksWJ5zwCx/tVfIefBDxJpgrOihQjAJfZMPfcQjKaNIAP7TQXEwtzGiSgg76+COQPUFIIZFFGimVhRgq2ZqGIuZyAhkh3kaiXyYGRocTrMCijAOXKBADjI3t+P+fC5PNNOCOPQa5JpvWDXkknHF+l+SSdZbV5Gx8/PICGbqISGWVgFEEyQyuvDJEABqJEaZ/YyZXppkyOKpmm5Vaitmbcmq66Wh02vkpngfxMdALIIo4IqAOWUnRCZKwogceEiAmAKOO/jeAgM9NeimvvWIHGqfBCpuVp5/WGapBfMSTSxoFSTllqrqtegoaFLhCBRdfIDZArbZ6KyOlvoorbqbDmntuscYqiaxBv5DBRRK+RNletAvFR9EMkLgiyQCYYHKBBqssFuO3yWmwAcII7zouwwyXey7EnKar7oXs0kbGk0lUcoLG0NZ77yn1ocFFJpgwcowi3RYMGS5m1pT/ZsMx+/pwxDXDOTHF5FmcxAkba8wxvfUmBLIqdJBARROYfKGAESqvfFMOP9zygwgiuLCwzFm3SbPNXVOIc86vWTxHlBynQUZtHkdLNCuuwLKHv5hw4PTTLbXwwwBV1JL3yzOGqzXgC3LtNeHegR02k+fNhgCfAyHwp9CWsO02OHHvQHfdK92tgQsuyGDjmH8HPvp0gxd+eoWqIb6u4rPZhdepkUs+7XyUW4555inVWEstMlXRN7ikCy84sKgb393hq5sX16nNoyr05LBU7u8ZuOdOo3MD1CLDB1gP/31nph8/vlbJK39n6+2y98sJCDQbNPS0tw0LJXFjYn3uL5kp/xPwCIoOPgCJIj7yEdArqjufztJXifTUhmy/6NCz9hK56L3CfvjLnP721z8A/S+AHvzJAAsowtQcEIFiUyDPCpKFFxTkBOyZjewoaMGBiel6Ksle9rz3wR0KJYQjHKH5TAgJZKWwEgjwk8/g9zH5ue0VnYhbJGjYKBvasIM83KEPf1jAIJoQWfJKAx/IoLEwvlCC8RMUimDxih3E7RFSpCJLBiADF9RiA7fQ4RXzuJMsapF8XEQgu7JABjKwsBLuiiBdYshENfKgjW+Eo0ogtYGodQ9merzkHovXx02SECxCPCHz9JKLJEgpF2U04xLRWDs1stFfbjRODSFpkrvVwv8FG6iRjiyJyUvykZOo++P5LOY895zxRKt8RdL8VYBHynKWeLPlB0Cny13msZe+LBwwlSfMYRZEkaqcXyySiYllwnKKkIzJLXCRzirgkZoftOY1vZbN1W2Tm9405vyQGTdy9qeZKOndTGrRTncGEJ7xtNk8EVfPYd5TPvlkR9w4wEx/ciEHCMtBJadJ0Hdq8qA/TGjYFuq8hvYmn9PDxA4mKss6HogLtfhd6DZ6RYN6FGIgzZlIm0fSNL4iBpZTKRw/94MqtECoG/yPFWUKOJrW1Fw3pVhOYzfBRb7ipCktJ0WrUIUNVMF3DRioUoXH1KYK66nqiirkiunQJtYvbkD/tWGNNsCFz92ipTENqwfHSlaJlfCTb0GrEtdG1VjY763Xi+sAXqIrjeJ1eHrdq6bMaizAqi1VFCSsW7HazBrtD293bSz4HgvZOEkWVArkJjFTic8mxuKJ/oqEZmXJWQ1+FrSO7ehojVdaO1EWhlP9JmtbiYlHxFa2OGwOWG2bNdHm1ki7PdZpUdvN365WjbEQLnH7SdG6JVW55MJtc7HZV7/CJbrS3ekxY9FIVxZ3u9/qrnd7xdzwfm285CVLb1EpWOBatwD7RIV23Vsw+Mb3UvOlr4Seu6T8JpK6a1WjLMRZgPYKOLkFHteBETwn+95XLAxO7X6r+4pY+FeZACZY/4W9ReALbw28Gq6ZglkXSuk2WK0lZa04OUDhFPuNxYHL8Iu5E2MMfdgg6M1nLHzqrx2cOJY8ZqyPHebiIKOLwx0u8nRtzNMkW27HT+ZglLUGZCqnzpMdLu+MaWxkB9/YukpGaZPN+WUwh1lmYyZzaYZcMfOi9sisZYD9vDxn5ay4zj66M547ZeX7Yvl5qn3wiGUR6AAP2n+GjhmiE90VPWeIz/Zk85YlHTdBVxoyhb40gzKtafAsmryN9rN1Rf1aSpcaOqdG9XVUvWpitdqvrwZ1emWBXVrXOjm3xnV1dL3rq3A6gWlWs6NDDOlYCDtucSB2sU2N7O8yZdlO7fUnf/+t5WAPG8XZNva2ZzZlb98M3EIU96PbHGkOxM0H2D63ZdIt33Wz27nu7qKnGQpsJMuixOO8N76jo29eKbvfSPo3IAM+0oGzNsL7LIW5E+6YYy98Mw13eCdXc2b8SlynFI+1wQuAcI3jpOOW+jjIndLs8cBb2vKmNtyWjHEns1zhLm9xt2Mup5mDUjbQznK8Q/1mJme85yzh+M+TAvOYE901NbfsYGWx9J3L2ekJijqbpg7yqifu2WqGdaTffIaVe50LUAe7UcTucLKz5uqAuqwsZmE/tnv97XAXIL+FHiG6/7XkUh03wfUeN7473e9/72HgBW84iAfT8GlNerAV7y//xvfc8Y8Hitz7TfjlGf3oaKf2LFyLCX80ve0o8fznPxN5yQuZ8tq0fGCxzt9Iz0K4cWi963kUeweFnt2jR3PpoX36vPse+MGH/fAzGXTaF+n46DM7jZffe2s73/XQjz4biu9t65Mc++c9Oe/p7S8fdL/t34+++JdN/rHYnUp4n0XKP8Hz4Asf/LmePfWVmciNnIfhXmXdXdbh38XtH/+93/DF367NXwGaX5+hH+qlnCcw4PP53/9NXwBOiAQOkQH6FuJV3CxAlM5poPdxoJsA4AeSRgjWH4nc39LpX9dtIAtSBwSuWgyOoH7pnoih3tapoPvloA664AuKRg9S4KeV/2CszUINEmHfGWHpIGEScsUSJt/ZWWDeDeENriAVho8VXmH52B49+WCNYV7iZYP9tN8UhuGDjCEZYkUWHt2aOSHv0UIbSmHjwWEceuAcbkcd2mG0AeG05Z0exo0b9qEfasYOatog2qH2JaK/LGLnNaIjymEgGpCZEeAEamH2ceEsUCImWCLLOWDsPWKiRaLpiSItnIG18eElYiKmaOImTgUrKp8r+p4sniIt1iIg3mKemaFCoSGIGeLNISIvfmER/iJSqCKe5eIW4iHq0cIy8t9KoOLnQSOZSWMoUqMyxiIzvqEzxp0tCmPIiYcnfiIhFiIC7l41CpcPeMI4MmI5Fv8FN1KZN54fOI5i/tXjLN4j4AUjOiohMYaUMd6hGpogLWAgQPqiQA5kaBTkMHaiJ8rge9xfQ+5TL2qcNj5ePgbZPlZgP26kMtEjNrZcRCrFOVLkSDbhQj6hSY4TSqbk660kSxIkRbKaRRIgRuaGRvqA5dSkTfYfToJeSxbkSwpcP87CI1hORybcR/5dSL7YUk5cST7lkhFlUU4l3FWlhl2lyWUlVD6kRx5lUIAlgonl4cVkHmolSnGlTXol2KklfbHl5dlcqI0iXJ5BVOIbXUadXYYXXubeOwYhIrJh3PzluQXmzw1mcxXmAdpfAtJCK9gPY2abY7ocZOaWZJKgW1b/42UupllKJVoipU7uJK/15Mj9ZInAIyKOpr9kZrElVQSUgU/cJhV25mh95g8e5iGOomyuXmkCZlFEwA9EQE8gp3IaIW9Clm+moV5mnmXCor/EQXE2JlEgpzUs5w90524mJTpG5zECZzIKp+9lJxVNjdQQ2lAwp3c2Z3impmoy20HiVEIi3XQmHi2sQnqWWi3gQnPggkBVhuhwp3eCZxg+516Rp0LuJ0O2wn9WmggUaC2IALoBBXzyxIbCIYOSlYPqJzLuZX+qHybMY6nhwldxQQNcjYFq6HcmKCZ+aFOFqDtSJmwKJwam6Iq2qEpkUGcFaXJ6p5AWqZEeKZImqZIu/ymTNqmTPimURqmUTimVVqmVXimWRqlc5U6FmsQGYKiMNMAPrOhJiCmZFiWapqmarmnwBeiAFiiAmGlKyCmb1qmd3imephh73hGC0GmZjmmeBqqgDiqhPpmfmsShFqqiLiqjNmqYAipKJKqjTiqlVuqkysCZmgSmWiqndqqnfiqohqqojiqplqqpniqqpqqqriqrtqqrviqsxqqsziqt1qqt3iqu5qqu7iqv9qqv/iqwBquwDiuxFquxHiuyJquyLiuzNquzPiu0Rqu0Tiu1Vqu1Xiu2BmtXsROPacBRZSu4nqqYykSmblc0cU+4piuqTk1X8SkXiIDvUA0XDAC8yvMEnD7Nnparuu6rpcbED0QNTHDBS9zRS2Do1AxIy6DJ04yr72yAXfErxDpq79xRmQhUmXxVwfrrZNyrl2apmShsxIZsobbMZOACF1yswFKNvz5s5jDsUDmsyMYsoQLsgfhrDnyOpMArhpYJmIpALuGrTNyCvsos0dYpXZ3E1MjAALBnmUiKHM1EXdXNuWZU0VbtpFasLHmr1W4to0ZTQHEt2Iat2I4t2Zat2Z4t2qat2q4t27at274t3Mat3M4t3dat3d4t3uat3u4t3/at3/4t4Aau4A4u4Rau4R4u4iau4i4u4zau4z4u5Eau5E4u5QpqQAAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This conceptual framework for the natural history of calcific aortic valve disease illustrates the spectrum of disease from the 'at risk' patient to the patient with end-stage severe symptomatic aortic stenosis. Once aortic sclerosis is detectable, there is an increased risk of cardiovascular events, as shown by deviation of the survival curve (purple line) from the expected event-free survival (light blue line). At the onset of even mild symptoms, survival deviates even more from expected, with a dramatic decline in survival with severe symptomatic aortic stenosis. Aortic valve replacement (AVR) at the onset of early symptoms prevents these late adverse outcomes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Otto CM. Calcific aortic valve disease: outflow obstruction is the end stage of a systemic disease process. Eur Heart J 2009; 30:1940, by permission of the European Society of Cardiology. Copyright &copy; 2012 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_22_41327=[""].join("\n");
var outline_f40_22_41327=null;
